<?xml version="1.0" encoding="UTF-8"?>
<root>
    <row>
        <APP_ID>2022203</APP_ID>
        <Date_Announced>2023-03-29T00:00:00</Date_Announced>
        <CIA_Name>Dr Yijun Pan</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 NHMRC-AMED Dementia Collaborative Research Joint Funding</Sub_Type>
        <Grant_Title>Exploring biomarkers, therapeutic targets, and modifiable risk factors for non-Alzheimer's dementia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$499,806.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>biomarkers </Res_KW2>
        <Res_KW3>therapeutic target </Res_KW3>
        <Res_KW4>lifestyle factors </Res_KW4>
        <Res_KW5>risk management </Res_KW5>
        <Plain_Description>There are various form of dementia, e.g. Alzheimer's disease (AD), vascular dementia (VaD), and frontotemporal dementia (FTD). AD has been a research focus in the last decade as it is the major form of dementia, while there is far less research progress in VaD and FTD. Our project aims to improve understanding on VaD and FTD, focusing on accurate diagnosis, potential therapeutic targets and modifiable risk factors, with the ultimate goal to improve quality of life of people living with dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022535</APP_ID>
        <Date_Announced>2023-03-29T00:00:00</Date_Announced>
        <CIA_Name>Dr Chien-Hsiung Yu</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 NHMRC-AMED Dementia Collaborative Research Joint Funding</Sub_Type>
        <Grant_Title>Novel therapeutic strategies to intervene in tau-associated neurodegeneration by modulating tau clearance and neuroinflammation </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$499,644.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>neuroinflammation </Res_KW1>
        <Res_KW2>dementia </Res_KW2>
        <Res_KW3>frontotemporal dementia </Res_KW3>
        <Res_KW4>neurodegeneration </Res_KW4>
        <Res_KW5>alzheimer disease </Res_KW5>
        <Plain_Description>Research has shown that abnormal build-up of tau protein triggers neuron death and the onset of dementia. Investigators in this project will develop the rationale to link pathways that contribute to dangerous levels of tau protein trash and examine if our candidate therapeutics can block these damaging cascades and thus delay the progression of dementia. A positive outcome for this study will be to identify specific and effective therapies to transition to a phase 1 clinical trial for dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022961</APP_ID>
        <Date_Announced>2023-03-29T00:00:00</Date_Announced>
        <CIA_Name>Dr Quan Huynh</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 NHMRC-AMED Dementia Collaborative Research Joint Funding</Sub_Type>
        <Grant_Title>Reducing Cognitive impairment by management of Heart Failure as a Modifiable Risk Factor: the Cog-HF trial</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$499,487.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | </Fields_of_Research>
        <Res_KW1>cognitive decline </Res_KW1>
        <Res_KW2>chronic heart failure (chf) </Res_KW2>
        <Res_KW3>clinical trial </Res_KW3>
        <Res_KW4>cardiac rehabilitation </Res_KW4>
        <Res_KW5>health services research </Res_KW5>
        <Plain_Description>This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. The program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative technology for wide scale rollout and implementation. These findings will transform the way healthcare is delivered to cognitively-impaired patients with heart disease, and substantially reduce dementia in Australia and Japan.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020410</APP_ID>
        <Date_Announced>2023-04-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Abdullah Mamun</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 Global Alliance for Chronic Diseases</Sub_Type>
        <Grant_Title>Implementing a life course approach in antenatal and postnatal care settings for prevention and reduction of non-communicable disease risks in Nepal (IpreventNCD)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,211,303.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>implementation </Res_KW1>
        <Res_KW2>antenatal care</Res_KW2>
        <Res_KW3>pregnancy</Res_KW3>
        <Res_KW4>behaviour change</Res_KW4>
        <Res_KW5>health systems</Res_KW5>
        <Plain_Description>IpreventNCD takes a life course approach to reduce the risks for noncommunicable diseases (NCDs) in young people and the next generation. Our implementation research aims at strengthening the reduction of premature mortality from NCDs; reduction of health inequities; and advancing preventive health programs and policies in Nepal. Findings will provide the missing evidence for the implementation of evidence-based integration of primary health care and health promotion in low resource settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022036</APP_ID>
        <Date_Announced>2023-04-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Brian Oldenburg</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 Global Alliance for Chronic Diseases</Sub_Type>
        <Grant_Title>Structured Health Interventions to reduce cardiometaboLic risk among adoLescents and yOuNG adults in tribal communities in North-eastern India (SHILLONG): A type 2 hybrid Cluster-Randomized Trial</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,499,746.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>implementation </Res_KW1>
        <Res_KW2>adolescent health</Res_KW2>
        <Res_KW3>physical activity</Res_KW3>
        <Res_KW4>dietary factors</Res_KW4>
        <Res_KW5>cardiovascular disease</Res_KW5>
        <Plain_Description>Meghalaya is a hilly state in north-eastern India where many Indigenous people from the Khasi tribe live. Our recent study with residents from this state found that high blood sugar, high blood pressure and overweight are very common. The development of heart disease and diabetes starts early in life and lifelong patterns of behaviour are well established by early adulthood. Our program will evaluate a lifestyle change program with young people from these communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022355</APP_ID>
        <Date_Announced>2023-04-12T00:00:00</Date_Announced>
        <CIA_Name>Prof David Peiris</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 Global Alliance for Chronic Diseases</Sub_Type>
        <Grant_Title>Adolescent resilience-building in urban slums - a multifaceted trial of life skills education in India (ANUMATI)</Grant_Title>
        <Admin_Institution>The George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,658,669.24</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>adolescent health </Res_KW1>
        <Res_KW2>resilience</Res_KW2>
        <Res_KW3>psychological stress</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>chronic diseases</Res_KW5>
        <Plain_Description>India’s 12 million+ adolescents who live in slums are exposed to many stressors which affect current and future well-being. Life skills education programs can enhance young people’s resilience to these stressors, but little is known about how to implement them in resource-constrained setting like slums. We will test two strategies to improve uptake of life skills education in 102 slums in New Delhi and Hyderabad, assess their cost-effectiveness and use the findings to inform policy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022566</APP_ID>
        <Date_Announced>2023-04-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Bindu Patel</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 Global Alliance for Chronic Diseases</Sub_Type>
        <Grant_Title>Evaluating the impact, investment case and scale-up of 'Health Promoting Schools' in Fiji</Grant_Title>
        <Admin_Institution>The George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,388,931.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | public health | health promotion | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>school health promotion </Res_KW1>
        <Res_KW2>physical activity</Res_KW2>
        <Res_KW3>dietary lifestyle</Res_KW3>
        <Res_KW4>mental health promotion</Res_KW4>
        <Res_KW5>health education</Res_KW5>
        <Plain_Description>Health Promoting Schools was implemented in a selection of schools in Fiji in 2016 to improve long term health and well-being by addressing lifestyle-related risk factors. This Australia-Fiji collaboration will assess the lessons from that initial rollout, co-design with communities the next phase to 200 schools, and then assess effectiveness, investment case and sustainability. The findings will ensure the potential for sustainable health and social benefits from the program are realised.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018718</APP_ID>
        <Date_Announced>2023-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Helena Teede</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Advancing Women in Healthcare Leadership- Implementation research </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,494,778.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>implementation </Res_KW1>
        <Res_KW2>health services research </Res_KW2>
        <Res_KW3>gender </Res_KW3>
        <Res_KW4>health systems </Res_KW4>
        <Res_KW5>organisational processes </Res_KW5>
        <Plain_Description>Women comprise 75% of the healthcare workforce, yet are highly under-represented in leadership, impacting equity and health outcomes. With unprecedented partnership, we have generated evidence on effective organisational interventions to advance women in healthcare leadership. Here we aim to address partner priorities with implementation research on evidence-based organisational interventions, generating an implementation toolkit for scale to advance leadership equity and improve healthcare.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022546</APP_ID>
        <Date_Announced>2023-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Fiona Coyer</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Eliminating harm from devices across the life span in critical illness: The DEFENCE study.</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,499,947.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | acute care | health sciences | health services and systems | patient safety | </Fields_of_Research>
        <Res_KW1>nursing care </Res_KW1>
        <Res_KW2>early prevention </Res_KW2>
        <Res_KW3>pressure ulcers </Res_KW3>
        <Res_KW4>critical care </Res_KW4>
        <Res_KW5>evidence-based clinical practice </Res_KW5>
        <Plain_Description>Therapeutic monitoring devices are essential to guide clinical care in all intensive care units. Skin injury (harm) from devices is a constant threat. This study aims to eliminate device-related patient harm. Working with our partners we will co-develop implementation strategies to guide local execution of evidence-based practices and then test and evaluate these in critically ill patients of all ages. Our disseminated results will advance practice, and improve patient safety and outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023359</APP_ID>
        <Date_Announced>2023-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Robyn A Clark</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>safe@home: effectiveness and cost effectiveness of telemonitoring and virtual care supported by primary care for people living with chronic disease in low socioeconomic neighbourhoods for reducing ambulance ramping, readmission and GP clinic block. </Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,096,999.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>readmission rates </Res_KW1>
        <Res_KW2>chronic diseases </Res_KW2>
        <Res_KW3>economic analysis </Res_KW3>
        <Res_KW4>primary care </Res_KW4>
        <Res_KW5>telementoring </Res_KW5>
        <Plain_Description>This project will contribute to a substantial breakthrough in the care of patients with chronic conditions living in low socioeconomic neighbourhoods. Safe@home model of care will directly address barriers to access and health inequalities. Through augmenting the opportunities for care provision at home and integration with the primary and secondary care, the model of care has the potential to reduce health care utilisation of hospitals and EDs and improve survivorship and quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023737</APP_ID>
        <Date_Announced>2023-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Bell</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Systems Thinking with Active Implementation Research (STAIR) to prevent childhood obesity: an effectiveness-implementation trial</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,406,917.90</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>overweight/obesity </Res_KW1>
        <Res_KW2>implementation </Res_KW2>
        <Res_KW3>primary school-aged children </Res_KW3>
        <Res_KW4>social determinants of health </Res_KW4>
        <Res_KW5>preventive health </Res_KW5>
        <Plain_Description>Society asks a lot of schools, including that they protect children's health and wellbeing. This trial will work out the best way of supporting schools, teachers and school communities to create and sustain school environments that protect children's physical and mental health. We will measure the impact and return on investment of this support on children's health and education outcomes as well as on the schools themselves.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023842</APP_ID>
        <Date_Announced>2023-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Mario Alvarez-Jimenez</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>EValuating the Impact Of DigitaLly Enhancing Australian Youth Mental Health SerVicEs (the EVOLVE project): A Large Scale, Controlled, Process and Economic Evaluation of a Blended Digital Intervention</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,498,289.80</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>mental health services </Res_KW1>
        <Res_KW2>youth </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>clinical psychology </Res_KW4>
        <Res_KW5>economic evaluation </Res_KW5>
        <Plain_Description>The mental health system is overwhelmed and has catastrophically failed to meet the needs of those with mental-ill health. Despite the potential for digital technology to be a pillar of a modern, sustainable, and effective mental health system, digital interventions have not been integrated into mental health services. This aim of this project is to address this global failure by evaluating the real world impact of digitally enhancing a a large network of mental health services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023898</APP_ID>
        <Date_Announced>2023-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Catherine Sherrington</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Quality coaching to implement a hospital fall prevention strategy: intervention development and evaluation in a stepped wedge trial</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$979,506.10</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>falls prevention </Res_KW1>
        <Res_KW2>implementation </Res_KW2>
        <Res_KW3>quality improvement </Res_KW3>
        <Res_KW4>aged health </Res_KW4>
        <Res_KW5>hospitals </Res_KW5>
        <Plain_Description>This project will assess whether the use of a quality coaching approach enhances implementation and effectiveness of falls prevention initiatives in partner Sydney Local Health District (SLHD).     Stage 1 of the project will involve co-design of a quality coaching approach for falls prevention in wards of partner Sydney Local Health District using data from pilot work in our two partner Health Districts.    Stage 2 of the project will involve a stepped wedge trial to test the quality coaching approach.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024551</APP_ID>
        <Date_Announced>2023-07-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Lily Dongxia Xiao</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Cultural Ethnic and Linguistic Diversity in Dementia Research</Sub_Type>
        <Grant_Title>A ‘culturally tailored iSupport model’ for carers of people with dementia</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,555,078.05</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | aged care nursing | health sciences | health services and systems | aged health care | economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>dementia care </Res_KW1>
        <Res_KW2>cultural perceptions </Res_KW2>
        <Res_KW3>health service accessibility </Res_KW3>
        <Res_KW4>translational research </Res_KW4>
        <Res_KW5>health economics </Res_KW5>
        <Plain_Description>Our study aims to co-design and embed a culturally tailored iSupport model in dementia care services and evaluate its effectiveness with stakeholders. The model is designed to enhance culturally and linguistically congruent support for carers and improve their ability to manage dementia at home and relieve pressure on dementia care services. The expected outcomes are improved quality of life and health for carers and people with dementia, improved quality of care and cost-effective care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024575</APP_ID>
        <Date_Announced>2023-07-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Lee-Fay Low</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Cultural Ethnic and Linguistic Diversity in Dementia Research</Sub_Type>
        <Grant_Title>A community based participatory approach to decreasing dementia stigma and increasing help-seeking </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,520,259.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>culturally appropriate methodology </Res_KW1>
        <Res_KW2>ethnic health promotion </Res_KW2>
        <Res_KW3>diagnosis </Res_KW3>
        <Res_KW4>translation </Res_KW4>
        <Res_KW5>social and cultural issues </Res_KW5>
        <Plain_Description>This project brings together multicultural community organisations, public health campaigners, and researchers to decrease stigma and increase help-seeking for dementia diagnosis. We will be working with the Chinese, Vietnamese, Indian and Arabic communities in South Western Sydney. We will co-design and deliver a community-based campaign, and evaluate whether it increases dementia help-seeking, assessment and diagnosis rates in comparison to a non-campaign region.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024768</APP_ID>
        <Date_Announced>2023-07-10T00:00:00</Date_Announced>
        <CIA_Name>Dr Joyce Siette</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Cultural Ethnic and Linguistic Diversity in Dementia Research</Sub_Type>
        <Grant_Title>Transforming inclusive multidomain dementia prevention lifestyle initiatives for culturally and linguistically diverse older Australians</Grant_Title>
        <Admin_Institution>Western Sydney University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$418,433.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>public health impact </Res_KW1>
        <Res_KW2>ethnic health promotion </Res_KW2>
        <Res_KW3>brain ageing </Res_KW3>
        <Res_KW4>healthy ageing </Res_KW4>
        <Res_KW5>health psychology </Res_KW5>
        <Plain_Description>Australia's population is multiculturally and linguistically diverse, with Western Sydney being the epicentre of Australian migration. Yet much research targeting dementia prevention does not address diversity challenges such as cultural and language barriers. This project will run co-designed pop-up brain health campaigns targeting dementia risk reduction awareness for Western Sydney's top three cultural communities (Arabic, Chinese and Vietnamese) to drive dementia risk change.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024751</APP_ID>
        <Date_Announced>2023-07-13T00:00:00</Date_Announced>
        <CIA_Name>Prof Viviana Wuthrich</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Loneliness Social Isolation and Chronic Disease Management</Sub_Type>
        <Grant_Title>Targeting mechanisms underlying loneliness in chronic conditions</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$787,880.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>chronic diseases </Res_KW1>
        <Res_KW2>mental health </Res_KW2>
        <Res_KW3>psychosocial </Res_KW3>
        <Res_KW4>clinical psychology </Res_KW4>
        <Res_KW5>behavioural intervention </Res_KW5>
        <Plain_Description>This project aims to understand the causal psychological mechanisms that underlie the relationship between social isolation, loneliness and poorer outcomes in chronic disease populations. This study will identify the causal factors and then use this information to develop and evaluate a psychological intervention that targets these factors to better treat social isolation and loneliness in a chronic disease population. This project is likely to lead to improved chronic disease management.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024805</APP_ID>
        <Date_Announced>2023-07-13T00:00:00</Date_Announced>
        <CIA_Name>Prof Cathrine Mihalopoulos</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Loneliness Social Isolation and Chronic Disease Management</Sub_Type>
        <Grant_Title>Towards a holistic priority setting approach for chronic disease management to tackle loneliness and social isolation in Australia  </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,703,439.75</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | economics | applied economics | health economics  | health sciences | epidemiology | epidemiological modelling | </Fields_of_Research>
        <Res_KW1>health economics </Res_KW1>
        <Res_KW2>chronic diseases </Res_KW2>
        <Res_KW3>epidemiology </Res_KW3>
        <Res_KW4>mental health </Res_KW4>
        <Res_KW5>population health </Res_KW5>
        <Plain_Description>Loneliness and social isolation are two of the most pressing public health challenges of our society. Our goal is to provide planners with the knowledge and tools to successfully implement acceptable, targeted, equitable and cost-effective strategies for tackling loneliness and social isolation as part of a more holistic approach to chronic disease management in Australia. We will do this via a program of research that involves a diverse team with the consumer and community voice at its core.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024853</APP_ID>
        <Date_Announced>2023-07-13T00:00:00</Date_Announced>
        <CIA_Name>Dr Kate Filia</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Loneliness Social Isolation and Chronic Disease Management</Sub_Type>
        <Grant_Title>SIncere: Developing resources to support Socially INClusivE caRE for mental ill-health  </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,783,246.90</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | health sciences | public health | social determinants of health | </Fields_of_Research>
        <Res_KW1>social determinants of health </Res_KW1>
        <Res_KW2>mental illness </Res_KW2>
        <Res_KW3>psychosocial factors </Res_KW3>
        <Res_KW4>outcome measures </Res_KW4>
        <Res_KW5>clinical practice guidelines </Res_KW5>
        <Plain_Description>Chronic mental disorders are disabling disorders with high rates of social isolation and loneliness. The Social INClusion focusEd caRE (SIncere) project will develop and test the acceptability of much-needed resources to support mental health services to identify and address social exclusion as part of routine mental healthcare. Addressing social exclusion in care will help improve social and clinical outcomes for people with mental disorders, by providing more holistic and personalised care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024872</APP_ID>
        <Date_Announced>2023-07-13T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Kelly</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Loneliness Social Isolation and Chronic Disease Management</Sub_Type>
        <Grant_Title>Groups for Belonging: a parallel cluster randomised controlled trial of a group-based loneliness intervention for people attending treatment for alcohol or substance use disorders</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,290,844.65</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | health psychology | </Fields_of_Research>
        <Res_KW1>substance dependence </Res_KW1>
        <Res_KW2>alcohol dependence </Res_KW2>
        <Res_KW3>health psychology </Res_KW3>
        <Res_KW4>group therapy </Res_KW4>
        <Res_KW5>clinical psychology </Res_KW5>
        <Plain_Description>Loneliness is a significant issue for people accessing drug and alcohol treatment. Re-establishing meaningful social relationships is a core process of recovery. Our team developed Groups for Belonging. It is the first loneliness intervention developed for people accessing alcohol and other drug treatment. We plan to conduct a randomised controlled trial examining the effectiveness of Groups for Belonging for people accessing community-based and residential substance use treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023690</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Dietze</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Determining health needs and outcomes of key populations of people who use drugs</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,967,346.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>drug addiction </Res_KW1>
        <Res_KW2>injecting drug use </Res_KW2>
        <Res_KW3>overdose </Res_KW3>
        <Res_KW4>heroin dependence </Res_KW4>
        <Res_KW5>drug dependence </Res_KW5>
        <Plain_Description>Injecting drug use and methamphetamine smoking are the two forms of drug use linked to the majority of illicit drug related harm in Australia. We will establish a new cohort study to establish how these types of drug use evolve and how interventions such as supervised injecting facilities and drug treatment work to reduce harm. Our findings will inform priority responses to prevent associated drug-related harms in a changing social, health and service delivery environment over the coming decade.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023730</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Dr Jasmine Menant</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Cognitive-motor step training to reduce chemotherapy-induced peripheral neuropathy (CIPN) symptoms in cancer survivors</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$808,942.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | rehabilitation | </Fields_of_Research>
        <Res_KW1>chemotherapy treatment effects </Res_KW1>
        <Res_KW2>peripheral neuropathy </Res_KW2>
        <Res_KW3>cognitive dysfunction </Res_KW3>
        <Res_KW4>exercise therapy </Res_KW4>
        <Res_KW5>balance impairment </Res_KW5>
        <Plain_Description>Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side-effect in many cancers. Our trial will test whether a four-month rehabilitation program targeting balance and cognition, commonly impaired in cancer survivors with CIPN, can reduce symptoms and improve balance and quality of life. This highly scalable intervention  has potential to accelerate access to effective rehabilitation for cancer survivors with CIPN to regain everyday function and live well in remission.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023752</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Andreas Obermair</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ENDO3: A Phase III Randomised Controlled Clinical Trial Comparing Disease-Free Survival of Patients with or without Lymph Node Dissection in clinical stage I Endometrial Cancer (ANZGOG trial #1911/2020)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,158,864.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>lymph node </Res_KW2>
        <Res_KW3>lymphoedema </Res_KW3>
        <Res_KW4>surgical outcomes research </Res_KW4>
        <Res_KW5>endometrial cancer </Res_KW5>
        <Plain_Description>The current treatment for stage I endometrial cancer is surgery– a hysterectomy and a lymph node dissection performed under the one anaesthetic. The benefit for a lymph node dissection has never been established in a randomised trial and patients are concerned this surgery may cause ‘more harm than good’. Our proposed ENDO3 clinical trial will directly address patient concerns regarding this practice and establish the benefits or harms of this surgery to reduce the potential for overtreatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023830</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Tony Butler</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The Ageing in Prison Longitudinal Study (A-PLUS): health and frailty trajectories of older people in prison</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,907,874.25</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cohort study </Res_KW1>
        <Res_KW2>prison population </Res_KW2>
        <Res_KW3>frailty </Res_KW3>
        <Res_KW4>social determinants of health </Res_KW4>
        <Res_KW5>health inequalities </Res_KW5>
        <Plain_Description>Australia's prisoner population is ageing rapidly. Evidence suggests older prisoners experience poorer health outcomes compared to those from the general community, and this has important health, justice and cost implications. This project will produce world-first data regarding the health of older prisoners in Australia and its implications. It will inform strategies and policies to better manage this growing population both in prison and upon release.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023832</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kym Rae</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>First Peoples co-designed cohort to support improved perinatal and early childhood outcomes</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$4,687,885.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander lifecourse | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander midwifery and paediatrics | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | </Fields_of_Research>
        <Res_KW1>longitudinal cohort study </Res_KW1>
        <Res_KW2>aboriginal health </Res_KW2>
        <Res_KW3>aboriginal child </Res_KW3>
        <Res_KW4>parenthood </Res_KW4>
        <Res_KW5>child development </Res_KW5>
        <Plain_Description>This research team will improve the health of mothers and children from First People communities of QLD through a longitudinal study from pregnancy through early childhood. The cohort protocol will be co-designed with First People and undertaken at 6 sites and will examine the strengths and risks to health for both mothers and their infants. Where required, mothers and their infants will referred into culturally designed programs to improve mental health and neurodevelopmental outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023845</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kathy Petoumenos</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Improving the long-term health in people living with HIV: The Respond Study</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$983,939.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>comorbidity </Res_KW2>
        <Res_KW3>prospective cohort study </Res_KW3>
        <Res_KW4>ageing population </Res_KW4>
        <Res_KW5>antiretroviral therapy </Res_KW5>
        <Plain_Description>People with HIV are living longer and now experiencing a number of age-related comorbidities. Several interacting factors contribute to these conditions, including traditional risk factors, HIV infection and long term antiretroviral (ARV) exposure. In the absence of vaccines and cures, treatment with ARVs will be lifelong (for decades). Through the RESPOND study we will investigate the impact of longer-term ARV exposure on the risk of comorbidities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023931</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Dr Giovanni Ferreira</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>DREAM: An adaptive placebo-controlled trial of duloxetine for the treatment of chronic sciatica</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,804,701.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | </Fields_of_Research>
        <Res_KW1>sciatica </Res_KW1>
        <Res_KW2>chronic back pain </Res_KW2>
        <Res_KW3>antidepressants </Res_KW3>
        <Res_KW4>pain management </Res_KW4>
        <Res_KW5>pharmacological intervention </Res_KW5>
        <Plain_Description>Sciatica affects 400,000 Australians every year. Easily available treatments like opioids and pregabalin are not effective. Our team has shown that duloxetine, an antidepressant, may be a promising treatment for chronic sciatica. We propose DREAM - a trial that will use rigorous methods to determine if duloxetine is effective, safe, and cost-effective for people with chronic sciatica. If effective, DREAM will transform how chronic sciatica is treated.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023935</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Fancourt</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Delayed versus early opportunistic pneumococcal conjugate vaccination in severe acute malnutrition in Timor-Leste: a randomised controlled trial (RCT) </Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,427,458.38</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>pneumococcal vaccination </Res_KW1>
        <Res_KW2>malnutrition </Res_KW2>
        <Res_KW3>vaccination immunology </Res_KW3>
        <Res_KW4>pneumonia </Res_KW4>
        <Res_KW5>clinical trial </Res_KW5>
        <Plain_Description>Malnutrition is a global public health problem worsening due to effects of the COVID-19 pandemic. Recovery from malnutrition is often complicated by pneumonia or death. It is critical that malnourished children receive vaccines like the pneumococcal conjugate vaccine (PCV), which prevents pneumonia. But we don’t know when the best time is to vaccinate. This study will answer important questions about when to use PCV in children with severe acute malnutrition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023952</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mark Baker</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The use of scrotal cooling to improve semen quality and pregnancy rates within infertile men</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,164,666.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproduction  | </Fields_of_Research>
        <Res_KW1>sperm function </Res_KW1>
        <Res_KW2>sperm function testing </Res_KW2>
        <Res_KW3>male infertility </Res_KW3>
        <Res_KW4>male reproduction </Res_KW4>
        <Res_KW5>in vitro fertilisation (ivf) </Res_KW5>
        <Plain_Description>Couples in which the man diagnosed with male-factor infertility have very little choice but to attend assisted reproduction centers and go through in vitro fertilisation or intra-cellular sperm injection. These procedures are very "female focused", expensive and there is concerns over the health of the offspring. We will test whether scrotal cooling is a simple, cost effective alternative that may enable men, and ultimate couples, avoid the clinic altogether</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023961</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Mimi Tang</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Identifying a Remission Treatment for Peanut Allergy: head-to-head comparison with an approved peanut allergy treatment</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,552,736.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | allergy | </Fields_of_Research>
        <Res_KW1>food allergy </Res_KW1>
        <Res_KW2>young children </Res_KW2>
        <Res_KW3>patient safety </Res_KW3>
        <Res_KW4>quality of life </Res_KW4>
        <Res_KW5>treatment outcomes </Res_KW5>
        <Plain_Description>In 2020/21, the first peanut allergy treatment, Palforzia (a low dose peanut oral immunotherapy that protects against accidental reactions) was approved overseas. There are no approved treatments that induce remission of peanut allergy. Remission allows children to stop treatment and eat peanut freely. This study tests the effectiveness of Probiotic Peanut Oral Immunotherapy (PPOIT) compared with Palforzia at inducing remission of peanut allergy, which will allow children to live allergy free.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023962</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Mimi Tang</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Does peanut OIT provide greater benefit than allergen avoidance (current standard care) in the real world?</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,633,869.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | allergy | </Fields_of_Research>
        <Res_KW1>food allergy </Res_KW1>
        <Res_KW2>young children </Res_KW2>
        <Res_KW3>patient safety </Res_KW3>
        <Res_KW4>quality of life </Res_KW4>
        <Res_KW5>treatment outcomes </Res_KW5>
        <Plain_Description>There is an urgent unmet need for a safe and effective peanut allergy treatment. Oral immunotherapy (OIT) has been heralded as a promising treatment but experts have questioned whether OIT offers greater benefit than avoidance (current care), due to a lack of long-term data on safety and Quality of Life (QoL) benefit. This study will determine the long-term safety, effectiveness, QoL impact and cost-effectiveness of peanut OIT, to inform national and international practice and policy decisions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023989</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Philip Peyton</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ROCKet Trial completion</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$967,027.05</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | anaesthesiology | </Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>surgery </Res_KW2>
        <Res_KW3>anaesthesia </Res_KW3>
        <Res_KW4>analgesia </Res_KW4>
        <Res_KW5>pain minimisation </Res_KW5>
        <Plain_Description>The ROCKet Trial (NHMRC GNT 1120848, 2017) is a large multicentre trial of the effectiveness of ketamine to reduce the risk of chronic post-surgical pain (CPSP) after major surgery. Trial recruitment has reached 3,200 patiens and involves over 30 hospitals, but has been heavily impacted by the COVID-19 pandemic and healthcare system response, delaying trial completion by 2 year. Further funds are needed to achieve the planned target of 4,884 patients and preserve trial integrity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024015</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Joshua Davis</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ROADMAP trial: RandOmised Arthroplasy infection worlDwide Multidomain Adaptive Platform trial</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$4,744,165.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | clinical sciences | orthopaedics  | </Fields_of_Research>
        <Res_KW1>joint replacement </Res_KW1>
        <Res_KW2>bacterial infection </Res_KW2>
        <Res_KW3>antibiotic therapy </Res_KW3>
        <Res_KW4>orthopaedic surgery </Res_KW4>
        <Res_KW5>arthritis </Res_KW5>
        <Plain_Description>Knee and hip replacement are very common and usually highly effective operations, but unfortunately lead to deep infection in over 3,900 patients per year in Australia. These infections are complicated to treat, usually requiring surgery (either to clean up and retain the artificial joint, or to remove and replace it), combined with long courses of antibiotics. We propose a large randomised trial which will establish the optimal surgical and antibiotic treatment strategies for these infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024018</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Alice Rumbold</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Giving donor milk instead of infant formula in moderate-late preterm infants: the GIFT trial</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,243,377.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>premature infant </Res_KW1>
        <Res_KW2>breast milk </Res_KW2>
        <Res_KW3>infant feeding </Res_KW3>
        <Res_KW4>neonatology </Res_KW4>
        <Res_KW5>randomised controlled trial (rct) </Res_KW5>
        <Plain_Description>Babies born 4 to 6 weeks early (moderate-late preterm) often have trouble feeding. Most will need extra nutrition while breastfeeding is established. Infant formula is regularly used but is often not well tolerated, increasing feeding problems and days spent in hospital. Pasteurised donor human milk (donor milk) may be a better option but has not been studied in these infants. This trial will examine the health and economic impacts of donor milk versus formula in moderate-late preterm infants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024025</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Alicia Jenkins</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Oral fenofibrate therapy to retard Chronic Kidney Disease in Type 2 diabetes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,736,695.64</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>diabetic nephropathy </Res_KW2>
        <Res_KW3>clinical trial </Res_KW3>
        <Res_KW4>clinical patient management </Res_KW4>
        <Res_KW5>randomised controlled trial (rct) </Res_KW5>
        <Plain_Description>Kidney disease is a major cause of illness and death in people with diabetes. A low-cost, well-tolerated drug, fenofibrate, appears to reduce kidney protein leak and protect kidneys from further damage.  This trial, enrolling patients across Australia, New Zealand and Asia (Malaysia, Hong Kong and Vietnam) aims to confirm our preliminary findings as to whether this treatment can delay late-stage kidney failure (which may require dialysis, kidney transplantation or cause death).</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024030</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Dr Lauren Gardner</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A cluster randomised controlled trial of a novel and scalable eHealth intervention to prevent e-cigarette use among adolescents: The OurFutures Vaping Program</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,791,239.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>smoking intervention </Res_KW1>
        <Res_KW2>tobacco control </Res_KW2>
        <Res_KW3>adolescent health </Res_KW3>
        <Res_KW4>school-based intervention </Res_KW4>
        <Res_KW5>prevention </Res_KW5>
        <Plain_Description>The use of electronic-cigarettes (vapes) among adolescents has drastically increased in recent years, making it a public health priority. Effective and scalable prevention approaches are urgently needed to reduce the short- and long-term harms associated with vaping. This study will evaluate the efficacy and cost-effectiveness of the first school-based eHealth preventive intervention targeting e-cigarette use among young Australians; the OurFutures Vaping program.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024039</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof David Tingay</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Beyond bronchopulmonary dysplasia: Defining the early respiratory phenotypes of prematurity to predict long-term respiratory risk</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,179,128.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>premature infant </Res_KW1>
        <Res_KW2>lung injury </Res_KW2>
        <Res_KW3>bronchopulmonary dysplasia </Res_KW3>
        <Res_KW4>lung inflammation </Res_KW4>
        <Res_KW5>lung function assessment </Res_KW5>
        <Plain_Description>Preterm birth can cause life-long lung problems. This project will allow clinicians to provide the right lung protective treatment, at the right time, to the right preterm baby. We will generate the first set of practical repeatable measures to predict the risk of chronic lung problems in preterm babies; empowering clinicians with the information to precisely guide decisions that will improve life-long lung outcomes, and better prepare infants and families for later life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024053</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Susana Nery</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Moxidectin versus ivermectin as mass drug administration for the control of onchocerciasis and other neglected tropical diseases:  A cluster-randomised trial</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,375,687.78</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>tropical disease </Res_KW1>
        <Res_KW2>epidemiology </Res_KW2>
        <Res_KW3>clinical trial </Res_KW3>
        <Res_KW4>helminth infection </Res_KW4>
        <Res_KW5>scabies </Res_KW5>
        <Plain_Description>Moxidectin is a new drug approved to treat river blindness, a disease affecting poor, rural communities in low- and middle- income countries. Clinical trials have shown advantages over existing drugs used in public health programs to control river blindness and other important parasitic diseases. We will conduct a randomized controlled trial in Angola to establish the public health role of moxidectin, and complement the trial with acceptability research and transmission modelling.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024074</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Medland</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The population effectiveness of HIV pre-exposure prophylaxis in elimination of transmission of HIV in gay and bisexual men in Australia.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,226,418.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | epidemiology | disease surveillance | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>population-based </Res_KW2>
        <Res_KW3>cohort study </Res_KW3>
        <Res_KW4>primary prevention </Res_KW4>
        <Res_KW5>effectiveness </Res_KW5>
        <Plain_Description>HIV pre-exposure prophylaxis (PrEP) is a daily tablet highly effective in preventing HIV infection. Despite being subsidised in Australia since 2018 with an initial $A180 million five-year funding commitment, impact on population HIV rates have been disappointing. We will measure PrEP use and HIV diagnoses in more than 100,000 gay and bisexual men, the group most affected by HIV, over a 14 year period, to answer this question: can HIV transmission be eliminated in a population?</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024079</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Dr Sradha Kotwal</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$6,665,773.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>albuminuria </Res_KW2>
        <Res_KW3>evidence-based </Res_KW3>
        <Res_KW4>novel therapeutic agents </Res_KW4>
        <Res_KW5>randomised controlled trial (rct) </Res_KW5>
        <Plain_Description>Chronic kidney disease (CKD) is common and becoming more so, however treatment options are limited. It is associated with kidney failure, heart conditions, disability and early death. This research aims to identify effective drugs to prevent CKD progression in a cost and resource efficient way. A new platform trial model will be used to reach patients globally across multiple stages and time periods. The first drug to be tested is called eplerenone in combination with standard CKD treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024081</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bette Liu</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Post-acute COVID-19 Outcomes Study</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$898,414.30</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | health sciences | health services and systems | primary health care | health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>chronic diseases </Res_KW2>
        <Res_KW3>record linkage </Res_KW3>
        <Res_KW4>epidemiology </Res_KW4>
        <Res_KW5>vaccination </Res_KW5>
        <Plain_Description>This study will follow a cohort of Australians who have had COVID-19 to examine the longer-term effects of COVID-19 on people's health and their use of health services by linking the cohort to their health records over time. This will provide new and important information on what are the long term health consequences of COVID-19 and the impacts our health system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024091</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kamala Ley-Thriemer</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A revised tafenoquine dose to improve radical cure for vivax malaria </Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,929,071.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>malaria therapy </Res_KW2>
        <Res_KW3>antimalarial </Res_KW3>
        <Res_KW4>malaria control </Res_KW4>
        <Res_KW5>public health impact </Res_KW5>
        <Plain_Description>Tafenoquine (TQ) is a new treatment to prevent relapsing malaria. It is given as a single dose, which is a major advantage to the current primaquine treatment which needs to be given over 2 weeks. Recent evidence however suggests that the current recommended fixed dose TQ regimen doesn’t convey adequate efficacy. Our multicentre trial will assess the safety and efficacy of a revised weight-based dosing strategy of TQ. This trial is expected to directly influence global treatment policies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024097</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Zoe McQuilten</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Clonal haematopoiesis of indeterminate potential and ageing-related diseases: the ASPREE-CHIP Extension (ASPREE-CHIP-XT) Study</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,107,081.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | </Fields_of_Research>
        <Res_KW1>cohort study </Res_KW1>
        <Res_KW2>haematological malignancy </Res_KW2>
        <Res_KW3>haematopoiesis </Res_KW3>
        <Res_KW4>cardiovascular disease </Res_KW4>
        <Res_KW5>geriatrics </Res_KW5>
        <Plain_Description>In otherwise healthy individuals, acquired genetic mutations that are normally associated with leukaemia and other blood cancers, can be detected in the blood or bone marrow. The presence of these mutations is more common with increasing age and has been associated with a number of diseases that are common in the elderly. We will study how common this condition is and its consequences for health outcomes within a large clinical trial of otherwise healthy participants aged 70 or older.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024134</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Robert Sanders</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Dexmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (DECIDE)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$4,057,466.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | other health sciences | other health sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cardiac surgery </Res_KW1>
        <Res_KW2>delirium </Res_KW2>
        <Res_KW3>anaesthetics </Res_KW3>
        <Res_KW4>cognition </Res_KW4>
        <Res_KW5>mortality </Res_KW5>
        <Plain_Description>Death, postoperative confusion (delirium) often associated with prolonged stay in hospital and cognitive decline are major concerns for patients undergoing cardiac surgery. Preliminary studies suggest a cheap sedative, dexmedetomidine, may reduce these risks. This triple blind, placebo-controlled, randomised trial of 1100 older participants undergoing heart surgery will determine whether dexmedetomidine increases the number of Days Free of Delirium or Coma and Alive.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024177</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof George Patton</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>CATS: a prospective cohort to guide contemporary responses for youth mental health</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,847,563.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | behavioural epidemiology | </Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>prevention </Res_KW2>
        <Res_KW3>youth </Res_KW3>
        <Res_KW4>adolescent health </Res_KW4>
        <Res_KW5>prospective cohort study </Res_KW5>
        <Plain_Description>Youth mental health problems carry huge health, social and economic consequences across the life-course. Increasing rates of mental disorders in young people have further accelerated across the COVID-19 pandemic, with little evidence that clinical responses are sufficiently effective. This proposal outlines plans to extend an existing prospective cohort as the Child to Adult Transition Study (CATS) to provide guidance for future investments in prevention and early clinical intervention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024198</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Tony Butler</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Understanding mortality among adults and young people in contact with the criminal justice system in New South Wales, Australia: a twenty-year linkage update. </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$863,851.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>prison population </Res_KW1>
        <Res_KW2>mortality </Res_KW2>
        <Res_KW3>aboriginal health </Res_KW3>
        <Res_KW4>health inequalities </Res_KW4>
        <Res_KW5>longitudinal cohort study </Res_KW5>
        <Plain_Description>People interact with the justice system in prisons and the community (e.g. through community supervision, fines, or programs for people living with mental illness or intellectual disability who commit offences). These people tend to have poorer health - and die earlier - than the general population. We will use data from NSW administrative databases to look at when and how people involved with the criminal justice system die, and factors that may contribute, to help prevent future deaths.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024234</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Garvey</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A First Nations Cancer Cohort Study (CanCo)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,431,484.10</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>cancer </Res_KW2>
        <Res_KW3>health services research </Res_KW3>
        <Res_KW4>cancer epidemiology </Res_KW4>
        <Res_KW5>prospective cohort study </Res_KW5>
        <Plain_Description>First Nations Australians are more likely to die from cancer than other Australians, and the mortality gap is widening. CanCo will establish a population-based cohort of First Nations Queenslanders diagnosed with cancer and their caregivers to comprehensively map their cancer care pathways and experiences. CanCo will strengthen data linkage and reporting of cancer stage, treatment, and recurrence to strive for more equitable cancer outcomes for First Nations peoples.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024299</APP_ID>
        <Date_Announced>2023-07-31T00:00:00</Date_Announced>
        <CIA_Name>Prof Jamie Craig</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2022 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A randomised controlled trial in genetically at-risk individuals to determine the efficacy of early laser treatment in preventing glaucomatous vision loss.</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,734,318.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | traditional, complementary and integrative medicine | traditional, complementary and integrative medicine not elsewhere classified | </Fields_of_Research>
        <Res_KW1>primary open angle glaucoma </Res_KW1>
        <Res_KW2>clinical genetics </Res_KW2>
        <Res_KW3>laser </Res_KW3>
        <Res_KW4>randomised controlled trial (rct) </Res_KW4>
        <Res_KW5>disease prevention </Res_KW5>
        <Plain_Description>Glaucoma is the leading cause of irreversible blindness worldwide, and we have recently developed a tool for predicting an individual's risk of developing glaucoma. We will use this tool to identify those at greatest risk of developing glaucoma, and preemptively treat high risk individuals, with the aim of preventing glaucoma blindness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024515</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Alexandra McCarthy</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>The Enhancing Women's Recovery after Cancer Treatment Program (RECENTRE): A values-based implementation and evaluation</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,306,874.08</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>health services research </Res_KW1>
        <Res_KW2>cost-effectiveness </Res_KW2>
        <Res_KW3>rehabilitation </Res_KW3>
        <Res_KW4>gynaecological cancers </Res_KW4>
        <Res_KW5> breast cancer </Res_KW5>
        <Plain_Description>Almost 27000 Australian women are diagnosed with cancers of the breast or reproductive system every year, and many will survive into old age after successful treatment. Survival does not mean women automatically return to good health. They need support to manage the detrimental effects of their cancer experience—support that is scarce in this country. This project tests a cancer recovery program, which aims to ensure women who survive cancer have the same quality of life as their peers.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024539</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anne Marie Thow</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Strengthening policy for healthy and sustainable diets: learning from innovation in practice</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$737,956.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | public health nutrition | human society | policy and administration | public policy | </Fields_of_Research>
        <Res_KW1>nutrition </Res_KW1>
        <Res_KW2>policy analysis </Res_KW2>
        <Res_KW3>public health policy </Res_KW3>
        <Res_KW4>food </Res_KW4>
        <Res_KW5>chronic diseases </Res_KW5>
        <Plain_Description>This project brings together government Partners in Australia and the World Health Organization European Region with leading Australian nutrition policy researchers. We will support better policy making on food systems and nutrition, by studying specific instances where recommended policies have been successfully adopted and implemented. The research will identify strategies to improve food policies across government sectors, to improve outcomes for nutrition and environmental sustainability.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024541</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Ken Butcher</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Integration of Cloud Based Artificial Intelligence Assisted Medical Image and Clinical Data Analysis into Workflows for Regional Stroke Patients (Cloud AI Stroke)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,482,950.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>acute stroke </Res_KW1>
        <Res_KW2>ischaemic stroke </Res_KW2>
        <Res_KW3>artificial intelligence </Res_KW3>
        <Res_KW4>intracerebral haemorrhage </Res_KW4>
        <Res_KW5>computer-assisted diagnosis </Res_KW5>
        <Plain_Description>Regional Australians are more likely to suffer a stroke and have worse outcomes than those living in urban centres. We have developed a clinical program known as Telestroke that narrows this gap by bringing specialists, patients and brain scans together virtually using 'cloud' computing. We will use cloud based Artificial Intelligence to improve stroke diagnosis, find the causes of stroke and predict outcomes as well as response to therapy in Telestroke patients as they are being assessed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024549</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Prof David Hunter</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Osteoarthritis management: Face to face versus remote care</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,370,877.17</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>knee osteoarthritis </Res_KW1>
        <Res_KW2>chronic diseases </Res_KW2>
        <Res_KW3>health services research </Res_KW3>
        <Res_KW4>clinical trial </Res_KW4>
        <Res_KW5>osteoarthritis </Res_KW5>
        <Plain_Description>We will compare two evidence-informed approaches to enhancing best-practice management of knee osteoarthritis. This trial will compare the effectiveness of a telehealth approach with optimal face-to-face treatment, to gather evidence of the relative costs and benefits of implementing these models. The trial will provide valuable information for policymakers and service providers on how to optimally configure clinical services for knee osteoarthritis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024579</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Prof John Kaldor</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Infectious pathogens and associated risk factors in blood donors: protecting the blood supply while providing a window into the wider community</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,496,854.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>blood transfusion </Res_KW1>
        <Res_KW2>infectious diseases </Res_KW2>
        <Res_KW3>risk prediction </Res_KW3>
        <Res_KW4>population health </Res_KW4>
        <Res_KW5>surveillance </Res_KW5>
        <Plain_Description>Australia Red Cross Lifeblood, the Kirby Institute, University of Queensland, and the National Centre for Immunisation Research and Surveillance will partner to conduct research to answer pertinent questions about community understandings, attitudes and risk factors related to blood donation; predict and evaluate the impact of changes in policy aimed at protection against infectious pathogens; and design population surveillance strategies to monitor emerging and re-emerging infectious pathogens</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024607</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jennifer Koplin</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Pasteurised donor human milk supplementation for term babies</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,126,309.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | nutrition and dietetics | nutrition and dietetics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>breast milk </Res_KW1>
        <Res_KW2>infant feeding </Res_KW2>
        <Res_KW3>maternal mental health </Res_KW3>
        <Res_KW4>breastfeeding </Res_KW4>
        <Res_KW5>food allergy </Res_KW5>
        <Plain_Description>Breastmilk is the ideal source of nutrition for infants. However, many term-born infants do not have access to sufficient maternal breast milk in the first days of life. This research program will assess the use of pasteurised donor human milk as an alternative to infant formula in term-born infants requiring additional nutritional supplementation in hospital to determine whether this practice should be adopted in Australian hospitals to improve maternal and infant health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024766</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Dianne Shanley</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>The Tracking Cube: Improving Health Equity by Screening for fetal alcohol spectrum disorder (FASD) in primary healthcare</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,499,291.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | health sciences | health services and systems | implementation science and evaluation | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | </Fields_of_Research>
        <Res_KW1>primary care </Res_KW1>
        <Res_KW2>child development </Res_KW2>
        <Res_KW3>fetal alcohol syndrome </Res_KW3>
        <Res_KW4>aboriginal health </Res_KW4>
        <Res_KW5>clinical psychology </Res_KW5>
        <Plain_Description>We worked with a remote Indigenous community to co-create how local doctors screen and support children at risk of Fetal Alcohol Spectrum Disorder. The approach worked, and local children are now 4.5 times more likely to be identified and supported. This project will use rigorous methods to examine whether the same approach works at different Indigenous health services nationwide. This will provide a roadmap for future services and help families receive quality, local healthcare close to home.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024770</APP_ID>
        <Date_Announced>2023-08-21T00:00:00</Date_Announced>
        <CIA_Name>Dr Benjamin Bavinton</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Implementation science to guide the effective introduction of long-acting injectable HIV pre-exposure prophylaxis (PrEP) in Australia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,499,911.22</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>primary prevention </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>evaluation </Res_KW4>
        <Res_KW5>prophylaxis </Res_KW5>
        <Plain_Description>Australia has committed to the goal of eliminating HIV transmission. HIV pre-exposure prophylaxis (PrEP; when people take antiretroviral drugs to prevent HIV infection) is almost 100% effective but gaps in scale-up remain. Long-acting injectable Cabotegravir (CAB-LA) is a new, proven form of PrEP. Implementation science research is needed to determine how best to implement it. We will conduct an implementation trial of 900 patients and 24 clinic staff at 6 clinical sites in 3 Australian states.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024589</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Alice Rumbold</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Optimising human milk nutrition to improve the long-term health of preterm infants</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>premature birth </Res_KW1>
        <Res_KW2>neonatal </Res_KW2>
        <Res_KW3>breastfeeding </Res_KW3>
        <Res_KW4>breast milk </Res_KW4>
        <Res_KW5>infant development </Res_KW5>
        <Plain_Description>Improving breastfeeding in children born premature will have lasting impacts on their long-term health and development. Our program of research involves working with families and health care providers to understand why breastfeeding rates are lower in premature infants than full term infants, to improve breastfeeding support after birth, to optimise the use of donor human milk, and to develop new nutritional interventions that harness the unique components of human milk.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024601</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Franz Babl</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Paediatric Emergency Medicine</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | emergency medicine | </Fields_of_Research>
        <Res_KW1>paediatric </Res_KW1>
        <Res_KW2>clinical trial </Res_KW2>
        <Res_KW3>emergency medicine </Res_KW3>
        <Res_KW4>multicentre </Res_KW4>
        <Res_KW5>implementation </Res_KW5>
        <Plain_Description>Building on prior research, this CRE will address evidence gaps in high frequency and high severity emergency conditions in children - sepsis, asthma, bronchiolitis, pneumonia and intubation. The program will develop and incorporate advanced research methods into the Australian and New Zealand paediatric emergency research network, improve efficiency of clinical translation and develop future leaders in paediatric emergency medicine by funding higher degree and postdoctoral opportunities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024602</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Clark</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>The Centre of Research Excellence for Applied Innovations in Oral Cancer</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | otorhinolaryngology | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | biomedical and clinical sciences | medical biotechnology | medical biotechnology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>reconstructive surgery </Res_KW1>
        <Res_KW2>oral </Res_KW2>
        <Res_KW3>bioinformatics </Res_KW3>
        <Res_KW4>targeted therapy </Res_KW4>
        <Res_KW5>tissue engineering </Res_KW5>
        <Plain_Description>Patients with oral cancer have reduced quality of life because curative treatment relies on aggressive surgery.  The Centre of Research Excellence for Applied Innovations in Oral Cancer is using five healthcare strategies (prevention, organ-preserving therapies, innovative reconstructive techniques, more equitable rehabilitation, and monitoring outcomes) across four flagship technology-based research programs to reduce treatment side-effects and improve function in patients with oral cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024615</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Fuller</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Primary Aldosteronism Centre of Excellence (PACE): optimising the diagnosis and management of a common, curable but neglected cause of hypertension</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>aldosterone </Res_KW1>
        <Res_KW2>hypertension </Res_KW2>
        <Res_KW3>cardiovascular disease prevention </Res_KW3>
        <Res_KW4>general practice </Res_KW4>
        <Res_KW5>biochemistry </Res_KW5>
        <Plain_Description>Primary aldosteronism (PA) is a hidden cause of high blood pressure known to cause stroke, irregular heartbeat and heart attack. It is caused by excessive production of aldosterone from the adrenal glands and is potentially curable. Our goal is to find over half a million patients with high blood pressure caused by undiagnosed PA. We will revamp guidelines, develop better tests and train doctors to ensure that every patient in Australia has the opportunity for optimal diagnosis and treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024622</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Freya Fowkes</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>MASTER-MAP: Modern Acceleration STrategies for ERadication of Malaria in the Asia-Pacific</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>surveillance </Res_KW2>
        <Res_KW3>disease prevention </Res_KW3>
        <Res_KW4>antimalarial </Res_KW4>
        <Res_KW5>epidemiology </Res_KW5>
        <Plain_Description>In the Asia-Pacific, more than two billion people are at risk of malaria and progress towards malaria elimination has stalled. A Centre for Research Excellence in Malaria Elimination will develop better ways to 1) detect and target malaria and drug resistance, 2) reduce malaria by preventing infection, and 3) safely treat all infected people with highly effective drugs. Evidence generated will guide malaria elimination policy and accelerate progress towards malaria elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024658</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Caroline Homer</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>ARPAN - Accelerating Research and Progress in maternal And Newborn health: A Centre for Research Excellence to improve maternal and newborn health in the post-COVID-19 pandemic era</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | other health sciences | other health sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>maternal health </Res_KW1>
        <Res_KW2>newborn </Res_KW2>
        <Res_KW3>quality of care </Res_KW3>
        <Res_KW4>stillbirth </Res_KW4>
        <Res_KW5>quality improvement </Res_KW5>
        <Plain_Description>Maternal and newborn health in the Asia Pacific region has suffered during the COVID-19 pandemic. The ARPAN Centre for Research Excellence will accelerate research and progress in maternal and newborn health to recover from COVID-19 disruptions and accelerate progress. We bring together three outstanding research groups from India, Thailand and Papua New Guinea and Australia. This is a unique opportunity to harness strengths across the region to improve outcomes for mothers and babies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024716</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Adrian Cameron</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Food Retail EnvironmentS for Health: Next Generation (RE-FRESHING)</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>public health policy </Res_KW1>
        <Res_KW2>indigenous health </Res_KW2>
        <Res_KW3>diet </Res_KW3>
        <Res_KW4>disease prevention </Res_KW4>
        <Res_KW5>food </Res_KW5>
        <Plain_Description>The Australian retail food environment is dominated by unhealthy foods, resulting in a significant burden from diet-related disease. The Centre of Research Excellence in Food Retail EnvironmentS for Health: Next Generation (“RE-FRESHING”) will drive change in food retail with research addressing: a) policy options for governments; b) accountability mechanisms to incentivise food retailers to adopt healthier practices; and c) ways of working with retailers to create healthy business practices.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024717</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Danielle Mazza</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>SPHERE - The Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | health sciences | public health | public health not elsewhere classified | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>women's health </Res_KW1>
        <Res_KW2>primary care </Res_KW2>
        <Res_KW3>contraception in female </Res_KW3>
        <Res_KW4>abortion </Res_KW4>
        <Res_KW5>consumer preferences </Res_KW5>
        <Plain_Description>Australia’s 6 million women of reproductive age continue to struggle with accessing high quality care to optimise their health prior to pregnancy, prevent unplanned pregnancy or terminate a pregnancy when desired or required. The aim of SPHERE 2.0 is to increase access to high quality, patient-centred sexual and reproductive health care so that women in Australia can achieve bodily autonomy and have the number of children they want when they want them.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024750</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Virginia Wiseman</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Stronger Investments for Infectious Diseases (STRIDE)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>health economics </Res_KW1>
        <Res_KW2>infectious diseases </Res_KW2>
        <Res_KW3>public health policy </Res_KW3>
        <Res_KW4>economic evaluation </Res_KW4>
        <Res_KW5>cost-effectiveness </Res_KW5>
        <Plain_Description>STRIDE will be Australia’s first dynamic hub for applied and policy-relevant research on the economics of infectious disease interventions. STRIDE will provide the framework, enhanced capacity among researchers and policymakers, and robust evidence needed to comprehensively assess the full impacts of infectious disease interventions, placing Australia and countries in the region in a stronger position to optimise substantial future investments in pandemic preparedness at a national level.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024782</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Valsamma Eapen</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in supporting child and family health for priority populations:  Addressing inequity and supporting positive life trajectories through strengths-based tiered access and resources (STAR-CRE)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>developmental outcomes </Res_KW1>
        <Res_KW2>early intervention </Res_KW2>
        <Res_KW3>child development </Res_KW3>
        <Res_KW4> amily health </Res_KW4>
        <Res_KW5>social disadvantage </Res_KW5>
        <Plain_Description>This CRE aims to create a strengths-based tiered access and resources (STAR-CRE) care model in the first 2000 days from pregnancy to start of school. This CRE will pursue four themes: (i) Integrate new knowledge by evidence synthesis and co-designing the STAR framework; (ii) Implement and evaluate tiered care model; (iii) Incorporate learnings via policy and service translation; and (iv) Increase capacity with training on novel strengths-based framework that will shift the way we deliver care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024796</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Jill Newby</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>CORE-DEP: Centre of Research Excellence in Depression Treatment Precision</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>depression </Res_KW1>
        <Res_KW2>psychotherapy </Res_KW2>
        <Res_KW3>clinical psychology </Res_KW3>
        <Res_KW4>health informatics </Res_KW4>
        <Res_KW5>health economics </Res_KW5>
        <Plain_Description>Advances in artificial intelligence and data analytics have made it possible to personalise solutions in a manner like never before. This CRE will bring together diverse perspectives from leading experts in computer science, data analytics, psychology/psychiatry, digital health, and health economics, to tackle the critical question of how advanced data analytics can be harnessed to personalise treatment for depression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024803</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Kim Felmingham</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Boosting Exposure Therapy Through Enhanced Research</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>anxiety disorders </Res_KW1>
        <Res_KW2>posttraumatic stress disorder (ptsd) </Res_KW2>
        <Res_KW3>cognitive behaviour therapy </Res_KW3>
        <Res_KW4>functional magnetic resonance imaging (fmri) </Res_KW4>
        <Res_KW5>clinical trial </Res_KW5>
        <Plain_Description>The BETTER CRE will develop new knowledge leading to better treatment for anxiety-related disorders. Anxiety-related disorders are the most common and costly mental health disorder in Australia: only 50% of patients respond to our gold-standard exposure-therapy. Advances in exposure therapy have stalled due to poor integration of basic science, neuroimaging and clinical research - this CRE brings together leading researchers in these fields to drive innovative research and improved treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024867</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Shuai Li</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence and Expertise in Genetic Epidemiology for Precision Population Health </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>genetic epidemiology </Res_KW1>
        <Res_KW2>population health </Res_KW2>
        <Res_KW3>data linkage </Res_KW3>
        <Res_KW4>family studies </Res_KW4>
        <Res_KW5>interdisciplinary </Res_KW5>
        <Plain_Description>We will utilise our expertise to study how genes and environment combined to influence disease, the causes of diseases and how to better predict disease risk. We will transfer our findings to health policy and practice, and build Australia's capacity in the interdisciplinary field of genetic epidemiology and population health to transform Australia into a worldwide leader in precision population health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024876</APP_ID>
        <Date_Announced>2023-09-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Erica Wood</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>OPTIMAL: OPTimising Immunoglobulin Management in Australia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | health sciences | epidemiology | epidemiological modelling | economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>blood transfusion </Res_KW1>
        <Res_KW2>haematology </Res_KW2>
        <Res_KW3>health economics </Res_KW3>
        <Res_KW4>epidemiology </Res_KW4>
        <Res_KW5>health services research </Res_KW5>
        <Plain_Description>Immunoglobulin products, made from donated plasma, are precious (and costly) national resources. How best to use them for individual patients, and patient preferences on how immunoglobulin therapy is delivered, are not known. We will study how care is currently delivered and provide resources to improve it, by understanding current use and costs, asking people their values and preferences, and designing and introducing clinical guidelines and better models of care to help meet their needs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025098</APP_ID>
        <Date_Announced>2023-09-28T00:00:00</Date_Announced>
        <CIA_Name>Dr Alyssa Milton</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Improving Physical Health of People with a Mental Illness</Sub_Type>
        <Grant_Title>Self-care of Multimorbidity in schizophrenia supported by Peer workers: a Co-designed health Information Technology (SiMPlicITy)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,184,994.45</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health | health sciences | health services and systems | mental health services | </Fields_of_Research>
        <Res_KW1>schizophrenia and related disorders </Res_KW1>
        <Res_KW2>mental health services </Res_KW2>
        <Res_KW3>self-management </Res_KW3>
        <Res_KW4>comorbidity </Res_KW4>
        <Res_KW5>physical health </Res_KW5>
        <Plain_Description>People with schizophrenia are dying 15-20 years younger than the general population due to poorer physical health. This project will address this stark health inequality by working directly with consumers and their supporters to understand barriers and solutions to this problem, then co-design, build and test a world-first peer-supported digital App (SiMPliCITy) that promotes self-care strategies to address the physical health needs of people with schizophrenia using mental health services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025162</APP_ID>
        <Date_Announced>2023-09-28T00:00:00</Date_Announced>
        <CIA_Name>Prof Jackie Curtis</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Improving Physical Health of People with a Mental Illness</Sub_Type>
        <Grant_Title>No-one left behind - Integrated Physical Health Care for People living with Severe Mental Illness</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,996,738.25</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | health sciences | health services and systems | multimorbidity | health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>physical health </Res_KW1>
        <Res_KW2>mental illness </Res_KW2>
        <Res_KW3>primary care </Res_KW3>
        <Res_KW4>metabolic disease </Res_KW4>
        <Res_KW5>cardiovascular disease prevention </Res_KW5>
        <Plain_Description>Our co-produced Integrated Peer-Supported Physical Health Service (IPPHS) is designed so that no-one misses out on holistic, person-centred healthcare by meeting the person wherever they are at in the healthcare system. IPPHS offers support through peer-worker health coaching, General Practitioner/Nurse Practitioner support and mobile phone application. Importantly, IPPHS will facilitate transition to a Medicare-supported General Practitioner in the community for long-term physical health care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025179</APP_ID>
        <Date_Announced>2023-09-28T00:00:00</Date_Announced>
        <CIA_Name>Prof Russell Roberts</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Improving Physical Health of People with a Mental Illness</Sub_Type>
        <Grant_Title>Consumers and carers as Physical Health Care Navigators in rural Australia: A randomised trial</Grant_Title>
        <Admin_Institution>Charles Sturt University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$969,737.52</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | health sciences | health services and systems | multimorbidity | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>mental health services </Res_KW1>
        <Res_KW2>rural and remote health services </Res_KW2>
        <Res_KW3>consumer participation </Res_KW3>
        <Res_KW4>comorbidity </Res_KW4>
        <Res_KW5>access to health care </Res_KW5>
        <Plain_Description>This project has four stages. Stage one investigates the experiences of rural people with severe mental illness and their carers when seeking to access health care, and also  seeks to understand the support rural mental health workers need to provide good care. Stage two uses these findings to inform a co-designed model of physical health care navigation. Stage three tests the effectiveness of this physical health care navigator model of care in rural towns.  Stage four transfers this knowledge.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034415</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Louise Morgan</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$115,290.71</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034160</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Cherry Yu</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$61,766.13</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034161</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Haley Jacobi</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Bond University Limited</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$12,208.07</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034163</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Nadine Barnes</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$58,940.68</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034165</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Christine Hanley</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Central Queensland University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$7,273.73</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034166</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Raja Choudhury</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$23,126.79</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034169</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Hemali Seneviratne</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Charles Darwin University</Admin_Institution>
        <State>NT</State>
        <Sector>University</Sector>
        <Total>$6,289.92</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034170</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Damon Lalich</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$34,514.56</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034171</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Chinmay Arun Sonawane</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$79,516.93</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034172</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Sharon York</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$12,740.93</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034173</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Lucy Sheehan-Hennessy</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$103,921.13</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034175</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Andrea Richardson</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Florey Institute of Neuroscience and Mental Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$18,761.05</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034177</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Lynette Farquhar</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$66,361.65</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034186</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Javier Balanzategui</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$34,998.07</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034188</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Kvansakul</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$58,315.58</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034189</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dorothy Pham</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$71,312.64</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034221</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Jodie Ellis</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$77,136.03</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034222</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Michelle McMurtrie</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$822,293.22</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034223</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Donker</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$159,764.76</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034224</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Kerrie Carr</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Murdoch University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$12,246.33</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034227</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Marcia Fearn</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$8,634.24</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034228</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Katie York</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$29,749.19</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034229</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Jane Holt</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$32,759.86</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034230</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Leanne Sutherland</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$21,858.16</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034231</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Colleen Elso</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$34,125.68</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034233</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dora Horvath</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$13,557.52</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034234</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Marc Campitelli</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$104,223.96</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034236</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Kerry Jenson</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,801.95</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034262</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Emilie Corrick</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$146,223.60</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034263</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Melinda Tooze</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$114,008.81</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034265</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Clare Johnson</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The University of Notre Dame Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$5,760.64</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034283</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Emma Livingstone</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$504,406.60</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034285</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Hayden</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$244,820.96</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034286</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Anne Coco</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$895,326.51</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034287</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Debbie Docherty</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$644,667.82</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034289</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark Geier</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$65,997.08</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034296</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Nicole Makoviney</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$659,265.87</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034298</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Jodie Lamont</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$43,345.27</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034299</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Katherine Waldron</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$44,110.00</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034301</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Fiona Miotti</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$192,626.48</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034302</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Monica Birrento</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$33,161.93</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034303</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Fiona Smith</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Victoria University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$6,766.12</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034304</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Liesel Senn</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2023 Equipment Grant</Grant_Title>
        <Admin_Institution>Western Sydney University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$11,022.84</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2033841</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Cherry Yu</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,736,389.32</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2033842</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Nadine Barnes</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,656,959.37</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2033844</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Gary Richardson</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Cabrini Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$8,947.46</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2033845</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Alysha Cameron</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Cancer Council Victoria</Admin_Institution>
        <State>VIC</State>
        <Sector>Other</Sector>
        <Total>$31,968.63</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2033847</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Anand Gururajan</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Centenary Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$20,540.18</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2033849</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Raja Choudhury</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,147.73</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034019</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Ramona Grimm</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Children's Medical Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$23,253.03</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034020</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Virginia Macdonald</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Family Planning NSW</Admin_Institution>
        <State>NSW</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$8,442.35</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034022</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Andrea Richardson</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Florey Institute of Neuroscience and Mental Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$527,416.59</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034023</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Rosalba Drummond</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Institute for Breathing and Sleep</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$139,255.48</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034025</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Valerie Jakrot</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Melanoma Institute Australia</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$41,650.26</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034030</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Donker</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$4,491,358.09</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034036</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Marcia Fearn</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$242,728.55</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034055</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Stephanie Miller</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>Royal Brisbane and Women's Hospital Foundation</Admin_Institution>
        <State>QLD</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$4,801.48</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034056</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Leanne Sutherland</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$614,483.60</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034059</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Colleen Elso</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$959,352.08</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034062</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Saleela Ruwanpura</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>The Bionics Institute of Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$129,036.72</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034063</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Marc Campitelli</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,929,977.28</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034066</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Sonja Bates</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>The Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$27,026.52</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034067</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Kerry Jenson</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>The George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$191,218.62</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034068</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Michael Frommer</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>The Sax Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$78,396.19</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034069</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Hayden</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,882,485.10</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2034070</APP_ID>
        <Date_Announced>2023-10-26T00:00:00</Date_Announced>
        <CIA_Name>Michelle Critchley</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2023</Grant_Title>
        <Admin_Institution>VCS Foundation Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$91,976.83</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031902</APP_ID>
        <Date_Announced>2023-11-21T00:00:00</Date_Announced>
        <CIA_Name>Asst Prof Luis Pedro Coelho</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 Joint Programming Initiative on Antimicrobial Resistance</Sub_Type>
        <Grant_Title>SEARCHER_AU: Surveillance for Emerging Antimicrobial Resistance through Characterization of the uncharted Environmental Resistome</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$510,187.65</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | microbiology | microbial ecology | </Fields_of_Research>
        <Res_KW1>antibiotic resistance</Res_KW1>
        <Res_KW2>microbiology</Res_KW2>
        <Res_KW3>bioinformatics</Res_KW3>
        <Res_KW4>environmental health</Res_KW4>
        <Res_KW5></Res_KW5>
        <Plain_Description>Antibiotic resistance is a serious threat, risking millions of lives and costing billions in increased healthcare costs. Currently, we cannot detect new forms of resistance, hindering prevention efforts. This project aims to identify emerging resistance in environmental bacteria. By assessing their spread and risks, we can develop a surveillance system to prevent their transmission to disease-causing bacteria. This will help preserve the effectiveness of antibiotics and protect human health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031946</APP_ID>
        <Date_Announced>2023-11-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Steven Djordjevic</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 Joint Programming Initiative on Antimicrobial Resistance</Sub_Type>
        <Grant_Title>“Development of innovative strategies, tools, technologies, and methods for diagnostics and surveillance of antimicrobial resistance (DISTOMOS)”</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,009,665.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | microbiology not elsewhere classified | biological sciences | bioinformatics and computational biology | sequence analysis | </Fields_of_Research>
        <Res_KW1>antimicrobial resistance</Res_KW1>
        <Res_KW2>microbial ecology</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>health surveillance</Res_KW4>
        <Res_KW5>microbial infections</Res_KW5>
        <Plain_Description>There is growing recognition that reducing global AMR requires integrated surveillance of clinically relevant markers however, there is no consensus regarding the markers to target, what exposures are safe, or what technologies are most suitable for monitoring the selected markers. This project will define a suite of genetic markers that best describe AMR status of a targeted location &amp; integrate them into multiplexed platforms using new technologies that do not require cultivation of bacteria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032022</APP_ID>
        <Date_Announced>2023-11-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Anton Peleg</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 Joint Programming Initiative on Antimicrobial Resistance</Sub_Type>
        <Grant_Title>RESERVOIR - EnviRonmEnt and waStEwateR surVeillance in hOspitals for antImicrobial Resistance</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$737,291.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>antimicrobial resistance</Res_KW1>
        <Res_KW2>bacteria</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>cross-infection</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>In order to better understand transmission and acquisition dynamics of AMR pathogens in hospital settings, we will screen patients and water environments for AMR in hospital wards. Teams of experts will develop approaches in four clinical centers from Australia, France, Israel and Switzerland. These settings represent different AMR rates, patient mix and climate, supporting a thorough validation of the surveillance protocols. We will focus on WHO high priority pathogens.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026319</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Golledge</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>AAA-MEDICAL: INTEGRATING SYNERGISTIC EXPERTISE FOR BETTER TREATMENT OF ABDOMINAL AORTIC ANEURYSM</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>abdominal aortic aneurysm </Res_KW1>
        <Res_KW2>aortic aneurysm </Res_KW2>
        <Res_KW3>drug development </Res_KW3>
        <Res_KW4>cohort study </Res_KW4>
        <Res_KW5>cardiovascular disease </Res_KW5>
        <Plain_Description>Twenty million people worldwide (100K Australians) have weakening of their main abdominal artery, known as abdominal aortic aneurysm, which can lead to sudden death or the need for hazardous surgery. Currently the only treatment for this disease is surgery but this has poor durability and safety concerns. Our multidisciplinary team will discover and test new ways to personalise management and treat this problem non-surgically with drugs in an integrated laboratory and clinical research program.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026505</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Christensen</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>Using AI to create smarter, personalised, and scalable interventions for psychological distress</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>clinical psychology </Res_KW1>
        <Res_KW2>behaviour genetics </Res_KW2>
        <Res_KW3>health economics </Res_KW3>
        <Res_KW4>health informatics </Res_KW4>
        <Res_KW5>artificial intelligence </Res_KW5>
        <Plain_Description>Two thirds of people who receive psychological therapy do not benefit. To address this problem, INSPIRE’s Synergy program will harness advances in artificial intelligence, digital mental health, and health economic modelling, to develop new approaches to improving therapy personalisation, appeal, generalisability and scalability. It also aims to deliver new insights into how alternative funding models could be adopted to drive innovation in therapy design and delivery within the health system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026555</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Risbridger</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>An Integrated Approach to CAR-T cell therapy in prostate cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>experimental oncology </Res_KW1>
        <Res_KW2>prostate biology </Res_KW2>
        <Res_KW3>cancer immunotherapy </Res_KW3>
        <Res_KW4>imaging </Res_KW4>
        <Res_KW5>mouse models </Res_KW5>
        <Plain_Description>Prostate cancer is the most comon cancer in Australia and new treatmetns are needed for men with advanced incurable disease.  Immunotherapy (known as Chimeric Antigen Receptor (CAR) T cell therapy) is a new treatment that has worked in blood tumors but is ineffective in prostate cancer.   Our approach will use new ways of making CART cells, a range of models to test them and state of-the-art imaging tools, to bring this therapy to the clinic</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027153</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Darren Gray</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>Ending the neglect – setting the platform for strongyloidiasis elimination in Australia</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified | biomedical and clinical sciences | medical microbiology | medical parasitology  | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </Fields_of_Research>
        <Res_KW1>strongyloidiasis </Res_KW1>
        <Res_KW2>indigenous health </Res_KW2>
        <Res_KW3>community intervention </Res_KW3>
        <Res_KW4>diagnostic techniques </Res_KW4>
        <Res_KW5>disease transmission </Res_KW5>
        <Plain_Description>Strongyloidiasis is a disease caused by a parasitic worm and is the most neglected of the Neglected Tropical Diseases. It is a disease of poverty linked to poor sanitation and hygiene. Infection can be acute and chronic and even fatal. Surprisingly, Strongyloidiasis is endemic in rural and remote parts of Australia and disproportionately affects Indigenous communities. We will utilise a multidisciplinary approach to provide the blueprint for its elimination in Australia</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027315</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Shaun Jackson</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>Developing innovative new treatments for stroke</Grant_Title>
        <Admin_Institution>Heart Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>ischaemic stroke </Res_KW1>
        <Res_KW2>antithrombotic </Res_KW2>
        <Res_KW3>anticoagulants </Res_KW3>
        <Res_KW4>thrombolysis treatment </Res_KW4>
        <Res_KW5>cardiovascular disease </Res_KW5>
        <Plain_Description>Stroke is a leading cause of death/disability worldwide. Identification of novel drugs that can break down blood clots and improve blood flow to the brain would represent a major advance in stroke treatment. We are developing a suite of anticlotting drugs that targets discrete elements of blood clots. These agents have potential to dramatically improve the quality-of-life of 1000's of stroke sufferers in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027459</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Delphine Merino</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>Targeting lethal metastases: finding new targets in the tumour/microenvironment interface</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>clonal diversity </Res_KW1>
        <Res_KW2>microenvironment </Res_KW2>
        <Res_KW3>cancer metastasis </Res_KW3>
        <Res_KW4>cell lineage </Res_KW4>
        <Res_KW5>sequencing </Res_KW5>
        <Plain_Description>While a growing arsenal of anticancer drugs, targeting cancer cells or normal cells such as immune cells, is becoming available, some cancers remain difficult to treat. This is a case of a subset of breast and colorectal cancers, as well as other types of cancer, such as pancreatic cancer. Our team will explore multiple strategies to concurrently target both cancer cells and normal cells, to eradicate the most aggressive form of cancer and therefore, improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027469</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Aletta Schutte</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>Solving Australia's Hypertension Treatment Problem</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | health sciences | health services and systems | implementation science and evaluation | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>hypertension </Res_KW1>
        <Res_KW2>high blood pressure </Res_KW2>
        <Res_KW3>prescribing </Res_KW3>
        <Res_KW4>medication compliance </Res_KW4>
        <Res_KW5>consumer preferences </Res_KW5>
        <Plain_Description>Over 3 million Australians have hypertension, our leading cause of heart attack and stroke. Most do not have their high blood pressure adequately treated, and there has been little progress in the last decade. This grant is to support the new multi- and cross-disciplinary approaches required to solve this important problem. A key focus is the consumer and improving value for money, since of the $1.4 billion dollars spent annually on hypertension treatment, over 20% is out-of-pocket co-payments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027473</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Hodges</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>DISCERN - Disciplinary Integration to Solve the Enigma of Chronic Pain: Evaluating Personalised Care and its Impact with Innovative Clinical Trials and Research in Neurobiology, Psychology and Society</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | biomedical and clinical sciences | neurosciences | peripheral nervous system | health sciences | allied health and rehabilitation science | rehabilitation | </Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>clinical trial </Res_KW2>
        <Res_KW3>pain mechanisms </Res_KW3>
        <Res_KW4>pain assessment </Res_KW4>
        <Res_KW5>pain management </Res_KW5>
        <Plain_Description>Chronic pain has enormous burden, but we don’t know how to match patients with the right treatments. This Synergy brings together diverse experts in musculoskeletal, cancer, visceral and trauma pain to address three major issues. We will refine methods to identify mechanisms explaining pain across conditions, apply discovery research to develop treatments to address mechanisms, and design a game-changing clinical trial to simultaneously test and refine how treatments are matched to patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027475</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Garvey</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>ACHIEVING EQUITY IN CANCER SCREENING FOR FIRST NATIONS PEOPLES</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health equity | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health and wellbeing not elsewhere classified | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>cancer screening </Res_KW2>
        <Res_KW3>health inequalities </Res_KW3>
        <Res_KW4>health services research </Res_KW4>
        <Res_KW5>cancer research </Res_KW5>
        <Plain_Description>The cancer mortality gap between First Nations  and non-Indigenous Australians continues to widen. National cancer screening programs are not meeting the needs of First Nations people.  Achieving long term improvements in cancer disparities is most effective when programs are developed in partnership with Indigenous leadership and communities.  Our aim is to co-design, co-implement and evaluate strategies to achieve equity cancer screening for Australia’s First people.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027497</APP_ID>
        <Date_Announced>2023-11-23T00:00:00</Date_Announced>
        <CIA_Name>Prof Margaret Hellard</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2023 Synergy Grants</Sub_Type>
        <Grant_Title>Achieving the final phases of hepatitis C elimination using innovative models of care.</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | epidemiology | behavioural epidemiology | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>hepatitis c infection </Res_KW1>
        <Res_KW2>community intervention </Res_KW2>
        <Res_KW3>disease modelling </Res_KW3>
        <Res_KW4>treatment strategies </Res_KW4>
        <Res_KW5>diagnostic test </Res_KW5>
        <Plain_Description>Direct acting antivirals have revolutionised hepatitis C (HCV) care with cure rates of over 90%.  Unfortunately many people in Australia and globally are not yet treated, with ~ 290,000 people worldwide dying each year from HCV and ~120,000 Australians yet to be treated.  Over the next 5 years our research program will identify innovative models of care that engage with the people at greatest risk of HCV to ensure no-one misses out on HCV care in Australia and globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030699</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Peter Bell</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Immune Regulation of Lung Injury: Pathways to Repair, Restoration and Fibrosis </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>innate immunity </Res_KW1>
        <Res_KW2>fibrosis</Res_KW2>
        <Res_KW3>respiratory diseases</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>gene transcription</Res_KW5>
        <Plain_Description>Pulmonary fibrosis is a common lethal lung condition without any effective treatment options. In this project we will use cutting-edge genetic techniques to understand how and why some individuals develop fibrosis in the lung. Ultimately, it is hoped that this knowledge can be used to develop drugs that can prevent, halt or even reverse fibrosis in the lung.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030705</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Mrs Victoria-Rae Sinka</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Aboriginal and Torres Strait Islander Health Research</Sub_Type>
        <Grant_Title>Development of a co-produced community-based kidney health promotion program for young Aboriginal people</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$94,474.08</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | health sciences | health services and systems | health services and systems not elsewhere classified | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | </Fields_of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>health promotion</Res_KW2>
        <Res_KW3>chronic diseases</Res_KW3>
        <Res_KW4>kidney disease</Res_KW4>
        <Res_KW5>early prevention</Res_KW5>
        <Plain_Description>Chronic kidney disease (CKD) disproportionally impacts Aboriginal and Torres Strait Islander people. Including onset at a younger age. I aim to partner with the Aboriginal community-controlled health sector to implement results of Antecedents of Renal Disease in Aboriginal Children and Young People (ARDAC study) and empower young people to identify local and culturally-specific, biological, social and systemic determinates of kidney health and set CKD prevention priorities.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030732</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Claire Bavor</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Supporting Choice for Cervical Screening: Implementing HPV self-collection using innovative models of screening in the Australian National Cervical Screening Program </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$96,857.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>cervical screening </Res_KW1>
        <Res_KW2>women's health</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>health systems</Res_KW5>
        <Plain_Description>In Australia's National Cervical Screening Program, all eligible screening participants should be offered the choice of self-collection. Self-collection addresses barriers to screening and there is flexibility in how it can be provided. However, there is limited guidance for health services about this. To bridge this gap, a toolkit for healthcare providers will be developed to facilitate the choice of self-collection in ways that are acceptable for people who under-screen or have never-screened.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030762</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Mawson Wang</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Making the first osteoporotic fracture the last: Evaluating a new integrated Model of osteoporosis management in primary care. </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>osteoporosis </Res_KW1>
        <Res_KW2>fracture</Res_KW2>
        <Res_KW3>secondary prevention</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>fracture risk</Res_KW5>
        <Plain_Description>Osteoporosis is an extremely common condition affecting the strength of bones, and will become more common with an ageing population. Any fracture due to osteoporosis increases the risk of future fractures, leading to associated health and economic burden. Unfortunately, osteoporosis is under-recognised and under-treated by GPs. Our study aims to implement a model which targets and alerts GPs of their patient's fractures and prompts them to investigate and treat osteoporosis more effectively.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030763</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jason Vuong</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Characterisation and treatment of patients with medium sized cerebral vessel occlusions</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>ischaemic stroke </Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>stroke outcome</Res_KW3>
        <Res_KW4>neurological diseases</Res_KW4>
        <Res_KW5>neuroimaging</Res_KW5>
        <Plain_Description>Ischaemic stroke is a leading cause of deaths in Australia. Clot extraction as a treatment option has made large advancements in the past decade for patients with large strokes however it is unclear if the same applies for patients with moderate sized debilitating strokes. This study aims to address the question of clot extraction in patients with moderate sized strokes with a view to improve stroke recovery and reduce disability.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030764</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Danny Con</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Mathematical and computational methods for precision medicine in Acute Severe Ulcerative Colitis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | mathematical sciences | applied mathematics | biological mathematics  | </Fields_of_Research>
        <Res_KW1>ulcerative colitis </Res_KW1>
        <Res_KW2>pharmacokinetics</Res_KW2>
        <Res_KW3>inflammatory bowel disease (ibd)</Res_KW3>
        <Res_KW4>gastroenterology</Res_KW4>
        <Res_KW5>tumour necrosis factor (tnf)</Res_KW5>
        <Plain_Description>Ulcerative colitis is an inflammatory condition affecting the large bowel with potential life-threatening complications. Infliximab is a drug given to high-risk patients who present with a severe flare to reduce the need for emergency surgery to remove the large bowel. To predict outcomes in these patients, this study will use mathematical and computer-based models to describe how infliximab is broken down and affects inflammation, as well as how gut bacteria can be used to predict outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030765</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Myfanwy Graham</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Examining pharmacovigilance and health outcomes with access to unapproved psychoactive medicines </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$102,367.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>human society | policy and administration | health policy | health sciences | public health | public health not elsewhere classified | human society | policy and administration | policy and administration not elsewhere classified | </Fields_of_Research>
        <Res_KW1>psychoactive drugs </Res_KW1>
        <Res_KW2>novel therapeutic agents</Res_KW2>
        <Res_KW3>regulation</Res_KW3>
        <Res_KW4>public health policy</Res_KW4>
        <Res_KW5>patient safety</Res_KW5>
        <Plain_Description>A growing number of medicines are available via special access pathways for prescription, including medicinal cannabis, and psychedelics. Historically, these medicines were used for end-of-life care and other life-threatening conditions in the short term. Now, these medicines are commonly used for long-term mental health and pain conditions. This research project will produce new information on 1) patient safety; 2) patient access and use; and 3) health care professional educational needs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030768</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Zhou</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The role of clinical trials and invasive haemodynamics in optimising outcomes for patients with aortic stenosis </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>cardiology </Res_KW1>
        <Res_KW2>aortic stenosis</Res_KW2>
        <Res_KW3>heart failure</Res_KW3>
        <Res_KW4>cardiovascular physiology</Res_KW4>
        <Res_KW5>heart valve disease</Res_KW5>
        <Plain_Description>Aortic stenosis (AS) is a serious condition where the aortic valve narrows and stiffens. Currently, the only effective treatment is valve replacement. My PhD aims to better understand AS and its relationship to a condition called heart failure with preserved ejection fraction (HFpEF), and will assess whether dapagliflozin, a drug used in HFpEF, also benefits patients with AS. This study will improve our understanding of how AS affects the heart and may lead to development of new treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030786</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Wootton</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Denosumab vs zoledronic acid for the treatment of moderate-to-severe hypercalcaemia: a randomised controlled trial</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>humoral hypercalcaemia of malignancy </Res_KW1>
        <Res_KW2>endocrine disorder</Res_KW2>
        <Res_KW3>calcium</Res_KW3>
        <Res_KW4>cancer care</Res_KW4>
        <Res_KW5>primary hyperparathyroidism</Res_KW5>
        <Plain_Description>High blood calcium levels (hypercalcaemia) are common and can cause severe symptoms and death. Standard treatment includes a drug to prevent calcium release from bones, traditionally zoledronic acid, although this is not always effective and can cause side effects. Denosumab could be more effective and is better tolerated, but has not been formally tested to treat hypercalcaemia. This trial will compare the benefits and risks of denosumab against zoledronic acid in patients with hypercalcaemia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030795</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Richard Kha</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Aboriginal and Torres Strait Islander Health Research</Sub_Type>
        <Grant_Title>Prevalence, risk factors and impact of visual impairment in Australia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$117,302.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | health sciences | epidemiology | major global burdens of disease | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander epidemiology | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>diabetic retinopathy</Res_KW3>
        <Res_KW4>macular degeneration</Res_KW4>
        <Res_KW5>sensory impairment</Res_KW5>
        <Plain_Description>Vision impairment (VI) remains a key health issue today, particularly for Aboriginal and Torres Strait Islander peoples. VI and blindness affect currently affect 840000 people in Australia and this number is expected to exceed 1.04 million by 2030.  My project is a cross-sectional study aiming to examine 1750 Indigenous and 3250 non-Indigenous Australians across 30 nation-wide sites to establish the prevalence, risk factors and impact of VI and major eye diseases among the Australian population.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030805</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Rebecca Wigan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Increasing the reach of syphilis diagnostics and management</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$122,741.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>syphilis </Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>sexually-transmitted infections (sti)</Res_KW3>
        <Res_KW4>diagnosis</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>Syphilis is a worsening but preventable public health issue that disproportionately affects those experiencing disadvantage. These projects aims to improve detection and management of syphilis among these vulnerable populations through a multifaceted approach utilising novel technologies that reduce barriers to testing, treatment and contact tracing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030809</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Eddie Chan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Laboratory detection and clinical significance of the cefazolin inoculum effect for Staphylococcus aureus bloodstream infections</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$121,195.92</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical infection agents (incl. prions) | biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>staphylococcus aureus </Res_KW1>
        <Res_KW2>antimicrobial therapy</Res_KW2>
        <Res_KW3>treatment outcomes</Res_KW3>
        <Res_KW4>clinical microbiology</Res_KW4>
        <Res_KW5>diagnostic</Res_KW5>
        <Plain_Description>Staphylococcus aureus is the leading bacterial cause of global mortality. Studies hypothesise that expression of specific S. aureus strain traits, such as the Cefazolin inoculum effect (CzIE) might impact on the effectiveness of cefazolin antibiotic therapy, and therefore adversely affect clinical outcome. This project aims to establish lab methods to identify S. aureus strains that have the CzIE, better define high inoculum infection states, and to determine the clinical relevance of the CzIE.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030836</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Bindra</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Australian Multiple Endocrine Neoplasia Type 1 Study (AusMEN Study)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | </Fields_of_Research>
        <Res_KW1>endocrinology </Res_KW1>
        <Res_KW2>multiple endocrine neoplasia</Res_KW2>
        <Res_KW3>endocrine tumours</Res_KW3>
        <Res_KW4>endocrine therapy</Res_KW4>
        <Res_KW5>medical genetics</Res_KW5>
        <Plain_Description>Multiple endocrine neoplasia 1 (MEN1) is a genetic condition that results in tumours which lead to premature death in up to 50% of patients. Current guidelines are debated due to a lack of high-quality evidence. This project aims to create a national MEN1 database and use this to evaluate the current health-related quality of life (HRQOL) and optimal screening and management of MEN1-related tumours. Ultimately, we aim to create new guidelines to individualise MEN1 management and improve HRQOL.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030847</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Sanjay Dutta</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>Evaluation of a novel cyclic peptide to protect against myocardial ischaemia reperfusion injury and improve donor heart preservation for heart transplantation</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | </Fields_of_Research>
        <Res_KW1>cardiac transplantation </Res_KW1>
        <Res_KW2>heart transplantation</Res_KW2>
        <Res_KW3>transplant</Res_KW3>
        <Res_KW4>myocardial reperfusion injury</Res_KW4>
        <Res_KW5>heart failure</Res_KW5>
        <Plain_Description>Preserving donor heart health is a challenge during transplants, and improved preservation is needed to meet the growing burden of heart disease.  My project will assess if a new molecule can reduce the injury that occurs to hearts following a period of no blood supply, and improve the function of donor hearts.    We expect with this research we can begin testing this molecule in patients undergoing transplants, improving the function of the heart and increasing the number of transplants performed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030872</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Josipa Petric</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding patient burden and preferences for the management of oesophageal cancer</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$128,982.75</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | rural and remote health services | </Fields_of_Research>
        <Res_KW1>rural and remote health </Res_KW1>
        <Res_KW2>health service accessibility</Res_KW2>
        <Res_KW3>oesophageal cancer</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>surgery</Res_KW5>
        <Plain_Description>Rural and remote communities in Australia often have a lack of access to specialist medical practitioners for sub-specialist surgical services. This project aims to understand patient preferences for delivery of surgical services and of centralisation of surgical services, and to explore the importance of health-related quality of life and cost-effectiveness, in order to help us understand how to best manage oesophageal cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030874</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Arthur Thevathasan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Delivering personalised, adaptive deep brain stimulation for Parkinson’s disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | engineering | biomedical engineering | medical devices | </Fields_of_Research>
        <Res_KW1>parkinson disease </Res_KW1>
        <Res_KW2>evoked response potentials (erp)</Res_KW2>
        <Res_KW3>cortical evoked potentials</Res_KW3>
        <Res_KW4>basal ganglia</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>Parkinson’s disease is a common neurodegenerative disorder with great impact on death and suffering. Deep brain stimulation (DBS) is an effective therapy for managing symptoms. However, it often has unreliable outcomes due to difficulties with manual programming, limited device technology and finite specialist access. We aim to prove that DBS can be improved using brain feedback signals to automatically adjust stimulation to personalise therapy to each patient for improved outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030899</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanna Gong</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Advancing Effective Prevention and Management of the Cardiovascular Complications of Diabetes Using Multinational Big Data and Prospective Studies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>diabetes mellitus </Res_KW1>
        <Res_KW2>diabetic complications</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>cardiovascular disease</Res_KW4>
        <Res_KW5>medications</Res_KW5>
        <Plain_Description>Diabetes affects 1.5 million Australians and cardiovascular complications are a leading cause of death and disability among these patients. We will identify critical risk factors and targets for preventing and treating cardiovascular disease in diabetes. This will be done by examining large, multinational big data and studying inpatients at a major hospital. Our vision is of a healthier Australia where focused interventions limit global morbidity, mortality and healthcare expenditure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030913</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Mr Bradley Menz</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Optimising Breast Cancer Treatment: Unravelling the Influence of Concomitant Medicines and Patient Subgroups through Machine Learning and Big Data</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$88,785.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | health sciences | epidemiology | epidemiological modelling | </Fields_of_Research>
        <Res_KW1>cancer epidemiology </Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>clinical pharmacology</Res_KW4>
        <Res_KW5>disease modelling</Res_KW5>
        <Plain_Description>My research will leverage established arrangements to consolidate high-value data from many major contemporary breast cancer trials. State-of-the-art statistical methods will be employed to analyse the data, providing world-leading insights into the safety of commonly used concomitant non-cancer medicines in patients with breast cancer, and advanced methodologies for routinely identifying which patients will respond best to specific therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030914</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Imogen Hartley</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Prospective Randomised Controlled Trial of Adult Patients with Perianal Fistulising Crohn’s Disease and Optimised Therapeutic Infliximab Levels (PROACTIVE)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$70,091.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>crohn's disease</Res_KW2>
        <Res_KW3>biological therapy</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>chronic inflammatory disease</Res_KW5>
        <Plain_Description>Perianal fistulising Crohn’s disease is a burdensome and difficult to treat condition. This project aims to assess the current “one size fits all” dosing of the medication infliximab compared it to individualised medication dosing. Individualised dosing is achieved by monitoring drug levels and escalating medication as required to achieve higher levels of the drug. We believe this proactive approach will lead to improved healing of perianal fistulas and patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030921</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Miss Jessica Bellamy</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Lifestyle related diseases &amp; preventative healthcare for people with intellectual disabilities</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$88,785.17</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | sports science and exercise | exercise physiology | health sciences | health services and systems | people with disability | </Fields_of_Research>
        <Res_KW1>intellectual disability </Res_KW1>
        <Res_KW2>lifestyle factors</Res_KW2>
        <Res_KW3>capacity building</Res_KW3>
        <Res_KW4>allied health</Res_KW4>
        <Res_KW5>health care delivery</Res_KW5>
        <Plain_Description>Although people with intellectual disabilities are living longer, they continue to experience health inequities and inequalities which lead to potentially avoidable deaths. Potentially preventable deaths lead the way for policy change. Early detection of modifiable risk factors, with early referral to appropriate preventative health strategies and professionals, could improve the health and quality of life of people with intellectual disabilities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030934</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Miriam Cameron</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Aspiration and Respiratory Muscle Strength in Children</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$128,982.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>aspiration syndrome </Res_KW1>
        <Res_KW2>respiratory muscles</Res_KW2>
        <Res_KW3>lung function</Res_KW3>
        <Res_KW4>paediatric</Res_KW4>
        <Res_KW5>strength training</Res_KW5>
        <Plain_Description>When food or fluid enter the lungs (aspiration), it causes significant damage to the lungs. Children with aspiration are often hospitalised with pneumonia, which cause poor quality of life and stress for families. Children who aspirate may have weaker muscles of breathing. Studies in adults that sought to improve muscle strength are promising but there is no research in children. My PhD aims to look for novel treatments in improving muscle strength, to prevent aspiration and its consequences.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030939</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Samuel Stevens</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Evaluating the time toxicity of cancer treatments in patients with advanced solid-organ malignancy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$128,982.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health care administration  | </Fields_of_Research>
        <Res_KW1>medical oncology </Res_KW1>
        <Res_KW2>metastatic cancer</Res_KW2>
        <Res_KW3>palliative treatment</Res_KW3>
        <Res_KW4>decision making</Res_KW4>
        <Res_KW5>patient preference</Res_KW5>
        <Plain_Description>People being treated for advanced cancer spend a large amount of their survival time receiving cancer treatments, which can affect their ability to do other things that are important to them. My research will measure the time-impact of cancer treatments, how time-in-treatment affects patients and caregivers, and how information about time-in-treatment affects peoples' treatment choices. By understanding time trade-offs, patients can make treatment choices that make the best use of their time.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030942</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Amy Mitchell</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Clinical and Genetic Investigation of Inherited Heart Disease and Sudden Death Families</Grant_Title>
        <Admin_Institution>Centenary Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$122,741.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>cardiovascular disease </Res_KW1>
        <Res_KW2>genetic analysis</Res_KW2>
        <Res_KW3>sudden cardiac death</Res_KW3>
        <Res_KW4>cardiomyopathy</Res_KW4>
        <Res_KW5>arrhythmia</Res_KW5>
        <Plain_Description>This project aims to improve the health outcomes and clinical care of individuals and families with inherited heart disease. We will seek to identify novel underlying genetic causes of sudden unexplained death in young individuals and heart conditions that run in families. We will also look for links between a patient’s genes and their long-term health outcomes to improve our ability to identify individuals at risk of adverse health outcomes and sudden death, to enable preventative intervention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030954</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Asha Jois</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Cellular and molecular profiling to advance precision medicine in paediatric IBD</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>individualising management</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>targeted therapy</Res_KW5>
        <Plain_Description>The cause of inflammatory bowel disease is complex, and we don't understand why some patients have a more complicated disease course including hospital admissions, surgery and cancer risk. We aim to follow patients from diagnosis, and take blood and gut tissue specimens to apply newer technologies to try to understand IBD at the level of the body's individual cells. This will enable a better understanding of the disease itself, and how to target therapies at an individual level.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030958</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Tahnee Bridson</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Biological predictors of clinical, functional, social and cognitive responses to clozapine</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$121,195.92</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>clozapine </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>glutamate</Res_KW3>
        <Res_KW4>treatment-resistant</Res_KW4>
        <Res_KW5>schizophrenia</Res_KW5>
        <Plain_Description>Schizophrenia can be a disabling condition unless effective treatment can be provided. There are a proportion of individuals who do not respond to regular medications and require clozapine, which can have serious side effects. This project aims to identify which patients are more likely to respond to clozapine and have the least chance of side effects. In this way, treatment can be tailored to individuals allowing a personalised approach and improve the futures of all people with schizophrenia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030968</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Yun Phua</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Tissue scaffolds for bony and soft tissue facial reconstruction in patients with congenital craniofacial conditions</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$109,515.67</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | surgery | biomedical and clinical sciences | medical biotechnology | medical biotechnology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cleft lip and palate </Res_KW1>
        <Res_KW2>craniofacial malformations</Res_KW2>
        <Res_KW3>facial deformity</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>tissue engineering</Res_KW5>
        <Plain_Description>Facial birth defects are a significant health issue affecting 1 in 500 Australian children. A new clinical trial based at the Queensland Children’s Hospital has the potential to revolutionise the care of children with facial deformities. Congenital skull deformities and cleft lip are two of the most common facial birth defects. This trial will use 3D printed tissue scaffolds that allow guided bone and soft tissue regeneration, to reconstruct deformities related to these conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030970</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Debjyoti Karmakar</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Exploring novel AI for improving diagnosis in Obstetrics and Gynaecology</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$97,835.42</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | biomedical and clinical sciences | reproductive medicine | reproduction  | </Fields_of_Research>
        <Res_KW1>artificial intelligence </Res_KW1>
        <Res_KW2>obstetrics</Res_KW2>
        <Res_KW3>gynaecology</Res_KW3>
        <Res_KW4>computer-assisted diagnosis</Res_KW4>
        <Res_KW5>diagnostic applications</Res_KW5>
        <Plain_Description>Baby heartbeat monitoring is a critical tool used to prevent stillbirth/brain injury in high-risk pregnancies. The current technology requires bulky sensors and human interpretation. Our collaborative group has developed a new non-invasive abdominal sensor patch that is applied to the pregnant woman’s abdomen. I will develop and use artificial intelligence (AI) techniques to improve the signal collection, interpretation and prediction of bad outcomes, including in preterm and twin pregnancies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030973</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Benjamin Cailes</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Cirrhotic Cardiomyopathy and Improving Cardiovascular Risk Prediction in Patients Undergoing Liver Transplantation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>cardiovascular complications </Res_KW1>
        <Res_KW2>cardiovascular disease prevention</Res_KW2>
        <Res_KW3>echocardiography</Res_KW3>
        <Res_KW4>end-stage liver disease</Res_KW4>
        <Res_KW5>liver transplantation</Res_KW5>
        <Plain_Description>Liver transplantation (LT) offers a cure for Australians with end-stage liver disease. Cardiovascular disease remains a leading cause of death post-LT. This may be due to undetected cardiac dysfunction, termed cirrhotic cardiomyopathy (CCM). We aim to evaluate whether CCM increases the risk of post-transplant cardiac events and whether LT leads to a reversal of CCM. This will allow personalized risk stratification of patients undergoing LT and identify whether therapies could improve outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030979</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Sandy</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Paediatric X-linked Hypophosphataemia in Australia: more than a disease of the growth plate</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$128,982.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | paediatrics | adolescent health | </Fields_of_Research>
        <Res_KW1>bone </Res_KW1>
        <Res_KW2>rickets</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>adolescent health</Res_KW4>
        <Res_KW5>endocrinology</Res_KW5>
        <Plain_Description>XLH (X linked hypophosphataemia) is an inherited disorder of low phosphate that causes impaired bone growth, bone and muscle pain, mobility issues, leg bowing, dental abscesses, premature fusion of skull bones and impaired quality of life and wellbeing. However, there are many aspects of this disease that are poorly understood. This project aims to improve the knowledge of XLH to improve knowledge of this disease to improve management, outcomes and quality of life for individuals with XLH.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031009</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Emma Smith</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Remote Aboriginal Communities Ending Tuberculosis: REACT Co-design of a holistic package of care moving towards elimination</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | epidemiology | disease surveillance | </Fields_of_Research>
        <Res_KW1>tuberculosis </Res_KW1>
        <Res_KW2>indigenous australians</Res_KW2>
        <Res_KW3>remote communities</Res_KW3>
        <Res_KW4>health care delivery</Res_KW4>
        <Res_KW5>latency</Res_KW5>
        <Plain_Description>Tuberculosis (TB) disproportionately affects First Nations Australians, particularly those living in the remote Northern Territory. Working in partnership with community members and clinician-researchers, my PhD will develop, implement and evaluate community-led strategies to assess and improve the current ways in which we diagnose and treat TB. The goal is to close the gap in new TB cases between First Nations and non-Indigenous Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031043</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Beatrice Sim</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>NHMRC postgraduate scholarship</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>infectious diseases </Res_KW1>
        <Res_KW2>immunocompromised</Res_KW2>
        <Res_KW3>viral infection</Res_KW3>
        <Res_KW4>immune response</Res_KW4>
        <Res_KW5>organ transplantation</Res_KW5>
        <Plain_Description>Patients who have decreased immune systems due to cancer or transplantation are at higher risk of rare and difficult-to-diagnose viral infections. Because the organisms that cause these infections are difficult to grow in the lab, there is often a delay to diagnosis - this can result in prolonged hospital stays and delay to correct treatment. This PhD aims to identify and diagnose these patients by characterising key immune responses to these infections for quick prediction and treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031044</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Imants Rubenis</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The Coronary Microcirculation in Heart Failure </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>congestive heart failure </Res_KW1>
        <Res_KW2>cardiomyopathy</Res_KW2>
        <Res_KW3>microcirculation</Res_KW3>
        <Res_KW4>cardiovascular physiology</Res_KW4>
        <Res_KW5>echocardiography</Res_KW5>
        <Plain_Description>Heart failure is a common and severe health condition. It affects more than 450000 people Australia-wide, and results in more than 170000 hospital admissions per year. Up to 40% of patients with heart failure die within four years of diagnosis. Recent research has been largely focused on treatment, as opposed to fundamental understanding of the disease. We aim to map the baseline abnormalities present in a patient with heart failure, and to identify patients at risk of adverse health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031045</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Amelia Fernandes</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Optimising Preconception Health In Women With Overweight And Obesity</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>overweight/obesity </Res_KW1>
        <Res_KW2>fertility</Res_KW2>
        <Res_KW3>antenatal care</Res_KW3>
        <Res_KW4>metabolic disease</Res_KW4>
        <Res_KW5>polycystic ovarian syndrome (pcos)</Res_KW5>
        <Plain_Description>Almost half of all Australian women entering pregnancy have overweight or obesity. This directly affects fertility and can lead to serious consequences during or after pregnancy.    Ultimately, I aim to improve the preconception health of women with overweight or obesity. The study aims to identify lifestyle factors, metabolic profiles and subgroups of women who benefit most from a weight loss program prior to pregnancy and evaluate the impact on their fertility and pregnancy.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031096</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Priya Garg</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Infection prevention and surveillance in Australian cancer and transplant populations</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>immunocompromised </Res_KW1>
        <Res_KW2>infection</Res_KW2>
        <Res_KW3>infection control</Res_KW3>
        <Res_KW4>cancer</Res_KW4>
        <Res_KW5>transplant</Res_KW5>
        <Plain_Description>Transplant recipients and cancer patients are at a greater risk of infection compared to the general population. Opportunistic and healthcare associated infections (OIs/HAIs) increase the chance of critical illness or death. This project will explore the epidemiology of OIs/HAIs in this cohort through a systematic review, point prevalence study and coordination of expert opinion to inform national control guidelines and create key performance indicators for surveillance and infection control.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031119</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Paolo D'Ambrosio</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Intensive Endurance Exercise and Cardiac Arrhythmias </Grant_Title>
        <Admin_Institution>Melbourne Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$109,515.67</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | sports medicine | </Fields_of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>exercise</Res_KW2>
        <Res_KW3>athlete training programs</Res_KW3>
        <Res_KW4>cardiac arrhythmia</Res_KW4>
        <Res_KW5>cardiac hypertrophy</Res_KW5>
        <Plain_Description>Despite the known health benefits of low to moderate intensity exercise, intensive endurance exercise is now recognised as a significant risk factor for cardiac arrhythmias. By analysing a large cohort of endurance athletes of both sexes and across a wide variety of ages (16-80yr), we aim to describe the prevalence and types of arrhythmias associated with intensive endurance exercise as well as how structural, functional and electrical cardiac remodelling predisposes to these arrhythmias.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031128</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Mr Benjamin Johnson</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Learning from the opioid crisis - Preventing the proliferation of prescription stimulant for non-medical use</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$64,738.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | public health | social determinants of health | </Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>harm minimisation</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>stimulant medication</Res_KW4>
        <Res_KW5>addiction prevention</Res_KW5>
        <Plain_Description>Rising prescription rates of stimulant medications have raised concerns over misuse and health risks. However, research has been restricted to university students, leaving other groups underexplored. By utilising social media and interview data, our project aims to capture experiences from a diverse range of individuals, providing a more comprehensive understanding of individuals motives, outcomes and use of prescription stimulants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031138</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jason Ha</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding the contribution of adaptive and innate immunity to RPE/choroidal dysfunction in diabetic retinopathy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$97,835.42</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | biomedical and clinical sciences | medical physiology | cell physiology | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>diabetic retinopathy </Res_KW1>
        <Res_KW2>diabetic complications</Res_KW2>
        <Res_KW3>diabetes</Res_KW3>
        <Res_KW4>retinal disease</Res_KW4>
        <Res_KW5>immunotherapy</Res_KW5>
        <Plain_Description>Certain layers of the retina in the eye are critical in supporting vision, but are damaged by diabetic eye disease. However, the mechanism for this damage, and the role of the immune system in influencing this process are still unclear. We intend to perform animal studies to better understand the structural and immunological differences between diabetic eyes and non-diabetic controls, and assess if a targeted dietary supplementation and immunotherapies can attenuate disease progression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031147</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Yao</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding the long-term cardiovascular consequences of preeclampsia</Grant_Title>
        <Admin_Institution>Melbourne Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>cardiovascular disease prevention </Res_KW1>
        <Res_KW2>pre-eclampsia</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>coronary artery disease</Res_KW4>
        <Res_KW5>heart failure</Res_KW5>
        <Plain_Description>Women who have had preeclampsia (PE) are at increased risk of cardiovascular disease (CVD) including heart attacks and heart failure. No CVD screening programs currently exist in this high-risk group. This study aims to identify   1) Genetics/biomarkers that increase risk of CVD in PE   2) Typical timing of clinical and subclinical CVD after PE.   This will enable development of CVD screening and intervention strategies before it's too late.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031152</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Jeremy Tan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Improving the detection of disease progression in neuroprotective clinical trials using vision home-monitoring.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$117,302.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>neurodegeneration </Res_KW1>
        <Res_KW2>neuroprotection</Res_KW2>
        <Res_KW3>visual fields</Res_KW3>
        <Res_KW4>glaucoma</Res_KW4>
        <Res_KW5>disease progression</Res_KW5>
        <Plain_Description>Glaucoma is a leading cause of irreversible sight loss. Research studies for new glaucoma treatments are expensive and challenging to perform, due to the current difficulty of measuring if the disease has progressed. This study will use home monitoring of visual fields via a portable device and novel analytical methods to measure disease progression in a large international trial setting. If successful, the results may help greatly improve how future glaucoma clinical trials are performed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031158</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Sohaib Virk</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Mapping persistent atrial fibrillation: Identification of amplifier sites responsible for arrhythmia maintenance</Grant_Title>
        <Admin_Institution>Melbourne Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>atrial arrhythmias </Res_KW1>
        <Res_KW2>atrial fibrillation</Res_KW2>
        <Res_KW3>cardiac electrophysiology</Res_KW3>
        <Res_KW4>cardiology</Res_KW4>
        <Res_KW5>cardiovascular disease</Res_KW5>
        <Plain_Description>Atrial fibrillation (AF) is the most common heart rhythm disorder. Catheter ablation (CA) is a minimally invasive procedure used to treat AF and restore normal heart rhythm, but it is not as effective for patients with long-lasting (persistent) AF because the electrical mechanisms driving abnormal heart rhythms in this cohort is unclear. This study will use novel mapping technologies to identify specific areas of the heart that amplify the electrical disturbances underpinning persistent AF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031165</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Krispin Hajkowicz</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Clinical metagenomics for improved pathogen diagnosis, characterisation and genomic epidemiology in hospitalised patients with suspected infection.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$121,195.92</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>medical virology </Res_KW1>
        <Res_KW2>respiratory infection</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>clinical diagnosis</Res_KW4>
        <Res_KW5>molecular epidemiology</Res_KW5>
        <Plain_Description>Many individuals admitted to hospital with a suspected viral infection do not find out the cause. This leads to inappropriate treatments and distress from uncertainty. It also limits our ability to detect new emerging viruses. We will improve diagnosis and detection of new/emerging infectious diseases by optimising a new, powerful laboratory technique called "metagenomics," which finds all of the viruses in a sample The research will enhance the laboratory processes and reporting of results.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031185</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Kim Waters</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Assessing the effectiveness, usability, acceptability, user experience, and preliminary effectiveness of a machine learning chatbot intervention to improve physical activity in older adults</Grant_Title>
        <Admin_Institution>Central Queensland University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$80,797.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | health psychology | health sciences | public health | health promotion | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>older people </Res_KW1>
        <Res_KW2>machine learning</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>physical activity</Res_KW4>
        <Res_KW5>behaviour change</Res_KW5>
        <Plain_Description>The proposed study aims to assess older adults’ engagement, acceptability, and experience of a machine learning-based chatbot intervention to improve physical activity in older adults. A personalised chatbot can be an effective tool providing tailored guidance, support, and motivation to become more active. Overall, the power of a chatbot intervention designed to increase physical activity, could improve health outcomes, reduce healthcare costs, and enhance quality of life of older adults.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031190</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Stephanie Rowe</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Imaging and genetic determinants of the small heart syndrome and its association with heart failure</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$105,622.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>heart failure </Res_KW1>
        <Res_KW2>exercise intolerance</Res_KW2>
        <Res_KW3>polygenic diseases</Res_KW3>
        <Res_KW4>magnetic resonance imaging (mri)</Res_KW4>
        <Res_KW5>echocardiography</Res_KW5>
        <Plain_Description>Emerging evidence suggests that people who are physically inactive and less fit have smaller, stiffer hearts compared to active people. Low fitness is a known risk factor for heart failure and death, but how heart size relates to this is unclear. This research will investigate the link between having a small heart and poor outcomes, as well as how our genetics might alter this risk. This will help develop novel ways to identify people at risk of heart failure who would benefit from prevention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031231</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas D'Elia</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>DELIA PhD RISK STRATIFICATION OF POST INFARCT MALIGNANT ARRYTHMIAS</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>acute myocardial infarction (ami) </Res_KW1>
        <Res_KW2>ventricular tachycardia</Res_KW2>
        <Res_KW3>sudden death</Res_KW3>
        <Res_KW4>coronary artery disease</Res_KW4>
        <Res_KW5>heart failure</Res_KW5>
        <Plain_Description>Many patients suffer from sudden death post heart attack. The main cause is dangerous heart rhythms. Defibrillators are an effective treatment. Working out who needs defibrillators is difficult.     We plan to measure the pressure in the heart arteries at the time of heart attack, and take pictures of the heart with an MRI and electrical traces. We then plan to try and induce bad rhythms in a controlled environment to ascertain how best to predict them and reduce the rate of sudden death.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031240</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Mr James Sotiropoulos</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Evidence synthesis in MOTION: Developing and applying Methods Of next-generation meta-analysis to Trials of Initial Oxygen in preterm Newborns</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$72,767.75</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological methods | biomedical and clinical sciences | paediatrics | neonatology | mathematical sciences | statistics | biostatistics | </Fields_of_Research>
        <Res_KW1>meta-analysis </Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>very preterm birth</Res_KW3>
        <Res_KW4>oxygen therapy</Res_KW4>
        <Res_KW5>evidence-based health care</Res_KW5>
        <Plain_Description>How much oxygen to help babies born early with after birth is unclear. To answer this question, researchers would traditionally bring together results from multiple clinical trials by extracting data from journal articles. This approach is flawed and has not given a clear answer. I will develop and apply emerging ‘next generation’ methods to answer this question, involving the use of full datasets of past studies and new ways of analysis. This will improve the health of vulnerable babies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031260</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Arunima Jain</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Improving diagnosis and management of kidney disease in and beyond pregnancy</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>hypertension</Res_KW2>
        <Res_KW3>pregnancy complications</Res_KW3>
        <Res_KW4>pregnancy outcome</Res_KW4>
        <Res_KW5>pre-eclampsia</Res_KW5>
        <Plain_Description>Women with kidney disease and damage to kidney cells, or kidney injury, during pregnancy have higher risk of serious complications such as heart disease in the future. Despite this, not all women have kidney function tests before or during pregnancy which can lead to missed chances for prevention. Our research aims to better understand and improve methods for detecting kidney disease and injury in pregnancy, in order to reduce short and long-term preventable health issues for mothers and babies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031264</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Melissa Chu</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Unconventional T-Cells: a potential new treatment target in multiple sclerosis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$105,622.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>neuroimmunology </Res_KW1>
        <Res_KW2>multiple sclerosis (ms)</Res_KW2>
        <Res_KW3>t cells</Res_KW3>
        <Res_KW4>immune dysfunction</Res_KW4>
        <Res_KW5>mucosal immunity</Res_KW5>
        <Plain_Description>This project aims to investigate the role of Unconventional T-cells in immune dysfunction in patients with Multiple Sclerosis (MS). By examining unconventional T-cell activation and migration, interactions with other immune cells and potential inciting antigens, this project aims to improve our understanding of MS immunopathology and identify therapeutic targets for treatment, particularly in the areas of progressive disease and disease prevention</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031288</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Stephen Boyle</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Developing more effective Chimeric Antigen Receptor (CAR) T cell therapy for multiple myeloma</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$105,622.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>myeloma </Res_KW1>
        <Res_KW2>t cell immunotherapy</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>t cell receptor</Res_KW4>
        <Res_KW5>intracellular signal transduction</Res_KW5>
        <Plain_Description>Myeloma is an aggressive blood cancer that kills over 1000 Australians every year and which remains incurable.  Chimeric antigen receptor T-cell (CAR-T) therapy involves taking blood from a cancer patient and genetically engineering their own cells in the laboratory so that they can recognise and kill cancer cells.  CAR-T effectiveness in myeloma is unprecedented but there is no access in Australia due to cost. My PhD aim is to develop a novel myeloma CAR-T therapy and use it to treat patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031293</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Paul Kinsella</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>PhD application</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | microbial genetics  | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>medical genomics </Res_KW1>
        <Res_KW2>clinical microbiology</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>drug resistant</Res_KW4>
        <Res_KW5>immunocompromised</Res_KW5>
        <Plain_Description>Advances in medical technology have led to an increase cohort of patients with compromised immune systems who suffer infections with multi-drug resistant organisms (MDROs). This study aims to use whole genome sequencing to better understand these resistant pathogens at a genetic level. By monitoring changes in the individual’s microbiome , we aim to not only identify the presence of MDROs, but to also identify opportunities to prevent MDROs from causing invasive infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031305</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Tomasz Block</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>RNA therapy targeting Connective Tissue Growth Factor in diabetic kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>diabetes </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>diabetic nephropathy</Res_KW3>
        <Res_KW4>proximal kidney tubules</Res_KW4>
        <Res_KW5>antisense oligonucleotides</Res_KW5>
        <Plain_Description>RNA is a revolutionary new tool to treat human diseases, and like RNA vaccination, will rapidly become the standard approach to address new and emerging targets.    RNA therapy has already been used to great effect in difficult-to-treat diseases, like spinomuscular atrophy and elevated Lipoprotein(a).    I will apply this novel RNA technology to target pathways critically involved in kidney scarring, towards new treatments for impaired chronic kidney diseases, including diabetes</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031307</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Grace Currie</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Clinical research for the digital era: embedding analytic technologies to improve health outcomes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$85,389.58</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>electronic health information </Res_KW1>
        <Res_KW2>health systems</Res_KW2>
        <Res_KW3>vaccine-preventable diseases</Res_KW3>
        <Res_KW4>information systems/decision support systems</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>There is increasing need for health systems to develop new digital technologies that use patient data to inform best care. This program of research will design and implement new technologies for health systems that can learn from every patient encounter. In the hospital setting, we will co-design a digital tool to help doctors make better clinical decisions. In primary care, we will design a trial that can run automatically in the background of Australian GP clinic systems.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031331</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Kenneth Cho</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Smart-phone based digital atrial fibrillation care plans for optimising risk factor modification in patients with atrial fibrillation</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>health promotion </Res_KW1>
        <Res_KW2>atrial fibrillation</Res_KW2>
        <Res_KW3>stroke prevention</Res_KW3>
        <Res_KW4>cardiovascular health</Res_KW4>
        <Res_KW5>cardiovascular risk factors</Res_KW5>
        <Plain_Description>For patients with atrial fibrillation (AF), controlling risk factors including blood pressure, diabetes, weight, cholesterol, sleep apnoea and alcohol intake has been shown in large clinical studies to reduce the amount of AF and avoid the need for invasive procedures. This project seeks to develop and clinically validate a smartphone based app to create a digital AF care plan to engage the patient and their doctors to optimise their AF management.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031373</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Eden Andrew</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>‘PEGASUS’ Quantifying PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in a cohort of Paediatric and Adolescent and Young AdultS during treatment for Acute Lymphoblastic LeUkaemia, Lymphoma or proceeding to Bone Marrow TranSplantation </Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacogenomics | biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>pharmacogenomics </Res_KW1>
        <Res_KW2>supportive care</Res_KW2>
        <Res_KW3>survivorship</Res_KW3>
        <Res_KW4>cancer</Res_KW4>
        <Res_KW5>childhood</Res_KW5>
        <Plain_Description>With increased genetic testing we are learning that some people handle drugs differently to how their genetics would predict. This mismatch, termed 'phenoconversion' has not been studied in children with cancer and may impact treatment effectiveness and side effects. Our study aims to understand the incidence and patterns of phenoconversion in children/youth with cancer by investigating the relationship between genotype and and phenotype for three enzymes (CYP3A4, CYP2C19, and CYP2D6).</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031389</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Edwards</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Evaluating the effectiveness of interventions to prevent and manage infectious diseases in Australia </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$132,876.17</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance | </Fields_of_Research>
        <Res_KW1>vaccine-preventable diseases </Res_KW1>
        <Res_KW2>vaccine efficacy</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>antiviral therapy</Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>This research will evaluate how effective vaccines are at preventing hospital admissions and deaths from respiratory diseases. It will also analyse how commonly COVID-19 antivirals have been used to manage COVID-19 and whether the people recommended to receive antivirals actually received them. Data linkage will be used to bring together information on vaccine-preventable diseases, hospitalisations, deaths and COVID-19 antivirals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031401</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Johanna Birrell</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Epidemiology and equity of kidney failure in Australasia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$121,195.92</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | health sciences | public health | health equity | health sciences | health services and systems | multimorbidity | </Fields_of_Research>
        <Res_KW1>clinical epidemiology </Res_KW1>
        <Res_KW2>equity</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>nephrology</Res_KW4>
        <Res_KW5>social determinants of health</Res_KW5>
        <Plain_Description>There is a rising health burden from kidney failure in Australia and New Zealand. However, current health systems may serve some people better than others, creating variation in access to kidney failure treatments and health outcomes for patients. This project will map the impact of factors such as socio-economic status and proximity to health services on kidney failure care across Australasia. The results will provide a foundation for targeted health system improvement.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031419</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Ms Germaine Tan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Finding the right time for rehabilitation to optimise physical activity of people living with cancer</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$122,741.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | allied health and rehabilitation science not elsewhere classified | health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>allied health </Res_KW1>
        <Res_KW2>oncology</Res_KW2>
        <Res_KW3>physiotherapy</Res_KW3>
        <Res_KW4>physical activity</Res_KW4>
        <Res_KW5>rehabilitation services</Res_KW5>
        <Plain_Description>Physical activity enables people living with cancer to combat treatment side effects such as fatigue, improve quality of life and reduce the risk of cancer recurrence. Exercise rehabilitation is now recommended as a way for people to optimise physical activity. However, people struggle to find the right time for rehabilitation and fail to regain premorbid function. My research will determine the right time for people to access rehabilitation in order to survive longer and live better lives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031425</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexander Troelnikov</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Proteo-genomic profiling of antibodies</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$105,622.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </Fields_of_Research>
        <Res_KW1>humoral immunology </Res_KW1>
        <Res_KW2>autoimmune disease</Res_KW2>
        <Res_KW3>immune deficiency</Res_KW3>
        <Res_KW4>antibody</Res_KW4>
        <Res_KW5>immunoglobulin (ig)</Res_KW5>
        <Plain_Description>Antibodies are responsible for both protection from infections and occasionally for autoimmune disease. The breadth and diversity of antibodies arises from the recombination of one of each V, D and J genes in each antibody chain. However, many important antibodies have been found to be highly restricted in their underlying gene usage and there exists great genetic diversity in these genes. How this diversity impacts generation of important antibodies in disease states is the focus of this study.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031436</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucy Haggstrom</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding the Effects of Antibody Drug Conjugates on the Tumour Microenvironment</Grant_Title>
        <Admin_Institution>The Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>antibody cancer therapy </Res_KW1>
        <Res_KW2>breast cancer</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>immune modulation</Res_KW4>
        <Res_KW5>anticancer drug action</Res_KW5>
        <Plain_Description>Antibody drug conjugates (ADCs) are an emerging class of highly effective drugs. This project will explore the effects of an ADC called sacituzumab govitecan on the triple negative breast cancer (TNBC) tumour microenvironment (TME). It will also explore whether administering this drug before or after surgery influences outcomes. Potential novel combination strategies will also be examined in order to improve outcomes for TNBC patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031478</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Nadia Coscini</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The design, implementation, and evaluation of a systematic approach to improving the mental health of parents of children with chronic medical conditions.</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$101,728.83</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>health services </Res_KW1>
        <Res_KW2>maternal mental health</Res_KW2>
        <Res_KW3>men's mental health</Res_KW3>
        <Res_KW4>mental health promotion</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>Parents of children with chronic illness are at risk of poor mental health.  Parents are not usually asked about this in busy hospital clinics.  We will work with parents and clinicians to develop a program to make sure parents are asked about their mental health and given support if they are struggling.  This is an important step in having evidence for how to improve mental health and quality of life for parents and their children in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031486</APP_ID>
        <Date_Announced>2023-12-01T00:00:00</Date_Announced>
        <CIA_Name>Dr Kerry Jewell</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Theranostic Opportunities for Metastatic Castration-Sensitive Prostate Cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$140,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nuclear medicine | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </Fields_of_Research>
        <Res_KW1>androgen independent prostate cancer </Res_KW1>
        <Res_KW2>prostate cancer</Res_KW2>
        <Res_KW3>nuclear medicine</Res_KW3>
        <Res_KW4>positron emission tomography (pet)</Res_KW4>
        <Res_KW5>molecular imaging</Res_KW5>
        <Plain_Description>Recent advances in imaging and targeted treatments using radioactive molecules have improved longevity and quality-of-life for patients with late-stage prostate cancer. This research will investigate whether these interventions can also achieve better outcomes in earlier-stage prostate cancer. An additional focus of this study will examine the impact on regional and remote patients to ensure equality in care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025181</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Anna Ross</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Mitigating the impact of the media on stigmatising attitudes towards people with severe mental illness</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>mental illness</Res_KW1>
        <Res_KW2>attitudes</Res_KW2>
        <Res_KW3>mass media</Res_KW3>
        <Res_KW4>psychosis</Res_KW4>
        <Res_KW5>communications/social research</Res_KW5>
        <Plain_Description>News reports that link mental illness to violence are overrepresented and are among the most stigmatising of portrayals. This world-first research aims to mitigate the impacts of media-driven stigma on people living with severe mental illness. It will test an education intervention with journalism students, trial and evaluate training for media professionals, and assess recent guideline effectiveness. My findings will inform a national implementation strategy for reducing media-based stigma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025205</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Matthew Spittal</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Real-time monitoring of suicide and self-harm clusters</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | injury prevention | </Fields_of_Research>
        <Res_KW1>suicide</Res_KW1>
        <Res_KW2>suicide risk</Res_KW2>
        <Res_KW3>suicide prevention</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>injury prevention</Res_KW5>
        <Plain_Description>Suicide is a major health problem and especially when suicides occur in clusters. Currently, coroners largely rely on community member reports to initiate an investigation into the presence of a cluster. This program will address this substantial gap by developing and implementing a real-time suicide and self-harm cluster monitoring system. Outcomes include a monthly reporting system about clusters to coroners and state health departments so that they can initiate an evidence-informed response.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025210</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Prasanti Kotagiri</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving long term outcomes post kidney transplant through study of the immune receptor repertoire</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$497,224.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>kidney transplantation</Res_KW1>
        <Res_KW2>b cells</Res_KW2>
        <Res_KW3>antibody</Res_KW3>
        <Res_KW4>allograft rejection</Res_KW4>
        <Res_KW5>accommodation</Res_KW5>
        <Plain_Description>Kidney donation is a life changing treatment for patients with kidney disease, drastically improving recipients’ quality of life and survival. Antibodies which are made by B cells can attack the donated kidney causing rejection of the kidney. I wish to study the B cells in patients with and without kidney rejection in more detail than has been done before. I will 1) learn more about how these cells go wrong and make these damaging antibodies and, 2) understand ways the body can avoid this.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025222</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Justine Smith</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Addressing the Greatest Unmet Needs in Uveitis</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>ophthalmology</Res_KW1>
        <Res_KW2>uveitis</Res_KW2>
        <Res_KW3>toxoplasmosis</Res_KW3>
        <Res_KW4>macular disease</Res_KW4>
        <Res_KW5>lymphoma</Res_KW5>
        <Plain_Description>Uveitis is a disease that affects the tissues inside the eye. It may be caused by an infection, inflammation or a cancer. Seven in 10 people who have uveitis experience poor eyesight. The goal of my research is to protect and restore the sight of people with uveitis. Over the next 5 years, my team will work across the laboratory and clinic to address problems in different types of uveitis: Toxoplasma parasite infection, accumulation of fluid in the retina during inflammation, and lymphoma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025225</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Alistair Forrest</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Single-cell and spatial profiling of poor prognosis cancers</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | biological network analysis | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>systems biology</Res_KW1>
        <Res_KW2>cell-cell communication</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>dna sequencing</Res_KW5>
        <Plain_Description>Tumours are mixtures of normal and cancer cells. The types of normal cells present and how they interact with the cancer cells has been shown to be important in treatment response, metastasis and prognosis. Here we will use advanced single cell and spatial methods to measure the cell types present in each tumour and predict which messages they are sending to each other. Ultimately, we hope to identify molecules that could be used to change the mix of cells present and help kill the tumour.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025228</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Muireann Irish</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Enhancing the early and accurate diagnosis of frontotemporal dementia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | cognitive neuroscience | </Fields_of_Research>
        <Res_KW1>frontotemporal dementia</Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>brain imaging</Res_KW3>
        <Res_KW4>cognitive assessment</Res_KW4>
        <Res_KW5>caregiver burden</Res_KW5>
        <Plain_Description>Frontotemporal dementia (FTD) is a devastating disease that strikes in middle age. Misdiagnosis is common, with long lag times between symptom onset and formal diagnosis compared to other forms of dementia.  This program will address this knowledge gap by creating new clinical tools with improved diagnostic precision. Outcomes will transform the early detection of FTD, enabling us to intervene quickly, improve access to support, and decrease the physical and mental health burden of this condition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025240</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Skye McGregor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Generating new knowledge to ensure Australia achieves the goal of elimination of HIV transmission</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance | </Fields_of_Research>
        <Res_KW1>epidemiology</Res_KW1>
        <Res_KW2>sexual health</Res_KW2>
        <Res_KW3>human immunodeficiency virus (hiv)</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>prevention</Res_KW5>
        <Plain_Description>My research will use data linkage to produce a national longitudinal cohort of people living with HIV. This will provide comprehensive information needed to inform and evaluate equitable HIV responses in Australia, strengthened by qualitative research to understand why gaps persist. Findings from the research will support the development of tailored HIV prevention and treatment programs to ensure equitable outcomes for all people living with or at risk of HIV in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025252</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Rosemary Wyber</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Putting an end to rheumatic heart disease: evidence into action</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | general practice | health sciences | epidemiology | environmental epidemiology | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>primary care</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>rheumatic heart disease</Res_KW4>
        <Res_KW5>group a streptococcal disease</Res_KW5>
        <Plain_Description>Strep A infections &amp; subsequent rheumatic heart disease (RHD) disproportionately affect Aboriginal &amp; Torres Strait Islander people, driven by inadequate housing and health access. My research addresses the 3 highest-impact implementation questions to achieve elimination of RHD: Measuring changes in Strep A infection when housing is improved; meaningfully describing RHD severity for patients, health services and researchers; and, accelerating implementation of new drug treatments into use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025266</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Yugeesh Lankadeva</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Targeted therapies to reduce sepsis- and heart surgery-associated brain and kidney injury</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,351,714.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | systems physiology  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>sepsis</Res_KW1>
        <Res_KW2>cardiopulmonary bypass</Res_KW2>
        <Res_KW3>acute renal failure</Res_KW3>
        <Res_KW4>microcirculation</Res_KW4>
        <Res_KW5>neuroinflammation</Res_KW5>
        <Plain_Description>Injury to the brain and kidneys are frequent, life-threatening, unresolved complications arising from sepsis and heart surgery. My research program will advance our knowledge of the disease pathology of sepsis- and heart surgery-associated brain and kidney injury. It will provide the scientific rationale and safety and efficacy data for designing clinical trials of new targeted therapies to improve brain and kidney health outcomes in patients with sepsis and in those undergoing heart surgery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025274</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Mr William Roman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Investigating the transcriptional repair program during muscle reconstruction</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | engineering | biomedical engineering | tissue engineering | </Fields_of_Research>
        <Res_KW1>skeletal muscle</Res_KW1>
        <Res_KW2>gene transcription</Res_KW2>
        <Res_KW3>satellite cells</Res_KW3>
        <Res_KW4>sarcomeric proteins</Res_KW4>
        <Res_KW5>repair</Res_KW5>
        <Plain_Description>Movement is so natural to us that we sometimes omit the incredible biology that is required to crawl out of bed, eat, breath or sprint to catch the bus. But like any mechanical machine, muscle is prone to rip and tear. In this project, we will identify how muscle cells repair the small damages that they endure in every day life and if we can harness these findings to preserve muscle health in exercise, aging and diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025280</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Gething</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Geospatial analytics to transform malaria strategies in Africa</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | health sciences | epidemiology | major global burdens of disease | </Fields_of_Research>
        <Res_KW1>malaria control</Res_KW1>
        <Res_KW2>malaria transmission</Res_KW2>
        <Res_KW3>public health</Res_KW3>
        <Res_KW4>mosquito transmission</Res_KW4>
        <Res_KW5>climate change</Res_KW5>
        <Plain_Description>Malaria is a leading cause of death in Africa. Declining trends since 2005 are now reversing and new strategies are required. I will build on the unique data, analytics and engagement capabilities of my program, the Malaria Atlas Project, to discover why progress has stalled and plan more effective strategies. I will analyze the impact of current tools across the continent, and explore how impact can be maximized by reducing deployment inefficiencies and better responding to climatic influences.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025285</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Patrick McGorry</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>PRECISION PSYCHIATRY: WORKING BACKWARDS TO MOVE FORWARDS: PERSONALISING PROGNOSIS AND TREATMENT FROM THE EARLIEST STAGES OF PSYCHOTIC ILLNESS</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>high risk</Res_KW1>
        <Res_KW2>early psychosis</Res_KW2>
        <Res_KW3>early intervention</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>therapeutics</Res_KW5>
        <Plain_Description>My program is aimed at developing new treatments for young people in the earliest stage of psychotic illness. We urgently need a breakthrough to make “precision psychiatry” a reality and move past “trial and error”. This would mean personalising treatments to individual patients. I am going to do this by turning the traditional research approach on its head, working backwards in people who respond to specific treatments to understand exactly why they have got better.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025289</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Ms Aili Langford</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Deprescribing opioid analgesics in primary care to reduce medication-related harm</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>clinical practice guidelines</Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>opioid analgesia</Res_KW3>
        <Res_KW4>prescribing</Res_KW4>
        <Res_KW5>chronic pain</Res_KW5>
        <Plain_Description>My research aims to reduce medication-related harm caused by opioid analgesics (opioids). This will be achieved by supporting healthcare professionals and people living with chronic pain to safely and effectively reduce or stop opioids that may be causing more harm than benefit. I will work with consumers, healthcare professionals and organisations to ensure my findings are translated into practice to improve the quality of care for Australians taking opioids for chronic pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025294</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Catherine Bell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Driving the transition to high value testing to benefit the health of all</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>diagnostic test</Res_KW1>
        <Res_KW2>early detection</Res_KW2>
        <Res_KW3>evidence-based clinical practice</Res_KW3>
        <Res_KW4>cancer</Res_KW4>
        <Res_KW5>cardiovascular risk</Res_KW5>
        <Plain_Description>Medical tests are done at much higher rates than ever before. This is good if it helps people live longer or better. But the benefits from tests are often much smaller than hoped, and come with possible harms: through false alarms, false reassurance, and detection and treatment of inconsequential disease.  This program of research investigates ways to shift policy and practice to high value testing where the benefits to health outweigh the harms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025305</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Janette Kazenwadel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Characterizing haemogenic endothelial cell potential in the lymphatic vasculature</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | genetics | genome structure and regulation | </Fields_of_Research>
        <Res_KW1>transcription factor</Res_KW1>
        <Res_KW2>lymphatics</Res_KW2>
        <Res_KW3>haematopoiesis</Res_KW3>
        <Res_KW4>endothelial cells</Res_KW4>
        <Res_KW5>progenitor cells</Res_KW5>
        <Plain_Description>Current understanding is that all blood cells are produced from a rare population of stem cells initially arising from the walls of blood vessels during embryonic development. I made a ground-breaking discovery that cells lining lymphatic vessels also have the capacity to produce blood cells. My research will translate this game-changing finding to define how and when lymphatic vessels produce blood. This may prove valuable in situations of  anaemia, infection, immunity and potentially cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025333</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Julia Stone</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>A digital biomarker for circadian medicine: timing is key</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | psychology | biological psychology  | behavioural neuroscience | biomedical and clinical sciences | neurosciences | computational neuroscience (incl. mathematical neuroscience and theoretical neuroscience) | </Fields_of_Research>
        <Res_KW1>sleep disturbance</Res_KW1>
        <Res_KW2>circadian rhythms</Res_KW2>
        <Res_KW3>modelling</Res_KW3>
        <Res_KW4>sleep/wake patterns</Res_KW4>
        <Res_KW5>melatonin</Res_KW5>
        <Plain_Description>Circadian disruption leads to poor health. Measurement of circadian timing in sleep and circadian rhythm disorders is critical for accurate diagnosis and treatments, but these assessments are almost never conducted clinically due to lack of practical methods. My research program will develop a scalable method for digital circadian rhythm assessments using wearable monitors and advanced modelling, that can be used in sleep clinics around the world to improve diagnostic and therapeutic outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025346</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Janani Thillainadesan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Microlearning-Enhanced Education of Junior Doctors to Improve the Care and Outcomes of Hospitalised Older Adults</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$497,224.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | education | curriculum and pedagogy | medicine, nursing and health curriculum and pedagogy | </Fields_of_Research>
        <Res_KW1>geriatrics</Res_KW1>
        <Res_KW2>geriatric assessment</Res_KW2>
        <Res_KW3>acute care</Res_KW3>
        <Res_KW4>medical education</Res_KW4>
        <Res_KW5>health care worker education</Res_KW5>
        <Plain_Description>Older people in hospitals experience worse outcomes because of complications such as confusion and falls. We can prevent these complications in hospital by delivering education to junior doctors, who are key frontline carers. In partnership with clinicians and consumers, this research program will develop, utilise and evaluate innovative education modes to train junior doctors, preparing them for a lifelong career of looking after older patients and leading to safer and more effective care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025348</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Vijayalakshmi Easwar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Neuromarkers of intervention success in children with hearing loss</Grant_Title>
        <Admin_Institution>National Acoustic Laboratories</Admin_Institution>
        <State>NSW</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$1,151,714.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | biomedical and clinical sciences | clinical sciences | otorhinolaryngology | </Fields_of_Research>
        <Res_KW1>audiology</Res_KW1>
        <Res_KW2>hearing aids</Res_KW2>
        <Res_KW3>cochlear implant</Res_KW3>
        <Res_KW4>electroencephalogram (eeg)</Res_KW4>
        <Res_KW5>child</Res_KW5>
        <Plain_Description>Despite exceptional clinical care for infants with hearing loss, their language abilities are not commensurate with their age and cognition. Ensuring and enabling optimal listening through hearing aids as soon as they are fit (~1-2 months of age) is critical. To facilitate such a proactive approach, we will identify novel brain markers of successful listening and develop clinical tests that can help optimise listening experience from the time hearing aids are provided in infancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025349</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Elina Hypponen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Transforming nutritional epidemiology research: A fresh look on diet and brain health</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | nutrigenomics and personalised nutrition | health sciences | epidemiology | epidemiological methods | health sciences | epidemiology | nutritional epidemiology | </Fields_of_Research>
        <Res_KW1>nutrition</Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>disease prevention</Res_KW3>
        <Res_KW4>gene-environment interaction</Res_KW4>
        <Res_KW5>genetic epidemiology</Res_KW5>
        <Plain_Description>Dementia is a devastating disease affecting every aspect of life. There is no effective prevention and due to methodological challenges, evidence for the role of diet is often contradictory. My aim is to improve methods for nutrition research and to discover diet related approaches to reduce the risk of dementia. I will focus on early dementia related changes in the brain, as this can help to stop the disease process before cognitive symptoms have had the time to develop.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025350</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Buck</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing more effective and less toxic treatments for embryonal brain tumours</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$673,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>brain tumours</Res_KW1>
        <Res_KW2>radiation oncology</Res_KW2>
        <Res_KW3>dna damage</Res_KW3>
        <Res_KW4>neuroimaging</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>Childhood brain tumours have poor outcomes, and we desperately need treatments that can increase cure rates and maintain quality of life. This project uses sophisticated mouse models of childhood brain cancer to test new drugs that can make radiotherapy more effective. I will also test the safety of these drugs by measuring the effect on mouse brains and behaviour. This will help us to design clinical trials of safer and more effective treatments for childhood brain cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025357</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Gibson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Future Frontiers in Asthma</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,553,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>asthma</Res_KW1>
        <Res_KW2>airway inflammation</Res_KW2>
        <Res_KW3>asthma management</Res_KW3>
        <Res_KW4>asthma therapy</Res_KW4>
        <Res_KW5>asthma exacerbation</Res_KW5>
        <Plain_Description>This research program will investigate how different types of treatment can achieve the complete removal of asthma symptoms and attacks, called treatment-induced asthma remission. Clinical trials of treatments and their combination, will be used. Possible tests of asthma remission will be characterised. The cost savings of achieving asthma remission will be identified.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025360</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Vilija Jokubaitis</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>What's pregnancy got to do with it? Prevention of disability in people with Multiple Sclerosis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>multiple sclerosis (ms)</Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>disease outcome</Res_KW3>
        <Res_KW4>neuroimmunology</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Pregnancy is a time of disease remission for many women with multiple sclerosis (MS). Women with MS who have children often develop less disability than those who do not. This project will examine the immune and nervous system changes that occur during pregnancy to identify new neuroprotective and immune-based drug targets for MS. For those women who need to remain on MS therapies through pregnancy, we will determine how best to use them to ensure both the health of the mother and her baby.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025362</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Angela Devine</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Economic analyses to optimise malaria control and elimination</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$587,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>economics | applied economics | health economics  | health sciences | epidemiology | disease surveillance | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>malaria</Res_KW2>
        <Res_KW3>economic analysis</Res_KW3>
        <Res_KW4>costs</Res_KW4>
        <Res_KW5>modelling</Res_KW5>
        <Plain_Description>Malaria is a disease of poverty that affects almost 40% of the global population with over 241 million cases each year. Working with partners in Indonesia and Papua New Guinea, my economic models will help national policy makers to select the best combination of tools to reduce the greatest number of malaria cases. My goal is to select policies that will maximise health benefits with the currently available tools and funding, to eliminate malaria as quickly as possible.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025363</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Simpson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>The Nutritional Geometry of Immunity, Obesity and Appetite</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | nutritional science | </Fields_of_Research>
        <Res_KW1>dietary macronutrients</Res_KW1>
        <Res_KW2>infection</Res_KW2>
        <Res_KW3>immune function</Res_KW3>
        <Res_KW4>fibroblast growth factors (fgf)</Res_KW4>
        <Res_KW5>appetite regulation</Res_KW5>
        <Plain_Description>We are urged to eat a healthy, balanced diet. But what does that mean? Balanced with respect to what - and what are the consequences of failing to achieve a balanced diet? The project will study how nutrition impacts upon our responses to infection, immunisation and chronic diseases, and the physiological signals that control these responses. The aim is to provide science-based nutritional information on how individuals and populations can optimize their lives and minimize the impact of diseases</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025371</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Anna Ralph</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Improving health outcomes for First Nations Australians through communicable disease control and culturally safe practice</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,717,732.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>clinical practice guidelines</Res_KW3>
        <Res_KW4>patient/professional communication</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>This program delivers solutions to health system challenges in First Nations healthcare. My research improves diagnosis &amp; management of priority infectious diseases by developing evidence &amp; guidelines to support best practice. This is important but insufficient for good outcomes: care must also be culturally safe. Therefore, my program delivers innovative strategies to train health providers and strengthen First Nations workforce including interpreters, to transform patient experience of care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025376</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Steven Kho</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Understanding the large Plasmodium reservoir in the spleen – a hidden barrier to malaria elimination</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$587,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical parasitology  | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>organ-specific</Res_KW2>
        <Res_KW3>splenectomy</Res_KW3>
        <Res_KW4>parasitology</Res_KW4>
        <Res_KW5>pathophysiology</Res_KW5>
        <Plain_Description>Malaria is a parasitic disease infecting >240 million people and causing >600 thousand deaths annually. I recently discovered that its major infectious reservoir is hidden in the spleen. My research vision is to provide a deep biological understanding of the hidden splenic reservoir in malaria. My research will inform the development of new and improved control strategies for the detection, treatment and prevention of malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025377</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sarah Auburn</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Accelerating Plasmodium vivax malaria elimination with molecular information</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,670,201.45</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>genetic epidemiology</Res_KW2>
        <Res_KW3>malaria drug resistance</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>population genetics</Res_KW5>
        <Plain_Description>Plasmodium vivax parasites form dormant liver stages that awaken weeks to months later causing clinical malaria and confounding surveillance. My program will develop laboratory and data analysis tools that use information on Plasmodium vivax genetics to inform researchers and policy makers on antimalarial treatment efficacy and community transmission.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025379</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Anne Chang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving children’s lung health especially for First Nations children through feasible interventions, complemented by novel discovery science</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,608,931.28</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>aboriginal child</Res_KW1>
        <Res_KW2>chronic suppurative lung disorders</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>bronchiectasis</Res_KW4>
        <Res_KW5>cough</Res_KW5>
        <Plain_Description>As a paediatric respiratory specialist &amp; continuous NHMRC Practitioner Fellow since 2004, I lead 2 research teams (Brisbane &amp; Darwin) in a highly translational program towards improving the lung health of children. My L3 fellowship vision will be achieved through mentorship of juniors &amp; studies that centres on, but are not restricted to, Indigenous children’s lung health. All studies are multi-disciplinary and collaborative, and most extends current NHMRC/MRFF funded trials with novel science.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025412</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacob Lewis</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Human replication fork stalling and implications for new cancer therapeutics</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$661,814.84</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | enzymes | chemical sciences | medicinal and biomolecular chemistry | characterisation of biological macromolecules | </Fields_of_Research>
        <Res_KW1>dna replication</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>dna repair</Res_KW3>
        <Res_KW4>protein biochemistry</Res_KW4>
        <Res_KW5>enzymes</Res_KW5>
        <Plain_Description>The DNA in our cells needs to be copied for the cells to divide and grow. This copying process involves a group of proteins that work together, forming a complex called the replisome. Replisomes can run into obstacles and stall, which can cause errors leading to diseases like cancer. This research program will focus on understanding how human replisomes keep the DNA copying process accurate and how replisome stalling can cause problems leading to human disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025415</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Bellgrove</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Neurobiology of decision making in health and disorder</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,297,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | cognitive neuroscience | </Fields_of_Research>
        <Res_KW1>cognition</Res_KW1>
        <Res_KW2>attention deficit hyperactivity disorder (adhd)</Res_KW2>
        <Res_KW3>decision making</Res_KW3>
        <Res_KW4>electroencephalogram (eeg)</Res_KW4>
        <Res_KW5>attention</Res_KW5>
        <Plain_Description>Decision making is critical to human cognition and frequently impaired in clinical disorders, ADHD. This project will identify the fundamental brain processes governing decision making by conducting studies across healthy humans, non-human primates and patients with ADHD. It will identify the critical brain networks that allow organisms to efficiently make decisions and the chemicals which modulate these networks. Knowledge gained will inform treatment of clinical disorders of decision making.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025437</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Catherine Chamberlain</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Strengthening foundations for Closing the Gap</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | health sciences | health services and systems | implementation science and evaluation | health sciences | midwifery | psychosocial aspects of childbirth and perinatal mental health | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>social and cultural issues</Res_KW2>
        <Res_KW3>family health</Res_KW3>
        <Res_KW4>perinatal</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>This proposal to strengthen foundations for Closing the Gap in health outcomes between Aboriginal and Torres Strait Islander peoples and other Australians, has two major streams: (1) supporting families to transform cycles of intergenerational trauma to that of nurturing and recovery in the first 2000 days; and (2) establishing an international community-controlled health research journal to build the Indigenous-led evidence base to inform acceptable and effective policy, programs and research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025441</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Linda Dalic</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Optimising patient outcomes from epilepsy neuromodulation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>intractable epilepsy syndromes</Res_KW1>
        <Res_KW2>neuromodulation</Res_KW2>
        <Res_KW3>epilepsy</Res_KW3>
        <Res_KW4>generalised seizures</Res_KW4>
        <Res_KW5>epilepsy surgery</Res_KW5>
        <Plain_Description>There is an urgent need to improve the health outcomes &amp; life trajectory for people with uncontrolled seizures, and to reduce the economic burden on our health system. Neuromodulation with deep brain stimulation (DBS) can benefit people struggling with the impacts of epilepsy. My program will focus on improving DBS settings, investigating long-term effects, and understanding how the treatment works, accelerating clinical translation to improve outcomes for people living with epilepsy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025442</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jiayan Liao</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Biomarker MicroRNAs Profiling for Early Cancer Detection</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomaterials  | </Fields_of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>microrna</Res_KW2>
        <Res_KW3>targeting</Res_KW3>
        <Res_KW4>molecular imaging</Res_KW4>
        <Res_KW5>biochemistry</Res_KW5>
        <Plain_Description>I will detect a way to detect markers for cancer through advances in nanotechnology, artificial intelligence algorithms, and optical engineering. I propose to develop a device that can effectively profile and rapidly detect molecules called microRNAs that are expressed as a result of many diseases. This program focuses on mesothelioma in particular. My approach is expected to be faster than traditional PCR diagnosis and more sensitive and reliable for detecting microRNAs that are similar.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025445</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Tanya Golubchik</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Expanding the field of view: from pathogen-centric to syndromic genomics</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | health sciences | epidemiology | disease surveillance | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>infection</Res_KW1>
        <Res_KW2>blood-borne communicable diseases</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>diagnostic techniques</Res_KW5>
        <Plain_Description>How are pathogens evolving in the era of climate change and post-pandemic immunity shifts? This program addresses a critical need for improved multi-pathogen surveillance. Combining state-of-the-art genomics methods with new computational tools, it will analyse key cohorts and develop a framework for gathering genetic data from many co-circulating pathogens at once, quickly and cheaply enough to provide insights for clinical and public health applications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025453</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mary Ann Anderson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Optimizing the Potential of BH3 Mimetics in B Cell Malignancy</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,293,095.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>apoptosis</Res_KW1>
        <Res_KW2>resistance</Res_KW2>
        <Res_KW3>genetics</Res_KW3>
        <Res_KW4>therapy</Res_KW4>
        <Res_KW5>blood</Res_KW5>
        <Plain_Description>Non-chemotherapy-based approaches to treating blood cancer have advantages in terms of toxicity and efficacy. There has been significant progress most notably with BH3 mimetics of which venetoclax is an example with regulatory approval worldwide. Despite this success many diseases either fail to respond or respond and then become refractory. I plan to understand the reasons why blood cancer may be refractory to venetoclax and to use this to develop rational strategies to overcome resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025487</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Gabrielle Haeusler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Management of infective complications of childhood cancer treatment: driving innovation, enhancing diagnosis and accelerating implementation</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,347,479.03</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | health informatics and information systems | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>young children</Res_KW1>
        <Res_KW2>acute leukaemia</Res_KW2>
        <Res_KW3>fever</Res_KW3>
        <Res_KW4>antibiotic use</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Infections are a common complication of childhood cancer treatment, often resulting in prolonged antibiotic courses. With rising rates of antibiotic resistance, there is an urgent need to improve the way we predict, diagnose and treat infection in these patients. This program will explore new ways to detect and monitor complicated infections, assess the safety of shortening antibiotic courses and develop a national guideline for infection management to improve outcomes of childhood cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025504</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jillian Eyles</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Strategies to promote best-practice osteoarthritis care</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>osteoarthritis</Res_KW1>
        <Res_KW2>health professionals</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>evidence-based clinical practice</Res_KW4>
        <Res_KW5>health care worker education</Res_KW5>
        <Plain_Description>Osteoarthritis, a painful joint disease, is a major cause of disability, but 64% of patients do not receive the treatments proven to work best. This research will assess the efficacy of three strategies to influence and support health professionals to deliver best OA care:  1. audit and feedback for surgeons to reduce unnecessary surgeries  2. an eLearning program to train health professionals to deliver the best OA care   3. a strategy to improve existing OA management programs in hospitals.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025511</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Le Couteur</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Harnessing the Therapeutic Potential of Hepatotropic Silver Sulfide Quantum Dot Nanomedicines for Ageing and Age-Related Diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical delivery technologies | </Fields_of_Research>
        <Res_KW1>ageing</Res_KW1>
        <Res_KW2>nanotechnology</Res_KW2>
        <Res_KW3>clinical pharmacology</Res_KW3>
        <Res_KW4>comorbidity</Res_KW4>
        <Res_KW5>drug development</Res_KW5>
        <Plain_Description>This Application builds on over 25 years of research on ageing and the liver, and on our recent discovery of quantum dot nanomedicines for targeting drugs and peptides to the liver. The studies will lead to new knowledge and development of quantum dot formulations for treating and preventing ageing, metabolic health, inflammaging, impaired immune tolerance and longevity, with the capacity to fast track these to the marketplace through our commercialization partnerships and pipeline.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025514</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Oliver Rackham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Harnessing synthetic biology to develop new gene therapies for difficult-to-treat diseases</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,697,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | synthetic biology | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>gene therapy</Res_KW1>
        <Res_KW2>protein engineering</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>mitochondria</Res_KW4>
        <Res_KW5>inherited metabolic disorders</Res_KW5>
        <Plain_Description>Synthetic biology is revolutionizing the programming of molecules and cells with new functions. Professor Rackham is a pioneer in this field and is harnessing the tremendous potential of synthetic biology to create new therapeutic technologies. These include protein-based gene therapies to cure inherited genetic diseases and cancer. The impacts of these new technologies are already being realised through collaborations with industry and dissemination of critical new knowledge.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025515</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Gerry Tonkin-Hill</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Scalable genotype to phenotype prediction for pathogen tracking and diagnostics</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | microbiology | microbial genetics  | </Fields_of_Research>
        <Res_KW1>statistical genetics</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>molecular epidemiology</Res_KW4>
        <Res_KW5>antimicrobial resistance</Res_KW5>
        <Plain_Description>Genomics plays a critical role in tracking the transmission of pathogens and in the prediction of drug resistance and virulence. This project will develop computational and statistical methods which can automatically adapt as pathogens evolve to help public health officials and clinicians make optimal decisions. The tools will apply to a wide range of pathogen species including antibiotic-resistant bacteria and viruses such as SARS-CoV-2.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025521</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ram Bhusal</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing ticks' tricks to develop therapies for inflammatory diseases</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>protein engineering</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>protein-protein interaction</Res_KW3>
        <Res_KW4>biophysics</Res_KW4>
        <Res_KW5>chemokines</Res_KW5>
        <Plain_Description>Inflammatory diseases are caused by the release of chemokines at the affected site. Chemokines attract immune cells to the site, leading to inflammation and tissue damage.  Blocking the activity of chemokines is a promising approach to suppress inflammation. I propose to modify natural chemokine binding proteins from ticks called “evasins”, so that they effectively block the activity of chemokines involved in various inflammatory diseases. This could lead to new anti-inflammatory treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025522</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Osborne</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Scaling up health literacy development for the prevention and control of noncommunicable diseases (NCDs)</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>health inequalities</Res_KW1>
        <Res_KW2>quality improvement</Res_KW2>
        <Res_KW3>health care evaluation</Res_KW3>
        <Res_KW4>primary prevention</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>This research will develop and test new tools and processes that enable Australian and international organisations to understand and improve how people with low health literacy get fair access and use of health information and services. The health programs developed and tested will be codesigned with communities so that they are what they need and want and are widely implementable.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025529</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Joanne Reed</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Using Genomics to Transform the Diagnosis and Treatment of Autoimmune Disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,670,201.45</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </Fields_of_Research>
        <Res_KW1>systemic lupus erythematosus (sle)</Res_KW1>
        <Res_KW2>sjogren's syndrome</Res_KW2>
        <Res_KW3>autoantibodies</Res_KW3>
        <Res_KW4>b cells</Res_KW4>
        <Res_KW5>autoimmune disease</Res_KW5>
        <Plain_Description>One in twelve people suffer from an autoimmune disease where their immune cells that normally attack viruses and bacteria “go rogue” and attack healthy parts of the body. There is no cure and treatments are limited to drugs that suppress all immune cells, causing adverse side effects and vulnerability to infection. This research will use new genomic technology to study rogue immune cells and select treatments to eliminate the rogue cells while preserving the rest of the immune system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025534</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Tony Butler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Violence and domestic violence prevention using new insights, approaches, and data sources.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | health sciences | epidemiology | disease surveillance | health sciences | public health | injury prevention | </Fields_of_Research>
        <Res_KW1>domestic violence</Res_KW1>
        <Res_KW2>prison population</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>young offenders</Res_KW4>
        <Res_KW5>impulsivity</Res_KW5>
        <Plain_Description>Preventing crime, including violent crime, presents a ‘wicked’ problem for public health requiring new insights, novel approaches to prevention, identification of key intervention points, and new data sources. Working with industry partners, consumers and Aboriginal groups across the health, justice, and welfare sectors, and employing diverse methodologies, the research program focuses on violence and domestic violence prevention in men and women, across the life course.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025541</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Catherine Sherrington</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Falls and mobility impairment: generating and testing equitable solutions to implement and scale-up</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | health services and systems | aged health care | health sciences | health services and systems | people with disability | </Fields_of_Research>
        <Res_KW1>falls prevention</Res_KW1>
        <Res_KW2>mobility</Res_KW2>
        <Res_KW3>physical activity</Res_KW3>
        <Res_KW4>physiotherapy</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Injuries from falls cause 135,000+ Australians aged 65+ to be admitted to hospital each year—at a cost of $2.3 billion. Difficulty or inability to walk 200 metres is reported by 1.2 million Australians. We know that exercise can make a big difference. We don't how to embed exercise and other interventions into health and aged care services in a sustainable way.   This project seeks to develop and evaluate solutions to falls and mobility impairment that can be made broadly available.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025553</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Teresa MacDonald</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Checkpoints of placental health during pregnancy to minimise stillbirth risk</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$497,224.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>placental function</Res_KW1>
        <Res_KW2>stillbirth</Res_KW2>
        <Res_KW3>fetal growth restriction</Res_KW3>
        <Res_KW4>ultrasound</Res_KW4>
        <Res_KW5>pregnancy complications</Res_KW5>
        <Plain_Description>Most cases of stillbirth occur because the placenta- the baby’s life support system- is not working well. If we detect unhealthy placentas, we can monitor, and deliver in time to save the baby. The problem is that we lack tools to find failing placentas.    I propose 3 new tools to check placental health:   1) baby's mid-pregnancy size (currently measured but not used)  2) baby's growth rate  3) a novel blood test    By detecting failing placentas and babies at risk, these new tests will reduce stillbirth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025606</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Herbert Herzog</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Identification of neuronal networks driving combined HFD/chronic stress acceleration of obesity development</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,753,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | other biological sciences | other biological sciences not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>obesity</Res_KW1>
        <Res_KW2>food intake</Res_KW2>
        <Res_KW3>hypothalamus</Res_KW3>
        <Res_KW4>neuropeptide y (npy)</Res_KW4>
        <Res_KW5>adeno-associated virus</Res_KW5>
        <Plain_Description>Obesity-associated diseases are leading causes of death and are expected to increase as the obesity epidemic worsens. New evidence also shows that stress, an ever-increasing factor of life, can when combined with high caloric food accelerate the development of obesity. The results from this study will identify the critical brain pathways responsible for this and identify the most promising targets that will help to reduce body weight and fat mass particular under conditions of increased stress</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025610</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Shobi Sivathamboo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Preventing sudden unexpected death in epilepsy: Discovery of predictive biomarkers and risk factors for precision-based care</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>cardiac</Res_KW3>
        <Res_KW4>sudden death</Res_KW4>
        <Res_KW5>seizures</Res_KW5>
        <Plain_Description>Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death from epilepsy. This research program will examine national and international data to understand how common SUDEP is and who is at greatest risk (e.g., individuals with specific heart rate patterns). Software will then be developed for real-time seizure detection that can be operated at home and installed on existing smart technology. This will be used to provide timely alerts for life saving interventions to prevent SUDEP.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025614</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Shengbo Zhang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing a next generation dendritic cell therapy for solid tumours</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | medical biotechnology | nanomedicine | </Fields_of_Research>
        <Res_KW1>dendritic cell</Res_KW1>
        <Res_KW2>solid tumours</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>messenger rna (mrna)</Res_KW4>
        <Res_KW5>toll-like receptors</Res_KW5>
        <Plain_Description>Cellular therapies are designed to boost the patient's immune system to better fight cancer. Dendritic cells (DCs) are sentinel cells whose normal function is to alert the immune system to infection or cancer. We are developing a method to engineer DCs that we aim to deliver to patients as a new class of cell therapy. In this project we aim to produce enough supportive data to progress this therapy towards a clinical trial in solid cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025619</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Sinclair</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Translating multi-omics into improved clinical outcomes for patients with disorders of sex development.</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,753,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biomedical and clinical sciences | clinical sciences | endocrinology | biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>gonadal dysgenesis</Res_KW1>
        <Res_KW2>gonadal development</Res_KW2>
        <Res_KW3>sex reversal</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>testis development</Res_KW5>
        <Plain_Description>Disorders of sex development (DSD) are complex genetic conditions where sexual development is atypical. Currently, 60% of DSD patients do not receive a diagnosis making their clinical management extremely difficult. To address this problem, I will use several novel integrated approaches to identify all genes underlying these conditions and provide a diagnosis to those 60% undiagnosed DSD patients, facilitating their clinical management and improving their health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025634</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Meghan Bohren</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Implementation Research on Respectful Maternity Care for all Women and Families</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | health sciences | midwifery | midwifery not elsewhere classified  | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>maternal health</Res_KW1>
        <Res_KW2>maternal and child health</Res_KW2>
        <Res_KW3>public health</Res_KW3>
        <Res_KW4>midwifery</Res_KW4>
        <Res_KW5>qualitative research</Res_KW5>
        <Plain_Description>Over 1 in 3 women worldwide experience mistreatment during childbirth, including physical or verbal abuse, discrimination, and non-consented care. These experiences negatively impact women’s physical and mental health, deter future health-seeking, and violate human rights. My vision is to ensure that all women globally have access to high quality, respectful maternity care. My research will answer critical questions about the barriers and facilitators to implementing respectful maternity care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025641</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Belinda Phipson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Statistical methods for advancing cutting edge single cell and spatial 'omics data</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>applied statistics</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>genetics</Res_KW4>
        <Res_KW5>cancer biology</Res_KW5>
        <Plain_Description>Medical research is becoming increasingly quantitative as new technologies emerge that can capture thousands of measurements at increasingly higher resolution. Over the last decade, we have progressed from profiling whole samples to profiling individual cells. In order to translate these complex, large datasets into medical discoveries we need robust statistical methods and software. My research will fill this gap and deliver new tools to better understand healthy development and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025645</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Gordon Smyth</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Statistical bioinformatics for medical research</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>differential gene expression</Res_KW3>
        <Res_KW4>biostatistics</Res_KW4>
        <Res_KW5>proteomics</Res_KW5>
        <Plain_Description>I develop innovative computational, statistical and bioinformatics strategies to process and interpret data from cutting-edge genomic technologies. I implement these strategies in high-quality publicly available software, which can then used by biomedical researchers around the world. Working closely with biomedical collaborators, I use these techniques to study cell biology and the genesis of cancer and other diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025648</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Kim-Anh Lê Cao</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>New data integration methods to unlock the potential of clinical omics data</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | </Fields_of_Research>
        <Res_KW1>multivariate statistics</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>systems biology</Res_KW5>
        <Plain_Description>Technological advances are producing big and complex data in an effort to understand the biology of health and disease. However, making sense of such data requires advanced statistical methods. In six large collaborative clinical studies, this project will develop new analytical methods to extract relevant molecular markers of disease. The tools created will empower many other researchers from diverse fields to conduct their own analyses leading to new therapeutics and interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025651</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jia Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Unravelling mechanisms of blood-brain barrier disruption for developing innovative therapeutics against brain diseases</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | medical biotechnology | nanomedicine | </Fields_of_Research>
        <Res_KW1>neurovascular mechanism</Res_KW1>
        <Res_KW2>blood-brain barrier</Res_KW2>
        <Res_KW3>drug delivery systems</Res_KW3>
        <Res_KW4>cardiovascular disease</Res_KW4>
        <Res_KW5>cerebrovascular</Res_KW5>
        <Plain_Description>Brain diseases, such as stroke and dementia, are major causes of disability and death worldwide. There are often no good treatments available. To create new and effective treatments, we need to understand what causes these diseases. This project aims to uncover the causes of different brain diseases and then use that knowledge to create treatments that are tailored to each patient's specific needs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025656</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Murray Cairns</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Using genetically informed precision medicine to improve the treatment of schizophrenia</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | </Fields_of_Research>
        <Res_KW1>psychiatry</Res_KW1>
        <Res_KW2>complex genetic disease</Res_KW2>
        <Res_KW3>pharmacogenomics</Res_KW3>
        <Res_KW4>medical genetics</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>We urgently need new treatments for schizophrenia that reach beyond the broad symptom categories to target the molecular basis of disease as it manifests in individuals. My research program will establish a new precision medicine approach that uses a patient's genetic profile to specifically match their disease-associated biology with a broad spectrum of treatments, including existing medications used in psychiatry, as well as those currently used for other conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025661</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Denise O'Connor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Harnessing research translation science to drive ‘the right care’</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | health systems | health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>translational research</Res_KW1>
        <Res_KW2>evidence-based health care</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Health systems worldwide aim to deliver ‘the right care’ to patients but realising this remains a major challenge. Only about 60% of patients receive effective and appropriate care, while about 30% receive unnecessary, ineffective care and 10% is potentially harmful. Over the next 5 years I will use cutting-edge behavioural science methods to evaluate novel strategies to reduce low-value care and advance new knowledge for health system improvement.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025665</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Tracey Wade</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Revolutionising early intervention outcomes for youth with emerging eating disorders</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>eating disorders</Res_KW1>
        <Res_KW2>early intervention</Res_KW2>
        <Res_KW3>depression</Res_KW3>
        <Res_KW4>anxiety disorders</Res_KW4>
        <Res_KW5>suicide risk</Res_KW5>
        <Plain_Description>Eating disorders are commonly experienced by adolescents in Australia but effective treatment is difficult to obtain in primary mental health care settings. This program will address this gap through development and testing of online single session interventions to determine what works to decrease disordered eating in youth up to 25 years of age. The developed interventions will lead to substantial improvement in outcomes for youth seeking help for emerging eating disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025670</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Rolnik</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Preventing Pre-eclampsia to Improve Outcomes for Mothers and Babies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$793,095.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>pre-eclampsia</Res_KW1>
        <Res_KW2>pregnancy complications</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>early prevention</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Pre-eclampsia, a serious hypertensive disorder of pregnancy, is a leading cause of morbidity and mortality for mothers and babies. Effective prevention is available, but identifying women at risk who benefit from treatment is challenging. I have formed an internationally recognised research team and will lead a research program to implement an effective first trimester screening program in Victoria, better understand the disease, identify high-risk women, and improve pregnancy outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025671</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr William Reay</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Using genetics to improve the clinical management of common, chronic disorders and enable precision medicine</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | biomedical and clinical sciences | nutrition and dietetics | nutrigenomics and personalised nutrition | </Fields_of_Research>
        <Res_KW1>statistical genetics</Res_KW1>
        <Res_KW2>chronic diseases</Res_KW2>
        <Res_KW3>genetic epidemiology</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>drug targeting</Res_KW5>
        <Plain_Description>Millions of Australians live with chronic disorders, which are conditions that can last years and include diagnoses like heart disease, diabetes, and depression. Many individuals do not respond well to current treatments for these disorders, and it is often difficult to uncover why this is the case. My research aims to use genetics to both identify new and better treatments for these disorders, as well as target them to patients more effectively.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025674</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Medland</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Using genomics and imaging to advance our understanding of mental health challenges</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | health sciences | health services and systems | mental health services | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | </Fields_of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>brain imaging</Res_KW2>
        <Res_KW3>genetic association</Res_KW3>
        <Res_KW4>side-effects</Res_KW4>
        <Res_KW5>treatment efficacy</Res_KW5>
        <Plain_Description>Over the next five years I will use statistical genetics approaches to: (i) characterise the effects of genetic variants associated with psychiatric disorders on brain structure and connectivity; (ii) improve our understanding of the genetics of psychiatric disorders focusing on individual differences in the response to pharmacological treatments of these disorders and side-effects associated with these treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025694</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Patrick Sexton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Structure, function and modulation of peptide hormone G protein-coupled receptors (GPCRs)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>g protein-coupled receptors</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>molecular pharmacology</Res_KW3>
        <Res_KW4>receptor signalling</Res_KW4>
        <Res_KW5>electron microscopy</Res_KW5>
        <Plain_Description>Cell surface proteins called GPCRs provide critical control of communication within the body to maintain optimal human health. Dysregulation of these proteins can lead to disease, but they can also be targeted to treat disease. Indeed, GPCRs are current targets of ~30% of approved drugs. GPCR function can be altered by accessory proteins, making understanding of this phenomenon critical for future drug development, but this is poorly understood. This project addresses this key knowledge gap.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025728</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ilia Voskoboinik</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Regulation of cytotoxic lymphocyte function - health or disease?</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,497,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | biomedical and clinical sciences | medical biochemistry and metabolomics | metabolic medicine | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>lysosomal storage disorder</Res_KW1>
        <Res_KW2>mucopolysaccharidoses</Res_KW2>
        <Res_KW3>tumour immunotherapy</Res_KW3>
        <Res_KW4>protein trafficking</Res_KW4>
        <Res_KW5>congenital disorders</Res_KW5>
        <Plain_Description>Cytotoxic lymphocytes are white blood cells that protect an organism against pathogens and cancer by killing rogue cells. How cytotoxic lymphocytes develop their killing capacity, and how cancer cells develop resistance to cytotoxic lymphocytes are poorly understood areas of science. My multidisciplinary research program will explore these fields, and is expected to provide novel directions for cancer immunotherapy and for the treatment of immunodeficient patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025733</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Rana Hinman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Increasing lifestyle management of hip &amp; knee osteoarthritis to improve health outcomes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,847,438.22</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | allied health and rehabilitation science | rehabilitation | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>physiotherapy</Res_KW1>
        <Res_KW2>knee osteoarthritis</Res_KW2>
        <Res_KW3>allied health</Res_KW3>
        <Res_KW4>exercise</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>One in 5 Australians over 45 have osteoarthritis. Lifestyle management is the best approach for most people, with education, self-management, exercise &amp; weight loss recommended. This research program will test different lifestyle strategies to see if they are effective, including if technology can help to deliver &amp; support lifestyle care. I will also test strategies for increasing clinician &amp; patient knowledge about lifestyle care. Findings will improve osteoarthritis care &amp; self-management.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025750</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Natalie Sims</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Defining the mechanisms that control age-related bone fragility</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | systems biology | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>bone biology</Res_KW1>
        <Res_KW2>osteoporosis</Res_KW2>
        <Res_KW3>bone architecture</Res_KW3>
        <Res_KW4>osteoblast</Res_KW4>
        <Res_KW5>inter-cellular signalling</Res_KW5>
        <Plain_Description>Fractures commonly occur at the hip or wrist in older people because the outer shell of bone becomes weaker. It is not known how this happens as we age, and we cannot currently treat it effectively. I aim to identify the changes in cells and signals that specifically cause these age-related changes to the skeleton. We expect this will generate new understanding on how the skeleton ages and, in the long term, inform better ways to prevent fractures in older people.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025759</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kha Phan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Therapeutic manipulation of apoptotic bodies formation to prevent respiratory infectious diseases</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>cell death</Res_KW1>
        <Res_KW2>apoptosis</Res_KW2>
        <Res_KW3>infection</Res_KW3>
        <Res_KW4>mycobacterium tuberculosis</Res_KW4>
        <Res_KW5>sars-cov-2</Res_KW5>
        <Plain_Description>Tuberculosis, COVID-19 and emerging respiratory infections are a continuing medical threat. At the same time, current effective anti-infective therapies are concerningly limited. This research program aims to develop novel treatments for infectious respiratory diseases by targeting the process in which infected host cells undergo fragmentation when they die. This will lead to more effective anti-infective treatments, thus relieving the rising burden of infectious diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025776</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Silvia Velasco</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Novel brain organoid models to study and identify new therapies for neurodevelopmental disorders.</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>early brain development</Res_KW1>
        <Res_KW2>stem cell biology</Res_KW2>
        <Res_KW3>neurodevelopmental disorders</Res_KW3>
        <Res_KW4>autism spectrum disorders</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Pediatric neurological diseases have a major impact on children, families, and societies. Using stem cells, we can now generate complex human neural tissues, named “brain organoids”, to investigate processes of brain development and disease. I recently developed a method to generate brain organoids with enhanced experimental features. My proposed research program seeks to take advantage of the full potential of brain organoids to develop new effective therapies for children’s brain diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025780</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Dezerae Cox</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>A molecular map of human endogenous retroviruses in neurodegenerative disease. </Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | characterisation of biological macromolecules | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>protein aggregation</Res_KW1>
        <Res_KW2>endogenous retroviruses</Res_KW2>
        <Res_KW3>protein interactions</Res_KW3>
        <Res_KW4>proteomics</Res_KW4>
        <Res_KW5>motor neuron disease (mnd)</Res_KW5>
        <Plain_Description>Almost one-tenth of the human genome originated from ancient viruses capable of writing their DNA into our own. This project will explore how these inherited viral building blocks can contribute to neurodegenerative diseases. Success of this project will super-charge diagnostic and therapeutic strategies for Motor Neuron disease while expanding our understanding of a fundamental aspect of humanity; how our DNA contributes to human health and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025815</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Adam Bartlett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Geospatial analytics for the control and elimination of neglected tropical diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$497,224.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | health sciences | epidemiology | disease surveillance | health sciences | epidemiology | epidemiological modelling | </Fields_of_Research>
        <Res_KW1>tropical disease</Res_KW1>
        <Res_KW2>geographic variations</Res_KW2>
        <Res_KW3>antiparasitic chemotherapy</Res_KW3>
        <Res_KW4>disease modelling</Res_KW4>
        <Res_KW5>helminth infection</Res_KW5>
        <Plain_Description>My research program integrates geospatial analytics to produce policy-driven outcomes for the control and elimination of neglected tropical diseases (NTDs). This will be achieved through the incorporation of geospatial analytics in designing, implementing, evaluating, and informing interventions for programs across Angola, Timor-Leste, Vanuatu and Vietnam that aim to control and eliminate schistosomiasis, soil-transmitted helminths, lymphatic filariasis, trachoma, scabies and yaws by 2030.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025837</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Emmanuel Adewuyi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Characterising the biological mechanisms of dementia via genetic dissection of comorbidities</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | genetics | neurogenetics | </Fields_of_Research>
        <Res_KW1>statistical genetics</Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>comorbidity</Res_KW3>
        <Res_KW4>complex disease</Res_KW4>
        <Res_KW5>genetics</Res_KW5>
        <Plain_Description>Dementia often co-occurs with other disorders (comorbidity) which may predispose to disease worsening. The co-occurring conditions may also be involved in the poorly understood mechanisms of dementia, hence the importance of studying them. This research aims to understand the biological mechanisms of dementia via its shared genetic origin with co-occurring disorders. Findings will identify targets for further investigation and provide opportunity for preventive or treatment development efforts.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025839</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Samantha Teague</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Supporting mothers' and fathers’ perinatal mental health via digital technology and couple engagement</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>perinatal</Res_KW1>
        <Res_KW2>postnatal depression</Res_KW2>
        <Res_KW3>intervention</Res_KW3>
        <Res_KW4>postnatal</Res_KW4>
        <Res_KW5>digital parental support</Res_KW5>
        <Plain_Description>Both mothers and fathers experience mental health difficulties including postpartum depression and anxiety. Support to date has typically focused on one parent only, when strengthening family relationships is shown to help prevent and treat postpartum depression and anxiety. This research program aims to support parents using digital tools to identify those in need of support and deliver evidence-based psychological treatment to both parents individually and as a couple.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025840</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Marcus Chen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>A new model for improved syphilis management and control</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | venereology | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>syphilis</Res_KW1>
        <Res_KW2>sexually-transmitted infections (sti)</Res_KW2>
        <Res_KW3>sexual health</Res_KW3>
        <Res_KW4>public health</Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>The global syphilis epidemic is worsening, leading to serious health problems and deaths. Earlier diagnosis and treatment are needed to improve the control of syphilis. This program of research will trial new interventions that increase syphilis testing and detection, and improve treatment and surveillance, enabling better targeting of public health responses. Together, these will revolutionize how we manage syphilis epidemics, reducing the growing burden of this stigmatizing disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025844</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Romain Ragonnet</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Designing adaptive strategies to drive tuberculosis towards elimination</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>tuberculosis</Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>public health policy</Res_KW4>
        <Res_KW5>disease prevention</Res_KW5>
        <Plain_Description>Tuberculosis (TB) remains a major infectious killer and 25% of the global population are estimated to have latent TB infection. While preventive treatment is recognised as a critical tool for effective TB control, its optimal implementation remains uncertain. Improved detection through active case finding (ACF) is also known to be effective to reduce TB burden. This project will use modelling to identify the best strategies combining preventive treatment and ACF in high TB burden countries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025849</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Patrick Kwan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Transforming epilepsy outcomes through innovative technologies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,697,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>clinical outcome</Res_KW2>
        <Res_KW3>artificial intelligence</Res_KW3>
        <Res_KW4>neural stem cell</Res_KW4>
        <Res_KW5>biosensor</Res_KW5>
        <Plain_Description>Current drugs for epilepsy are ineffective in 1/3 of patients. Drug selection remains ‘trial and error’, with patients often enduring years of recurrent seizures and side effects. My research will create a paradigm shift in management by developing more ‘personalised’ and effective diagnostic and treatment strategies. Through the use of AI, stem cell and medical technologies this research will lead to better quality of life, fewer deaths, and higher productivity for people living with epilepsy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025853</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Ron Firestein</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Targeting the cancer epigenome for therapy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,717,732.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics | </Fields_of_Research>
        <Res_KW1>cancer therapy</Res_KW1>
        <Res_KW2>molecular oncology</Res_KW2>
        <Res_KW3>experimental oncology</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Precision medicine is a vital approach to treating cancer and is based on the unique genetic makeup of each patient's tumour. This proposal employs an integrative genomic approach to identify the next-generation of precision drugs. We will use AI technology to integrate genomic data, such as DNA sequencing, RNA expression, and epigenetic information with functional genomics to gain a deeper understanding of cancer vulnerabilities and develop effective and personalised treatments for patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025864</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Elizabeth Manias</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>ENgaginG older people Across transitions of care to improve medication manaGEment (The ENGAGE Project)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | acute care | health sciences | health services and systems | patient safety | </Fields_of_Research>
        <Res_KW1>communications/social research</Res_KW1>
        <Res_KW2>medications</Res_KW2>
        <Res_KW3>patient participation</Res_KW3>
        <Res_KW4>geriatrics</Res_KW4>
        <Res_KW5>families</Res_KW5>
        <Plain_Description>This research involves developing and testing strategies to bring about shared decision making between hospitalised older people, their families and health professionals; determining if these strategies reduce hospital readmission; and putting together resource materials to support older people and their families in managing medications as older people move between settings. The strategies are likely to work because they will be created with extensive input from older people and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025886</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Bastien Lechat</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Redefining sleep disordered breathing diagnostics and management: A novel data-driven digital health approach </Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | engineering | communications engineering | signal processing | </Fields_of_Research>
        <Res_KW1>obstructive sleep apnoea</Res_KW1>
        <Res_KW2>sleep</Res_KW2>
        <Res_KW3>biotechnology</Res_KW3>
        <Res_KW4>signal processing</Res_KW4>
        <Res_KW5>machine learning</Res_KW5>
        <Plain_Description>Sleep-disordered breathing are common respiratory disorders that affect over a billion people worldwide, disrupting sleep and impacting quality of life. Current methods of diagnosis can be costly and time-consuming, with misdiagnoses occurring in up to 50% of cases and wait times of up to two years. To address these challenges, I propose a novel, multi-modal, data-driven approach to diagnose and manage sleep-disordered breathing using affordable technology that can be implemented in the home.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025894</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Suzanne Nielsen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Transforming approaches to reduce opioid mortality and related harm</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | injury prevention | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacy and pharmacy practice | </Fields_of_Research>
        <Res_KW1>opioid dependence</Res_KW1>
        <Res_KW2>overdose</Res_KW2>
        <Res_KW3>health policy</Res_KW3>
        <Res_KW4>substance dependence</Res_KW4>
        <Res_KW5>poisoning</Res_KW5>
        <Plain_Description>Preventable opioid overdose deaths and related harms are increasing. Yet, few people who experience such harms seek help. Treatment for opioid dependence is hard to access, and policy interventions may actually push people away from health care into non-prescribed and more hazardous use. This research will facilitate earlier help-seeking, increase the reach of overdose prevention, test novel ways to make treatment easier to access, and enable the identification of effective opioid policy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025898</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Rachael Zemek</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>USING TIME AGAINST CANCER - IMPROVING RESPONSES TO CANCER IMMUNOTHERAPY</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | biological network analysis | biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>cancer immunology</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>surgery</Res_KW4>
        <Res_KW5>tumour immunology</Res_KW5>
        <Plain_Description>Cancers frequently grow back at the site of removal after surgery. I have found that surgery causes an increased local immune response and can expose vulnerabilities in cancer cells, which can be boosted by immunotherapy to kill any remaining cancer. Using gene mapping technology, I will discover how surgery impacts the immune response over time, in order to develop therapies that can be applied after surgery to kill remaining cancer cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025900</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Ms Jane Tiller</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Addressing barriers to public trust and participation in genomic medicine </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | health sciences | public health | preventative health care | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>bioethics</Res_KW1>
        <Res_KW2>public health policy</Res_KW2>
        <Res_KW3>medical genetics</Res_KW3>
        <Res_KW4>genetic counselling</Res_KW4>
        <Res_KW5>legal issues</Res_KW5>
        <Plain_Description>Genetic testing can improve healthcare and save lives, but some concerns affect the public's trust and involvement in DNA testing programs and must be addressed. This project will use innovative research methods to understand barriers which affect public trust and participation in genetic testing. It will involve the public in co-developing strategies to address those barriers, and make recommendations about how health policy can be changed to protect consumers and the future of genetic testing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025925</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Stephen Scally</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Exploiting malarial invasion proteins for novel multi-stage malaria vaccines</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>antibody</Res_KW3>
        <Res_KW4>vaccine</Res_KW4>
        <Res_KW5>immunology</Res_KW5>
        <Plain_Description>Malaria is an infectious disease with a complex lifecycle that moves between mosquito and human hosts. This proposal will study the role of a protein complex important for parasite invasion in both humans and mosquitoes and structurally and functionally characterize how antibodies can prevent this. Insights generated will then be used to develop and test a novel multi-stage malaria vaccine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025931</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Bostjan Kobe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Proteins in innate immunity pathways: from protein structure to therapeutic targeting</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | signal transduction | biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>toll-like receptors</Res_KW1>
        <Res_KW2>protein structure</Res_KW2>
        <Res_KW3>structure-function</Res_KW3>
        <Res_KW4>protein interactions</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>Inflammation is an early response to infection and damage. It is triggered by the immune system, to clear the pathogen and repair the tissue. However, this response often fails to be kept under control, leading to disorders associated with infection, autoimmunity, neurodegeneration, stroke, heart disease, cancer and diabetes. My work will provide strategies to develop anti-inflammatory therapies that are more effective and have less side effects than what is currently available.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025937</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jian Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Combating antimicrobial resistance: From bedside to bench and therapeutics</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | toxicology (incl. clinical toxicology)  | </Fields_of_Research>
        <Res_KW1>antibiotic resistance</Res_KW1>
        <Res_KW2>antibiotic therapy</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>pharmacodynamics</Res_KW4>
        <Res_KW5>systems biology</Res_KW5>
        <Plain_Description>Bacterial ‘superbugs’ and the lack of new antibiotic drugs have caused an unmet need of global significance. My research will generate and translate new knowledge to improve the clinical use of antibiotics worldwide; develop international dosing guidelines; discover and commercialise novel therapeutics against bacterial ‘superbugs’. My multidisciplinary program addresses the global health priority of combating antibiotic resistance and has a far-reaching impact on clinical practice worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025939</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Nagham Ailabouni</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Knowledge translation by Implementing Nudging to optimise medicines for people living with Dementia (KIND) </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | health sciences | health services and systems | implementation science and evaluation | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacy and pharmacy practice | </Fields_of_Research>
        <Res_KW1>dementia</Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>geriatrics</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>aged care</Res_KW5>
        <Plain_Description>My proposal aims to reduce harm people living with dementia in aged care experience from taking too many medicines. Alongside a diverse stakeholder steering group, I will co-design easy-to-use health resources to empower people living with dementia, carers and those who care for them to review medicines. This will reduce the number of medicines taken by people living with dementia reducing their risk of experiencing harm such as falls or hospitalisations and improving their overall health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025943</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Biesiekierski</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Changing the way we use diet in gut disorders: Generating mechanistic knowledge and clinical evidence to inform integrated management</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>functional bowel disorder</Res_KW1>
        <Res_KW2>dietary intervention</Res_KW2>
        <Res_KW3>gastrointestinal symptoms</Res_KW3>
        <Res_KW4>irritable bowel syndrome (ibs)</Res_KW4>
        <Res_KW5>diet</Res_KW5>
        <Plain_Description>Gut disorders are complex, chronic, relapsing and incompletely understood. These disorders affect more than 9 million Australians and hundreds of millions worldwide, and current treatments are often unsuccessful.  My research will perform novel mechanistic studies and international dietary trials, to inform therapy and improve treatment outcomes for patients with gut disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2025960</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jane Hocking</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Tackling Australia’s rapidly growing burden of sexually transmitted infections (STIs) by digitally transforming STI healthcare</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | general practice | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>primary care</Res_KW1>
        <Res_KW2>clinical decision making</Res_KW2>
        <Res_KW3>sexually-transmitted infections (sti)</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>internet service delivery</Res_KW5>
        <Plain_Description>Sexually transmitted infections (STI) are an increasing public health burden in Australia with rates increasing dramatically in recent years. Our specialist STI clinics are at capacity causing people to seek care in general practice where STI testing is not routinely offered. To increase access to STI care &amp; reduce the burden of STIs, I will develop an online testing service that provides access to testing across Australia and equip general practice with the tools to be proactive in STI care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026004</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Geoffrey Lindeman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Exploiting breast stem cell research discoveries for transfer to the clinic</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>breast cancer</Res_KW1>
        <Res_KW2>mammary gland cancer</Res_KW2>
        <Res_KW3>stem cell biology</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>My group discovered breast stem cells and their ‘daughter’ progenitor cells and developed a breast cell 'atlas'. These serve as a blueprint for defining molecular and cellular regulators of breast development to shed light on events that go awry in cancer. Based on these findings my team will advance efforts to prevent breast cancer in women with a faulty BRCA1 or BRCA2 gene. We will also progress preclinical and clinical studies aimed at taking a new class of drug to the clinic in breast cancer  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026038</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Christina Abdel Shaheed</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Optimising the quality use of medicines for pain</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,561,326.61</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>chronic pain</Res_KW1>
        <Res_KW2>acute pain</Res_KW2>
        <Res_KW3>back pain</Res_KW3>
        <Res_KW4>dependence</Res_KW4>
        <Res_KW5>opioid analgesia</Res_KW5>
        <Plain_Description>Pain is one of the most costly and difficult to treat conditions. There is a lack of clarity regarding best treatment options for specific pain conditions. My research program will produce the knowledge necessary to support clinicians and patients make informed decisions about what treatment to use, when to use it and for how long. It will support two major trials aimed at providing patients with back pain safe and effective care, whilst reducing the burden from high-risk medicines like opioids.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026053</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Sophia Davidson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Proteotoxic stress, Protein Kinase R and human disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,553,129.89</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>inflammation</Res_KW1>
        <Res_KW2>neuroinflammation</Res_KW2>
        <Res_KW3>interferon (ifn)</Res_KW3>
        <Res_KW4>proteasome</Res_KW4>
        <Res_KW5>anti-inflammatory agents</Res_KW5>
        <Plain_Description>Cells recycle old components using a system called the proteasome. Certain neurodevelopmental disorders have been shown to be caused by loss of proteasome function. We have identified an inflammatory pathway that is activated by loss of proteasome function and suspect this contributes to neurodevelopmental disease. We also propose to utilize lipid nanoparticle RNA delivery to develop novel therapeutics for inhibition of this inflammation as a treatment for neurodevelopmental disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026057</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Evan Cunningham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Interventions to improve diagnosis and treatment of hepatitis C</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | health sciences | epidemiology | behavioural epidemiology | health sciences | health services and systems | health and community services | </Fields_of_Research>
        <Res_KW1>diagnostic</Res_KW1>
        <Res_KW2>injecting drug use</Res_KW2>
        <Res_KW3>hepatitis c infection</Res_KW3>
        <Res_KW4>hepatitis c virus</Res_KW4>
        <Res_KW5>diagnosis</Res_KW5>
        <Plain_Description>Viral hepatitis causes more deaths than any other infectious disease globally. New highly effective treatments have led to global targets to eliminate hepatitis C by 2030, although there has been a reduction in testing and treatment for hepatitis C since the introduction of these new treatments. New hepatitis C tests and treatment strategies are needed to ensure that these targets are met. My program will find and evaluate new testing and treatment strategies to eliminate hepatitis C.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026065</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Roger Smith</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Advancing Treatment for Preterm Labour</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>premature birth</Res_KW1>
        <Res_KW2>nuclear factor kappa-b (nf-kb)</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>contraction</Res_KW4>
        <Res_KW5>novel therapeutic agents</Res_KW5>
        <Plain_Description>Premature birth is a major cause of newborn baby deaths and life long disability. Current treatment can only delay birth for a few days. Our new treatment is based on our studies of the uterus in labour. We will combine drugs that block different pathways to arrest premature contractions with nucleic acid therapeutics to turn the contracting muscle back to a relaxed state, these drugs will be given in targeted nanoparticles that go just to the uterus, improving safety for mother and baby.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026079</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Natasha Harvey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Defining the genetic and developmental basis of human lymphatic vascular disease</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,600,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>lymphangiogenesis</Res_KW1>
        <Res_KW2>lymphatic disease</Res_KW2>
        <Res_KW3>vascular development</Res_KW3>
        <Res_KW4>developmental genetics</Res_KW4>
        <Res_KW5>gene regulation</Res_KW5>
        <Plain_Description>Lymphatic vessels play crucial roles in development and disease by controlling tissue fluid balance, directing immune cell traffic and absorbing dietary lipids. Defects in the construction of lymphatic vessels underlie human disorders including lymphatic malformations and primary lymphoedema. The goal of this application is to define the genes and developmental events underlying lymphatic disorders so that new therapeutic agents for the treatment of these complex disorders can be developed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026083</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Abby Douglas</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving outcomes in high risk cancer patients through rational antimicrobial use</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$496,165.26</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | biomedical and clinical sciences | clinical sciences | diagnostic radiography | </Fields_of_Research>
        <Res_KW1>antimicrobial therapy</Res_KW1>
        <Res_KW2>neutropenia</Res_KW2>
        <Res_KW3>fever</Res_KW3>
        <Res_KW4>fungal diagnosis</Res_KW4>
        <Res_KW5>diagnostic imaging</Res_KW5>
        <Plain_Description>Life threatening infection frequently occurs in patients with low white blood cells following chemotherapy for blood cancer and bone marrow transplants. Antibiotics can be life-saving, but fever is not always infection and we know that prolonged antibiotics are associated with poor outcomes such as developing antibiotic-resistant infections. This program will study cutting-edge new diagnostic tests and clinical trials of antibiotic cessation to reduce antibiotic use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026084</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Nutt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Harnessing the humoral immune system to treat disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,753,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>b cells</Res_KW1>
        <Res_KW2>humoral immunity</Res_KW2>
        <Res_KW3>dendritic cell lineages</Res_KW3>
        <Res_KW4>gene transcription</Res_KW4>
        <Res_KW5>transcription factor</Res_KW5>
        <Plain_Description>Our immune system has to recognise and respond to many possible types of threats in the environment, while at the same time ignoring the multitude of benign and often helpful microorganisms that inhabit our body. The immune system achieves this balance by producing many specialised cell types that act in unison to maintain our immune health. My research aims to understand how this complex system is put together and what goes wrong in blood cell cancers or in autoimmune diseases such as lupus.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026098</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jovana Maksimovic</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Unlocking the full potential of clinical single-cell gene expression data using novel analytical approaches</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | bioinformatics and computational biology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>data analysis</Res_KW2>
        <Res_KW3>differential gene expression</Res_KW3>
        <Res_KW4>gene transcription</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>Recent technological advances mean that we can simultaneously peek inside millions of single cells to understand what they are doing in health &amp; disease. However, this technology produces lots of noisy data that is difficult to interpret. My program will develop computational methods to improve how we analyse data obtained from single cells from human samples. This will allow us to see how healthy cells behave &amp; help us better understand what goes wrong in disease &amp; how we can improve treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026100</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Emily Stockings</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>The VAPE Program: Trends, prevention and implementation of evidence-based strategies for reducing vaping among young people in Australia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,561,326.61</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | behavioural epidemiology | health sciences | health services and systems | health and community services | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>smoking</Res_KW1>
        <Res_KW2>behavioural intervention</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>school health promotion</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>E-cigarette use and associated harms are rising rapidly. The VAPE Program proposes three world-first streams of research to address this:   1) Trends: detailed monitoring of e-cigarette use among young Australians;   2) Resource Development: a new evidence-based suite of prevention resources; and  3) Implementation: translating resources into real-life practice in existing health and education services.   This project will directly reduce use of, and harms associated with e-cigarettes in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026105</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Gregory Walker</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>A comprehensive pathogen surveillance approach to reduce the burden of viral infections</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>respiratory viruses</Res_KW1>
        <Res_KW2>molecular diagnostics</Res_KW2>
        <Res_KW3>viral immunity</Res_KW3>
        <Res_KW4>surveillance</Res_KW4>
        <Res_KW5>virus detection</Res_KW5>
        <Plain_Description>Respiratory viruses represent a major health burden, causing pandemics and seasonal epidemics. My program aims to improve upon current methods of pathogen surveillance by applying cutting-edge techniques to detect and monitor viral infections. This will help to characterise new viruses and variants, inform prevention and treatment strategies for viral infections, and enhance preparedness for epidemic and pandemic threats.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026122</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Tri Phan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Niche-specific control of B cell fate by macrophages in health and disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,697,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>humoral immunity</Res_KW1>
        <Res_KW2>affinity maturation</Res_KW2>
        <Res_KW3>germinal centre</Res_KW3>
        <Res_KW4>macrophages</Res_KW4>
        <Res_KW5>autoimmunity</Res_KW5>
        <Plain_Description>Immune responses involve the orchestration of complex dynamic cellular and molecular interactions across space and time deep inside living tissues. We have pioneered intravital microscopy tools and techniques to visualise these interactions in real-time in living animals (the 'ground truth') and use them to discover mechanisms and pathways that can be exploited to improve vaccination, treat autoimmune diseases, osteoporosis and prevent cancer metastatic relapse.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026126</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Harriet Dashnow</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Rare disease diagnosis and discovery at short tandem repeat loci</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | genetics | genomics | biological sciences | bioinformatics and computational biology | sequence analysis | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>rare diseases</Res_KW2>
        <Res_KW3>genetics</Res_KW3>
        <Res_KW4>population genetics</Res_KW4>
        <Res_KW5>sequence analysis</Res_KW5>
        <Plain_Description>Half of rare disease patients don’t receive an adequate diagnosis. This is especially true for diseases caused by repetitive genetic variants like Short Tandem Repeats (STRs). To address this, I will improve methods for detecting and interpreting STRs in genomes. I will accomplish this by developing software to analyse patient genomes and studying STRs in both patients and the general population. This work will benefit patients by increasing the diagnosis and understanding of rare diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026130</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jeremy Barr</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Investigating fundamental phage biology to improve the clinical translation of phage therapy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>bacteriophage</Res_KW1>
        <Res_KW2>antimicrobial resistance</Res_KW2>
        <Res_KW3>antibiotic resistance</Res_KW3>
        <Res_KW4>bacterial pathogen</Res_KW4>
        <Res_KW5>antimicrobial therapy</Res_KW5>
        <Plain_Description>The widespread use of antibiotics has resulted in the emergence of ‘superbugs’ that can no longer be treated by existing drugs. As a result, many patients are dying from these infections, with antibiotic resistance listed as the third-leading cause of death world-wide. In this Investigator grant, I will deliver phage therapy–the use of viruses to treat bacterial infections–into Victorian hospitals to treat antibiotic-resistant infections and fight superbugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026131</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Elissa Deenick</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>A new strategy to transform classification and treatment of autoimmune diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </Fields_of_Research>
        <Res_KW1>immunodeficiency</Res_KW1>
        <Res_KW2>autoimmunity</Res_KW2>
        <Res_KW3>t cells</Res_KW3>
        <Res_KW4>b cells</Res_KW4>
        <Res_KW5>humoral immunity</Res_KW5>
        <Plain_Description>In some people immune cells become dysregulated and attack tissues of the body, resulting in autoimmune diseases such as systemic lupus erythematosus and thyroiditis. Treatments for these diseases often non-specifically suppress the immune system leaving patients susceptible to infection. This project aims to identify what initiates this misguided attack in each patient so that treatment can be personalised to target what is driving their disease rather than just treating the symptoms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026151</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Natalie Fini</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Tailoring Physical Activity Interventions After Stroke to Promote Lifelong Adherence</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$579,632.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | allied health and rehabilitation science | rehabilitation | </Fields_of_Research>
        <Res_KW1>stroke</Res_KW1>
        <Res_KW2>physical activity</Res_KW2>
        <Res_KW3>rehabilitation</Res_KW3>
        <Res_KW4>community intervention study</Res_KW4>
        <Res_KW5>consumer preferences</Res_KW5>
        <Plain_Description>Physical activity is vital for good health, yet the consequences of stroke make being physically active challenging. Generic physical activity programs fail long term after stroke. This Investigator Grant will test tailored programs, that I co-designed with stroke survivors &amp; carers, in innovative early phase trials to guide the next big stroke recovery trial. Ultimately, this research aims to help stroke survivors engage in sustainable physical activity to their improve health long term.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026153</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Zhian Chen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Decipher interleukin-21’s biochemical interactions and engineer next-generation immunotherapies</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>t cells</Res_KW1>
        <Res_KW2>cellular immunology</Res_KW2>
        <Res_KW3>cytokine modifying agents</Res_KW3>
        <Res_KW4>antibody cancer therapy</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>Chronic infections and cancer induce the exhaustion of the immune system. Therapies that prevent such exhaustion provide extraordinary results to some patients with cancer, but the majority show insufficient responses.  I recently identified a novel mechanism that regulates the function of a molecule, which centrally controls immune cell exhaustion. This project will characterise such mechanism and develop next-generation therapies to target this new immune regulatory mechanism.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026158</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Anthea Lindquist</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Using big data and novel methods to inform clinical decision making in obstetrics</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$497,224.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | health sciences | epidemiology | epidemiology not elsewhere classified | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>obstetrics</Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>childhood</Res_KW3>
        <Res_KW4>perinatal</Res_KW4>
        <Res_KW5>maternal health</Res_KW5>
        <Plain_Description>Most perinatal research focusses on short-term maternal and neonatal outcomes. As a result, little is known about the long-term implications, for mothers and children, of exposure to different events or treatments during pregnancy. We propose linking large population-wide datasets together to examine the health and wellbeing of mothers and their babies from conception, through to pregnancy and right through into a child's school years.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026163</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Rebecca Goldstein</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Diabetes and cardiometabolic risk and prevention in pregnancy and beyond </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$445,775.29</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | biomedical and clinical sciences | clinical sciences | endocrinology | health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>diabetes mellitus</Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>overweight/obesity</Res_KW3>
        <Res_KW4>gestational diabetes</Res_KW4>
        <Res_KW5>cardiovascular disease prevention</Res_KW5>
        <Plain_Description>As an active clinician, academic and emerging leader, I bring a strong track record at my early career stage with a research and translation progress that addresses priorities, identifies women at risk for gestational diabetes and cardiometabolic disease and implements interventions to achieve healthy pregnancies in high-risk women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026176</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Elizabeth Elliott</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Fetal Alcohol Spectrum Disorder: improving knowledge, diagnosis and health outcomes </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | health sciences | health services and systems | health surveillance | </Fields_of_Research>
        <Res_KW1>fetal alcohol syndrome</Res_KW1>
        <Res_KW2>child health</Res_KW2>
        <Res_KW3>aboriginal child</Res_KW3>
        <Res_KW4>neurodevelopmental disorders</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>Fetal alcohol spectrum disorder (FASD) is a devastating brain injury caused by exposure to alcohol in pregnancy. It occurs in up to one in 20 children and impacts health, education and justice systems.  As Australia's lead FASD researcher, I will address recommendations in the national action plan and fill knowledge gaps in diagnosis, treatment and prevention of FASD. This work, in remote communities, juvenile justice and out-of-home care, will inform models of care and improve life outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026191</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ian Harding</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Hereditary Cerebellar Ataxias: Next-Generation Biomarker Discovery on a Global Scale</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>ataxia</Res_KW1>
        <Res_KW2>magnetic resonance imaging (mri)</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>neurodegeneration</Res_KW4>
        <Res_KW5>spino-cerebellar disturbance</Res_KW5>
        <Plain_Description>Hereditary cerebellar ataxias (HCAs) are rare, fatal genetic disorders that severely impact day-to-day function and currently have no cure. The relative rarity of HCAs makes it challenging to understanding how different patterns of brain changes and symptoms may affect different people. This research will take a global approach to understanding HCAs using magnetic resonance imaging, web-based clinical assessments, and testing of new measurement approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026257</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Stacey Ellery</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Creatine: The Next Frontier in Nutritional Supplements to Reduce Perinatal Brain Injury</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>birth asphyxia</Res_KW1>
        <Res_KW2>very preterm birth</Res_KW2>
        <Res_KW3>maternal nutrition</Res_KW3>
        <Res_KW4>brain metabolism</Res_KW4>
        <Res_KW5>cerebral palsy treatments</Res_KW5>
        <Plain_Description>Birth complications, caused by arriving too early or after a difficult labour, are associated with poor brain outcomes for the baby. This stems from the baby’s brain cells not having enough energy after birth. Creatine serves as our cell’s back-up energy generator. I propose that supplementing pregnant women or newborns with creatine will supercharge this battery, ensuring energy resources are available to prevent injury and support growth and development in the event of birth complications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026259</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kate Hodgson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving respiratory outcomes for preterm infants</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$497,224.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>premature infant</Res_KW1>
        <Res_KW2>resuscitation</Res_KW2>
        <Res_KW3>neonatal respiratory distress syndrome</Res_KW3>
        <Res_KW4>caffeine</Res_KW4>
        <Res_KW5>neonatal intensive care (nicu)</Res_KW5>
        <Plain_Description>Babies born early (preterm) often need support to breathe and are at risk of long-term health problems with their lungs. The treatments that we provide to help preterm babies’ breathing soon after birth are life-saving. It is important to improve care for preterm babies during this critical period, to maximise their chances of a healthy, productive life. My research looks at ways to improve the procedures and medicines used for babies born early.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026262</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jieying Liang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Hetero-Single Atom Nanozymes Cascade for Oncotherapy</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | nanotechnology | nanomaterials | chemical sciences | inorganic chemistry | metal organic frameworks | </Fields_of_Research>
        <Res_KW1>experimental oncology</Res_KW1>
        <Res_KW2>cell killing</Res_KW2>
        <Res_KW3>biomaterials</Res_KW3>
        <Res_KW4>cancer</Res_KW4>
        <Res_KW5>anti-tumour agents</Res_KW5>
        <Plain_Description>Each year, many Australians die from one of the biggest killers in Australia and globally, malignant tumors. There is a high demand for effective treatment strategies. However, published evidence suggests that it is still a challenge to develop novel nanoplatform for highly efficient oncotherapy due to the complexity and heterogeneity of the tumoral tissues. My research aims to provide effective strategies to highly efficient oncotherapy and improve survival from the malignant tumors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026263</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Sharon Goldfeld</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Changing Children's Chances: a research framework to take evidence into action</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,448,582.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | health sciences | health services and systems | implementation science and evaluation | health sciences | epidemiology | social epidemiology | </Fields_of_Research>
        <Res_KW1>translational research</Res_KW1>
        <Res_KW2>child health</Res_KW2>
        <Res_KW3>child development</Res_KW3>
        <Res_KW4>equity</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Addressing inequities early in life will fundamentally change children’s chances and create a healthier and more productive future adult population. My exciting research program will provide robust evidence to help transform the Australian service system through studies that focus on using data to understand what works, testing interventions in the field and using new system tools to enable change. We will work with our partners and end users to go fast and ensure effective changes last.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026272</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr John Kemp</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Using human genetics, single cell transcriptomics and animal models to accelerate drug development for patients with osteoporosis. </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>statistical genetics</Res_KW1>
        <Res_KW2>genetic epidemiology</Res_KW2>
        <Res_KW3>musculoskeletal disorders</Res_KW3>
        <Res_KW4>genetic association</Res_KW4>
        <Res_KW5>differential gene expression</Res_KW5>
        <Plain_Description>Osteoporosis is a major health burden for society. It is associated with progressive bone loss, which leads to bone fractures. This project applies innovative statistical and molecular analyses to identify new cell types that regulate bone, as well as genes that control the function of these cells. Many of the cells, and genes uncovered by this study are likely to represent new treatment opportunities that restore bone and prevent fracture in patients with osteoporosis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026300</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Denise Wootten</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Mechanistic understanding of biased agonism and dimerisation for co-targeting incretin receptors for metabolic diseases</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>g protein-coupled receptors</Res_KW1>
        <Res_KW2>receptor dimerisation</Res_KW2>
        <Res_KW3>structural biology</Res_KW3>
        <Res_KW4>molecular pharmacology</Res_KW4>
        <Res_KW5>intracellular signalling</Res_KW5>
        <Plain_Description>Receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are attractive therapeutic targets for type 2 diabetes and obesity, with drugs that co-target both receptors having potential for superior clinical outcomes. This proposal will determine the mechanisms for how these receptors work, and insights into how to co-target them for better therapeutic efficacy, which will impact on the development of future drugs to treat major metabolic health burdens.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026307</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lucy Palmer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Decoding the brain: the function and dysfunction of cortical neurons</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,569,655.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>cortex</Res_KW1>
        <Res_KW2>neurons</Res_KW2>
        <Res_KW3>learning</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>memory disorders</Res_KW5>
        <Plain_Description>The function of the largest area of our brain, the cortex, is one of the great mysteries of neuroscience and despite decades of research, its role in complex brain function, such as learning and memory, is largely unrealised. This project will reveal the role the cortex play in learning and memory formation, and will probe how cortical neurons are disrupted in brain cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026315</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Aleksandra Filipovska</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Tackling mitochondrial dysfunction: understanding and treating metabolic diseases</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,697,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>mitochondria</Res_KW1>
        <Res_KW2>mitochondrial disease</Res_KW2>
        <Res_KW3>inherited metabolic disorders</Res_KW3>
        <Res_KW4>mitochondrial respiration</Res_KW4>
        <Res_KW5>therapeutics</Res_KW5>
        <Plain_Description>Research into mitochondrial diseases (MD) is critical as recent work has shown that mitochondrial mutations can affect at least one in 200 Australians, who are at an increased risk of developing serious health problems. Because MD results in energy depletion in the body, the consequences are usually devastating and include neurological disorders and heart failure that can result in premature death. My research will provide new hopes for diagnosing and treating MD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026317</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Didu Kariyawasam</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>The development and clinical translation of a precision medicine paradigm for children with neurogenetic diseases: harnessing the potential of neurodiagnostics and advanced therapeutics to improve outcomes. </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>rare diseases</Res_KW1>
        <Res_KW2>neurological diseases</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>newborn screening</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>Advances in genetic technology mean that early diagnosis and individualized treatment for previously fatal rare neurological diseases are now possible. My program will improve diagnostic efficiency through development of a national newborn screening framework for rare neurological diseases, deliver targeted and individualistic treatments equitably and effectively through a program of biomarker discovery and evaluate optimal ways to translate research innovations into best clinical practice.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026318</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Reuben Rideaux</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Using artificial intelligence to understand impaired sensory processing in autism </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$641,550.58</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | cognitive and computational psychology | sensory processes, perception and performance | biomedical and clinical sciences | neurosciences | computational neuroscience (incl. mathematical neuroscience and theoretical neuroscience) | </Fields_of_Research>
        <Res_KW1>cognitive neuroscience</Res_KW1>
        <Res_KW2>artificial neural networks</Res_KW2>
        <Res_KW3>sensory systems</Res_KW3>
        <Res_KW4>functional magnetic resonance imaging (fmri)</Res_KW4>
        <Res_KW5>magnetic resonance spectroscopy (mrs)</Res_KW5>
        <Plain_Description>Our perception of the world is shaped by combining information from our senses. Deficits in multisensory integration are thought to underlie some of the core impairments of brain disorders such as autism and schizophrenia. This research will characterise the brain mechanisms and consequences of multisensory integration impairments using machine learning and brain imaging. Ultimately, this work will inform targeted interventions and help us to better treat people with brain disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026320</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Daisy Coyle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Combating the rise of ultra-processed food consumption in Australia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>food intake</Res_KW1>
        <Res_KW2>diet</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>disease modelling</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>One in every five deaths are linked to unhealthy diets.  A major issue with Australian diets is the high level of ultra-processed foods, which is driving excess intakes of sugar, salt and unhealthy fats. Despite this, there are currently no government policies in place that specifically target these foods.  This program of work aims to improve existing policies and deliver new regulation that can effectively reduce ultra-processed food consumption for healthier Australian diets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026321</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Hart</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Mental Health in Schools: Research and development of MHFA training to increase early intervention and suicide prevention in primary and secondary schools</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,468,952.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | adolescent health | health sciences | public health | community child health  | psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>primary school-aged children</Res_KW2>
        <Res_KW3>adolescent health</Res_KW3>
        <Res_KW4>school-based intervention</Res_KW4>
        <Res_KW5>suicide prevention</Res_KW5>
        <Plain_Description>Mental health first aid (MHFA) is the help provided to a person who is developing a mental health problem or experiencing a mental health crisis, until appropriate professional help is received, or the crisis resolves. MHFA training programs are known to increase knowledge and skills in responding to mental ill-health. This research will develop and evaluate new MHFA training programs for Australian parents, teachers and students to improve mental health in primary and secondary schools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026322</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Hooper</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Assisting Infants transition at birth</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>birth</Res_KW1>
        <Res_KW2>premature birth</Res_KW2>
        <Res_KW3>apnoea of prematurity</Res_KW3>
        <Res_KW4>neonatal respiratory distress syndrome</Res_KW4>
        <Res_KW5>fetal circulation</Res_KW5>
        <Plain_Description>The transition from life in the womb to life after birth, is an incredibly challenging and vulnerable period of our lives. For most, the birth of a newborn baby is a joyous occasion, but this event can be marred by tragedy and life-long disability. I am a world leader in how babies transition to newborn life and my aim is to minimise these adverse outcomes by understanding why things go wrong and targeting treatments to the different needs of the infants as they transition to newborn life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026325</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Paul Lacaze</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Genomics applied to public health and prevention</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>genomics</Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>disease prevention</Res_KW3>
        <Res_KW4>genetic screening</Res_KW4>
        <Res_KW5>genetic predisposition</Res_KW5>
        <Plain_Description>Genomic testing has the potential to deliver public health benefits to Australians through improved risk prediction, early detection and disease prevention. I am positioned ideally to take a leadership role in helping realize this potential. My research proposal includes work in genomic risk prediction, population DNA screening and health economics to deliver benefit to Australians through genomics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026331</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Peter Georgeson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Clinical application of tumour mutational signatures for precision prevention of colorectal cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>colorectal cancer</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>cancer genetics</Res_KW4>
        <Res_KW5>molecular oncology</Res_KW5>
        <Plain_Description>Colorectal cancer is the second deadliest cancer, and is rapidly increasing in incidence in younger Australians, but colorectal cancer can be prevented with targeted screening of high-risk individuals.     I aim to reduce the burden of colorectal cancer by utilising state-of-the-art computational methods that identify patterns in DNA mutations to accurately identify which individuals are most at risk of developing colorectal cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026339</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Alison Yung</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Negative symptoms and metabolic abnormalities in early psychosis </Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>early psychosis</Res_KW1>
        <Res_KW2>negative symptoms</Res_KW2>
        <Res_KW3>metabolic syndrome</Res_KW3>
        <Res_KW4>schizophrenia and related disorders</Res_KW4>
        <Res_KW5>psychosis</Res_KW5>
        <Plain_Description>Negative symptoms such as lack of drive and problems with communication, and metabolic problems such as diabetes and obesity are common in schizophrenia. They may have the same underlying cause. Possible causes are poorly functioning mitochondria (the parts of cells that generate energy), chronic inflammation, oxidative stress and problems with gut health. However we don’t know when these problems start and whether they can be prevented or reversed. This research will investigate these issues.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026349</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kevin M Koo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Integrated biosensor for multi-omics profiling of cancer biomarkers via molecular manipulation</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | chemical sciences | analytical chemistry | bioassays | </Fields_of_Research>
        <Res_KW1>molecular diagnostics</Res_KW1>
        <Res_KW2>biosensor</Res_KW2>
        <Res_KW3>cancer detection</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>prostate cancer</Res_KW5>
        <Plain_Description>For effective cancer treatment, it is necessary to gain complete understanding of the tumor’s mutations on all deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and protein levels. Currently, there is no quick and cost-friendly method to achieve this information for individual cancer patients. My proposal will provide new knowledge to create a world-first detection platform that integrates DNA, RNA and protein mutation analysis with quick results and low cost for widespread patient benefit.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026350</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr ERNEST EKPO</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>SMaRT-P: Streamlined Mammography Recall and Triaging Pathways 11</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </Fields_of_Research>
        <Res_KW1>breast cancer diagnosis</Res_KW1>
        <Res_KW2>breast cancer prevention</Res_KW2>
        <Res_KW3>breast cancer</Res_KW3>
        <Res_KW4>early detection</Res_KW4>
        <Res_KW5>early diagnosis</Res_KW5>
        <Plain_Description>Annually, 180,000 screened women are called back for additional testing because radiologists think their mammograms contain cancer. Luckily, only 1 in 10 women is confirmed to have cancer and 9 in 10 are given all clear after undergoing a series of unnecessary testing, which deters them from reattending screening. This program of research will reduce the number of women who are wrongly called back for additional testing and improve the testing that is done in assessment to reduce cost and harms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026356</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Jennings</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Discovery and exploitation of glycointeractions to create new opportunities to diagnose, prevent and treat disease</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | biological sciences | biochemistry and cell biology | glycobiology | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>bacterial toxins</Res_KW1>
        <Res_KW2>cell surface receptor</Res_KW2>
        <Res_KW3>glycobiology</Res_KW3>
        <Res_KW4>malaria</Res_KW4>
        <Res_KW5>cancer detection</Res_KW5>
        <Plain_Description>Carbohydrates cover the surface of every form of life from viruses and bacteria to human cells These carbohydrates are referred to as glycans and frequently serve as important recognition sites for biological processes that occur in health and disease. Disease causing viruses, bacteria and parasites often target human cells via glycan interactions. In this program, I will exploit our discoveries in glycan interactions to implement new strategies to diagnose, treat and prevent disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026357</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Louise Rowntree</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing optimal anti-viral CD8+ T cell immunity for high-risk populations</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>immunology</Res_KW1>
        <Res_KW2>cellular immunity</Res_KW2>
        <Res_KW3>viral immunology</Res_KW3>
        <Res_KW4>sars-cov-2</Res_KW4>
        <Res_KW5>influenza</Res_KW5>
        <Plain_Description>Killer T cells recognise short protein fragments (peptides) derived from viruses and presented on the surface of virus-infected cells. I will investigate killer T cells that recognise specific fragments from influenza viruses and SARS-CoV-2, and their ability to provide long-lasting immunity and hence protection against future infections in high-risk populations. This knowledge will be used in vaccine strategies aimed at providing universal immunity to influenza strains &amp; SARS-CoV-2 variants.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026360</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Deborah Cromer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Control of Infectious Disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | applied mathematics | biological mathematics  | health sciences | epidemiology | epidemiological modelling | </Fields_of_Research>
        <Res_KW1>mathematical modelling</Res_KW1>
        <Res_KW2>vaccination policy</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>human immunodeficiency virus (hiv)</Res_KW4>
        <Res_KW5>immunology</Res_KW5>
        <Plain_Description>This research will employ a truly unique interdisciplinary approach to understanding infection and immunity. Recently there has been an explosion in experimental and clinical data without a corresponding increase in the necessary skills to interpret them. In this investigator grant I will apply my strong and proven skills of communication across the two very diverse fields of mathematics and biology to answer fundamental questions in the fields of immunity and vaccination policy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026364</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Ester Derks</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Translating the results of genetic studies into more effective neuropsychiatric treatments</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,461,793.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | psychology | biological psychology  | biological psychology not elsewhere classified | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>treatment efficacy</Res_KW2>
        <Res_KW3>genetic association</Res_KW3>
        <Res_KW4>genetics</Res_KW4>
        <Res_KW5>neurodegenerative disorders</Res_KW5>
        <Plain_Description>Neuropsychiatric disorders are the leading cause of global disease burden. While current interventions are effective in some cases, there remains a substantial burden that cannot be mitigated with existing approaches. I will use genetic discoveries for neuropsychiatric disorders to identify more effective treatment for neuropsychiatric disorders and address the urgent need for drugs with improved efficacy and reduced toxicity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026377</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Mariapia Degli-Esposti</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Harnessing the immune system to treat viral infections and their complications</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,753,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>immunology</Res_KW1>
        <Res_KW2>viral infection</Res_KW2>
        <Res_KW3>immune regulation</Res_KW3>
        <Res_KW4>chronic inflammation</Res_KW4>
        <Res_KW5>bone marrow transplantation</Res_KW5>
        <Plain_Description>Immunological processes are responsible for fighting infection and cancer, but if not limited can result in inflammatory diseases and autoimmunity. Understanding how immune responses are regulated is key to striking the balance that ensures protection from infection but prevents deleterious inflammation (i.e. optimal immunity). My program will fundamentally advance knowledge of how the immune system is regulated so it can be harnessed to treat chronic viral infections and their complications.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026380</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lexine Stapinski</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Innovative solutions to prevent and treat the vicious cycle of anxiety and alcohol use</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,578,148.15</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>alcohol dependence</Res_KW1>
        <Res_KW2>anxiety</Res_KW2>
        <Res_KW3>mental health promotion</Res_KW3>
        <Res_KW4>aboriginal mental health</Res_KW4>
        <Res_KW5>substance use</Res_KW5>
        <Plain_Description>Alcohol use disorders are a leading cause of death and disability. They frequently co-occur with, and are developmentally related to, symptoms of anxiety. Alcohol is often consumed to reduce or cope with anxiety, and this maladaptive pattern of coping increases severity of both anxiety and alcohol use, and interferes with recovery. The proposed research will provide new knowledge and interventions to prevent and treat the mutually-reinforcing connections between anxiety and alcohol use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026395</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Clare Parish</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Utilising human stem cell to develop advanced therapies for brain repair</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | engineering | biomedical engineering | neural engineering | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | </Fields_of_Research>
        <Res_KW1>stem cells</Res_KW1>
        <Res_KW2>neural transplantation</Res_KW2>
        <Res_KW3>neural stem cell</Res_KW3>
        <Res_KW4>parkinson disease</Res_KW4>
        <Res_KW5>neural regeneration</Res_KW5>
        <Plain_Description>With a rapidly ageing population there is a pressing need to develop new therapies to treat neurological conditions. This grant focuses on the use of human stem cells to: (1) provide superior models of human brain diseases that can be used to enhance our understanding of disease mechanisms and screen new drugs and, (2) repair the injured brain through neural transplantation. The project will also test and deliver a human stem cell product for Phase I clinical trial in stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026397</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Katherine Mills</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Disrupting the cycle of post-traumatic stress and substance use disorders: Innovations in treatment and early intervention</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>posttraumatic stress disorder (ptsd)</Res_KW1>
        <Res_KW2>substance use disorders</Res_KW2>
        <Res_KW3>traumatic stress</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>addiction treatment</Res_KW5>
        <Plain_Description>Post-traumatic stress disorder (PTSD) is a chronic and disabling mental health disorder that is frequently complicated by co-occurring alcohol and/or other drug use. The proposed program of work builds on our pioneering discoveries in this field to improve our understanding of effective treatment and early intervention responses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026400</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Gillian Caughey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Harnessing Real-World Data to Drive High Quality Care for Australia's Aged Care Population</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,369,655.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | </Fields_of_Research>
        <Res_KW1>aged care</Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>pharmacoepidemiology</Res_KW3>
        <Res_KW4>health care evaluation</Res_KW4>
        <Res_KW5>ageing population</Res_KW5>
        <Plain_Description>The recent Aged Care Royal Commission recommended urgent action to improve the quality and safety of care for our older population receiving aged care. My research aims to inform the best ways to provide high-quality person centred-care using a national linked aged care and health care data platform, the Registry of Senior Australians. The evidence will inform policy and importantly improvements in care delivery, to improve the health and well-being of Australia's aged care population.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026403</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Phillip Darcy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Development of new strategies for enhancing CAR T cell therapy of cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>cancer immunology</Res_KW2>
        <Res_KW3>t cell immunotherapy</Res_KW3>
        <Res_KW4>tumour immunotherapy</Res_KW4>
        <Res_KW5>gene transfer</Res_KW5>
        <Plain_Description>Novel therapies that stimulate the immune system (immunotherapy) to fight cancer has resulted in unprecedented effects for some patients however many cancers remain resistant to all forms of treatment. My program will overcome the major barriers to the success of immunotherapy through the use of highly innovative approaches and cutting edge technologies. The most promising approaches will be translated into patients through the Peter Mac 'National Centre of Excellence in Cellular Immunotherapy'.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026408</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jane Pirkis</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Strengthening the evidence base for suicide prevention</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | social epidemiology | </Fields_of_Research>
        <Res_KW1>suicide</Res_KW1>
        <Res_KW2>suicide prevention</Res_KW2>
        <Res_KW3>suicide risk</Res_KW3>
        <Res_KW4>population health</Res_KW4>
        <Res_KW5>epidemiology</Res_KW5>
        <Plain_Description>Preventing suicide is critical. We know too little about how to do this, largely because the interventions we have available to us have not been evaluated in rigorous ways. The proposed research will use cluster randomised controlled trials, data linkage studies and interrupted time series studies that will allow us to determine whether certain interventions work and provide good value for money. The research will inform the roll-out of Australia’s new National Suicide Prevention Strategy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026413</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ye Ella Tian</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving physical health in people with mental illness </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>neuroimaging</Res_KW1>
        <Res_KW2>mental illness</Res_KW2>
        <Res_KW3>physical health</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>comorbidity</Res_KW5>
        <Plain_Description>Recognising and treating chronic physical illness (e.g., coronary heart disease, stroke, obesity, diabetes) in people with mental health challenges is an unmet clinical need. My research aims to study the biological underpinnings of physical illness in psychiatry. This is expected to provide a foundation for integrated physical-mental health care in psychiatry and ultimately improve the physical health of people with mental illness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026430</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Clark</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Defining the Impact of Epigenome Remodelling in Cancer </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,353,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | genetics | genome structure and regulation | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>epigenetics</Res_KW1>
        <Res_KW2>dna methylation</Res_KW2>
        <Res_KW3>chromatin structure</Res_KW3>
        <Res_KW4>control of gene expression</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>Current challenges to improving breast &amp; prostate cancer survival are a lack in the ability to identify mechanisms involved in therapy resistance &amp; lack of tests available to monitor therapy effectiveness or cancer relapse. This research program, using epigenomic &amp; single cell genomics, will deliver new mechanistic insights into how the cancer epigenome is disrupted; determine effectiveness of epigenetic therapy to combat endocrine resistance; &amp; develop new blood tests for clinical cancer care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026484</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof C. Barnaby Nelson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title> The Prediction and Treatment of Early Stage Psychosis: Sharpening the Tools, Broadening the Target, and Innovating the Interventions</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>early psychosis</Res_KW2>
        <Res_KW3>schizophrenia and related disorders</Res_KW3>
        <Res_KW4>prevention</Res_KW4>
        <Res_KW5>risk factors</Res_KW5>
        <Plain_Description>This research program will:   a) Develop tools for predicting which individuals with sub-threshold symptoms are at greatest risk of progressing to a psychotic disorder  b) Shed light on causes of psychotic disorders  c) Introduce a new approach for identifying help-seeking young people at risk of a range of serious mental disorders   d) Develop new treatments for individuals at high risk or in the early stages of psychotic disorders and enable us to better match treatments to individual patients  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026490</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Sharon Lewin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>NOVEL INTERVENTIONS TO TREAT AND CURE ACUTE AND CHRONIC VIRAL INFECTIONS</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv)</Res_KW1>
        <Res_KW2>anti-latency drugs</Res_KW2>
        <Res_KW3>immunotherapy</Res_KW3>
        <Res_KW4>messenger rna (mrna)</Res_KW4>
        <Res_KW5>covid-19</Res_KW5>
        <Plain_Description>Better treatments are needed for virus infections. In this project I will use novel approaches to quantify and also eliminate long lived forms of HIV that persist on antiviral therapy, through triggering suicide of the infected cells and boosting immunity. I will leverage advances in mRNA therapeutics and gene editing as a novel strategy to treat SARS-CoV2, which could be used to treat other new respiratory viruses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026504</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Wen Shi Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing antiviral antibodies for pandemic preparedness</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$579,632.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>antibody</Res_KW1>
        <Res_KW2>fc receptors</Res_KW2>
        <Res_KW3>coronavirus</Res_KW3>
        <Res_KW4>monoclonal antibody</Res_KW4>
        <Res_KW5>messenger rna (mrna)</Res_KW5>
        <Plain_Description>The COVID-19 pandemic emphasised the crucial role of antibodies in preventing and treating viral infections via vaccination or antiviral drugs. This project will enhance our comprehension of how antibodies contribute to antiviral immunity and develop innovative antibody therapeutics against emerging pandemic viruses. The knowledge gained will improve antibody drug manufacturing and delivery methods, enhancing preparedness against future pandemics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026519</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Perret</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Detecting and Preventing Lung and Heart Disease related to COPD at a “Young” Age</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>chronic obstructive pulmonary disease (copd)</Res_KW1>
        <Res_KW2>early detection</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>lung function</Res_KW4>
        <Res_KW5>early diagnosis</Res_KW5>
        <Plain_Description>Chronic obstructive pulmonary disease (COPD) is a major cause of premature lung and heart-related deaths. Yet we do not know how to best detect severe disease in younger adults when it is in its first stages of development. My research program will address key gaps in understanding ‘early-onset COPD’, advance its detection in young adults, and determine how to reduce risks for those who also have heart disease. The work will inform interventions and drug trials to prevent and better treat COPD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026525</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Fana Alemseged</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>IMPROVING OUTCOMES OF PATIENTS WITH POSTERIOR CIRCULATION ISCHEMIC STROKE</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>ischaemic stroke</Res_KW1>
        <Res_KW2>reperfusion</Res_KW2>
        <Res_KW3>stroke outcome</Res_KW3>
        <Res_KW4>thrombolysis</Res_KW4>
        <Res_KW5>alternative thrombolytic agents</Res_KW5>
        <Plain_Description>One in ?ve ischemic strokes affects the posterior circulation. Basilar artery occlusion is a rare but devastating (80-90% disability and mortality) type of stroke caused by a blockage in the basilar artery, a blood vessel in the back of the brain. The optimal treatment for this devastating and under-researched disease has not yet been identified. This research program aims to deliver improved outcomes in these patients through practice changing clinical care research in the hyperacute setting.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026530</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Yuchen Feng</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Exploiting long noncoding RNAs for lung cancer diagnosis and treatment</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$579,632.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>cancer cell biology</Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>therapeutic target</Res_KW4>
        <Res_KW5>molecular mechanisms</Res_KW5>
        <Plain_Description>Cancer cells exploit a newly discovered class of molecules for their growth and resistance to treatment. This research program will develop a better understanding of how these molecules influence lung cancer initiation and treatment response. It will also uncover new biomarkers that reveal the presence of lung cancer, as well as new molecular targets for anti-cancer drugs. Findings from this research will pave the way towards earlier detection of lung cancer and more effective cancer treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026533</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Arisbel Gondin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing safer therapeutic approaches for the treatment of pain via allosteric regulation of opioid receptors</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$587,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>g protein-coupled receptors</Res_KW1>
        <Res_KW2>molecular pharmacology</Res_KW2>
        <Res_KW3>membrane protein</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>structural biology</Res_KW5>
        <Plain_Description>This project aims to develop safer and more effective pain treatments by improving the pharmacological profiles and delivery methods of opioid allosteric drugs. Unlike conventional opioids that cause serious and potentially lethal adverse effects, these drugs enhance the body's natural pain-relief system and have fewer side effects. This research has the potential to benefit millions of people suffering from chronic pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026552</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Cath Chapman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Gender-informed prevention of mental health and substance use problems: addressing a changing global landscape in adolescence and beyond</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,578,148.15</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | epidemiology | social epidemiology | </Fields_of_Research>
        <Res_KW1>substance use</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>adolescence</Res_KW3>
        <Res_KW4>prevention</Res_KW4>
        <Res_KW5>gender differences</Res_KW5>
        <Plain_Description>Mental and substance use disorders are among the leading causes of burden of disease in Australia and globally. Yet, responses are not driven by understanding of gender-specific differences in prevalence, risk and harms. Moreover, recent evidence points to significant gender-specific shifts with respect to these disorders. This research will answer key questions on the impact of these gender-specific changes to inform the development of contemporary prevention programs for young Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026567</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Whiteman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Melanoma and Skin Cancer: Burden, Prevention and Control</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,610,344.39</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | dermatology | </Fields_of_Research>
        <Res_KW1>malignant melanoma</Res_KW1>
        <Res_KW2>sun protection</Res_KW2>
        <Res_KW3>non-melanoma skin cancer</Res_KW3>
        <Res_KW4>solar ultraviolet (uv) radiation</Res_KW4>
        <Res_KW5>cohort study</Res_KW5>
        <Plain_Description>Skin cancers are the most common cancers affecting humans, and Australians suffer the highest rates in the world. Most skin cancers are preventable, but regrettably, hundreds of thousands of Australians undergo painful skin cancer treatments each year, and thousands more die. This huge toll means that all Australians have a stake in arresting the skin cancer epidemic. This application focuses on building the evidence base needed to develop new approaches to prevent and control skin cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026573</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Mr Jeremy Anderson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Elucidating immune susceptibility to severe RSV disease in preterm infants</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>respiratory syncytial virus</Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>clinical immunology</Res_KW3>
        <Res_KW4>acute inflammation</Res_KW4>
        <Res_KW5>cellular immunity</Res_KW5>
        <Plain_Description>Respiratory Syncytial Virus (RSV) is the leading cause of respiratory infection in children under 2 years of age. Children born preterm are more likely to develop severe RSV disease and require hospitalisation. No vaccine is available and current therapies are limited. This study will use patient samples to investigate why children born preterm are more likely to develop severe RSV disease. This will help us to define strategies to reduce the burden of disease in this highly vulnerable group.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026574</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jake Baum</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Next generation malaria vaccines targeting the parasite cell surface</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biomedical and clinical sciences | immunology | immunology not elsewhere classified | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>malaria vaccine</Res_KW1>
        <Res_KW2>cell biology</Res_KW2>
        <Res_KW3>vaccines</Res_KW3>
        <Res_KW4>systems biology</Res_KW4>
        <Res_KW5>vaccination immunology</Res_KW5>
        <Plain_Description>More than half a million children die each year from malaria infection.  Infection starts with a mosquito bite when sporozoites, the single-celled malaria parasite form, are released into the skin. To advance the possibility of an effective, critically needed malaria vaccine, this Investigator will use unique tools to define sporozoites in precise genetic, protein and immunological detail - using these insights to design and test tomorrow’s malaria vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026577</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kristen Gibbons</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving the lives of critically ill children through innovative trials of precision medicine</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | biomedical and clinical sciences | clinical sciences | intensive care  | mathematical sciences | statistics | biostatistics | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>intensive care</Res_KW3>
        <Res_KW4>biostatistics</Res_KW4>
        <Res_KW5>methodology</Res_KW5>
        <Plain_Description>There is a lack of high-quality research to help doctors and nurses treat the sickest children in Australia. I will work with the families of these children to identify what research is most important them. I will then use information that is collected during the child's hospital stay and from blood test results to develop new treatments that are personalised for each child, and test this personalised approach in Paediatric Intensive Care Units internationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026593</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michelle Dickson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Aboriginal and Torres Strait Islander wellbeing: developing and implementing culturally relevant and robust wellbeing measures </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,769,655.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing | </Fields_of_Research>
        <Res_KW1>aboriginal mental health</Res_KW1>
        <Res_KW2>wellbeing</Res_KW2>
        <Res_KW3>health service utilisation</Res_KW3>
        <Res_KW4>aboriginal health</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>Aboriginal and Torres Strait Islander people’s understandings of wellbeing are holistic, multi-dimensional and connected with community, culture and Country. Existing quality of life measures do not capture Aboriginal and Torres Strait Islander understandings of wellbeing. The project will develop and implement wellbeing measures through an Aboriginal and Torres Strait Islander lens to seek better understanding of wellbeing and inform policy, systems and service change.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026621</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr BRENDON NEUEN</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving cardio-renal-metabolic outcomes with SGLT2 inhibitors</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>kidney disease</Res_KW1>
        <Res_KW2>cardiovascular disease</Res_KW2>
        <Res_KW3>diabetes</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>meta-analysis</Res_KW5>
        <Plain_Description>SGLT2 inhibitors are a new class of medicine that can lower the risk of heart and kidney disease, but there is still a lot we don't know about them and, as a result, they are underused. This research brings together all the data from clinical trials to better understand how effectively SGLT2 inhibitors work in different patients. It will also look at how often SGLT2 inhibitors are used in Australia and find ways to ensure those who would benefit most from this medicine receive it.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026628</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Fiona Simpson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Traffic calming: Clinically applicable ways of altering endocytosis (cell uptake) to improve drug pharmacology and efficacy.</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,697,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | protein trafficking | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>receptor trafficking</Res_KW1>
        <Res_KW2>protein trafficking</Res_KW2>
        <Res_KW3>endocytosis</Res_KW3>
        <Res_KW4>pharmacodynamics</Res_KW4>
        <Res_KW5>antibody</Res_KW5>
        <Plain_Description>My laboratory team discovered a way to improve antibody therapy in humans and showed the drug combination is safe and acceptable to people undergoing the treatment. I am developing this technology testing applications in various disease / antibody therapy setting and Phase II clinical trials.  We are developing research on controlling immune responses and on how cancer cells escape immune cells with an aim to identify drug targets to deliver cancer therapies which prevent tumour recurrence.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026631</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Philip Hogg</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving durability of treatment for haemophilia A</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,953,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | </Fields_of_Research>
        <Res_KW1>protein engineering</Res_KW1>
        <Res_KW2>protein biochemistry</Res_KW2>
        <Res_KW3>blood disorders</Res_KW3>
        <Res_KW4>haematological disorders</Res_KW4>
        <Res_KW5>haemorrhage</Res_KW5>
        <Plain_Description>Haemophilia A affects 1 in 5000 males and is due to dysfunctional clotting factor FVIII that results in significant morbidity and increased mortality. Treatment with replacement FVIII does not work in one third of patients due to production of neutralising antibodies. FVIII gene therapy is showing promise, however expression of FVIII kills the transfected cells. This project is based on a new discovery about FVIII that may be exploited to overcome these roadblocks with current therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026634</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sarah Bendall</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Towards a trauma-informed youth mental health service sector: Building the evidence-base</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,410,333.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | psychology | clinical and health psychology | clinical psychology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>posttraumatic stress disorder (ptsd)</Res_KW1>
        <Res_KW2>mental health services</Res_KW2>
        <Res_KW3>early intervention</Res_KW3>
        <Res_KW4>trauma</Res_KW4>
        <Res_KW5>traumatic stress</Res_KW5>
        <Plain_Description>Many young people have experienced traumas such as child abuse or community disasters such as bushfire or COVID-19. However, their needs are not adequately addressed in youth mental health services. Trauma-informed care has been stipulated in key mental health policy directives but not researched. In consultation with services and youth consumers, in this research program I will develop evidence-based trauma-informed care models for headspace and other youth mental health services in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026635</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Winnie Tan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Capturing atomic snapshots to visualise chromatin remodelling machinery for disease insights and drug discovery</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>protein biochemistry</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>molecular biology</Res_KW3>
        <Res_KW4>cellular mechanisms</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Packaging DNA into a 3D structure dictates how a gene functions. The Microrchidia CW-Type Zinc Finger 2 (MORC2) is an enzyme that modifies the structure of DNA for gene expression. Mutations in MORC2 are associated with severe muscle weakness and specific cancers, but we lack a thorough understanding of how it is regulated for disease prevention. This program will structurally investigate the regulation of MORC2 using cryo-electron microscopy to drive the development of treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026643</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Papenfuss</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Harnessing multi-omics for precise cancer insights</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>genomic instability</Res_KW4>
        <Res_KW5>data analysis</Res_KW5>
        <Plain_Description>Cancer progression and outcome are governed by diverse molecular factors in the patient and their tumour. This research will develop new computational methods to discover these molecular determinants of progression &amp; outcome from molecular snapshots of the patients with cancer. This will accelerate cancer discoveries, identify new predictive biomarkers, and advance precision medicine with new clinical decision support tools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026648</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Joseph Doyle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Innovative models of care to eliminate hepatitis C as a public health threat</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>hepatitis c infection</Res_KW1>
        <Res_KW2>health systems</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>clinical diagnosis</Res_KW4>
        <Res_KW5>antiviral therapy</Res_KW5>
        <Plain_Description>Seventy million people live with hepatitis C globally, which causes early death and liver disease, with ongoing transmission chiefly among vulnerable groups. Eliminating hepatitis C as a public health threat by 2030 is a WHO global health priority. My investigator grant will address key knowledge gaps in the elimination agenda. It will determine how effectively, efficiently, and sustainably new models of care delivered to key populations accelerate progress toward hepatitis C elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026668</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hannah Carter</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Health care delivery at the end of life: economic methods to improve value for patients, carers, and society</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$637,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | health sciences | health services and systems | palliative care | economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>economic evaluation</Res_KW1>
        <Res_KW2>costs</Res_KW2>
        <Res_KW3>end-of-life decision making</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>consumer preferences</Res_KW5>
        <Plain_Description>More than half of Australian deaths now occur in hospital, where some patients receive inappropriate or non-beneficial treatment. My research will estimate the patterns and drivers of healthcare costs over the last 12 months of life and model the impact of interventions to improve care. I will conduct choice experiments to better understand consumer, caregiver and community preferences. Outcomes will inform the development of higher quality, person centred models of care at the end of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026703</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Leanne Togher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Delivering technology-enabled care for people with acquired brain injury at scale</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,553,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | rehabilitation | </Fields_of_Research>
        <Res_KW1>allied health</Res_KW1>
        <Res_KW2>rehabilitation services</Res_KW2>
        <Res_KW3>speech pathology</Res_KW3>
        <Res_KW4>acquired brain injury</Res_KW4>
        <Res_KW5>communication skills</Res_KW5>
        <Plain_Description>Brain injury can occur to us at any time, with causes including car crashes and stroke (>135M). In 70% of severe cases, communication is affected, with inability to have conversations and be socially appropriate. Without intervention, social connections are lost, relationships breakdown, and unemployment occurs. The problem is poor access to specialist services. This program will deliver new methods to access healthcare, employment and social engagement using technology, and new models of care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026762</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Adam Wheatley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Rational Improvement of Vaccines and Therapeutics for Pandemic Threats</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | medical microbiology | medical virology  | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>vaccines</Res_KW1>
        <Res_KW2>antibody</Res_KW2>
        <Res_KW3>vaccination immunology</Res_KW3>
        <Res_KW4>vaccine design</Res_KW4>
        <Res_KW5>therapeutic antibodies</Res_KW5>
        <Plain_Description>Pandemic viruses constitute an existential threat to the health and economic well being of communities, highlighted by recent experience with SARS-CoV-2 and Influenza. An improved and fundamental understanding of protective immunity against pandemic threats is critical to guide the design of the next generation of vaccines and drugs. This project seeks to help define the rules that maximise immune protection and translate this knowledge into efficacious countermeasures for the next pandemic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026765</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Peiris</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>A National Continuous Quality Improvement Program for Chronic Conditions in partnership with the Aboriginal Community Controlled Health Service Sector</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | multimorbidity | health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>primary care</Res_KW1>
        <Res_KW2>quality improvement</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>computer-based decision support</Res_KW4>
        <Res_KW5>data linkage</Res_KW5>
        <Plain_Description>The goal of this research is to improve the quality of care for Aboriginal and Torres Strait Islander people with chronic conditions in partnership with the National Aboriginal Community Controlled Health Organisation. It includes a co-designed and rigorously evaluated continuous quality improvement program, expansion of prior work on digital clinical decision support tools for chronic conditions, and development of an economic case for investment in ACCHS-led CQI programs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026787</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jamie Craig</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Expanding the indications for polygenic risk testing in glaucoma.</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,476,520.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>vision</Res_KW1>
        <Res_KW2>glaucoma</Res_KW2>
        <Res_KW3>genetic susceptibility</Res_KW3>
        <Res_KW4>complex genetic disease</Res_KW4>
        <Res_KW5>genetic association</Res_KW5>
        <Plain_Description>Glaucoma is the commonest cause of irreversible blindness. Glaucoma is influenced by genetics, so having a close family member with glaucoma increases risk. We have partnered with industry to develop an effective genetic test known as a polygenic risk score (PRS) to guide glaucoma management. In this grant we will assess how the PRS can help determine if people with known risk factors will develop glaucoma. This will mean high risk individuals can avoid blindness by getting early treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026795</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Abdullah Mamun</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>A life course approach to early detection and prevention of noncommunicable diseases in priority populations</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander epidemiology | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander lifecourse | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>adolescent health</Res_KW2>
        <Res_KW3>young adults</Res_KW3>
        <Res_KW4>pregnancy</Res_KW4>
        <Res_KW5>health services</Res_KW5>
        <Plain_Description>Noncommunicable diseases disproportionally affect First Nations people and Low- and Middle-Income Countries. My research program will implement a new model of care in primary health care settings for the socially disadvantaged communities, targeting the detection and prevention of noncommunicable diseases in (pre)pregnancy, childhood, and young adulthood. Findings will improve health outcomes and reduce inequalities within and across generations among the socially disadvantaged population.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026797</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Yue Hui</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>A conductive hydrogel-based cardiac patch integrated with bioelectronics for repairing infarcted myocardium</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomaterials  | engineering | biomedical engineering | medical devices | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>biomaterials</Res_KW1>
        <Res_KW2>myocardial infarction</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>instrumentation</Res_KW4>
        <Res_KW5>tissue engineering</Res_KW5>
        <Plain_Description>Cardiovascular diseases including heart attack remain a globally leading cause of death, and we still lack effective remedies for the heart damage. This project aims to develop a cardiac patch device that can both promote the regeneration of damaged heart tissues and provide on-demand electrical stimulation to regulate the heart rate and rhythm to prevent irregular heartbeats. The success of this program will deliver a novel strategy for treating heart attacks with higher efficacy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026803</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hyun Jae Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Defining phenotypic diversity in CD4+ T cells to better protect against malaria.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>cellular immunology</Res_KW2>
        <Res_KW3>t cells</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Malaria remains a global health problem, particularly affecting children with high rates of illness and death. One of the challenges in fighting malaria is the lack of effective vaccines. Here, I will use advanced single-cell technology and computational approaches to closely examine immune cells that best protect against malaria. By doing so, I aim to contribute to the development of improved vaccines and more effective treatments for the disease, ultimately reducing burden of malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026806</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Miss Carmen Chia Wern Lim</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Breaking the Cycle: Leveraging Social Media to Address the Public Health Threat of Youth Vaping</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>addiction</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>population health</Res_KW4>
        <Res_KW5>young adults</Res_KW5>
        <Plain_Description>Youth vaping is an emerging public health threat despite prevention and cessation interventions, due to the pervasiveness of pro-vaping content on social media. There is a profound lack of effective interventions to counteract vaping-related content on social media. I will lead a research program to understand how pro-vaping content influences young people’s attitudes, develop a social media intervention, and propose regulatory solutions to reduce youth vaping.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026816</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirstine Shrubsole</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title> The Aphasia Implementation Toolkit Project: A sustainable intervention to improve outcomes for stroke survivors with aphasia</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | allied health and rehabilitation science | rehabilitation | health sciences | allied health and rehabilitation science | speech pathology | </Fields_of_Research>
        <Res_KW1>implementation</Res_KW1>
        <Res_KW2>aphasia</Res_KW2>
        <Res_KW3>stroke rehabilitation</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>behaviour change</Res_KW5>
        <Plain_Description>Aphasia (loss of communication ability following brain injury) is a devastating disability affecting over a third of stroke survivors. Speech pathologists face numerous barriers to providing vital treatment, including a lack of confidence and skills in changing practice. This results in inadequate and ineffective aphasia services. I will lead the development of an Aphasia Implementation Toolkit to achieve sustained service improvements and better health outcomes for post-stroke aphasia patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026826</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nicole Marsh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Optimising peripheral intravenous catheter access to treat infection </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | acute care | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>acute care</Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>nursing</Res_KW5>
        <Plain_Description>Most hospital patients have an IV (intravenous catheter) inserted upon admission to deliver antibiotics. IVs, however, are prone to failure which can lead to treatment delays. My research will explore strategies to improve IV integrity through testing better devices and building a team of highly skilled staff to select and insert IVs most suited to their patient’s needs. We expect our work will improve patient outcomes and health system efficiency by reducing hospital length of stay.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026836</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Tomas Kalincik</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>New paradigms in prevention of disability in multiple sclerosis </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>multiple sclerosis (ms)</Res_KW1>
        <Res_KW2>clinical outcome</Res_KW2>
        <Res_KW3>longitudinal cohort study</Res_KW3>
        <Res_KW4>neuroimmunology</Res_KW4>
        <Res_KW5>biostatistics</Res_KW5>
        <Plain_Description>Despite significant development in the treatment of multiple sclerosis, many patients still experience worsening of their condition while being treated. This program uses clinical cohorts, trials and large registries to diagnose insidious progression in multiple sclerosis and optimise the use of therapy to counter it. This program will create knowledge to guide individual choice of therapy and long-term treatment pathways. Its findings will also be applied to other neuroimmunological diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026837</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Marsland</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Harnessing microbes and metabolites to combat respiratory diseases</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | immunology | transplantation immunology  | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | </Fields_of_Research>
        <Res_KW1>allergic asthma</Res_KW1>
        <Res_KW2>lung</Res_KW2>
        <Res_KW3>airway epithelium</Res_KW3>
        <Res_KW4>metabolites</Res_KW4>
        <Res_KW5>bacteria</Res_KW5>
        <Plain_Description>Lung diseases represent an enormous burden on society and thus discovering and developing the means to predict, combat and prevent their progress is paramount. My research program aims to identify microbes and metabolites that have direct health benefits or that can be used as biomarkers to predict disease progression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026852</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Odette Pearson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Advancing health equity of the Aboriginal and Torres Strait Islander population</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,297,190.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>equity</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>healthy ageing</Res_KW5>
        <Plain_Description>My program of research works towards achieving improved health outcomes for Aboriginal and Torres Strait Islander people. It aims to increase the use of Indigenous data in informing and monitoring health policy and programs, including policy and service improvements in diabetes management and healthy ageing of the Aboriginal and Torres Strait Islander population. This work is underpinned by Indigenous research leadership, governance and capacity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026888</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Alison Marshall</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Reducing barriers to hepatitis C care among marginalised populations</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>hepatitis c virus</Res_KW1>
        <Res_KW2>injecting drug use</Res_KW2>
        <Res_KW3>public health policy</Res_KW3>
        <Res_KW4>treatment</Res_KW4>
        <Res_KW5>women's health</Res_KW5>
        <Plain_Description>In 2016, the advent of all oral therapies for hepatitis C viral (HCV) revolutionised the treatment field, offering >95% cure responses. However, HCV testing and treatment uptake remains low. My overall research aims to identify remaining barriers to HCV testing and treatment at policy, provider, and patient levels, particularly among people who inject drugs and to test interventions that will minimise such barriers to enhance engagement in HCV-related care and ensure equal care for all.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026897</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Kelleher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Harnessing RNA viral variability to end RNA viral pandemics</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>coronavirus</Res_KW1>
        <Res_KW2>human immunodeficiency virus (hiv)</Res_KW2>
        <Res_KW3>immune evasion</Res_KW3>
        <Res_KW4>rna</Res_KW4>
        <Res_KW5>molecular epidemiology</Res_KW5>
        <Plain_Description>Although the viruses that cause HIV and COVID-19 are very different in terms of the way they spread and their disease courses, both pose challenges to their prevention and treatment because of their high ability to evolve new strains that are resistant to therapy and to vaccination. This project will explore next generation treatment and prevention pathways for both viruses which will be based on sophisticated understanding of the interactions between these viruses and the immune system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026898</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Brian Abbey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>NanoMslide: Improving diagnosis of early-stage cancers via nanofabricated colorimetric histology platforms</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | medical devices | engineering | nanotechnology | nanomaterials | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </Fields_of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>diagnostic imaging</Res_KW2>
        <Res_KW3>cancer</Res_KW3>
        <Res_KW4>biophysics</Res_KW4>
        <Res_KW5>biotechnology</Res_KW5>
        <Plain_Description>Distinguishing cancerous from normal cells at the earliest stages is very challenging. I have developed a breakthrough new optical nanotechnology platform called NanoMslide. It allows cancer cells to be identified solely based on their colour - no labelling or staining is needed. I will perform a comprehensive clinical validation of this new technology, learn how cancer cells refract light differently, and adapt this to develop a new class of diagnostic test for the five most common cancers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026905</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Sean Humphrey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Unlocking molecular vulnerabilities in childhood brain cancers</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,486,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>medulloblastoma</Res_KW1>
        <Res_KW2>proteomics</Res_KW2>
        <Res_KW3>signal transduction</Res_KW3>
        <Res_KW4>cell signalling</Res_KW4>
        <Res_KW5>protein phosphorylation</Res_KW5>
        <Plain_Description>Medulloblastoma is the most common children’s brain cancer. Overall survival rates remain poor, side effects are severe and common, and relapse is almost universally fatal. We have recently developed innovative technologies that when applied to medulloblastoma could help identify effective new treatment targets. This Investigator Grant aims to leverage genome-wide technologies to unlock molecular vulnerabilities in medulloblastomas for the treatment of children with this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026910</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Si Ming Man</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Harnessing inflammasome pathways against bacterial infection </Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,461,793.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>inflammation</Res_KW1>
        <Res_KW2>innate immunity</Res_KW2>
        <Res_KW3>bacteria</Res_KW3>
        <Res_KW4>interferon (ifn)</Res_KW4>
        <Res_KW5>macrophages</Res_KW5>
        <Plain_Description>Infectious diseases are a leading cause of death globally. Disease-fighting proteins generated from a cell can kill harmful germs. In this application, I will explore the possibility of harnessing the activity of these disease-fighting proteins from our own immune system to destroy superbugs. Understanding the process of turning disease-fighting proteins into drugs could reveal new ways to fight multi-drug resistance and stop the spread of superbugs in our community.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026911</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Leah Roberts</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Understanding plasmid-mediated AMR dissemination in Australia</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatics and computational biology not elsewhere classified | biological sciences | microbiology | bacteriology  | health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>plasmids</Res_KW1>
        <Res_KW2>antimicrobial resistance</Res_KW2>
        <Res_KW3>bacteria</Res_KW3>
        <Res_KW4>comparative genomics</Res_KW4>
        <Res_KW5>disease transmission</Res_KW5>
        <Plain_Description>Antimicrobial resistance (AMR) is an ongoing threat to public health that requires continued attention. Plasmids are small molecular vehicles that can carry AMR genes and spread them between bacteria, thus contributing to rising drug resistance. In this project, we aim to better understand which plasmids confer AMR genes and where we find these plasmids (in hospitals and the environment). With this knowledge, we can better detect and combat plasmid-mediated resistance in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026929</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Pranesh Padmanabhan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Understanding the pathomechanisms in Alzheimer’s disease at the molecular, cellular, and neural network levels</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biological sciences | biochemistry and cell biology | protein trafficking | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>alzheimer disease</Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>systems biology</Res_KW3>
        <Res_KW4>brain disorders</Res_KW4>
        <Res_KW5>synapse</Res_KW5>
        <Plain_Description>Alzheimer’s disease currently has no cure, and there is a dire need to develop disease-modifying treatment strategies. This project aims to understand what goes wrong in Alzheimer’s disease at the molecular, cellular, and whole-brain levels through a unique combination of computational modelling and quantitative biological experimentation. It will identify new therapeutic avenues to prevent Alzheimer’s disease progression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026934</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Coghill</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>IMPROVING TREATMENT EQUITY and OUTCOMES for ADHD</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>attention deficit hyperactivity disorder (adhd)</Res_KW1>
        <Res_KW2>access to health care</Res_KW2>
        <Res_KW3>screening</Res_KW3>
        <Res_KW4>neurodevelopmental disorders</Res_KW4>
        <Res_KW5>outcome evaluation</Res_KW5>
        <Plain_Description>This 5-year research program addresses the most pressing dilemmas facing ADHD clinical services. The need for more efficient identification of ADHD, more equitable access to care and improved quality of care and better outcomes for people with ADHD.  The core research strategy is to determine current barriers and levers for change, combine this with knowledge from my screening and measurement-based-care studies to develop and evaluate novel scalable clinical solutions that improve ADHD outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026940</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Rowe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Imaging and Blood Biomarkers in a New Era for Alzheimer’s Disease Treatment.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,571,824.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nuclear medicine | biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | biomedical and clinical sciences | clinical sciences | clinical chemistry (incl. diagnostics) | </Fields_of_Research>
        <Res_KW1>alzheimer disease</Res_KW1>
        <Res_KW2>amyloid beta-protein</Res_KW2>
        <Res_KW3>astrocytes</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>positron emission tomography (pet)</Res_KW5>
        <Plain_Description>Effective therapy for Alzheimer's disease is likely to require a multitarget approach. Treatments that reduce amyloid, tau and neuroinflammation will be needed but there are large gaps in our understanding of how these processes interact to cause dementia. PET imaging and new blood tests can measure these pathological processes. Using these tests to better understand how they interact to destroy memory and the effect of reducing amyloid on these processes is the core objective of this program.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026963</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Christopher Wong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>New approaches to the prevention and management of heart rhythm disorders</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>arrhythmia</Res_KW1>
        <Res_KW2>atrial fibrillation</Res_KW2>
        <Res_KW3>sudden cardiac death</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Heart rhythm conditions (otherwise known as arrhythmias) are very common in the community. They can lead to troubling symptoms, complications, and death. However, our understanding of how to prevent and treat these arrhythmias remains limited. This program of work seeks to discover new targets for treatment, trial new therapies, and establish novel management approaches to patients with or at risk of arrhythmias.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026968</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Behzad Hajarizadeh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Hepatitis C elimination in Australia: Filling the gaps</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>hepatitis c infection</Res_KW1>
        <Res_KW2>injecting drug use</Res_KW2>
        <Res_KW3>prison population</Res_KW3>
        <Res_KW4>antiviral therapy</Res_KW4>
        <Res_KW5>continuity of care</Res_KW5>
        <Plain_Description>Hepatitis C causes liver diseases and, if not treated, can lead to liver cancer and death. Effective treatment is available, but treatment uptake is sub-optimal. Prisons are key settings for treatment delivery, given high prevalence of hepatitis C in prisons. My research aims to evaluate hepatitis C epidemiology and clinical care in prisons, and to evaluate novel interventions to enhance hepatitis C treatment uptake and maintain linkage to care after treatment in prisons and community.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026992</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Tony Blakely</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>SHINE: Scalable Health Intervention Evaluation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | health sciences | public health | preventative health care | economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>epidemiology</Res_KW1>
        <Res_KW2>computer simulation</Res_KW2>
        <Res_KW3>disease prevention</Res_KW3>
        <Res_KW4>health economics</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Much data and research knowledge exists but is seldom brought together systematically and comparably to answer questions like: “when applied to the population, how much health will intervention X gain compared to intervention Y?  Over what time?  With what cost?”     I will build an ambitious research programme that answers these questions, using computer simulation modelling and methods from epidemiology and economics. No such scaled capacity exists internationally; SHINE will be world-leading.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027002</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Mr Jackson Thorp</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Embracing clinical heterogeneity in depression: using symptom-level genetic modelling to pave the way towards more effective and personalised treatments</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>depression</Res_KW1>
        <Res_KW2>statistical genetics</Res_KW2>
        <Res_KW3>psychiatric disorders</Res_KW3>
        <Res_KW4>genetic variation</Res_KW4>
        <Res_KW5>comorbidity</Res_KW5>
        <Plain_Description>In psychiatric research, symptoms are treated primarily as indicators of an underlying syndrome, hence the syndrome is the primary target of investigation. An alternative approach is to target the symptoms themselves. This project will conduct genetic analyses of individual depression symptoms in order to dissect the genetic and biological mechanisms underlying the many diverse clinical presentations of depression, paving the way for the development of more personalised treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027006</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Sahar Keshvari</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Macrophage Therapeutic Potential in Paediatric Non-Alcoholic Fatty Liver Disease</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$637,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | medical biochemistry and metabolomics | metabolic medicine | </Fields_of_Research>
        <Res_KW1>macrophages</Res_KW1>
        <Res_KW2>fatty liver disease</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>colony stimulating factors (csf)</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>Macrophages are cells of the innate immune system present in every tissue. Recently we showed that increasing the number of macrophages using macrophage growth factor leads to reduced body fat and blood sugar and increased body lean mass. In liver, increasing macrophages promotes liver growth and improves inflammation and tissue injury. In this project we aim to investigate the potential use of macrophage growth factor as a novel treatment in children with non-alcoholic fatty liver disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027008</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr David Klyne</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>The role of sleep, physical activity and central sensitisation in chronic back pain development</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>chronic back pain</Res_KW1>
        <Res_KW2>pain mechanisms</Res_KW2>
        <Res_KW3>neuroimmunology</Res_KW3>
        <Res_KW4>sleep</Res_KW4>
        <Res_KW5>pain management</Res_KW5>
        <Plain_Description>This research aims to understand the neural and immune mechanisms that drive the transition from acute to chronic back pain, and the role of sleep and physical activity. Critical knowledge gaps relating to this transition will be closed and the capacity for sleep and physical activity to prevent it will be tested by applying an innovative blend of basic and clinical sciences. Findings will shift how we think about back pain in the context of these everyday factors and inform treatment advances.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027017</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Prashanth Ramachandran</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Advancing Diagnosis of Neuroinflammatory Diseases through Metagenomics, Host Transcriptomics and Genomics</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>genomics</Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>encephalitis</Res_KW3>
        <Res_KW4>meningitis</Res_KW4>
        <Res_KW5>diagnostic assay</Res_KW5>
        <Plain_Description>Inflammation of the brain can be devastating can lead to death or severe disability. Current diagnostic tests perform poorly and clinicians have a difficult time trying to identify the cause of the inflammation, which may be due to an infection, autoimmune causes or brain cancer. I intend to create a test that would simultaneously look for all possible infections, assess for brain tumours, and provide a probability score of whether the cause is an infection or autoimmune.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027019</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr John Woodford</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Malaria volunteer infection studies for Plasmodium vivax</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$456,020.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biomedical and clinical sciences | immunology | immunology not elsewhere classified | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>malaria therapy</Res_KW2>
        <Res_KW3>malaria vaccine</Res_KW3>
        <Res_KW4>malaria transmission</Res_KW4>
        <Res_KW5>model</Res_KW5>
        <Plain_Description>Plasmodium vivax is the second most common cause of malaria and causes 14 million cases per year. Most are in the Asia-pacific region. Despite this, there are few drugs and no vaccines available to treat P.vivax malaria. Controlled, experimental infection of healthy volunteers has been used as a safe and successful tool to study the more common species of malaria. Using existing models this project will establish volunteer infection studies for P.vivax to accelerate drug and vaccine development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027033</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Meera Agar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Optimising delirium prevention for older people with cancer</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | </Fields_of_Research>
        <Res_KW1>delirium</Res_KW1>
        <Res_KW2>cancer care</Res_KW2>
        <Res_KW3>prevention</Res_KW3>
        <Res_KW4>community geriatrics</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Delirium is a serious complication for older people with cancer that causes acute changes in cognition and awareness, leading to poor health outcomes and increased mortality. Strategies exist to prevent delirium but these are not embedded routinely in cancer care. Building on my previous work this research will determine the optimal approach to prevent delirium both in and out of hospital, and whether we can further prevent delirium with a new treatment, Bright Light Therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027034</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Everett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing novel strategies for stimulating the oxytocin system to treat methamphetamine addiction. </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | psychopharmacology | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>oxytocin</Res_KW1>
        <Res_KW2>amphetamine</Res_KW2>
        <Res_KW3>addiction</Res_KW3>
        <Res_KW4>pharmacotherapy</Res_KW4>
        <Res_KW5>neural pathways</Res_KW5>
        <Plain_Description>Methamphetamine addiction causes significant harm, and is a major burden on Australia's economy and society. Psychological treatments are inadequate, and no pharmacological therapies exist for methamphetamine addiction. The brain hormone oxytocin controls stress and social behaviour, and is a promising target for addiction, but its clinical use is limited. This project will develop new clinically viable strategies for stimulating the oxytocin system to treat methamphetamine addiction.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027049</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Laura Piccio</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>TARGETING NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES: INTEGRATED APPROACH TO STUDY PATHOGENIC MECHANISMS AND DEVELOP NEW TREATMENTS</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>neuroinflammatory disease</Res_KW1>
        <Res_KW2>brain metabolism</Res_KW2>
        <Res_KW3>dementia</Res_KW3>
        <Res_KW4>multiple sclerosis (ms)</Res_KW4>
        <Res_KW5>diet</Res_KW5>
        <Plain_Description>The research program proposed  will focus in the next 5 years on dissecting the potential roles of diet, gut microbiome, and metabolism in modulating neuroinflammation across different neurodegenerative diseases, such as Alzheimer’s disease and Multiple Sclerosis. A proof-of-concept clinical trial will be performed to evaluate the effects of marked and prolonged weight loss on sophisticated brain imaging, blood and central nervous system markers of neuroinflammation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027050</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jason Tye-Din</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Understanding acute gluten immunity to improve coeliac disease diagnosis, management and clinical trials</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>coeliac disease</Res_KW1>
        <Res_KW2>mucosal immunology</Res_KW2>
        <Res_KW3>diagnostic applications</Res_KW3>
        <Res_KW4>novel therapies</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>Coeliac disease (CD) is a serious illness caused by gluten. There is an unmet need to improve diagnosis, better manage unpleasant symptoms and develop effective treatments. We will assess volunteers with and without CD to: (i) determine if a new blood test can simply and accurately diagnose CD, (ii) examine the effects of gluten on blood and intestinal cells and use this information to develop better ways to treat symptoms, and (iii) evaluate the efficacy of new CD therapies using their cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027051</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Sandra Iuliano-Burns</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Food and Nutrition in Aged Care - Leading Reform</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | nutrition and dietetics not elsewhere classified | health sciences | health services and systems | aged health care | education | curriculum and pedagogy | vocational education and training curriculum and pedagogy | </Fields_of_Research>
        <Res_KW1>aged care</Res_KW1>
        <Res_KW2>food</Res_KW2>
        <Res_KW3>fracture</Res_KW3>
        <Res_KW4>nutrition</Res_KW4>
        <Res_KW5>malnutrition</Res_KW5>
        <Plain_Description>The aged care sector is undergoing major reform including improving nutritional care, achievable by upskilling the sector with evidence-based knowledge. We completed a 2-year food-based cluster randomised study involving 7000 older adults from 60 aged care homes that cost-effectively reduced fractures. Using intervention data, we will develop &amp; evaluate food standards, staff training for menu planning, eating assistance &amp; food-related dementia training to improve nutritional care in residents.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027058</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Gherardin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Understanding and Harnessing gamma-delta T cell-mediated tumour Immunity</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>t cell immunity</Res_KW1>
        <Res_KW2>cancer immunology</Res_KW2>
        <Res_KW3>tumour antigens</Res_KW3>
        <Res_KW4>cancer immunotherapy</Res_KW4>
        <Res_KW5>t cell receptor</Res_KW5>
        <Plain_Description>Immunotherapies have revolutionised the treatment of cancer, however they are only applicable to a relatively small number of patients, and new approaches are needed. Gamma-delta (gd) T cells are a unique immune population with excellent immunotherapeutic potential, however our lack of understanding of their basic biology is hampering the development of therapeutic strategies that harness this potential. This project will uncover this biology and develop now gd T cell-centric cancer therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027072</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ethan Scott</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Assessing the structure and function of brain-wide sensory networks</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,897,165.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | sensory systems | information and computing sciences | machine learning | adversarial machine learning | physical sciences | synchrotrons and accelerators | instruments and techniques | </Fields_of_Research>
        <Res_KW1>neuroscience</Res_KW1>
        <Res_KW2>zebrafish</Res_KW2>
        <Res_KW3>calcium imaging</Res_KW3>
        <Res_KW4>sensory systems</Res_KW4>
        <Res_KW5>sensorimotor</Res_KW5>
        <Plain_Description>Autism occurs in 1 out of 70 Australians, but we do not know how key sensory symptoms of autism arise because techniques are not available for defining brain-wide sensory networks. My group has developed cutting-edge methods to define whole-brain networks, including the fine structures and functions of individual brain cells. In this program, we will use these technologies to elucidate how the brain encodes sensory information, and how sensory networks change in novel genetic models of autism.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027074</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kevin Man</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Uncovering microenvironmental factors that regulate tissue resident memory T cell stability and function to treat inflammation and cancer. </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,486,190.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>t cell memory</Res_KW1>
        <Res_KW2>gastrointestinal disease</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>cellular interactions</Res_KW4>
        <Res_KW5>metabolism</Res_KW5>
        <Plain_Description>Specialized killer immune cells, T cells, survey tissues, blood and lymph for pathogens and tumour cells. Distinct immobile populations can also reside in tissues, known as resident memory T cells (TRMs).  TRMs are front-line defenders but also inadvertently kill and damage host cells contributing to cancer and inflammation.  This proposal aims to uncover the molecules that control T cell mobility, tissue retention and function to improve immunotherapies for inflammatory diseases and cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027093</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Chrishan Nalliah</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Atrial fibrillation and obstructive sleep apnoea: determining mechanisms and enhancing management</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>atrial fibrillation</Res_KW1>
        <Res_KW2>obstructive sleep apnoea</Res_KW2>
        <Res_KW3>continuous positive airway pressure (cpap)</Res_KW3>
        <Res_KW4>prospective cohort study</Res_KW4>
        <Res_KW5>stroke</Res_KW5>
        <Plain_Description>Atrial fibrillation (AF) is the most common heart rhythm disorder in human beings. It is a common cause of stroke and disability. Obstructive sleep apnoea is a condition where the airway closes during sleep and is also very common in patients with AF. This research will firstly evaluate the way in which AF and OSA are connected. It will also try to develop effective treatments for OSA that may reduce the severity of AF. The impact of OSA treatment on stroke risk will also be investigated.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027094</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Gareth Gregory</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving outcomes for patients with central nervous system lymphoma through precision medicine</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,293,095.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </Fields_of_Research>
        <Res_KW1>lymphoma</Res_KW1>
        <Res_KW2>non-hodgkin lymphoma</Res_KW2>
        <Res_KW3>central nervous system (cns)</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>cancer treatment</Res_KW5>
        <Plain_Description>When lymphomas relapse in the brain, the prognosis is very poor for affected patients. My research will use new diagnostic tests to detect asymptomatic lymphoma in the brain at a very early stage before symptoms develop. The tests will also identify what is causing the lymphoma to be resistant to treatment and guide use of new targeted therapies for these patients to improve their outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027104</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Adam Shahine</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Lipid antigen mediators of T cell responses against Mycobacterium tuberculosis infection</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$643,126.69</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>x-ray crystallography</Res_KW1>
        <Res_KW2>mycobacterium tuberculosis</Res_KW2>
        <Res_KW3>antigen presentation</Res_KW3>
        <Res_KW4>t cell receptor</Res_KW4>
        <Res_KW5>lipids</Res_KW5>
        <Plain_Description>Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, remains one of the top 10 causes of death in humans globally, resulting in 1.6 million fatalities annually. The human immune system is crucial in the protection against Mtb through complex interactions between immune system components. By better understanding how our immune system functions to recognise and clear this pathogen, we will be better equipped to develop new therapeutics that will reduce disease burden.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027105</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Andre La Gerche</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Genetic and environmental determinants of the small heart syndrome and its association with heart failure</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,719,928.22</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | health sciences | sports science and exercise | exercise physiology | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>heart failure</Res_KW1>
        <Res_KW2>exercise intolerance</Res_KW2>
        <Res_KW3>cardiac hypertrophy</Res_KW3>
        <Res_KW4>polygenic diseases</Res_KW4>
        <Res_KW5>myocardial dysfunction</Res_KW5>
        <Plain_Description>Heart failure (HF) is a devastating condition affecting 2% of Australians. My research supports a hypothesis that a major type of HF is caused by a genetic predisposition combined with insufficient physical activity and reduced heart size. I aim to: (1) further validate the association between small cardiac size and HF, (2) establish novel predictors of HF using specialised heart imaging and genetic tests, and (3) target high risk populations with interventions to prevent HF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027120</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Karla Hutt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Protecting the ovary from damage to optimise fertility and endocrine health in women</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,169,655.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified | </Fields_of_Research>
        <Res_KW1>ovarian function</Res_KW1>
        <Res_KW2>oocyte</Res_KW2>
        <Res_KW3>inflammation</Res_KW3>
        <Res_KW4>female infertility</Res_KW4>
        <Res_KW5>fertility</Res_KW5>
        <Plain_Description>Cancer treatments and infections can damage the ovary, leading to infertility and premature menopause, which negatively impact on the health and well-being of women. What goes wrong in the ovary remains poorly understood. This study will advance fundamental knowledge around precisely how cancer treatments and infections damage the ovary, and then use this knowledge to design protective strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027129</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Howell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>END-B: Using novel diagnostics, new models of care and economic modelling to achieve hepatitis B elimination and reduce liver cancer deaths </Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,351,714.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>hepatitis b infection</Res_KW1>
        <Res_KW2>hepatocellular carcinoma</Res_KW2>
        <Res_KW3>liver cirrhosis</Res_KW3>
        <Res_KW4>molecular diagnostics</Res_KW4>
        <Res_KW5>public health costs</Res_KW5>
        <Plain_Description>Hepatitis B infection is a major global killer: without treatment, two people die every minute from hepatitis B-related liver failure and liver cancer.   Globally, hepatitis B testing and treatment rates are very low.  My research program END-B uses novel diagnostic tools, cutting-edge data analytics and economic modelling to develop new simplified models of hepatitis B care.   My work will increase hepatitis B testing, linkage to care and treatment uptake to reduce deaths in Australia and globally.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027133</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Julie Brown</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title> Preventing road traffic injury through optimised use of safety technologies</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,494,791.61</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | injury prevention | </Fields_of_Research>
        <Res_KW1>road safety</Res_KW1>
        <Res_KW2>accidental injury</Res_KW2>
        <Res_KW3>child</Res_KW3>
        <Res_KW4>elderly</Res_KW4>
        <Res_KW5>motor vehicle accidents</Res_KW5>
        <Plain_Description>This research aims to prevent road traffic injury by improving use of existing safety technologies by children, older people and motorcyclists. It will do this using a series of different projects designed to address six major challenges in this field. This research will produce fundamental new knowledge and tangible solutions to these challenges. The outcomes from this work will reduce risk of traffic injury in Australia, China and India, and potentially prevent injury to millions of people.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027164</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Omer Gilan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Understanding and targeting the epigenome in blood cancers</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,188,491.67</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>gene regulation</Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>haematological malignancy</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>The ways that cells control genes determines their healthy behaviour and maturation. This is a delicate balance that is facilitated by epigenetic proteins that fine-tune the activity and expression of important genes. Understanding the functions of these epigenetic proteins and how they control different cellular processes that are often hijacked and disrupted in cancer is crucial in order to develop innovative therapeutic approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027171</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr S Ghazaleh Dashti</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>New statistical methods to maximise the impact of longitudinal cohort studies for investigating causal pathways to disease</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | biostatistics | </Fields_of_Research>
        <Res_KW1>statistics</Res_KW1>
        <Res_KW2>biostatistics</Res_KW2>
        <Res_KW3>epidemiological research methods</Res_KW3>
        <Res_KW4>longitudinal study</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Longitudinal studies are uniquely placed to advance our understanding of causal pathways to disease. However, analytic methods and expertise for extracting value from these studies are lacking. My program will address this gap by developing and disseminating new statistical methods and collaborating in prominent longitudinal studies. The outcomes will be much-needed tools for analysing longitudinal studies and new knowledge for improving health outcomes across the life course.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027186</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kenneth Pang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Ensuring Safe and Effective Puberty Suppression for Transgender Adolescents</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | adolescent health | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>gender differences</Res_KW1>
        <Res_KW2>gender</Res_KW2>
        <Res_KW3>puberty</Res_KW3>
        <Res_KW4>sex hormones</Res_KW4>
        <Res_KW5>adolescent health</Res_KW5>
        <Plain_Description>Increasing numbers of transgender adolescents are seeking specialist gender-affirming medical care. One of the cornerstones of this care is use of hormonal interventions to suppress puberty. While the mental health benefits of these hormonal interventions are evident, there remain critical knowledge gaps that undermine their safe and effective use.   This research program will generate new knowledge to fill these gaps, and translate this information into more evidence-based clinical practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027211</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr SHAFIQ SYED</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Dietary and metabolic control of Axin2+ stem cells in endometrial physiology and cancer</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>obesity</Res_KW1>
        <Res_KW2>endometrium</Res_KW2>
        <Res_KW3>nutrition</Res_KW3>
        <Res_KW4>uterus</Res_KW4>
        <Res_KW5>cancer</Res_KW5>
        <Plain_Description>While the incidence of most cancers is decreasing globally, endometrial cancer (EC) deaths are on the rise due to rising obesity. The underlying mechanisms are not known. Having recently identified the cell-of-origin for EC puts me in a unique position to investigate how obesity and high fat diet alter functioning of these critical cells during EC initiation. This study will provide novel metabolic targets for EC therapy and a rationale for modifying everyday diet to maintain a healthy state.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027213</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Irina Voineagu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Gene expression regulation in brain disorders: from mechanisms to therapeutics</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,369,655.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | </Fields_of_Research>
        <Res_KW1>functional genomics</Res_KW1>
        <Res_KW2>brain disease</Res_KW2>
        <Res_KW3>control of gene expression</Res_KW3>
        <Res_KW4>neuroblastoma</Res_KW4>
        <Res_KW5>neuropsychiatric disorders</Res_KW5>
        <Plain_Description>The way genes are turned on or off in the brain is very important for brain development and function. If these regulatory mechanisms don't work properly, it can lead to brain disorders like psychiatric disorders, brain cancer, and intellectual disability. This research program is looking into how gene expression regulation plays a role in brain disorders and will aim to develop new treatments that can modify gene expression in brain cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027219</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Tracy Leong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Overcoming immunotherapy-resistant lung cancer: identifying new biomarkers and therapeutic strategies</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$456,020.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>non-small cell lung cancer</Res_KW1>
        <Res_KW2>cancer immunotherapy</Res_KW2>
        <Res_KW3>treatment-resistant</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Lung cancer is the commonest cause of cancer death. Immunotherapy is a treatment that helps the immune system fight cancer and has revolutionised the treatment landscape of lung cancer. However, despite promising initial outcomes, many patients develop resistance to these drugs. This research aims to shed light on the mechanisms of treatment resistance through a program of advanced lung cancer sampling and analysis. These findings can be used to improve treatment strategies to prolong survival.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027224</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Virginia Wiseman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Using health economics and health systems research to improve access to testing and treatment for infectious diseases of global importance</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,769,655.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>health systems</Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>access to health care</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>health policy evaluation</Res_KW5>
        <Plain_Description>WHO global targets for the control of infectious diseases can only be attained if people at risk have access to accurate testing. ‘Test and treat’ strategies where populations at risk are tested using point of care tests, hold huge promise but have proven extremely difficult to bring to scale. My program will use health economics and health systems research to identify low-cost sustainable strategies to improve uptake of testing and treatment for infectious diseases of global importance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027235</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Mr Michael Traeger</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>A surveillance and prevention research framework to reduce sexually transmitted infections in gay and bisexual men</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance | health sciences | epidemiology | behavioural epidemiology | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>sexually-transmitted infections (sti)</Res_KW1>
        <Res_KW2>gonorrhoea</Res_KW2>
        <Res_KW3>chlamydia</Res_KW3>
        <Res_KW4>human immunodeficiency virus (hiv)</Res_KW4>
        <Res_KW5>sexual networks</Res_KW5>
        <Plain_Description>Globally, gay and bisexual men carry a high burden of sexually transmitted infections (STIs). The introduction of the HIV prevention drug PrEP led to significant changes in sexual behaviour and an increase in STIs among gay and bisexual men. My research will improve Australia’s ability to monitor STIs in the era of PrEP, lead to new insights into how STIs and antimicrobial resistance spread through sexual networks, and generate evidence for the development of interventions to prevent STIs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027256</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Corey Giles</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Deciphering Genetic Drivers of Lipid Dysregulation in Cardiometabolic Diseases: Large-Scale Stable Isotope Tracing Utilizing Population-Derived Immortalized Cell Lines</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$662,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | proteomics and metabolomics | biological sciences | biochemistry and cell biology | cell metabolism | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | </Fields_of_Research>
        <Res_KW1>blood lipid metabolism</Res_KW1>
        <Res_KW2>dyslipidaemia</Res_KW2>
        <Res_KW3>functional genomics</Res_KW3>
        <Res_KW4>genetic association</Res_KW4>
        <Res_KW5>immortalisation</Res_KW5>
        <Plain_Description>This project aims to better understand how genetic factors contribute to the development of cardiometabolic diseases. Using a novel approach to study how the thousands of lipid molecules are metabolised in our bodies, we can understand how these genetic factors affect the development of cardiometabolic disease. By studying human cells from a diverse range of people, we hope to identify new targets for therapies that can help prevent or treat these diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027259</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Gustavo Machado</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Reshaping the management of musculoskeletal pain</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | biomedical and clinical sciences | clinical sciences | emergency medicine | </Fields_of_Research>
        <Res_KW1>physiotherapy</Res_KW1>
        <Res_KW2>emergency medicine</Res_KW2>
        <Res_KW3>musculoskeletal</Res_KW3>
        <Res_KW4>back pain</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>The program will generate transformative knowledge on how to better manage musculoskeletal pain in emergency departments. The program aims to reduce unnecessary hospitalisations, find effective non-opioid treatments, and trial a physiotherapy-led model to reduce the pressure emergency departments are under. The work will involve an intersectoral team of clinicians, executives, patients, and partners. It will lead to highly significant findings that will influence policy and practice globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027284</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Benjamin Bavinton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Achieving HIV elimination in men who have sex with men (MSM) through  innovations in pre-exposure prophylaxis (PrEP)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,586,190.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv)</Res_KW1>
        <Res_KW2>disease prevention</Res_KW2>
        <Res_KW3>prophylaxis</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>HIV pre-exposure prophylaxis (PrEP) is almost 100% effective at preventing HIV acquisition. If scaled up, it can reduce HIV transmissions to zero. Major barriers to scale-up of effective PrEP use in key populations remain. My research program will address these gaps by improving oral PrEP services in Australia and Indonesia, evaluating the effectiveness and implementation of long-acting injectable PrEP in Australia, and identify implementation barriers to injectable PrEP in Indonesia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027300</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Marina Pajic</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Understanding and targeting tumour stroma co-evolution in pancreatic cancer progression: a new paradigm of precision medicine</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>pancreatic cancer</Res_KW1>
        <Res_KW2>mouse models</Res_KW2>
        <Res_KW3>cancer therapy</Res_KW3>
        <Res_KW4>cancer metastasis</Res_KW4>
        <Res_KW5>tumour targeting</Res_KW5>
        <Plain_Description>Pancreatic cancer (PC) has a dismal 5-year survival rate of 9%, and is predicted to be the 2nd leading cause of cancer death by 2025. Our research shows that PC is molecularly varied and a more personalised treatment approach may be beneficial, where cancers are selected for optimal therapy depending on their molecular “fingerprint”. My research goals are to identify the optimal cancer care pathway for PC patients, based on precision medicine principles and dramatically improve outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027536</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Alexander</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Gene Therapy Strategies for Genetic Kidney Disease and Transplantation Using Novel Patient Avatar Mouse Models</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,403,228.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>end-stage kidney disease </Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>genetic disorders</Res_KW3>
        <Res_KW4>gene therapy</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>Over half of children who develop kidney failure have an underlying genetic cause, for which therapy is limited. We aim to develop gene therapies to correct these underlying genetic disorders by testing them in mouse models derived from patients with genetic kidney disease. If successful, this study may improve future patient outcomes by developing new gene therapies, replacing the need for high-risk transplantation and other burdensome therapies required with these diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027555</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Vashe Chandrakanthan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Generation of Long-term Human Haematopoietic Stem Cells from Endothelium for Regenerative Medicine Solutions</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,330,585.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Fields_of_Research>
        <Res_KW1>haematopoietic stem cells </Res_KW1>
        <Res_KW2>stromal cells</Res_KW2>
        <Res_KW3>cell signalling</Res_KW3>
        <Res_KW4>proteomics</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>Identifying regulatory molecules and understanding their timely regulated involvement that govern the blood stem cell (BSC) production is extremely important if we want to generate BSCs to treat blood disorders. We have developed a novel method to generate BSCs outside the body. This project will identify timely regulated regulatory molecules and soluble factors that induce the BSC production and will translate this knowledge to develop a protocol to generate BSCs from human endothelium.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027559</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Thomas Hall</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Scalable Methodology for Personalised Evaluation of Genetic Variants of Uncertain Significance (VUS)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,228,060.30</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>genetic variation </Res_KW1>
        <Res_KW2>diagnosis</Res_KW2>
        <Res_KW3>clinical genetics</Res_KW3>
        <Res_KW4>lipid disorders</Res_KW4>
        <Res_KW5>cardiovascular disease</Res_KW5>
        <Plain_Description>This proposal will develop new technologies for the diagnosis of genetic disease. These technologies will allow us to understand which genetic changes will cause disease and which are benign. This will allow patients to make appropriate decisions about their own healthcare and will facilitate screening within families and related individuals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027569</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Adi Idris</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Developing a universal direct acting antiviral nasal spray against multiple respiratory viruses</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,550,922.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical delivery technologies | </Fields_of_Research>
        <Res_KW1>coronavirus </Res_KW1>
        <Res_KW2>rna interference</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>respiratory syncytial virus</Res_KW4>
        <Res_KW5>gene delivery</Res_KW5>
        <Plain_Description>We have developed a cheap and rapidly deployable direct acting nose spray that can destroy respiratory viruses replicating in the lungs of mice. Here, we want to further develop our therapy into a universal self-use nasal spray medicine that targets COVID-19 and other common cold viruses in both the lungs and the nose. This universal antiviral nasal spray will be the first of its kind as it will not only reduce respiratory viral illness, but also virus spread and transmission.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027597</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Luca Cocchi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Noninvasive ultrasonic deep brain stimulation as a novel tool to change brain activity in obsessive-compulsive disorder</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,243,629.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | cognitive neuroscience | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>functional magnetic resonance imaging (fmri) </Res_KW1>
        <Res_KW2>obsessive-compulsive disorder (ocd)</Res_KW2>
        <Res_KW3>neuroimaging</Res_KW3>
        <Res_KW4>neuromodulation</Res_KW4>
        <Res_KW5>cognitive neuroscience</Res_KW5>
        <Plain_Description>Obsessive-Compulsive Disorder (OCD) is a mental illness defined by distressing obsessions and compulsive actions. The condition maps onto changes in the activity of brain systems comprising the frontal cortex and a deep brain structure named the striatum inaccessible to existing non-invasive brain stimulation therapies. This project will assess if and how a new form of non-invasive ultrasound neuromodulation can change the activity of these brain systems and reduce the symptoms of OCD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027601</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ethan Goddard-Borger</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Glycosylation as a new target in myelofibrosis</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,097,377.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | glycobiology | biological sciences | biochemistry and cell biology | enzymes | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>glycobiology </Res_KW1>
        <Res_KW2>enzymology</Res_KW2>
        <Res_KW3>cytokine signalling</Res_KW3>
        <Res_KW4>glycosyltransferase</Res_KW4>
        <Res_KW5>myelodysplasia</Res_KW5>
        <Plain_Description>Myelofibrosis, a type of bone marrow cancer, is presently treated using drugs that cannot cure patients and that cause a heightened risk of infection. There are no back-up therapies for myelofibrosis that develops resistance to these drugs. To address these challenges, we are exploring the potential of an unstudied biochemical pathway as a new target for the development of myelofibrosis drugs. This work will provide the proof-of-concept data required to fuel future drug discovery efforts.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027602</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr GOKHAN CILDIR</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Elucidating the function of a novel regulator of IgE-mediated mast cell activation and chronic spontaneous urticaria development</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$822,457.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | biological sciences | genetics | genetic immunology  | biomedical and clinical sciences | clinical sciences | dermatology | </Fields_of_Research>
        <Res_KW1>mast cells </Res_KW1>
        <Res_KW2>urticaria</Res_KW2>
        <Res_KW3>immunoglobulin e (ige)</Res_KW3>
        <Res_KW4>skin disease</Res_KW4>
        <Res_KW5>allergy</Res_KW5>
        <Plain_Description>Chronic spontaneous urticaria (CSU) is a common skin disease caused by the uncontrolled activation of tissue-resident mast cells. Genetic factors underlying CSU are unknown. We identified a novel genetic association between an uncharacterised gene known as GCSAML and CSU and showed that GCSAML is a critical regulator of immunoglobulin E (IgE)-mediated mast cell activation. In this project, we will elucidate the role of GCSAML in mast cells to better understand and treat CSU and angioedema.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027621</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Janet van Eersel</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Development of next-generation gene therapy vectors for the treatment of epilepsy</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,034,448.70</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>mitogen activated protein (map) kinase </Res_KW1>
        <Res_KW2>microtubule associated protein (map)</Res_KW2>
        <Res_KW3>epilepsy</Res_KW3>
        <Res_KW4>gene therapy</Res_KW4>
        <Res_KW5>adeno-associated virus</Res_KW5>
        <Plain_Description>The neuronal cells of the brain utilise electrical signals in order to communicate with one another. In certain disorders, such as dementia and epilepsy, this electrical signaling can become excessive, causing the neurons to become overstimulated, which has a detrimental effect on brain function. This project aims to develop several brand new gene therapies that can prevent brain cells from becoming hyperactivated, and can therefore be used to treat disorders such as epilepsy and dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027649</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Nigel McMillan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Disassembled/reassembled extracellular vesicles (DR-EVs) - a new class of nanoparticles for disease treatment.</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,158,432.85</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | nanomedicine | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>nanotechnology </Res_KW1>
        <Res_KW2>vaccination</Res_KW2>
        <Res_KW3>messenger rna (mrna)</Res_KW3>
        <Res_KW4>rna interference</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>Extracellular vesicles (EVs) are nanoparticles shed naturally by all normal cells and are regarded as a highly promising platform drug delivery of mRNA. However, to date these efforts have had poor success. We have invented a new packaging process that is dramatically better  and will improve this further by adding new lipids and proteins. We will test them in our published animal model systems, as well as make vaccines to see if they are superior to current vaccines such as Spikevax.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027651</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Trichur Vidyasagar</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Exploring mechanisms underlying the effects of vagal stimulation in treatment of neurological disorders</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$865,928.72</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | medical physiology | systems physiology  | </Fields_of_Research>
        <Res_KW1>vagus nerve </Res_KW1>
        <Res_KW2>epilepsy</Res_KW2>
        <Res_KW3>autonomic function</Res_KW3>
        <Res_KW4>cerebral cortex</Res_KW4>
        <Res_KW5>hippocampus</Res_KW5>
        <Plain_Description>The vagus nerve transmits information between internal organs and the brain. Stimulation of the nerve is used for treating cases of epilepsy and depression that do not respond to medication, but the mechanism of this effect remains elusive. We will study VNS effects in the brain by recording neuronal activity from multiple brain areas. This will help in improving its efficacy, make it easier to predict whom it will benefit and reduce adverse effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027655</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Timothy Sargeant</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Imaging lysosomal function in the brain</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,187,853.77</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | biomedical and clinical sciences | clinical sciences | radiology and organ imaging | </Fields_of_Research>
        <Res_KW1>lysosome biology </Res_KW1>
        <Res_KW2>cell biology</Res_KW2>
        <Res_KW3>dementia</Res_KW3>
        <Res_KW4>biochemistry</Res_KW4>
        <Res_KW5>brain imaging</Res_KW5>
        <Plain_Description>The cells of our bodies possess a powerful recycling system that removes damaged material that accumulates with age and causes diseases such as dementia. This process is called 'autophagy', and relies on efficient function of the stomach of the cell - what scientists call the 'lysosome'. Although autophagy holds great promise for prevention of dementia, this will only be true while lysosomes work properly. We will develop a method for measuring lysosomal function in the brain using PET imaging.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027662</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Harrison</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Habenula circuitry mechanisms and ketamine rapid antidepressant treatment</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$995,560.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>depression </Res_KW1>
        <Res_KW2>brain function</Res_KW2>
        <Res_KW3>antidepressants</Res_KW3>
        <Res_KW4>functional magnetic resonance imaging (fmri)</Res_KW4>
        <Res_KW5>neuroimaging</Res_KW5>
        <Plain_Description>Depression is one of the leading causes of disability and morbidity worldwide. To reduce its substantial burden on individuals and society, there is an urgent need to identify more effective treatments. We will use advanced brain imaging technology to understand how ketamine – a rapid-acting antidepressant – improves brain function in depressed patients. By understanding ketamine’s brain mechanisms, it is hoped that safer and more effective treatments for depression will soon be discovered.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027674</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Lauren Holz</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Development of an efficacious malaria mRNA vaccine</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,384,754.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>memory t-cells</Res_KW2>
        <Res_KW3>malaria vaccine</Res_KW3>
        <Res_KW4>messenger rna (mrna)</Res_KW4>
        <Res_KW5>liver</Res_KW5>
        <Plain_Description>mRNA vaccines have been administered to millions of people and shown to be safe and effective at reducing COVID. This has opened the door for developing mRNA vaccines that target other human pathogens. We have shown liver-resident memory T cells (Trm), a specialised type of immune cell, can provide protection from malaria in mice and developed a novel mRNA vaccine approach to generate these cells. In this study we begin to investigate how this vaccine can be translated from mice into humans.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027709</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kelly Smith</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Redefining the control of trabecular fate</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,179,293.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>developmental biology </Res_KW1>
        <Res_KW2>cell development</Res_KW2>
        <Res_KW3>cell lineage</Res_KW3>
        <Res_KW4>organogenesis</Res_KW4>
        <Res_KW5>cell differentiation</Res_KW5>
        <Plain_Description>To form a correctly functioning heart, the cardiac muscle must form folds of tissue to help it grow and become more muscular. This project will investigate a factor required to make the folds in the heart form and grow. Defects in this process can cause cardiomyopathy and may result in heart failure therefore figuring out how these structures form will provide information for how to diagnose and potentially treat cardiac disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027729</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kelly Clemens</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Protecting the Unborn: Investigating Sodium Butyrate as a Treatment for Prenatal Opioid Exposure and Its Long-Term Effects</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$873,018.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | psychology | biological psychology  | psychopharmacology | </Fields_of_Research>
        <Res_KW1>opioids </Res_KW1>
        <Res_KW2>prenatal</Res_KW2>
        <Res_KW3>neuroscience</Res_KW3>
        <Res_KW4>infant mental health</Res_KW4>
        <Res_KW5>neuroinflammation</Res_KW5>
        <Plain_Description>Some of the most innocent victims of the current opioid epidemic are the children born to opioid-dependent mothers. Experiencing potentially fatal withdrawal symptoms at birth, these children have poor long-term mental health outcomes. There are currently no treatments available to treat the impact of prenatal opioid exposure. Here we will test whether the dietary supplement sodium butyrate could offer a cheap and effective means of reversing the impact of prenatal opioid exposure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027730</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kelly Clemens</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Next generation biological therapeutics for the treatment of addiction</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$853,056.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>addiction treatment </Res_KW1>
        <Res_KW2>gene therapy</Res_KW2>
        <Res_KW3>neuroscience</Res_KW3>
        <Res_KW4>brain-derived neurotrophic factor (bdnf)</Res_KW4>
        <Res_KW5>rat</Res_KW5>
        <Plain_Description>Drug addiction is a pervasive and debilitating disease. Despite much time and effort, our capacity to treat substance use disorder has stalled, with little advance in treatment options across the past 20 years. We are proposing to treat drug addiction through gene therapy. By tweaking how different genes related to drug addiction are used, we can adjust neuronal function to enable drug users to resist relapse. This could offer lasting relief to those affected by drug dependence.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027736</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Browne</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>The commercial determinants of Aboriginal and Torres Strait Islander health and wellbeing: building the evidence and co-designing action</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,223,516.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social determinants of health | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>public health</Res_KW3>
        <Res_KW4>equity</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>This project aims to identify the commercial drivers that influence Indigenous health and wellbeing. The project will provide a world-first examination of how private companies and their actions (such as marketing) impact Indigenous peoples’ lives. We will co-design policy recommendations to mitigate the negative impacts and enhance the potential positive impacts of commercial activity. Findings will support improved government and private sector accountability regarding Indigenous health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027755</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Antje Blumenthal</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Molecular drivers of metabolic reprogramming in Mycobacterium tuberculosis infection</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$897,069.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>bacterial infection </Res_KW1>
        <Res_KW2>macrophage activation</Res_KW2>
        <Res_KW3>cell signalling</Res_KW3>
        <Res_KW4>innate immunity</Res_KW4>
        <Res_KW5>glycolysis</Res_KW5>
        <Plain_Description>This project focuses on tuberculosis (TB), an infectious disease that remains one of the leading causes of death globally. Better TB treatments are urgently needed including those that are less dependent on antibiotics. This research will define thus far unrecognised molecular mechanisms that promote the ability of immune cells to control TB bacteria. In doing so, this work will provide the basis for developing new TB treatments that boost the patient’s immune defence mechanisms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027768</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ashraful Haque</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Fate and fidelity of T cell memory during repeated malaria infection</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,248,976.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>t cell memory </Res_KW1>
        <Res_KW2>malaria</Res_KW2>
        <Res_KW3>cd4</Res_KW3>
        <Res_KW4>mouse models</Res_KW4>
        <Res_KW5>clinical malaria</Res_KW5>
        <Plain_Description>Children rarely develop immunity to malaria after a first infection, leaving them susceptible to severe disease during each subsequent infection. Although immune cells called T cells can protect against malaria, we don’t understand how well they function during re-infection. We will define the impact of re-infections on T cells in children in a malaria-endemic region as well as in experimental models. Our data may assist in devising new ways to prevent children from dying with severe malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027770</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jiayu Wen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>The role of RNA-mediated spatio-temporal transcriptome changes in age-related macular degeneration</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,457,887.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genome structure and regulation | biomedical and clinical sciences | ophthalmology and optometry | vision science | biological sciences | bioinformatics and computational biology | bioinformatic methods development | </Fields_of_Research>
        <Res_KW1>rna binding proteins </Res_KW1>
        <Res_KW2>macular degeneration</Res_KW2>
        <Res_KW3>rna processing</Res_KW3>
        <Res_KW4>machine learning</Res_KW4>
        <Res_KW5>ageing</Res_KW5>
        <Plain_Description>Age-related Macular Degeneration (AMD) is a key cause of vision loss in older adults. The exact causes of AMD are unclear, making it hard to develop treatments. This research studies how certain proteins impact gene regulation in eye cells during AMD. By employing cutting-edge techniques, the project's focus is to understand the cellular and molecular mechanisms underlying AMD and pinpoint potential therapeutic targets. Ultimately, this research may improve the lives of millions affected by AMD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027804</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Niliksha Gunewardene</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Shining a light on deep brain stimulation</Grant_Title>
        <Admin_Institution>The Bionics Institute of Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,154,211.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>implants </Res_KW1>
        <Res_KW2>neuroscience</Res_KW2>
        <Res_KW3>parkinson disease</Res_KW3>
        <Res_KW4>electrophysiology</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>Deep brain stimulation (DBS) is an established therapy for several neurological and psychiatric conditions. Although beneficial, limited precision of neural activation and serious side-effects remain major issues with this therapy. We recently discovered that hybrid stimulation, a combination of electric and optogenetic stimulation, improves the precision of neural activation. This grant aims to explore the potential of this technology to improve the selectivity of neural stimulation via DBS.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027812</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Tremethick</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Investigating H2A.Z as the epigenetic link between cellular plasticity and cancer</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,271,140.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>chromatin </Res_KW1>
        <Res_KW2>chromatin structure</Res_KW2>
        <Res_KW3>transcriptional regulation</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>promoter analysis</Res_KW5>
        <Plain_Description>Although there has been a major effort to sequence the human genome, how this genomic information is selectively utilized to direct gene expression that is unique to each of the approximately two hundred different cell types of the human body remains to be elucidated. We have new data that strongly supports the notion that there is a second code contained in the way our DNA is packaged into chromosomes, which regulates the expression of gene responsible for determining the fate of a cell.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027815</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bernadette Saunders</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>miRNA as therapeutics and biomarkers for mycobacterial diseases</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,276,731.04</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>microrna </Res_KW1>
        <Res_KW2>mycobacterium tuberculosis</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>macrophages</Res_KW4>
        <Res_KW5>chronic inflammation</Res_KW5>
        <Plain_Description>Tuberculosis (TB) is a global health issue, new treatments and diagnostic tests are urgently required. We have shown that miRNAs, released by macrophages, are important in host immunity. One, miR-652, aids control of diseases. This study will:   1: investigate how miR-652 regulates the immune response to infection,   2: determine if modulating miR-652 can aid TB control and   3: test the diagnostic potential of a miRNA panel that includes miR-652 to diagnose TB disease and predict treatment outcome.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027850</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tina Skinner-Adams</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Combating treatment refractory giardiasis: New drugs and combination therapies</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$790,709.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Fields_of_Research>
        <Res_KW1>drug discovery </Res_KW1>
        <Res_KW2>drug action</Res_KW2>
        <Res_KW3>antiparasitic chemotherapy</Res_KW3>
        <Res_KW4>giardia</Res_KW4>
        <Res_KW5>giardiasis</Res_KW5>
        <Plain_Description>Giardia parasites cause significant disease and disability on a global scale. However, there is no vaccine to prevent infection and current treatments are failing due to parasite drug resistance. To combat drug resistant parasites new treatment strategies are needed. We aim to address this need and end treatment failures by identifying innovative multi-drug treatment options that include new anti-Giardia agents with 300-fold better activity and different modes of action to currently used drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027877</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Shayanti Mukherjee</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Transforming Treatment for Pelvic Organ Prolapse with Nanotechnology</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,399,615.81</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>urogenital disorders </Res_KW1>
        <Res_KW2>gynaecology</Res_KW2>
        <Res_KW3>surgical reconstruction</Res_KW3>
        <Res_KW4>biomaterials</Res_KW4>
        <Res_KW5>tissue engineering</Res_KW5>
        <Plain_Description>Pelvic organ Prolapse (POP) is a hidden, debilitating disorder affecting 25% of women causing sexual, bladder and bowel dysfunction. POP is the herniation of the uterus, bladder, or bowel into the vagina due to childbirth injury. Surgical treatment often fails and the use of vaginal mesh has been banned due to unacceptable side effects. There is no cure and no means to identify early damage. We are developing novel 3D printed therapies using stem cells and nanotechnology to prevent POP.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027880</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Brett Nixon</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting the epididymis to protect the integrity of the sperm epigenome</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$983,387.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | reproductive medicine | reproduction  | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </Fields_of_Research>
        <Res_KW1>sperm function </Res_KW1>
        <Res_KW2>male reproduction</Res_KW2>
        <Res_KW3>male infertility</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>embryo development</Res_KW5>
        <Plain_Description>This project will enhance our understanding of the molecular pathways by which environmental signals received by a father are transmitted to their offspring. Specifically, we shall determine how the male reproductive tract (epididymis) conveys epigenetic, environmental stress information onto sperm to influence offspring health. This work has major public health and socioeconomic implications in terms of minimising the risk of future generations inheriting stress-related health disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027881</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Ferrero</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>How H. pylori hijacks the nucleus: A new paradigm for cancer-causing bacteria</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,024,608.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical infection agents (incl. prions) | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | biological sciences | microbiology | microbiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>helicobacter pylori </Res_KW1>
        <Res_KW2>host/pathogen interaction</Res_KW2>
        <Res_KW3>bacterial pathogenesis</Res_KW3>
        <Res_KW4>bacterial pathogenicity</Res_KW4>
        <Res_KW5>pathogenic bacteria</Res_KW5>
        <Plain_Description>Bacterial cell walls are decorated by "blebs", or vesicles, which are released to the surrounding medium during growth. These vesicles play important roles in communication between bacteria and host cells. Vesicles from the stomach bacterium, H. pylori, carry a protein with cancer-causing properties. The proposed research project will demonstrate how these vesicles alter host cell functions, leading to cancer. This research will describe a new mechanism by which bacteria can cause cancer.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027932</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Harman</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Defining the Role of Antigen Presenting Cells in Crohn’s Disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,560,145.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | clinical sciences | surgery | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>crohn's disease </Res_KW1>
        <Res_KW2>cellular immunology</Res_KW2>
        <Res_KW3>chronic inflammation</Res_KW3>
        <Res_KW4>inflammatory bowel disease (ibd)</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Antigen presenting cells (APC) are essential mediators of whether the immune system attacks or tolerates microbes. Our ability to design new immunotherapies for Inflammatory Bowel Disease hinges on our understanding of how these APC work in a human setting. With our privileged access to human tissues, we will study these processes in the very tissues where infection and inflammation occurs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027951</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Joel Mackay</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>RaPID assessment of the chromatin remodeller CHD4 as a therapeutic target for hemoglobinopathies using a new target validation strategy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,133,816.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>protein biochemistry </Res_KW1>
        <Res_KW2>control of gene expression</Res_KW2>
        <Res_KW3>inhibitor design</Res_KW3>
        <Res_KW4>structural biology</Res_KW4>
        <Res_KW5>haematological disorders</Res_KW5>
        <Plain_Description>Recently, the enzyme CHD4 has emerged as a possible therapeutic target for hemoglobinopathies. However, no molecules exist that specifically inhibit its activity. The goal of this project is to develop specific chemical probes to assess the potential of CHD4 inhibition for the treatment of hematological disorders. The work will also provide proof-of-principle for a new strategy that we propose for faster validation of therapeutic targets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027965</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Guoping Zheng</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Preventing kidney failure using BMP-7 engineered macrophages in chronic kidney disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,063,137.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>chronic inflammation</Res_KW2>
        <Res_KW3>fibrosis</Res_KW3>
        <Res_KW4>transforming growth factor beta (tgf-beta)</Res_KW4>
        <Res_KW5>macrophages</Res_KW5>
        <Plain_Description>Chronic kidney disease (CKD) is a major cause of death and morbidity worldwide, as CKD often progresses to kidney failure. Current therapies are of limited efficacy in preventing kidney failure in CKD  We aim to target and use macrophages, the first line disease combatting immune cell, re-programming them into therapeutic cells for cell therapy in the treatment of CKD. A successful outcome will lead to a novel cure for preventing kidney failure and the failure of other organs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027979</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Yvonne Eiby</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Early transfusion to support blood volume in preterm piglets</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,032,159.47</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | medical physiology | systems physiology  | </Fields_of_Research>
        <Res_KW1>premature infant </Res_KW1>
        <Res_KW2>hypovolaemia</Res_KW2>
        <Res_KW3>cerebral blood flow</Res_KW3>
        <Res_KW4>hypotension</Res_KW4>
        <Res_KW5>blood transfusion</Res_KW5>
        <Plain_Description>Some premature babies have low blood volume which reduces oxygen delivery to the brain and contributes to high mortality and disability rates. We will test the efficacy of novel transfusion strategies for preventing low blood volume and protecting the developing brain in an established pre-clinical model. Identification of an effective strategy is essential for our team to conduct a trial in infants. Effective blood volume support may improve the quality of life for the smallest babies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027984</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Najla Nasr</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A novel strategy to reactivate HIV in CD4 T cells via interferon alpha treatment</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,023,319.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>t cells</Res_KW2>
        <Res_KW3>interferon (ifn)</Res_KW3>
        <Res_KW4>viral infection</Res_KW4>
        <Res_KW5>latency</Res_KW5>
        <Plain_Description>For an HIV cure, novel classes of latency reversal agents are needed to awaken silent HIV. This project will develop the finding that specific interferon subtypes (alpha 8 and 14) will reactivate silent HIV in CD4 T cells and reduce the HIV reservoir. It will pave the way to clinical trials in humans to determine whether IFNa8 and/or 14 therapy will reduce the residual low levels of infectious HIV in patients whose virus has been suppressed but not eliminated by antiretroviral therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027987</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Aaron Schindeler</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Gene Therapy for Neurofibromatosis types 1 and 2</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,450,562.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>adeno-associated virus </Res_KW1>
        <Res_KW2>gene targeting</Res_KW2>
        <Res_KW3>familial cancer</Res_KW3>
        <Res_KW4>knockout mouse</Res_KW4>
        <Res_KW5>cell culture</Res_KW5>
        <Plain_Description>Neurofibromatoses (NF) are genetic cancer disorders that can have a lifelong impact on affected individuals. Current medical treatments are reactive, but gene therapy offers the promise of early intervention to reduce or negate tumour burden. We are using CRISPR-based techniques to correct pathogenic mutations. This has the potential to transform the treatment of NF1 and NF2 with a “cancer vaccine”, but the findings may have broad applicability for other genetic conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028004</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jarmon Lees</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Advancing new therapies for Friedreich ataxia heart disease</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$788,041.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>friedreich ataxia </Res_KW1>
        <Res_KW2>cardiomyopathy</Res_KW2>
        <Res_KW3>stem cells</Res_KW3>
        <Res_KW4>tissue engineering</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>Friedreich ataxia is a devastating genetic disorder and heart disease is the leading cause of premature death in patients. There is currently no treatment for Friedreich ataxia heart disease. This project will use a combination of an innovative human ‘heart-in-a-dish’ and mouse model to validate two new therapeutic targets to combat Friedreich ataxia heart disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028020</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Little</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Getting to the Heart of Osteoarthritis (OA): targeting joint-derived micro-RNAs (miRs) to reduce OA-associated cardiovascular disease (CVD) risk</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$959,500.25</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>osteoarthritis </Res_KW1>
        <Res_KW2>microrna</Res_KW2>
        <Res_KW3>cardiovascular risk factors</Res_KW3>
        <Res_KW4>sex differences</Res_KW4>
        <Res_KW5>cardiovascular disease prevention</Res_KW5>
        <Plain_Description>Osteoarthritis (OA) is a major personal and healthcare burden projected to rise due to our ageing population. OA is a strong risk factor for cardiovascular disease (CVD), however the mechanism behind this is unknown. Our novel data has identified a previously unexplored biological link, where factors released from injured and OA joints directly affect heart cells to cause CVD. This study will define these molecular mechanisms, and if and when they can be targeted to reduce OA-driven CVD risk.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028025</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Liang Jin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Applying a pharmacometric approach to achieve personalised medicine in people with Alzheimer's disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$814,231.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>pharmacokinetics </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>mathematical modelling</Res_KW3>
        <Res_KW4>drug safety</Res_KW4>
        <Res_KW5>computer simulation</Res_KW5>
        <Plain_Description>Compared to those without AD, people with AD tend to consume 5-10 more medicines to treat comorbidities, which are prescribed using the same dosing regimens as those used in individuals without AD assuming that drug dispositions are not altered in AD. However, drug absorption are distinct between normal ageing and AD which may lead to adverse effects or suboptimal efficacy. We aim to develop dose adjustment tools purposely designed for people with AD utilising the longitudinal AD cohort AIBL.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028037</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Eva Kimonis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Using novel naturalistic eye tracking technologies to uncover emotional attention mechanisms underpinning early-onset, treatment-resistant conduct disorders</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$396,019.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | applied and developmental psychology | child and adolescent development  | psychology | cognitive and computational psychology | memory and attention | </Fields_of_Research>
        <Res_KW1>conduct disorder </Res_KW1>
        <Res_KW2>psychopathy</Res_KW2>
        <Res_KW3>facial emotion</Res_KW3>
        <Res_KW4>attention</Res_KW4>
        <Res_KW5>early childhood</Res_KW5>
        <Plain_Description>This project aims to understand the development of callous-antisocial behavior in children. Using new technology, child-worn eye-tracking glasses will be used to measure attention to social-emotional stimuli during early dyadic interactions. The team will compare attention patterns of children with callous-conduct disorders to those with non-callous conduct disorders and healthy controls. The new knowledge gained could be used to improve treatments for the most severely affected children.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028041</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Mariusz Skwarczynski</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Paving the way for a Clinical Vaccine Candidate against Hookworm Infection</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$855,524.33</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>vaccine </Res_KW1>
        <Res_KW2>hookworm infection</Res_KW2>
        <Res_KW3>adjuvant</Res_KW3>
        <Res_KW4>antigen</Res_KW4>
        <Res_KW5>formulation optimisation</Res_KW5>
        <Plain_Description>Hookworm infection affects 400 million people, worldwide, each year and costs the global economy billions of dollars. There is no commercial hookworm vaccine. This project will produce vaccine candidates against hookworm that are safe, potent against a variety of hookworm species, and induce strong, long-term immune responses after single immunisation. Ultimately, the project will lead to the development of the first highly effective vaccine candidate against hookworm for clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028045</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Brad Sutherland</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Checking the pulse of pericytes: Do microglia cause a breakdown of brain blood vessels in Alzheimer's disease?</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$1,278,439.02</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Fields_of_Research>
        <Res_KW1>cerebral blood flow </Res_KW1>
        <Res_KW2>neuroinflammation</Res_KW2>
        <Res_KW3>alzheimer disease</Res_KW3>
        <Res_KW4>neurovascular mechanism</Res_KW4>
        <Res_KW5>microglia</Res_KW5>
        <Plain_Description>Pericytes are cells that control blood flow through capillaries. Microglia in the brain respond to inflammation. Some microglia interact with pericytes which may control blood flow and brain function. In Alzheimer’s disease (AD), this interaction is disrupted. This proposal will use innovative techniques to understand how pericytes and microglia interact and how this goes wrong in AD. This opens up new potential treatment options for AD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028055</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Su Yin Lim</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Precision-based strategies to overcome treatment resistance in dedifferentiated melanoma</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$950,118.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cell differentiation </Res_KW1>
        <Res_KW2>targeted therapy</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>disease modelling</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>Melanoma cells have the unique ability to dedifferentiate, switching from a proliferative to an invasive cell state. Dedifferentiated cells are present in all melanoma tumours and are resistant to current clinical therapies. There is an urgent need to better understand this cellular state as patients with dedifferentiated melanomas have few effective treatment options. This project will answer the critical question of how patients with dedifferentiated melanomas can be treated effectively.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028078</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Nandita Vijayakumar</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Novel insights into adolescent stressors: Uncovering brain biomarkers and mental health consequences to inform intervention efforts</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$415,490.85</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | psychology | applied and developmental psychology | child and adolescent development  | psychology | biological psychology  | biological psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>youth </Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>social determinants of health</Res_KW3>
        <Res_KW4>puberty</Res_KW4>
        <Res_KW5>brain development</Res_KW5>
        <Plain_Description>Young adult mental health problems carry huge negative consequences that persist across the life course. This proposal applies methodological innovations to a unique longitudinal dataset, to identify the adolescent stressors with the greatest impact on the mental health of young adults and the biological pathways responsible for these impacts. Findings will enable targeted intervention strategies to promote well-being and reduce the burden of mental health problems in young adults.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028084</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kara Vine</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Advancing the delivery of gene therapy to motor neurons and glial cells using focused ultrasound</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$904,873.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | nanomedicine | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>drug delivery</Res_KW2>
        <Res_KW3>motor neuron disease (mnd)</Res_KW3>
        <Res_KW4>antisense oligonucleotides</Res_KW4>
        <Res_KW5>superoxide dismutase (sod)</Res_KW5>
        <Plain_Description>We designed a drug carrier that can boost the delivery of drugs into the brain. We now want to enhance this even further using externally applied, non-invasive focused ultrasound. Focused ultrasound is a safe technique that selectively disrupts the blood-brain barrier, increasing its permeability to drugs within the central nervous system. Outcomes will validate our ultrasound-mediated delivery strategy in Motor Neuron Disease models and will guide further preclinical testing for this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028135</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Alyssa Barry</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Predicting the emergence and spread of drug resistant malaria parasites</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,352,353.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | microbiology | microbial genetics  | health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>malaria drug resistance</Res_KW2>
        <Res_KW3>functional genomics</Res_KW3>
        <Res_KW4>population genetics</Res_KW4>
        <Res_KW5>epidemiology</Res_KW5>
        <Plain_Description>We will confirm if malaria parasite variants from Papua New Guinea with mutations that may cause drug resistance are resistant to current antimalarial treatments, and evaluate how these mutations emerge and spread in populations. This knowledge will enable the development of a mathematical model that predicts where drug resistance may emerge next and where it is most likely to become prevalent, helping the malaria control program to prevent, contain and eliminate drug resistant malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028153</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Natalie Lister</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Defining the role of MYBL2 inhibition in men with aggressive prostate cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,167,939.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>prostate cancer </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>oncology</Res_KW3>
        <Res_KW4>cancer therapy</Res_KW4>
        <Res_KW5>drug development</Res_KW5>
        <Plain_Description>To improve the survival of men with life-threatening cancers, new drugs are urgently required to treat aggressive prostate cancers that do not respond well to conventional treatment. MYBL2 is a promising cancer target for men with aggressive and therapy-resistant prostate cancer. Our multidisciplinary team aims to develop a new drug to target MYBL2 in patients with prostate cancer and develop markers to identify the patients who will benefit most from our therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028164</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anthony Don</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A new paradigm for how APOE genotype affects brain lipid homeostasis and dementia risk</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,229,748.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - lipids  | </Fields_of_Research>
        <Res_KW1>myelin </Res_KW1>
        <Res_KW2>sphingolipids</Res_KW2>
        <Res_KW3>alzheimer disease</Res_KW3>
        <Res_KW4>apolipoprotein e</Res_KW4>
        <Res_KW5>lipids</Res_KW5>
        <Plain_Description>Treatments for Alzheimer's Disease (AD) have very limited effect, and new therapies are needed. Naturally-occurring variants in the APOE gene are the dominant determinant of genetic risk for AD. This project will determine how these APOE gene variants affect risk for AD. Specifically, how they affect the normal function of APOE in regulating lipid membranes that control neurological function. This will inform clinical trials aimed at correcting brain lipid metabolism function to treat AD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028221</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanne O'Donnell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Low dietary fibre: a regulator of the immune system during high blood pressure</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,089,548.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>blood pressure </Res_KW1>
        <Res_KW2>inflammation</Res_KW2>
        <Res_KW3>dietary fibre</Res_KW3>
        <Res_KW4>molecular immunology</Res_KW4>
        <Res_KW5>intestine</Res_KW5>
        <Plain_Description>We aim to understand how eating long-term low-fibre diets contribute to high blood pressure, a major risk factor for cardiovascular disease. We believe this happens via the immune cells that live in the gut, which are primed for inflammation by the lack of beneficial substances produced by gut microbes when we eat fibre. We will determine whether these beneficial substances can mitigate the effects of a long-term low-fibre diet, informing their use as a new way to treat hypertension.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028226</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Smyth</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Unravelling the role of AURKA in Polycystic Kidney Disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,168,672.81</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>kidney </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>kidney development</Res_KW3>
        <Res_KW4>kidney failure</Res_KW4>
        <Res_KW5>end-stage kidney disease</Res_KW5>
        <Plain_Description>Polycystic Kidney Disease is a common and highly morbid condition which often leads to renal failure requiring transplant or dialysis.  We have identified a gene which is essential for disease initiation and progression.  We wish to understand why this gene is critical to the development of kidney cysts with a view to developing new treatments for this condition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028231</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Tessa Gargett</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Micro-targeting IL-2 delivery to remodel the glioblastoma microenvironment</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,138,627.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | medical biotechnology | medical biotechnology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>brain tumours </Res_KW1>
        <Res_KW2>interleukins (il)</Res_KW2>
        <Res_KW3>gene therapy</Res_KW3>
        <Res_KW4>cell therapy</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>The diagnosis of a brain tumour is devastating for the patient, their family and their doctors because these aggressive tumours have limited treatment options and extremely poor survival rates, with the worst types being universally fatal. Fortunately we are in the midst of a technological revolution when it comes to medical science and this project will take the very latest developments in cell and gene therapy and apply them to the challenge of treating brain cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028232</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Smyth</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding how binge drinking affects kidney development</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,212,255.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | zoology | animal developmental and reproductive biology | </Fields_of_Research>
        <Res_KW1>kidney development </Res_KW1>
        <Res_KW2>abnormal development</Res_KW2>
        <Res_KW3>fetal alcohol syndrome</Res_KW3>
        <Res_KW4>kidney disease</Res_KW4>
        <Res_KW5>developmental biology</Res_KW5>
        <Plain_Description>Changes to the fetal environment can affect the normal development of the kidney - the organ resposnbile for filtering blood.  We wish to study how and why fetal kidneys exposed to alcohol as a consequence of maternal binge drinking develop less nephrons - the functional units of the kidney.  We also wish to study whether and how a compound called choline can rescue these deficits and improve kidney function later in life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028235</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Paul Ekert</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Recovering lost therapeutic opportunities in high-risk paediatric cancer - novel drivers of receptor tyrosine kinase activation</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,332,440.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>paediatric </Res_KW1>
        <Res_KW2>cancer</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>therapeutic target</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>Cancers that effect children are very distinct from those which occur in adults. But like adult cancers, and in fact all cancers, the fundamental cause of the disease are the changes that occur in the genes of a normal cell which cause it to transform into a cancer cell. This projects is focused on understanding how these changed genes, specific to cancers in children, function to cause cancer, and how we can better target these genetic changes with therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028265</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kristie Stefanoska</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A phosphorylation signature controls memory traces</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$590,547.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>microtubule associated protein (map) </Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>phosphorylation</Res_KW3>
        <Res_KW4>memory</Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>Alzheimer’s disease is characterised by prominent memory loss. To improve treatments, a better understanding of the molecular basis of memory is needed. In this project, we describe a new explanation of memory based on a key Alzheimer’s factor. Using a series of innovative approaches in memory-containing brain cells, we will provide a compelling answer for how individual memories are created and maintained. Outcomes will help explain memory loss in dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028270</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ben Beck</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Designing streets for health: developing innovative methods and tools to make cycling safe, accessible and inclusive</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,263,469.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>transport </Res_KW1>
        <Res_KW2>physical activity</Res_KW2>
        <Res_KW3>injury prevention</Res_KW3>
        <Res_KW4>road safety</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>Cycling has substantial health, environmental and social benefits. However, the key barrier to increased participation is how unsafe people feel when riding. In this project, we will develop new methods that put people’s experience at the centre of how we design safe, accessible and inclusive streets. We will develop new tools to strategically prioritise bike infrastructure investment to maximise the equitable uptake of bike riding.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028286</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Liezhou Zhong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Printing an appetite for life: developing three-dimensional printed texture modified foods for aged care residents</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$719,037.20</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | biomedical and clinical sciences | nutrition and dietetics | nutrition and dietetics not elsewhere classified | agricultural, veterinary and food sciences | food sciences | food technology | </Fields_of_Research>
        <Res_KW1>dysphagia </Res_KW1>
        <Res_KW2>aged care</Res_KW2>
        <Res_KW3>food intake</Res_KW3>
        <Res_KW4>malnutrition</Res_KW4>
        <Res_KW5>nutritional support techniques</Res_KW5>
        <Plain_Description>This study will develop beautiful, tasty and healthy three-dimensional (3D) printed fruit and vegetable-based food for residents in Australian residential aged care facilities (RACFs) to increase their fruit and vegetable intake and fight against the prevalence of malnutrition in RACFs. Ready-to-eat and print novel fruit and vegetables based, protein enriched texture modified foods will be developed. 3D printed foods will be implemented in RACFs and their health benefits will be evaluated.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028298</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Dane Vassiliadis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting non-genetic mechanisms of therapeutic resistance in Acute Myeloid Leukaemia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$887,374.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | </Fields_of_Research>
        <Res_KW1>cancer biology </Res_KW1>
        <Res_KW2>transcriptional regulation</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>cell lineage</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Advances in DNA sequencing have revealed the vast landscape of genetic mutations that drive cancer initiation, treatment evasion and relapse. However, cancers can also change over time using non-genetic mechanisms that are poorly understood yet can significantly impact disease outcome. This proposal seeks to use a novel lineage tracing technology to understand at the single cell level, the non-genetic mechanisms that drive tumour evolution and treatment resistance in cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028308</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jeffrey Warner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Melioidosis on the move: Informing the public health response.</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,505,205.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | health sciences | epidemiology | disease surveillance | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>public health </Res_KW1>
        <Res_KW2>melioidosis</Res_KW2>
        <Res_KW3>burkholderia pseudomallei</Res_KW3>
        <Res_KW4>tropical health</Res_KW4>
        <Res_KW5>environment</Res_KW5>
        <Plain_Description>Melioidosis is an often fatal infectious disease acquired from the environment and cases are rising in Australia. It mostly affects people living in regional locations who suffer from conditions like diabetes. Without the correct treatment, people die so awareness that this disease exists in communities is important for successful outcomes. This study will use innovative microbiology, genome and public health tools to detect and predict current and future melioidosis risk across the country.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028330</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Emma Sierecki</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Strainotyping Synuclein aggregates in diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$835,804.30</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>alpha-synuclein </Res_KW1>
        <Res_KW2>parkinson disease</Res_KW2>
        <Res_KW3>protein aggregation</Res_KW3>
        <Res_KW4>differential diagnosis</Res_KW4>
        <Res_KW5>molecular basis of disease</Res_KW5>
        <Plain_Description>Having an accurate diagnosis for progressive neurodegenerative disorders is essential to the practician to choose the appropriate treatment option, as well as to the patient and their carers to prepare for the future. Here we propose to develop a differential molecular diagnostic for Parkinson's disease, Dementia with Lewy Bodies and multiple system atrophy, three diseases that often start with the same symptoms but become radically different over time and do not respond to the same treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028353</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jason Cain</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Exploiting epigenetic dysregulation to develop differentiation therapy in solid tumours.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,914,192.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>non-small cell lung cancer </Res_KW1>
        <Res_KW2>cell differentiation</Res_KW2>
        <Res_KW3>cancer therapy</Res_KW3>
        <Res_KW4>cancer cell biology</Res_KW4>
        <Res_KW5>cancer genetics</Res_KW5>
        <Plain_Description>Lung adenocarcinoma (LUAD) is treated with chemotherapy and immunotherapy which is largely ineffective. We show LUAD patients may benefit from epigenetic differentiation therapy. This project utilises human and mouse models of LUAD to define the mechanisms of epigenetic differentiation therapy in order identify biomarkers predictive of response, and synergistic therapies. These studies will demonstrate the utility of epigenetic differentiation therapy in LUAD, leading to successful translation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028360</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Freda Jen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Combating multidrug-resistant gonorrhoea by breaking down bacterial metal homeostasis.</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,382,509.21</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>gonorrhoea </Res_KW1>
        <Res_KW2>antibiotics</Res_KW2>
        <Res_KW3>sexually-transmitted infections (sti)</Res_KW3>
        <Res_KW4>neisseria gonorrhoeae</Res_KW4>
        <Res_KW5>antibiotic resistance</Res_KW5>
        <Plain_Description>Gonorrhea, caused by Neisseria gonorrhoeae, has become increasingly resistant to all currently prescribed antibiotics, posing a significant health burden if left untreated. With no effective drugs or vaccines available, the development of a new class of antibiotics has become a critical unmet need in human health. This project aims to address this challenge by developing a novel class of antibiotics capable of treating multidrug-resistant gonorrhea and other drug-resistant bacterial infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028369</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Hogan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Mechanisms to promote lymphatic vessel growth in tissue repair and disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,651,070.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>lymphatics </Res_KW1>
        <Res_KW2>zebrafish</Res_KW2>
        <Res_KW3>vascular biology</Res_KW3>
        <Res_KW4>cell biology</Res_KW4>
        <Res_KW5>developmental biology</Res_KW5>
        <Plain_Description>Lymphatic vessels drain tissue fluids and traffic immune cells. Recent studies discovered that promoting lymphatic vessel growth improves outcomes in cardiovascular disease, cancer and lymphoedema. A clinical need exists to be able to promote the formation of functional lymphatic vessel networks in patients. This project will characterise mechanisms and methods to promote robust lymphatic formation. Outcomes will inform future therapeutic approaches in lymphoedema and diverse clinical settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028382</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ali Zaid</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting Skin Immune Responses to Limit Mosquito-Borne Viral Infection and Disease</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,282,848.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>mosquito-borne disease </Res_KW1>
        <Res_KW2>viral immunology</Res_KW2>
        <Res_KW3>skin immunology</Res_KW3>
        <Res_KW4>arbovirus diseases</Res_KW4>
        <Res_KW5>epidemic polyarthritis</Res_KW5>
        <Plain_Description>Arboviruses such as chikungunya (CHIKV) and Ross River virus (RRV) are a global problem and can cause severe systemic disease. They are transmitted via mosquito bites to the skin and disseminate through the body. How this happens and how the immune system responds, remains unknown, because there is no experimental model of arboviral skin infection. We have developed an advanced skin infection model, and aim to investigate how the skin's immune system shapes the outcome of arboviral infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028388</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Miranda Davies-Tuck</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Elucidating the role of the endometrium in predicting pregnancy outcomes</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,282,017.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>menstruation </Res_KW1>
        <Res_KW2>stillbirth</Res_KW2>
        <Res_KW3>endometrium</Res_KW3>
        <Res_KW4>pregnancy complications</Res_KW4>
        <Res_KW5>implantation</Res_KW5>
        <Plain_Description>This program of work will uncover the role of the endometrial environment in stillbirth, elucidating the foundation of placental issues and ultimately lead to new strategies and interventions for stillbirth prevention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028398</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Juliana Hamzah</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Innovating a First-of-its-Kind Agent to Improve Blood Circulation</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,147,253.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>targeted therapy </Res_KW1>
        <Res_KW2>drug delivery</Res_KW2>
        <Res_KW3>arterial function</Res_KW3>
        <Res_KW4>pre-clinical studies</Res_KW4>
        <Res_KW5>protein engineering</Res_KW5>
        <Plain_Description>Cardiovascular disease is the world’s leading cause of death. It is often caused by build-up of fat deposits (plaque) in large blood vessels. At present, no medication can reverse this process. We have developed a combination drug that targets and shrinks plaque. In animal models, we will evaluate exactly how this agent works and whether it is safe. We will determine which patients would be most suitable for this treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028401</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Bridgette Semple</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Infant abusive head trauma: A new model to study chronic effects and potential biomarkers</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,080,187.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>traumatic brain injury (tbi) </Res_KW1>
        <Res_KW2>infant development</Res_KW2>
        <Res_KW3>retinal degeneration</Res_KW3>
        <Res_KW4>animal model</Res_KW4>
        <Res_KW5>brain pathology</Res_KW5>
        <Plain_Description>Abusive head trauma (AHT) is a severe condition that causes profound disabilities. There is still much to learn about how shaking of infants can cause brain damage. We aim to optimise a new mouse model of repetitive infant AHT, test a drug's potential to reduce brain damage after AHT, and explore inflammation in the eye as a sensitive diagnostic tool. Findings will transform our understanding of AHT, and improve diagnosis and treatment, to prevent repeated abuse and improve survivors' outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028421</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Meaghan O'Donnell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Creating a computational clinical decision tool for treatment selection in PTSD.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,648,077.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>posttraumatic stress disorder (ptsd) </Res_KW1>
        <Res_KW2>prediction</Res_KW2>
        <Res_KW3>psychological treatment</Res_KW3>
        <Res_KW4>treatment outcomes</Res_KW4>
        <Res_KW5>biological risk factors</Res_KW5>
        <Plain_Description>Psychiatry has a range of evidence-based treatments for posttraumatic stress disorder (PTSD) patients, but poor treatment response has led to an urgent need to improve treatment outcomes. This project will harness novel artificial intelligence to measure and predict whether an individual will respond to a given treatment for PTSD. We will create a computerised decision tool that will take the guesswork out of clinical decision-making to ensure a patient receives their most optimal treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028428</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Melinda Jackson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Sound asleep: A novel approach to treating Obstructive Sleep Apnoea and associated daytime impairment with acoustic slow wave sleep enhancement</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$751,375.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | cognitive neuroscience | </Fields_of_Research>
        <Res_KW1>obstructive sleep apnoea </Res_KW1>
        <Res_KW2>novel therapies</Res_KW2>
        <Res_KW3>cognition</Res_KW3>
        <Res_KW4>sleep architecture</Res_KW4>
        <Res_KW5>pathophysiology</Res_KW5>
        <Plain_Description>Obstructive Sleep Apnoea (OSA) affects one in five Australians, causing drops in blood oxygen levels and disruption to deep, or slow wave, sleep. Slow wave sleep is important for brain health. Current treatments for OSA are poorly tolerated and not effective in all patients. This study will examine whether a novel therapy for OSA, which enhances slow wave sleep through acoustic stimulation, improves patients’ daytime functioning and explore how it affects the underlying causes of OSA.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028435</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Susanna Guatelli</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Development of a novel Machine Learning-based dose engine for online adaptive radiotherapy</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$708,272.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>physical sciences | medical and biological physics | medical physics | biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </Fields_of_Research>
        <Res_KW1>radiotherapy </Res_KW1>
        <Res_KW2>treatment planning</Res_KW2>
        <Res_KW3>radiation dose</Res_KW3>
        <Res_KW4>head and neck cancer</Res_KW4>
        <Res_KW5>computer simulation</Res_KW5>
        <Plain_Description>We will develop DoseART, a novel Treatment Planning System dose engine based on machine learning, for adaptive radiotherapy (ART) with re-planning, the state of the art for personalised radiotherapy, to support its implementation, currently limited to few cancer centres, to a wider clinical setting, in Australia and internationally. We will tackle this challenge using a top multi-disciplinary team and we will focus on head and neck cancers, which proved to benefit substantially from ART.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028446</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Anna Hatton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Losing touch: Exploring the neurophysiological effects of bionic sensory insole technology for balance rehabilitation</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$864,535.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | podiatry | biomedical and clinical sciences | neurosciences | sensory systems | health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>peripheral neuropathy </Res_KW1>
        <Res_KW2>sensorimotor control</Res_KW2>
        <Res_KW3>postural control</Res_KW3>
        <Res_KW4>rehabilitation</Res_KW4>
        <Res_KW5>footwear</Res_KW5>
        <Plain_Description>Nerve damage (peripheral neuropathy) due to ageing or disease harms the sense of feeling in the feet. This is a major problem as loss of foot sensation impairs balance, leading to falls and injury. The project will engineer a state-of-the-art insole, designed to stimulate foot skin sensors, to improve how the muscles and nerves work to keep the body upright. Patient testing of the technology will generate knowledge to develop an efficient balance rehabilitation device for people with neuropathy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028501</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mary Kavurma</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>On the TRAIL of peripheral artery disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,654,781.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>cardiovascular system </Res_KW1>
        <Res_KW2>peripheral vascular disease</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>novel therapeutic agents</Res_KW4>
        <Res_KW5>endothelial dysfunction</Res_KW5>
        <Plain_Description>Peripheral artery disease (PAD) occurs because of blocked arteries in limbs resulting in amputation. This proposal has 3 aims: 1) Can the natural molecule called TRAIL identify patients progressing to the severe form of PAD?; 2) Can artery health be improved by activating TRAIL signals in diabetic PAD?; and 3) Are there other targets that may improve arterial health in PAD?  Results could bring TRAIL-based diagnostic/treatments to the clinic, contribute to knowledge, save limbs and lives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028506</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tara Roberts</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Combining liquid biopsy and radiomics to provide personalised management of PSMA-lutetium-177 treatment for metastatic prostate cancer patients</Grant_Title>
        <Admin_Institution>Western Sydney University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,582,740.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | </Fields_of_Research>
        <Res_KW1>prostate cancer </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>dna damage</Res_KW3>
        <Res_KW4>medical imaging</Res_KW4>
        <Res_KW5>artificial intelligence</Res_KW5>
        <Plain_Description>Prostate cancer is the most common cancer in men in Australia. A new treatment called LuPSMA targets radiation to prostate cancer cells. PET scans are currently used to select which patients receive treatment but up to half of patients selected do not respond. We will examine cancer DNA and cancer cells in blood as well as imaging data and then combine the data types with artificial intelligence to develop a method to predict which patients will respond to treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028520</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jamie Vandenberg</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>HERG Modulators: A new approach to anti-arrhythmic therapy</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,106,906.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>drug development </Res_KW1>
        <Res_KW2>cardiac arrhythmia</Res_KW2>
        <Res_KW3>ion channels</Res_KW3>
        <Res_KW4>structural biology</Res_KW4>
        <Res_KW5>molecular modelling</Res_KW5>
        <Plain_Description>The normal pumping of blood by the heart is dependent on a tightly regulated electrical communication system. Disturbances to electrical signalling in the upper chambers of the heart, Atrial fibrillation, increases the risk of stroke, dementia and death. At present there are no truly effective drugs for treating atrial fibrillation. Here, we are investigating how a new class of drugs could enhances the activity of ion channels that help to suppress cardiac arrhythmias.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028533</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Karly Turner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Compulsivity and inference-based predictions</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,327,679.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>obsessive-compulsive disorder (ocd) </Res_KW1>
        <Res_KW2>cortex</Res_KW2>
        <Res_KW3>decision making</Res_KW3>
        <Res_KW4>basal ganglia</Res_KW4>
        <Res_KW5>dopamine</Res_KW5>
        <Plain_Description>Obsessive thoughts and compulsive behaviours are symptoms of many disorders. Obsessions are thought to occur when inferred outcomes do not match reality. We will determine how decisions are made when based on inference versus experience to better understand obsessions. We will also determine if the same brain circuits underlie the processes behind obsessions and compulsions. This project will develop new knowledge about brain functions, allowing us to better understand and treat these symptoms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028555</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Eric Moses</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>GETTING TO THE HEART OF THE MATTER:  A Novel ‘Omics’ Risk Score for CVD Risk Assessment in Women Following Pre-Eclampsia</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$2,243,597.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>pre-eclampsia </Res_KW1>
        <Res_KW2>cardiovascular disease</Res_KW2>
        <Res_KW3>cardiovascular risk</Res_KW3>
        <Res_KW4>machine learning</Res_KW4>
        <Res_KW5>clinical decision making</Res_KW5>
        <Plain_Description>Women who have a pregnancy complicated by pre-eclampsia and other high blood pressure disorders are at much greater risk of heart disease later in life than women who have healthy pregnancies. There is currently no clinical test that can be used to identify those women at greatest risk. This project aims to develop a clinical test for this unmet need, using machine learning and large patient datasets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028572</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jai Tree</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Enhancing antisense RNA antibiotics using aptamers that trigger RNA decay</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$779,186.15</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | microbial genetics  | </Fields_of_Research>
        <Res_KW1>shiga-toxigenic escherichia coli (stec) disease </Res_KW1>
        <Res_KW2>antimicrobial resistance</Res_KW2>
        <Res_KW3>antisense rna</Res_KW3>
        <Res_KW4>bacterial genetics</Res_KW4>
        <Res_KW5>microbial pathogenesis</Res_KW5>
        <Plain_Description>Synthetic antisense RNAs can be used to re-sensitise pathogens to antibiotics, reduce virulence, or as RNA-based antibiotics.  They are active at concentrations comparable to antibiotics, but their activity needs to be enhanced for application in the clinic. Using new knowledge of how RNAs are recruited to the RNA degradation machinery in bacteria, aptamers that trigger target RNA decay will be used to enhance the activity of synthetic antisense RNAs for use as sequence-specific therapeutics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028578</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kim Loh</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Salt-Inducible Kinase 3 (SIK3): A new therapeutic target for diabetes.</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$922,820.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | cell physiology | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>pancreatic beta cell </Res_KW1>
        <Res_KW2>insulin secretion</Res_KW2>
        <Res_KW3>protein kinases</Res_KW3>
        <Res_KW4>glucose homeostasis</Res_KW4>
        <Res_KW5>diabetes</Res_KW5>
        <Plain_Description>Current efforts to enhance ß-cell function focus mostly on the pathways that stimulate insulin release. Improving ß- cell function by inhibiting the counter-regulatory pathway that suppresses the release of insulin remains largely unexplored as a therapeutic option. The main objective of this proposal is to explore the potential therapeutic possibility of targeting the newly identified molecule called SIK3, that inhibits insulin release for improving ß-cell function in type 2 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028579</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hamish King</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Molecular function of the chromatin reader SP140 in human B cells and autoimmune disease.</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,249,985.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genome structure and regulation | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>chromatin </Res_KW1>
        <Res_KW2>gene regulation</Res_KW2>
        <Res_KW3>functional genomics</Res_KW3>
        <Res_KW4>b cells</Res_KW4>
        <Res_KW5>autoimmune disease</Res_KW5>
        <Plain_Description>The causes of autoimmune disease (where the immune system attacks our own body) are poorly understood. B cells are part of our immune system involved in these diseases, such as lupus. Here we will study how the protein SP140, that binds to DNA to turn genes on or off, can lead to B cells “going wrong”. We will identify the genes controlled by SP140 and learn how this disrupts B cell function to discover how autoimmune diseases develop and provide information needed to develop new treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028599</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Hannah Keage</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Predicting delirium vulnerability from pre-surgery neurophysiological measures</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,215,441.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | psychology | biological psychology  | cognitive neuroscience | </Fields_of_Research>
        <Res_KW1>delirium </Res_KW1>
        <Res_KW2>psychogeriatrics</Res_KW2>
        <Res_KW3>electroencephalogram (eeg)</Res_KW3>
        <Res_KW4>cognition</Res_KW4>
        <Res_KW5>hospitalisation</Res_KW5>
        <Plain_Description>Delirium is a sudden impairment in thinking skills, that comes and goes, and is common after surgery (25-30% of patients). Older adults who develop delirium have a reduced life expectancy and are more likely to develop dementia. We don't know why some older adults develop delirium after surgery and others do not. Our study will identify patterns of brain activity associated with an increased delirium risk, which will ultimately improve care and enable prevention efforts to be targeted.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028605</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof James Fallon</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Improved recording technology for chronic monitoring of the peripheral nervous system</Grant_Title>
        <Admin_Institution>The Bionics Institute of Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,038,871.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | autonomic nervous system  | biomedical and clinical sciences | neurosciences | peripheral nervous system | </Fields_of_Research>
        <Res_KW1>electrophysiology </Res_KW1>
        <Res_KW2>peripheral nerve</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>somatosensory system</Res_KW5>
        <Plain_Description>Recording peripheral nerve activity has advanced in recent years. However, few methods are safe long-term and have limited clinical translational value. Here we aim to expand and demonstrate the chronic utility and stability of our novel recording and analysis techniques in exemplar autonomic (vagus nerve) and somatic (sciatic nerve) systems. Our technology is a powerful research tool that allows us to monitor peripheral pathways for application in disease and injury.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028610</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Antiopi Varelias</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing the gut microbiome to improve stem cell transplant outcome.</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,719,763.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | transplantation immunology  | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>haematopoietic stem cell transplantation </Res_KW1>
        <Res_KW2>graft versus host disease (gvhd)</Res_KW2>
        <Res_KW3>bacteria</Res_KW3>
        <Res_KW4>metabolites</Res_KW4>
        <Res_KW5>immunoglobulin a (iga)</Res_KW5>
        <Plain_Description>A major barrier of stem cell transplantation, the curative therapy for patients with high-risk blood cancer, is graft-versus-host disease (GVHD). Overall survival for patients with gut GVHD is 25% at 2 years. Treatment regimens damage the gut leading to bacterial exposure which impacts transplant outcome. This project focuses on advancing our understanding of immunomodulatory bacteria, generating new knowledge to inform the development of new treatments and predictive biomarkers for GVHD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028625</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jay Horvat</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Manipulating iron metabolism in the airway mucosa for the treatment of severe asthma and COPD</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,299,359.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>asthma severity </Res_KW1>
        <Res_KW2>chronic obstructive pulmonary disease (copd)</Res_KW2>
        <Res_KW3>respiratory infection</Res_KW3>
        <Res_KW4>iron metabolism</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>Asthma and chronic obstructive pulmonary disease (COPD) account for significant premature death, chronic suffering and massive health care costs in Australia. Our team conducted world first studies to show that altered iron levels in the airways affects disease severity in both asthma and COPD. In this study we will investigate how altered in iron levels in the airways affects disease and test therapies that correct altered iron levels in the airways for the treatment of both asthma and COPD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028650</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hong You</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing CRISPR-Cas13 molecular diagnosis in the fight against Intestinal parasitic worms</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$721,918.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | </Fields_of_Research>
        <Res_KW1>helminth infection </Res_KW1>
        <Res_KW2>molecular diagnosis</Res_KW2>
        <Res_KW3>medical parasitology</Res_KW3>
        <Res_KW4>schistosomiasis</Res_KW4>
        <Res_KW5>strongyloidiasis</Res_KW5>
        <Plain_Description>The availability of powerful diagnostics is key for controlling parasitic infections. We will use molecular CRISPR-based technologies to develop sensitive, use-friendly diagnostics for human strongyloidiasis and establish a high throughput platform that can detect multiple helminth infections simultaneously. Our discoveries will break the current diagnostic bottleneck and significantly enhance surveillance capabilities for diagnosis of human infections caused by parasitic worms globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028656</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Matthew Sunderland</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Standing on the shoulders of giants: harmonising 40 years of data to revolutionise Australia’s response to increases in psychological distress</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$498,463.02</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | health sciences | public health | social determinants of health | </Fields_of_Research>
        <Res_KW1>epidemiology </Res_KW1>
        <Res_KW2>psychological distress</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>data analysis</Res_KW4>
        <Res_KW5>repeated surveys</Res_KW5>
        <Plain_Description>Mental health disorders are the fourth leading cause of disability in Australia and cost approximately $43.5 billion. Australia has an extensive amount of population-based data on psychological distress, that could be used to monitor, forecast, and plan for mental ill health in the future, yet it remains substantially underutilised and often unused. The current study will apply novel techniques for data harmonisation to estimate and forecast age-periodcohort trends in psychological distress.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028681</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Lockhart</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the genetics and pathogenesis of repeat expansion disorders</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,668,755.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | genetics | neurogenetics | </Fields_of_Research>
        <Res_KW1>neurogenetics </Res_KW1>
        <Res_KW2>ataxia</Res_KW2>
        <Res_KW3>gene discovery</Res_KW3>
        <Res_KW4>disease mechanisms</Res_KW4>
        <Res_KW5>disease modelling</Res_KW5>
        <Plain_Description>Repeat expansion disorders are one of the most common genetic conditions encountered by clinicians but are poorly understood and have a very low genetic diagnostic rate. This project will identify new genes that cause these disorders and establish improved diagnostic pathways for affected individuals. Development and characterisation of induced pluripotent stem cell models will provide novel insights into disease mechanisms and provide a platform for screening to identify therapeutic drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028684</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanna Achinger-Kawecka</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Assessing the role of the tumour ecosystem in epigenetic therapy response in ER+ endocrine-resistant breast cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,090,079.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genome structure and regulation | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>chromatin structure </Res_KW1>
        <Res_KW2>chromosomal mapping</Res_KW2>
        <Res_KW3>gene regulation</Res_KW3>
        <Res_KW4>transcription factor</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Despite of tremendous advances in the treatment of ER+ breast cancer using hormonal therapy, patients frequently develop resistance to these therapies. These resistant tumors remain the most common cause of breast cancer death, yet mechanisms by which this resistance develops are poorly understood.  The goal of this project is to use cutting-edge genomic technology to delineate how ER+ breast cancers develop resistance to therapies and to identify new targets in resistant breast cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028698</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Louise Purton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>How does Hoxa1 alter blood-forming stem cells to cause blood cell diseases and cancer?</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,663,337.59</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>experimental haematology </Res_KW1>
        <Res_KW2>haematological malignancy</Res_KW2>
        <Res_KW3>myelodysplasia</Res_KW3>
        <Res_KW4>stem cell biology</Res_KW4>
        <Res_KW5>haematopoietic stem cells</Res_KW5>
        <Plain_Description>We make billions of blood cells every day, all made from blood-forming stem cells. Changes in the production of blood cells from stem cells can result in blood cell cancers. We have developed mice with changes in production of a protein that is altered in patients with an incurable blood cell cancer. The mice develop the blood cell cancer. We will further our studies to identify how this protein causes the blood cell cancer to enable identification of better therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028714</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Adele Lehane</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Na(+)-dysregulating antimalarials: blocking the roads to resistance by understanding PfATP4 and its place in parasite physiology</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$837,718.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biological sciences | microbiology | infectious agents | biological sciences | biochemistry and cell biology | receptors and membrane biology | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>plasmodium falciparum</Res_KW2>
        <Res_KW3>ion transport</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>antimalarial</Res_KW5>
        <Plain_Description>The most deadly malaria parasite has acquired resistance to most antimalarials, and there is a danger of malaria becoming an untreatable disease. Cipargamin is a promising new antimalarial that targets a protein needed for salt balance in the parasite. In this project we seek to understand the ways in which parasites can protect themselves from cipargamin, and explore strategies for preventing resistance. We will also characterise other proteins that regulate salt balance in malaria parasites.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028727</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Marcus Robinson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>What determines plasma cell longevity?</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,311,269.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>cellular immunology </Res_KW1>
        <Res_KW2>immunology</Res_KW2>
        <Res_KW3>molecular immunology</Res_KW3>
        <Res_KW4>cellular immunity</Res_KW4>
        <Res_KW5>adaptive immunity</Res_KW5>
        <Plain_Description>Antibody-secreting plasma cells (PC) can be protective in producing neutralising antibodies fighting infections, but also pathogenic in causing diseases like autoimmunity. In this project, we will examine whether PC form with pre-set lifespans that may also be regulated by different circumstances such as infection and inflammation. We seek to learn how to modulate PC lifespans to extend them when helpful, such as after a vaccine, and shorten them when unhelpful, such as in autoimmunity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028758</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Curtis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Bringing clonal haematopoiesis (CHIP) to the clinic through screening, risk profiling and treatment</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,990,620.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | </Fields_of_Research>
        <Res_KW1>haematopoietic stem cells </Res_KW1>
        <Res_KW2>gene mutations</Res_KW2>
        <Res_KW3>healthy ageing</Res_KW3>
        <Res_KW4>aspirin</Res_KW4>
        <Res_KW5>oncology</Res_KW5>
        <Plain_Description>CHIP is a disease of aging blood cells found in > 1 million Australians associated with age-related diseases including cancer. Using samples from a randomised study of aspirin in the elderly, this project will build a case for screening for CHIP to identify individuals with high levels of CHIP that will benefit from aspirin to prevent cancer. In those with low levels of CHIP, we will develop a risk scoring system to predict risk of progression and we will find ways of preventing growth of CHIP.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028761</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Uwe Dulleck</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Saving lives in rural and remote Australia: Tackling RHD related pathologies using Behavioural Economic interventions for early prevention, diagnosis, and managing disease progress</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,150,396.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | economics | applied economics | behavioural economics | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health and wellbeing not elsewhere classified | </Fields_of_Research>
        <Res_KW1>early prevention </Res_KW1>
        <Res_KW2>behaviour change</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>indigenous health</Res_KW4>
        <Res_KW5>rheumatic heart disease</Res_KW5>
        <Plain_Description>Rheumatic heart disease is associated with high mortality rates and premature deaths, especially among Indigenous Australians. Combining First Nations communities’ voices and perspectives, and insights from Behavioural Economics, this study will develop and evaluate interventions to increase early diagnosis, prevention, and improve the managing of disease. Furthermore, this study will develop and implement sustainable outcomes, while building significant capabilities in the community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028765</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Fabio Luciani</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing Pathogenic Immune Cells to Develop a New Diagnostic for Non-Responders and Refractory Conditions in Celiac Disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,094,640.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity  | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>coeliac disease </Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>immune tolerance</Res_KW3>
        <Res_KW4>somatic mutation</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>A key feature of the immune system is its capacity to respond to threats (infections, cancer) and ignore everything else. This function is missing in autoimmune disorders, as in coeliac disease where immune cells go “rogue” with gluten food. In this research we have proposed a ground-breaking solution to identify how immune cells develop aberrant responses against gluten and develop  complicated disease. This work will have consequences for discovery new immunotherapies and improve diagnosis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028766</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr David Herrmann</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting fibrosis in combination with standard-of-care in pancreatic cancer guided by single-cell intravital imaging</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$599,853.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>cell biology </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>imaging</Res_KW3>
        <Res_KW4>biosensor</Res_KW4>
        <Res_KW5>cancer chemotherapy</Res_KW5>
        <Plain_Description>Fibrosis is a well-known risk factor for cancer initiation, progression and prognosis that is commonly found in aggressive cancers, such as pancreatic cancer (PC). Fibrosis is known to fuel PC spread around the body (metastasis) and to protect PC cells from treatment including chemotherapy, which is the standard-of-care in PC. In this proposal we will test the hypothesis that reducing fibrosis enhances standard-of-care chemotherapy performance and improves outcomes in pre-clinical models of PC.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028773</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kazuhide Shaun Okuda</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Cellular signalling and growth control in vascular development and lymphatic malformations</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,022,935.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>lymphatics </Res_KW1>
        <Res_KW2>zebrafish</Res_KW2>
        <Res_KW3>vascular biology</Res_KW3>
        <Res_KW4>ribosome biogenesis</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Excessive lymphatic vessel growth leads to childhood lymphatic malformations, resulting in severe pain and deformities. There is an urgent unmet need for new and effective therapies for these patients. We recently found that Ddx21 and ribosome biogenesis are selectively required for lymphatic growth. This Ideas grant will explore the mechanisms that drive this selectivity and test if DDX21 and ribosome biogenesis can be new therapeutic targets for childhood lymphatic malformations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028787</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Hong Zhou</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Glucocorticoid rhythmicity and its critical role in bone loss and osteoarthritis during chronic disruption of circadian rhythm</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$850,602.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>osteoarthritis </Res_KW1>
        <Res_KW2>glucocorticoids</Res_KW2>
        <Res_KW3>circadian rhythms</Res_KW3>
        <Res_KW4>osteoporosis</Res_KW4>
        <Res_KW5>osteoblast</Res_KW5>
        <Plain_Description>Shift work has been found to increase the risk of osteoporosis and osteoarthritis in humans. Our studies in mice show that chronic environmental light disruption (mimicking shift work) accelerates the development of osteoporosis and osteoarthritis. Using mice in which important time-setting hormones, namely glucocorticoids, have been blocked in bone and cartilage cells, this proposal aims to examine how glucocorticoids regulate rhythms in bone and cartilage during chronic light disruption.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028804</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucille Rankin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Selective Targeting of Tissue-resident Tregs in Gastrointestinal Disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,435,168.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>gut immunity </Res_KW1>
        <Res_KW2>adaptive immunity</Res_KW2>
        <Res_KW3>molecular immunology</Res_KW3>
        <Res_KW4>cellular immunology</Res_KW4>
        <Res_KW5>cell death</Res_KW5>
        <Plain_Description>Treg cells suppress the immune system and are essential for a healthy gut. Without them, severe autoimmune disorders prevail. There are two "flavours" of Tregs in the gut and we want to know what controls how these cells live or die to maintain a healthy gut. By uncovering the molecular cues controlling survival of gut Treg populations, we can design therapies to boost or reduce the desired Treg "flavour" to treat disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028813</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Emma Hamilton-Williams</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting gut microbial metabolites to prevent type 1 diabetes</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,466,293.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity  | biological sciences | microbiology | microbial ecology | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>microbial ecology </Res_KW1>
        <Res_KW2>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW2>
        <Res_KW3>autoimmunity</Res_KW3>
        <Res_KW4>intestinal mucosa</Res_KW4>
        <Res_KW5>metabolomics</Res_KW5>
        <Plain_Description>Type 1 diabetes (T1D) is on the rise, especially in young children, with lifelong negative consequences. It is crucial to find new ways to prevent T1D and reduce this burden. Bacteria in the gut differ in children that develop T1D and may be a cause of disease progression. Our goal is to directly link the altered gut bacteria in at-risk children with diabetes progression, to identify and target the molecules produced by the bacteria and underlying processes that alter the course of disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028871</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr William Hamilton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>mRNA processing in development and disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$987,177.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | genetics | genome structure and regulation | </Fields_of_Research>
        <Res_KW1>embryonic stem cells </Res_KW1>
        <Res_KW2>messenger rna (mrna)</Res_KW2>
        <Res_KW3>control of gene expression</Res_KW3>
        <Res_KW4>rna processing</Res_KW4>
        <Res_KW5>human endogenous retroviruses (herv)</Res_KW5>
        <Plain_Description>The complement of genes which are active in any specific cell determines how that cell will behave. This is highly dynamic and tightly regulated during embryonic development but often altered in cancer. We have identified a novel pathway regulating how genes are processed that regulates how embryos grow, but is also coopted in cancer to evade certain drug treatments. Our research will uncover how we can target these cancers to improve patient treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028898</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Diana Hansen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Immune responses to asymptomatic malaria: dissecting cellular signatures to overcome immunosuppression and improve vaccination strategies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$873,270.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>immunosuppression</Res_KW2>
        <Res_KW3>malaria vaccine</Res_KW3>
        <Res_KW4>t cells</Res_KW4>
        <Res_KW5>systems biology</Res_KW5>
        <Plain_Description>This project will undertake a comprehensive immunological and molecular analysis of individuals experiencing asymptomatic malaria in an endemic area of Indonesia. The project will demonstrate that asymptomatic malaria is not benign as previously thought, providing a framework for new polices supporting mass-screening and treatment of asymptomatic malaria. We will also identify critical immune responses to eradicate these persistent infections with innovative vaccination strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028921</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr LOK HANG CARLSON Tsui</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the anatomical context and molecular mechanisms of T cell reinvigoration during therapeutic checkpoint blockade</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$875,952.91</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>cd8 t cells </Res_KW1>
        <Res_KW2>antiviral immunity</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>t cell immunotherapy</Res_KW4>
        <Res_KW5>adaptive immunity</Res_KW5>
        <Plain_Description>Immune checkpoint blockade (ICB) activates patient’s own T cells and has revolutionised cancer therapy. Our project aims to unravel how distinct anatomical sites and molecular pathways coordinate T cell reinvigoration upon ICB therapy. By integrating multidisciplinary expertise and innovative methods, the expected outcomes of this project will provide fundamental insights that will improve current therapeutic strategies and result in the development of novel immunotherapies for cancer treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028943</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Laura Tarzia</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>MeAsuring the beNefits of TRAuma-sensitive yoga for survivors of sexual violence (MANTRA Study)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$639,804.57</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | health sciences | traditional, complementary and integrative medicine | traditional, complementary and integrative medicine not elsewhere classified | health sciences | sports science and exercise | sports science and exercise not elsewhere classified | </Fields_of_Research>
        <Res_KW1>sexual abuse </Res_KW1>
        <Res_KW2>domestic violence</Res_KW2>
        <Res_KW3>posttraumatic stress disorder (ptsd)</Res_KW3>
        <Res_KW4>yoga</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Sexual violence is globally prevalent and associated with poor mental health, particularly post-traumatic stress. Despite this, effective therapeutic treatments to promote recovery are limited. This project will examine the benefits of trauma-sensitive yoga for survivors of sexual violence and explore how and why it works. We will generate new knowledge about the potential of yoga as a therapeutic intervention and challenge current paradigms for addressing sexual violence in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028952</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Gibson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>An immunogenomic roadmap to define drug- and tissue-relevant genetic-, cellular-, and structural-risk signatures of Stevens-Johnson syndrome/toxic epidermal necrolysis for population-personalized prevention and treatment in Australian populations.</Grant_Title>
        <Admin_Institution>Murdoch University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,493,326.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | biomedical and clinical sciences | immunology | allergy | </Fields_of_Research>
        <Res_KW1>human leukocyte antigen (hla) </Res_KW1>
        <Res_KW2>t cell receptor</Res_KW2>
        <Res_KW3>allergy prevention</Res_KW3>
        <Res_KW4>skin immunology</Res_KW4>
        <Res_KW5>adverse drug reactions</Res_KW5>
        <Plain_Description>Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis is the deadliest immune-mediated adverse drug reaction and results in severe complications such as blindness. Although genetic risk holds promise for pre-prescription screening, risk genes for Australian populations remain scarce. We will use innovative multi-omic approaches to define new genetic-, cellular-, and structural-risk signatures to improve drug safety in Australia with new strategies for prevention, diagnosis, and treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028972</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgina Trapp (nee Wood)</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Pioneering a national 'Food Atlas' to map, measure and monitor food access across Australia</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,878,044.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>built environment and design | urban and regional planning | urban planning and health | health sciences | public health | health promotion | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>public health </Res_KW1>
        <Res_KW2>health promotion</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>food</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>This innovative project aims to create a national "Food Atlas" to map, measure and monitor food access, providing evidence-based information for professionals in food policy, public health, and planning. The atlas will be able to identify areas with limited healthy food availability or an abundance of unhealthy options. This intelligence will inform food and nutrition policies, support planning decisions, and guide future policy directions to promote equitable, health-promoting communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028976</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jane Alty</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Hiding in plain sight:  Early identification of neurodegenerative disorders with computer analysis of face and eye movements</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$1,006,412.10</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | engineering | biomedical engineering | medical devices | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>computer-assisted diagnosis</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>neurodegenerative disorders</Res_KW4>
        <Res_KW5>parkinson disease</Res_KW5>
        <Plain_Description>Alzheimer’s disease (AD) and Parkinson’s disease (PD) start damaging the brain 15-20 years before symptoms begin. At the time of diagnosis, AD and PD are hard to treat because the damage is so severe. We need a way to detect AD and PD much earlier. We will develop a simple new computer test to detect early signs of AD and PD by analysing face and eye movements. Then people can start prevention earlier and scientists can research better treatments to improve people’s quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028979</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Benedikt Ley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Change of G6PD activity in the course of malaria</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,290,153.94</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>malaria therapy </Res_KW1>
        <Res_KW2>antimalarial</Res_KW2>
        <Res_KW3>enzyme activity</Res_KW3>
        <Res_KW4>treatment strategies</Res_KW4>
        <Res_KW5>malaria</Res_KW5>
        <Plain_Description>Malaria is a serious and potentially deadly disease. Following a first symptomatic phase, some malaria species develop asymptomatic forms that cause a second symptomatic phase weeks to months after the first episode. The drugs currently used to treat this malaria species can cause severe side effects in people with low activities of a particular enzyme (G6PD). This project will test whether G6PD levels increase during a malaria attack, rendering treatment much safer than what is assumed to date.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028987</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Leanne Dibbens</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Identifying new and personalised treatments for KCNT1 neurological disorders using pharmacogenetics</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,371,489.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacogenomics | </Fields_of_Research>
        <Res_KW1>pharmacogenetics </Res_KW1>
        <Res_KW2>drug discovery</Res_KW2>
        <Res_KW3>electrophysiology</Res_KW3>
        <Res_KW4>molecular neuroscience</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>KCNT1 mutations cause severe seizures and early death and there are currently no treatments. We identified 4 novel FDA approved drugs which inhibit the effects of 3 KCNT1 patient mutations. This project will investigate the ability of the 4 drugs to counteract effects of 24 different KCNT1 patient's mutations in animal models with the same mutations. Our findings will accelerate novel off-label use of these 4 FDA approved drugs to treat patients with KCNT1- neurological disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028995</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ariel Isaacs</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Cross-neutralising and variant resistant antibody therapies for henipaviruses</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,804,572.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>respiratory viruses </Res_KW1>
        <Res_KW2>antibody</Res_KW2>
        <Res_KW3>antibody engineering</Res_KW3>
        <Res_KW4>immunotherapy</Res_KW4>
        <Res_KW5>antiviral therapy</Res_KW5>
        <Plain_Description>Henipaviruses are highly lethal viruses, with no approved human vaccines or therapies. Several henipaviruses continuously spill over into human populations from animals and cause significant mortality, with the potential to spread globally. In this work, we aim to isolate antibody therapies that offer protection against a wide range of henipaviruses. This will mitigate viral spill over events and allow the world to be better prepared for future outbreaks against existing and emerging viruses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029002</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Marita Hefler</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>From ‘Dirty Ashtray’ to tobacco control innovator: co-design with remote First Nations communities in the Northern Territory to generate new approaches to reduce smoking</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,123,560.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>tobacco control </Res_KW1>
        <Res_KW2>indigenous health</Res_KW2>
        <Res_KW3>participatory action research</Res_KW3>
        <Res_KW4>consumer participation</Res_KW4>
        <Res_KW5>social environment</Res_KW5>
        <Plain_Description>Smoking is the leading cause of preventable diseases and avoidable death in Australia, and a major contributor to health disparities between First Nations and non-Indigenous peoples. This project will contribute to a transformative paradigm shift from controlling tobacco to ending the smoking epidemic. The aim is to co-design and pilot financially sustainable and culturally acceptable strategies to reduce commercial tobacco supply in remote First Nations communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029017</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Yuning Hong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Using novel chemical probes to identify damaged proteins as new biomarkers for Parkinson's disease</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,016,204.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | biological sciences | biochemistry and cell biology | analytical biochemistry | </Fields_of_Research>
        <Res_KW1>oxidative stress </Res_KW1>
        <Res_KW2>oxidative damage</Res_KW2>
        <Res_KW3>protein folding</Res_KW3>
        <Res_KW4>molecular diagnostics</Res_KW4>
        <Res_KW5>protein aggregation</Res_KW5>
        <Plain_Description>More than 80,000 Australians are affected by Parkinson's disease (PD), a progressive neurological disorder. There is a pressing need to develop reliable, easy-to-access biomarkers for early diagnosis of PD to enable effective treatment. This project aims to leverage cutting-edge technology to generate ‘molecular signatures’ of dysfunctional proteins that are unique in blood cells from individuals with PD, enabling translation for a blood test aiding in early PD diagnosis and drug evaluation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029019</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Louise Purton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>How do dysregulated bone marrow endothelial cells alter blood cell production?</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,665,078.21</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | bioinformatics and computational biology | biological network analysis | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>endothelial cells </Res_KW1>
        <Res_KW2>confocal microscopy</Res_KW2>
        <Res_KW3>bone marrow stroma</Res_KW3>
        <Res_KW4>experimental haematology</Res_KW4>
        <Res_KW5>haematological disorders</Res_KW5>
        <Plain_Description>We make billions of blood cells every day, all made from blood-forming stem cells. Changes in the factories that regulate the production of these blood-forming cells can significantly alter blood cell production, causing many complications. We have identified changes occurring in one of the non-blood cell types in the factory that results in reduced production of red cells and platelets. We will determine how this occurs and identify therapies to improve production of these blood cell types.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029067</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kylie Dunning</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Suspended by sound: A novel approach to grow developmentally competent oocytes in vitro</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,387,127.28</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproduction  | physical sciences | atomic, molecular and optical physics | lasers and quantum electronics | </Fields_of_Research>
        <Res_KW1>in vitro maturation of oocytes </Res_KW1>
        <Res_KW2>follicle</Res_KW2>
        <Res_KW3>embryo culture</Res_KW3>
        <Res_KW4>optical imaging</Res_KW4>
        <Res_KW5>tissue culture</Res_KW5>
        <Plain_Description>The number of Australians under 40 receiving a cancer diagnosis has almost doubled since the early 1980s. Advancements in therapies have dramatically improved chances of surviving cancer but can leave patients infertile. For young cancer survivors, safeguarding fertility is considered a top unmet need. This project will use a new and exciting method to grow frozen and revived ovary tissue (harvested before cancer treatment) to produce healthy eggs that can undergo IVF and restore fertility.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029078</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nathan Pavlos</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>‘Sorting-Out’ the Skeleton: The Role of Sorting Nexin 10 in Osteoclasts and Bone Disease</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$922,525.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | orthopaedics  | biological sciences | biochemistry and cell biology | receptors and membrane biology | </Fields_of_Research>
        <Res_KW1>osteoclast biology </Res_KW1>
        <Res_KW2>bone disease</Res_KW2>
        <Res_KW3>bone resorption</Res_KW3>
        <Res_KW4>membrane fusion</Res_KW4>
        <Res_KW5>rare diseases</Res_KW5>
        <Plain_Description>This proposal investigates the role of SNX10, a molecule that directs the transport of membrane proteins inside osteoclasts (OCs), giant bone-dissolving cells. Mutations in SNX10 cause autosomal recessive osteopetrosis (ARO), a rare but life-threatening bone disease in children associated with increased bone mass but increased risk of fractures and loss of the bone marrow cavity. This work will establish how SNX10 works in OCs and whether SNX10 can be targeted for the treatment of bone diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029087</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Natalie Hannan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A mother’s risk of future cardiovascular disease following preeclampsia: is early detection and prevention possible?</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,129,806.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>maternal health </Res_KW1>
        <Res_KW2>pre-eclampsia</Res_KW2>
        <Res_KW3>pregnancy complications</Res_KW3>
        <Res_KW4>hypertension</Res_KW4>
        <Res_KW5>early intervention</Res_KW5>
        <Plain_Description>Preeclampsia is a deadly complication of pregnancy. Worse yet, women with a history of preeclampsia are up to 5-times more likely to develop cardiovascular disease following pregnancy, putting them at serious risk of dying early.  This project aims to revolutionise our understanding of this serious condition and its longterm consequences, by determining if mother's at highest risk can be identified earlier and if promising medication can be used to prevent cardiovascular disease and early death.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029088</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Dale Garsed</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing the immune response in exceptionally long-term survivors of ovarian cancer to develop novel therapeutics</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,638,231.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>ovarian cancer </Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>cancer cell biology</Res_KW3>
        <Res_KW4>tumour immunology</Res_KW4>
        <Res_KW5>antibody cancer therapy</Res_KW5>
        <Plain_Description>Most women with high-grade serous ovarian cancer develop chemotherapy resistance and fail to benefit from today's immunotherapies. Nonetheless, a rare subset of patients experience exceptionally long-term survival, which we recently showed is linked to the presence of B cells, specialised immune cells that produce anti-tumour antibodies. We will identify the specific antibodies associated with exceptional survival, and evaluate their use as new therapeutic agents to target ovarian cancer cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029098</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Milroy</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding Aboriginal and Torres Strait Islander peoples concepts and experiences in mental health</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,963,874.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander psychology | indigenous studies | other indigenous data, methodologies and global indigenous studies | indigenous methodologies | </Fields_of_Research>
        <Res_KW1>aboriginal mental health </Res_KW1>
        <Res_KW2>aboriginal health</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>psychological health</Res_KW4>
        <Res_KW5>indigenous australians</Res_KW5>
        <Plain_Description>The current mental health system does not understand influences of Aboriginal and Torres Strait Islander culture on experiences of mental health. An Aboriginal and Torres Strait Islander-led, interdisciplinary team will work with Aboriginal and Torres Strait Islander Cultural Healers, mental health workers and community members, to understand mental health from an Indigenous worldview, including the cultural phenomenology of mental health challenges and these lived experiences.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029129</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ying Xia</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Optimising the therapeutic value of cholinesterase inhibitors in Alzheimer's disease</Grant_Title>
        <Admin_Institution>Commonwealth Scientific and Industrial Research Organisation</Admin_Institution>
        <State>ACT</State>
        <Sector>Government</Sector>
        <Total>$796,351.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>cholinesterase inhibitor</Res_KW2>
        <Res_KW3>neurodegeneration</Res_KW3>
        <Res_KW4>neuroimaging</Res_KW4>
        <Res_KW5>cognitive decline</Res_KW5>
        <Plain_Description>Early degeneration of the cholinergic system is a pathological feature of Alzheimer’s disease (AD) that contributes to cognitive decline. Cholinesterase inhibitors are commonly used to lessen or stabilize cognitive symptoms in AD, but only benefit a minority of patients. This project aims to understand early changes of the cholinergic system in aging and AD and establish benchmark measures of cholinergic dysfunction to aid in the development of enhanced and personalised treatment options.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029164</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Katherine Andrews</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Defining new mechanisms of action and resistance for the malaria drug proguanil</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$831,315.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>plasmodium falciparum</Res_KW2>
        <Res_KW3>drug action</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>mechanism of action</Res_KW5>
        <Plain_Description>Malaria causes >200 million clinical cases and >600,000 deaths annually. There is no broadly effective malaria vaccine and drug resistance is a significant global problem. Thus, it is  essential that we use current drugs effectively to limit parasite resistance development and to ensure their continued use. This project addresses the need to understand how existing malaria drugs work by investigating the mode of action and potential resistance mechanisms of the antimalarial drug proguanil.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029165</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Margaret Hibbs</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting granulocyte colony-stimulating factor to prevent early-life lung disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,299,786.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>bronchopulmonary dysplasia </Res_KW1>
        <Res_KW2>lung development</Res_KW2>
        <Res_KW3>colony stimulating factors (csf)</Res_KW3>
        <Res_KW4>airway epithelium</Res_KW4>
        <Res_KW5>vascular endothelium</Res_KW5>
        <Plain_Description>Bronchopulmonary dysplasia is a severe lung disease that is a main cause of disability and death in premature infants. There is no cure and understanding the disease process may lead to new therapies. We have found that deficiency of a growth factor protects the neonatal lung from structural and functional damage in response to supplemental oxygen, the mainstay of treatment. We will used advanced research methods to define how this factor contributes to disease and to develop a new therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029168</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Lorey Smith</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Investigating transcript diversity as a driver of therapy-induced plasticity in melanoma</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$728,091.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>anticancer drug </Res_KW1>
        <Res_KW2>plasticity</Res_KW2>
        <Res_KW3>rna processing</Res_KW3>
        <Res_KW4>cancer</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>Cancer cells have a remarkable ability to change their physical characteristics, which is known to allow their spread around the body, ability to resist therapies and to return post-treatment. For therapies targeting drivers of cancer, known as oncogenes, this ability to adapt contributes to therapeutic resistance and limits outcomes for patients. Understanding the fundamental cell and molecular biology underlying therapy induced adaptation will provide new ways to improve outcomes for patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029177</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christina Bursill</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Inhibition of Asialoglycoprotein Receptor 1: a novel strategy for atherosclerosis prevention</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,184,728.24</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>atherosclerosis </Res_KW1>
        <Res_KW2>lipids</Res_KW2>
        <Res_KW3>macrophages</Res_KW3>
        <Res_KW4>glycobiology</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>The glycan (sugar) protein 'ASGR1' was previously known only for its ability to remove unwanted glycans from the blood. We have discovered ASGR1 has an important role in the formation of the fatty blockages in the heart that cause heart attacks. This project will create a novel nanoparticle that tracks towards fatty blockages in the heart and liver to inhibit ASGR1. This will create a new therapy that adds benefit on top of traditional lipid-lowering drugs for the prevention of heart disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029183</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hazel Qian Yin Quek</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>PILRB: A potential mediator of microglia phagocytic failure in Alzheimer’s disease.</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$813,214.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>microglia </Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>phagocytosis</Res_KW3>
        <Res_KW4>neuroinflammation</Res_KW4>
        <Res_KW5>brain cell cultures</Res_KW5>
        <Plain_Description>Microglia are the resident immune cell population of the brain and have an important but uncharacterised role in Alzheimer's disease, the leading form of dementia. We have identified increased expression of a gene (called PILRB) in microglia grown from people with Alzheimer's disease. In this proposal, we will investigate how PILRB is linked to abnormal function of Alzheimer's microglia and whether new treatments for Alzheimer's can target microglia PILRB.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029190</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Bamini Gopinath</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>HearHealth: a co-designed online support service empowering consumers with hearing loss</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$660,737.05</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | people with disability | health sciences | health services and systems | digital health | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>hearing loss </Res_KW1>
        <Res_KW2>consumer information</Res_KW2>
        <Res_KW3>health information management</Res_KW3>
        <Res_KW4>access to health care</Res_KW4>
        <Res_KW5>health service decision making</Res_KW5>
        <Plain_Description>Hearing loss is the third leading cause of disability. This study involves the co-design of a novel online support service – HearHealth, with Deafness Forum Australia (peak body for people with hearing loss) and Google. HearHealth will: a) provide access to credible, consumer-friendly educational materials and resources; b) facilitate improved perspective of hearing health needs and hearing loss risk factors; and c) promote behaviour change via online self-assessment and tailored care plans.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029200</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Van Wijngaarden</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Clinical evaluation of novel retinal imaging biomarkers of Alzheimer’s disease</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$887,433.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>optical imaging </Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>alzheimer disease</Res_KW3>
        <Res_KW4>retina</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>The retina of the eye displays features of Alzheimer’s disease (AD). We have developed a new way to take photos of the eye with a rainbow-coloured flash to detect signs of AD. We now want to test how this and other eye imaging methods compare with brain scans and blood tests to identify people who are at risk of AD. We will use clinical studies and artificial intelligence to achieve our aims. Our goal is to improve AD detection and care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029215</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Godler</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Identifying novel points of prognostic utility and intervention in Prader Willi Syndrome.</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,268,359.10</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>imprinting </Res_KW1>
        <Res_KW2>autism spectrum disorders</Res_KW2>
        <Res_KW3>gene transcription</Res_KW3>
        <Res_KW4>genetic disorders</Res_KW4>
        <Res_KW5>genetic markers</Res_KW5>
        <Plain_Description>This project will address a pressing need for people with Prader-Willi syndrome (PWS), their families and clinicians caring for them. We will define biological predictors of disease severity in PWS including serious mental illness to enable evidence based choice of targeted treatments and supports. This project will identify: (i) genetic pathways dysregulated in PWS blood and brain (ii) existing medications used for other conditions to target these pathways in future PWS clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029218</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hsin-Hui Shen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Polysaccharide-targeting nanoantibiotics: A new approach to kill Gram-negative superbugs</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$746,398.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | macromolecular and materials chemistry | physical properties of materials | chemical sciences | physical chemistry | molecular imaging (incl. electron microscopy and neutron diffraction) | </Fields_of_Research>
        <Res_KW1>antimicrobial therapy </Res_KW1>
        <Res_KW2>membrane lipids</Res_KW2>
        <Res_KW3>biophysics</Res_KW3>
        <Res_KW4>nanotechnology</Res_KW4>
        <Res_KW5>cell membrane</Res_KW5>
        <Plain_Description>Antibiotics have started to fail against ‘superbugs’. Resistant bacteria are causing over 1 million deaths every year.  However, no new antibiotics have made it out of the lab for decades. This study will understand how the new class of nanoantibiotics interact with the membranes of ‘superbugs’. The results will allow us to design new nanoparticle-based combination therapies to treat pathogenic infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029227</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Patricia Illing</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Non-canonical antigen sources for cross-strain protective influenza immunity</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,444,449.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | immunology | cellular immunology | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>antigen processing </Res_KW1>
        <Res_KW2>antigen presentation</Res_KW2>
        <Res_KW3>influenza</Res_KW3>
        <Res_KW4>mass spectrometry</Res_KW4>
        <Res_KW5>cellular immunity</Res_KW5>
        <Plain_Description>The ideal influenza vaccine would stimulate immunity against all influenza viruses. This project will interrogate new immune targets with the capacity to stimulate cross-protective immunity across multiple influenza strains. These targets will be used to rationally design novel vaccine strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029240</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ian Parish</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting a novel T cell differentiation state for more effective cancer immunotherapy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,422,087.12</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>cd8 t cells</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>cellular immunology</Res_KW4>
        <Res_KW5>t cell immunotherapy</Res_KW5>
        <Plain_Description>Immunotherapies are a revolutionary approach for cancer treatment, but most people with cancer do not respond. We have identified a previously unknown process that shuts down anti-cancer immune function and limits responsiveness to existing immunotherapies. This proposal will pioneer new therapeutic strategies to disrupt this process in immunotherapy-resistant tumours, and identify the people with cancer who would best benefit from this treatment approach.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029249</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jennifer Byrne</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Problematic articles and literature reviews in molecular cancer research</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$442,040.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>molecular oncology </Res_KW1>
        <Res_KW2>cancer genetics</Res_KW2>
        <Res_KW3>molecular basis of disease</Res_KW3>
        <Res_KW4>cancer research</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>The preclinical cancer literature is likely to contain fabricated gene research papers produced at scale by paper mills. We will leverage problematic paper features to find new problematic papers in high profile cancer journals. We will analyse how these papers become influential, including a possible role for problematic literature reviews. Finally, we will identify recurring phrases in problematic papers that can be easily recognised by scientists to avoid being misled by unreliable research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029251</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Rebecca Ritchie</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Enhancing Cardiovascular cGMP to Target Hypertensive Heart Failure in Females</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,640,408.18</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>chronic heart failure (chf) </Res_KW1>
        <Res_KW2>diastolic dysfunction</Res_KW2>
        <Res_KW3>cardiac fibrosis</Res_KW3>
        <Res_KW4>cardiac hypertrophy</Res_KW4>
        <Res_KW5>metabolic syndrome</Res_KW5>
        <Plain_Description>The most common form of heart failure in women with high blood pressure is called heart failure with preserved ejection fraction. This type of heart failure, in which heart muscle is too stiff, is without effective treatment. We have discovered an exciting new treatment for this condition, which boosts natural mechanisms to relax the heart. Our approach offers new ways to reduce heart failure symptoms and improve quality of life, particularly in women, addressing an urgent unmet clinical need.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029256</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Catarina dos Santos Sa e Almeida</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A new approach to investigate how sulfa-drug-like small molecules induce hypersensitivities</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,061,773.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>adverse drug reactions </Res_KW1>
        <Res_KW2>t cell activation</Res_KW2>
        <Res_KW3>antigen presentation</Res_KW3>
        <Res_KW4>lipid</Res_KW4>
        <Res_KW5>structural immunology</Res_KW5>
        <Plain_Description>Sulfa-drugs include anti-microbial/-inflammatory therapeutics that sometimes elicit unwanted adverse reactions in >5% of the population, via an unknown cause. We have uncovered a mechanism where sulfa-drug-related molecules alter the self-reactivity of a previously unknown immune subset. Using innovative approaches we will study the cellular/molecular mechanisms behind it and contribution to drug allergies. This may help address a long-standing problem limiting the use of such valuable drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029265</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Blaskovich</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Seeing the Unseen: Imaging Bacterial Infections</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$833,782.70</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | </Fields_of_Research>
        <Res_KW1>diagnostic imaging </Res_KW1>
        <Res_KW2>bacterial infection</Res_KW2>
        <Res_KW3>antimicrobial resistance</Res_KW3>
        <Res_KW4>positron emission tomography (pet)</Res_KW4>
        <Res_KW5>antibiotics</Res_KW5>
        <Plain_Description>Bacterial infections are an increasing concern because antibiotics are losing their effectiveness due to the rise of drug-resistant bacteria. Infections are often difficult to detect, and improvement in diagnosis would lead to better therapeutic outcomes and reduced unnecessary antibiotic use. This project will develop imaging agents that selectively bind to bacteria and allow for whole body imaging using PET (Positron Emission Tomograpphy) scans to detect where infections are residing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029268</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Alec Redwood</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Silent mutations;  prognostic markers and therapeutic targets</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$949,388.35</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>cancer vaccine </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>tumour immunology</Res_KW3>
        <Res_KW4>t cell immunity</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>It is now possible to rapidly produce personalised anti-cancer vaccines for the treatment of cancer. These vaccines are undergoing clinical trials across the world. However, these vaccines all target the same sort of cancer specific mutation, or neoantigen. Here we will tap into a much broader repertoire of neoantigens, this will significantly improve the use of these vaccines, especially in cancers with a low mutation burden. Typically these cancers respond poorly to conventional immunotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029278</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Olivier Clement</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Unravelling the epigenomic, transcriptomic, and synaptic regulatory mechanisms governing memory processes to mitigate cognitive decline in aging</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,129,270.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>genomics </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>chromatin</Res_KW3>
        <Res_KW4>neuronal plasticity</Res_KW4>
        <Res_KW5>patch clamp</Res_KW5>
        <Plain_Description>Forgetfulness is a common complaint among many of us as we get older, but our limited understanding of the brain mechanisms underlying memory makes it difficult to provide an effective treatment for age related cognitive decline. Our project will decipher the molecular mechanisms and neuronal plasticity changes governing memory in adults and old individuals in order to further our knowledge of memory processes, and to reveal potential therapeutic targets to prevent cognitive decline in aging.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029282</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucy Coupland</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Fibrinolysis Resistance in the Critically Ill: Rapid Detection, Characterisation and Treatment Discovery.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,019,993.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | enzymes | biomedical and clinical sciences | clinical sciences | intensive care  | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>fibrinolysis </Res_KW1>
        <Res_KW2>sepsis</Res_KW2>
        <Res_KW3>trauma</Res_KW3>
        <Res_KW4>thrombosis</Res_KW4>
        <Res_KW5>inflammation</Res_KW5>
        <Plain_Description>Our body has a system to break down clots, but in critically ill patients the system becomes disordered which may result in blood clot formation, organ damage and death. This research team developed and recently published a way to rapidly assess and guide treatment of this condition by adapting approved technology. This project aims to validate this method, provide clinicians with a risk prediction tool, and identify potential treatments for future treatment trials in sepsis and severe trauma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029324</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Nikolic-Paterson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Preventing hypoperfusion-induced acute kidney injury.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$960,430.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>ischaemic acute renal failure </Res_KW1>
        <Res_KW2>chronic renal failure</Res_KW2>
        <Res_KW3>tubulointerstitial inflammation</Res_KW3>
        <Res_KW4>renal interstitial fibrosis</Res_KW4>
        <Res_KW5></Res_KW5>
        <Plain_Description>We lack specific treatments to prevent high-risk patients from developing acute kidney injury following cardiac surgery. To address this area of unmet clinical need, we have developed a new preclinical animal model that mimics the period of low blood pressure occurring during cardiac surgery in combination with patient-based risk factors. We plan to identify the mechanisms by which these risk factors promote this acute kidney injury and test new therapeutics to prevent this.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029330</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Eyre</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding and exploiting the mechanism of action of a novel dengue virus inhibitor</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$755,276.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>dengue virus </Res_KW1>
        <Res_KW2>antiviral agents</Res_KW2>
        <Res_KW3>viral replication</Res_KW3>
        <Res_KW4>proteomics</Res_KW4>
        <Res_KW5>molecular modelling</Res_KW5>
        <Plain_Description>There is an urgent need for safe and effective therapies to treat dengue virus (DENV) infection. Excitingly, potent and safe inhibitors that target the viral NS4B protein have recently been developed and are in advanced stages of clinical development. This project will employ advanced proteomics, molecular virology, high resolution microscopy and molecular modelling approaches to reveal new details about the of precise effects of these inhibitors and mechanisms of viral resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029331</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Pablo Canete</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Title: Understanding how regulatory T cells suppress the development of self-reactive B cells</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,358,984.78</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>humoral immunity </Res_KW1>
        <Res_KW2>regulatory t cells</Res_KW2>
        <Res_KW3>b cells</Res_KW3>
        <Res_KW4>t cells</Res_KW4>
        <Res_KW5>immune tolerance</Res_KW5>
        <Plain_Description>Autoimmune diseases are debilitating and incurable, affecting approximately 5% of the population. In these diseases, a person's own immune system attacks itself. Current treatments are broad and non-specific, typically leaving patients immunocompromised. We have identified a new group of cells that we believe are critical for ensuring the immune system does not attack itself. This project aims to understand how these cells function to develop novel safer therapies for autoimmune disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029332</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Joel Castro Kraftchenko</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Validation of a novel immunotherapeutic approach to treat chronic pelvic pain in endometriosis</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$841,760.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | clinical sciences | pain | biomedical and clinical sciences | neurosciences | peripheral nervous system | </Fields_of_Research>
        <Res_KW1>endometriosis </Res_KW1>
        <Res_KW2>chronic pain</Res_KW2>
        <Res_KW3>visceral sensation</Res_KW3>
        <Res_KW4>peripheral nerve</Res_KW4>
        <Res_KW5>pelvic pain</Res_KW5>
        <Plain_Description>Endometriosis is a painful disorder affecting 11% of females worldwide, costing Australia $9.7 billion/year. The causal mechanisms of endometriosis-associated chronic pelvic pain are poorly understood, with no efficacious treatments available. This project aims to validate the use of a clinically approved monoclonal antibody, known to regulate neuroangiogenesis and immune cell migration, for the treatment of chronic pelvic pain in endometriosis, alongside determining its mechanisms of action.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029334</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Julie McMullen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>New strategies for heart failure and atrial fibrillation by understanding differences between physiological &amp; pathological atrial enlargement, sex differences and organ cross-talk</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,468,123.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>mouse models </Res_KW1>
        <Res_KW2>atrial fibrillation</Res_KW2>
        <Res_KW3>exercise</Res_KW3>
        <Res_KW4>heart failure</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Heart failure (HF) &amp; atrial fibrillation (AF) is a complex disorder associated with complications in multiple organs and high mortality. New treatment strategies are urgently required for males and females. With a greater understanding of the biology of atria (upper chambers of the heart) and crosstalk between the heart and other organs, this project is expected to uncover new therapies for HF and AF, and markers in blood to predict and prevent AF in patients.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029343</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Angela Kelly-Hanku</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Ending AIDS in Papua New Guinea - A novel community-led approach to HIV prevention, testing, treatment and care with key and priority populations</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,262,214.10</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | pacific peoples health and wellbeing | pacific peoples public health and wellbeing | health sciences | health services and systems | health services and systems not elsewhere classified | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>papua new guinea </Res_KW1>
        <Res_KW2>human immunodeficiency virus (hiv)</Res_KW2>
        <Res_KW3>sexual health</Res_KW3>
        <Res_KW4>community-based</Res_KW4>
        <Res_KW5>collaboration</Res_KW5>
        <Plain_Description>In 2021 96% of all new HIV infections in Asia-Pacific were among key populations and their sexual partners.  Conventional HIV testing and treatment – delivered by health professionals in clinic settings – has not reduced their disproportionate burden of HIV. For the first time, this 4-year study will investigate, co-design and implement and evaluate new strategies for key and priority population-led, community-based HIV prevention, testing, treatment and care to end AIDS in PNG.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029349</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Phurpa Wangchuk</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Novel plant-derived anti-inflammatory drugs for treating Inflammatory bowel disease</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,789,652.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander medicine and treatments | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>inflammatory bowel disease (ibd)</Res_KW2>
        <Res_KW3>anti-inflammatory agents</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>alternative medicine</Res_KW5>
        <Plain_Description>Inflammatory Bowel Disease (IBD) affects 1 in 250 Australians, and its management costs $3.18 billion per annum. Given that IBD is a lifelong disease without a cure, and its prevalence is expected to increase sharply, there is an urgent need for new drugs. Our Ideas Grant proposal over the next five years aims to discover next-generation IBD therapeutics from four selected tropical plants by identifying novel drug lead candidates and undertaking pre-clinical development using animal IBD models.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029350</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Antonio Lauto</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Wireless stimulator with no impinging electrodes, circuitry and connections for improving nerve regeneration in a crush injury model</Grant_Title>
        <Admin_Institution>Western Sydney University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$749,157.02</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | peripheral nervous system | physical sciences | medical and biological physics | medical and biological physics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>peripheral nerve </Res_KW1>
        <Res_KW2>nerve regeneration</Res_KW2>
        <Res_KW3>nerve repair</Res_KW3>
        <Res_KW4>transcranial magnetic stimulation (tms)</Res_KW4>
        <Res_KW5>medical physics</Res_KW5>
        <Plain_Description>Peripheral nerve repair is a challenging problem because only 50% of patients regain some function after surgery. We have developed, for the first time, an innovative device (graft-antenna) able to concurrently stimulate and repair injured nerves with a conduit. The proposal aim is to prove the graft-antenna can stimulate nerves non-invasively resulting in enhanced regeneration and fast recovery. This proposal outcomes will accelerate the translation of our device towards clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029361</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tim Silk</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>The role of epigenetics in brain developmental trajectories and clinical outcomes in ADHD</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$587,349.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | applied and developmental psychology | child and adolescent development  | psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>attention deficit hyperactivity disorder (adhd) </Res_KW1>
        <Res_KW2>clinical outcome</Res_KW2>
        <Res_KW3>longitudinal</Res_KW3>
        <Res_KW4>neuroimaging</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Children with ADHD can present in very different ways, but we still do not know who will fare well or poorly, nor do we know the best ways to improve the outcomes of those affected. Epigenetics is one mechanism through which environmental exposures can change gene expression, influencing brain development and mental health. This research will examine how environmental factors interact with epigenetic processes and influence brain development, and pathways to better clinical outcomes for ADHD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029372</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Anne Karine Lagendijk</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Validating new druggable pathways for cerebral cavernous malformations</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$904,185.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | biological sciences | biochemistry and cell biology | signal transduction | engineering | biomedical engineering | mechanobiology | </Fields_of_Research>
        <Res_KW1>endothelial dysfunction </Res_KW1>
        <Res_KW2>extracellular matrix</Res_KW2>
        <Res_KW3>hyaluronic acid</Res_KW3>
        <Res_KW4>adhesion mechanisms</Res_KW4>
        <Res_KW5>adrenomedullin</Res_KW5>
        <Plain_Description>Cerebral Cavernous Malformation (CCM) is a vascular disease whereby blood vessels loose shape and grow into raspberry shaped lesions. CCM occurs specifically in veins of the brain and instability of these lesions can lead to brain bleeds (haemorrhagic stroke). Why CCM develops specifically in veins of the brain, is currently unknown. Here, we will examine factors that can explain this specificity and will uncover new concepts to manipulate CCM vasculature and prevent severe lesion formation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029390</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Craig Pennell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Precision medicine tools to predict spontaneous preterm birth in early pregnancy</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,363,053.70</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>premature birth </Res_KW1>
        <Res_KW2>pregnancy complications</Res_KW2>
        <Res_KW3>clinical research</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>early prevention</Res_KW5>
        <Plain_Description>Preterm birth (PTB) is the greatest cause of death and disability in children under five. Rates have remained unchanged for the last 10 years. Current tools to predict PTB early in pregnancy are poor and our ability to predict which interventions will be successful in high-risk women are limited. Building on 15 years of research, our team will use our previously successful bioinformatic pipeline to develop new genomic tools to predict PTB early in pregnancy in both low and high-risk women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029394</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel Brown</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A Sensor for Diagnostics and Closed-Loop Drug Delivery in the Inner Ear</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$584,941.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | otorhinolaryngology | </Fields_of_Research>
        <Res_KW1>biosensor </Res_KW1>
        <Res_KW2>meniere's disease</Res_KW2>
        <Res_KW3>implants</Res_KW3>
        <Res_KW4>sensory hearing loss</Res_KW4>
        <Res_KW5>vertigo</Res_KW5>
        <Plain_Description>Meniere's disease is a disorder of the inner ear, resulting in sudden vertigo attacks, hearing fluctuation and tinnitus. Symptoms arise due to excessive fluid in the membranous labyrinth of the inner ear, which can rupture, causing a sudden increase in potassium ions in the fluid that surrounds the sensitive inner ear hair cells. This project aims to develop a sensor for inner ear potassium, and use this to control drug delivery into the inner ear via an implantable device.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029395</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Lachlan Jolly</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Overcoming Silence in Neurodevelopmental Disorder Gene Diagnosis</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,134,812.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | neurogenetics | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>neurodevelopmental disorders </Res_KW1>
        <Res_KW2>splicing</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>transcriptional regulation</Res_KW4>
        <Res_KW5>molecular diagnosis</Res_KW5>
        <Plain_Description>Many patients with genetic causes of neurodevelopmental disorders go undiagnosed, partly because a quarter of involved genes (~500) are not active in accessible patient bio-samples like blood and skin, and so cannot be tested. Our research harnesses Nobel prize-winning genome editing and cell reprograming technologies to activate these genes in skin to enable tests that aid diagnosis. These revolutionary technologies also have potential therapeutic applications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029399</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Catcheside</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Personalised daily body-clock tracking and circadian light therapy retiming to improve sleep, performance, health and safety</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,335,760.35</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | systems physiology  | biological sciences | biochemistry and cell biology | systems biology | psychology | biological psychology  | biological psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>circadian rhythms </Res_KW1>
        <Res_KW2>sleep disorders</Res_KW2>
        <Res_KW3>sleep disturbance</Res_KW3>
        <Res_KW4>sleep/wake patterns</Res_KW4>
        <Res_KW5>temperature regulation</Res_KW5>
        <Plain_Description>The circadian body-clock regulates sleep, wake and brain and body functions across each day and night. This system adjusts according to the daily exposure timing and intensity of blue light. This project will combine wearable sensor data with high performance physiology and data-driven analysis methods to create the first practical daily tracking and light retiming method needed to accelerate body-clock adjustments in shift-workers and circadian sleep disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029405</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Lock</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A novel antibody-drug conjugate for the treatment of a high-risk subtype of leukaemia in adults and children</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$888,649.68</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>acute leukaemia </Res_KW1>
        <Res_KW2>xenografts</Res_KW2>
        <Res_KW3>mouse models</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>therapeutic antibodies</Res_KW5>
        <Plain_Description>We aim to develop a novel antibody-based therapeutic to target a cell surface protein (CRLF2) that is vital for the survival of a high-risk leukaemia subtype. This novel approach will reduce the likelihood of relapse associated with loss of the cell surface target. Besides targeted drug delivery, this multipronged therapeutic approach will disrupt the function of CRLF2 and recruit the body’s own immune system against cancer cells thus improving the treatment of high-risk patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029411</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Lock</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Molecular Characterisation of Relapse-Initiating Acute Lymphoblastic Leukaemia Cells for Targeted Therapy</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,657,400.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </Fields_of_Research>
        <Res_KW1>minimal residual disease </Res_KW1>
        <Res_KW2>mouse models</Res_KW2>
        <Res_KW3>acute lymphoblastic leukaemia (all)</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>genetic screening</Res_KW5>
        <Plain_Description>Relapsed acute lymphoblastic leukemia (ALL) in children has limited treatment options. Minimal residual disease (MRD) predicts ALL outcomes and is associated with relapse. Here we will use single-cell multi-omics to characterize these MRD cells, determine how they avoid cell death after chemotherapy and use gene editing technology to identify new therapeutic targets. These findings will lead to new risk-adapted therapeutic strategies for the treatment children with ALL.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029421</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Matthew Call</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Optimising CAR-T cell immunotherapy through targeted modulation of signalling pathways</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,962,013.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biological sciences | biochemistry and cell biology | signal transduction | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>protein engineering </Res_KW1>
        <Res_KW2>receptor signalling</Res_KW2>
        <Res_KW3>transmembrane receptor</Res_KW3>
        <Res_KW4>protein structure</Res_KW4>
        <Res_KW5>t cell immunotherapy</Res_KW5>
        <Plain_Description>Cellular immunotherapies ‘train’ a patient’s own immune cells to eliminate tumours. This exciting new treatment works well for a limited range of advanced blood cancers, but it has dangerous side effects that limit its wider use. The new technology we develop in this study will improve our ability to specifically tailor the safety/efficacy balance of cellular immunotherapies for different tumour types and thereby facilitate their use in more types of cancer at earlier stages of disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029423</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jon Oakhill</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Precision regulation of AMPK in fatty liver disease</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,161,171.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | metabolic medicine | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>liver metabolism </Res_KW1>
        <Res_KW2>pharmacology</Res_KW2>
        <Res_KW3>nonalcoholic steatohepatitis</Res_KW3>
        <Res_KW4>messenger rna (mrna)</Res_KW4>
        <Res_KW5>amp-activated protein kinase</Res_KW5>
        <Plain_Description>Non-alcoholic fatty liver disease (NAFLD) is a disease in which fat accumulates in the liver, leading to risk of liver failure, heart attack and cancer. Activation of the protein AMPK in liver is a promising therapeutic strategy for NAFLD, however pre-clinical drugs activate AMPK in other organs with adverse effects. Our goal is to develop a precision drug that activates AMPK only in liver, thereby releasing a major block to progress AMPK drugs to clinical trials in humans.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029424</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Beard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Awakening the genome to understand and combat viral infection</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$874,646.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>flavivirus infection </Res_KW1>
        <Res_KW2>virus</Res_KW2>
        <Res_KW3>antiviral</Res_KW3>
        <Res_KW4>interferon (ifn)</Res_KW4>
        <Res_KW5>gene expression</Res_KW5>
        <Plain_Description>Infection with viral pathogens causes significant morbidity and mortality on a world-wide scale. To understand how a cell responds to control viral replication we will use CRISPR technology that will enable us to identify cellular factors that are key to viral lifecycles and the host antiviral response. This project will drive a deep understanding of viral host interactions that will be crucial for understanding pathogenesis and identify novel therapeutic target delivery mechanisms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029454</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Wei Tong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Sonogenetic Retinal Prosthesis for Vision Restoration Following Retinal Degeneration</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$700,587.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | neural engineering | engineering | biomedical engineering | medical devices | </Fields_of_Research>
        <Res_KW1>neuromodulation </Res_KW1>
        <Res_KW2>electrophysiology</Res_KW2>
        <Res_KW3>mechanotransduction</Res_KW3>
        <Res_KW4>ultrasound</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>This project seeks to revolutionise the field of vision restoration by pioneering an innovative approach that uses soundwaves to provide visual information to the blind. The soundwaves will bypass cells that are damaged by disease and provide the recipients with visual information via the surviving cells that have been genetically modified. This technique aims to reduce the cost of vision restoration and extend the benefits to a larger population affected by vision loss.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029461</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Joanne Dickinson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Accelerating precision medicine for PF: characterising the high-risk PF genetic landscape</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$4,409,340.03</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>pulmonary fibrosis </Res_KW1>
        <Res_KW2>rare diseases</Res_KW2>
        <Res_KW3>genetic predisposition</Res_KW3>
        <Res_KW4>lung disease</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Understanding the genes causing inherited disease is revolutionising how we diagnose and treat people with these conditions. The objective of this proposal is to bring these advances to those with devastating inherited fibrotic lung disease by addressing the current critical gaps in our knowledge of the genes involved. This knowledge will provide patients and their health care team with better options for early diagnosis, and improved tailored treatments for this fatal lung disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029501</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Toby Allen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Advancing BK channel pharmacology by targeting novel membrane drug pathways</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$616,654.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>potassium channels </Res_KW1>
        <Res_KW2>drug interactions</Res_KW2>
        <Res_KW3>molecular modelling</Res_KW3>
        <Res_KW4>electron microscopy</Res_KW4>
        <Res_KW5>electrophysiology</Res_KW5>
        <Plain_Description>  Big potassium conductance (or BK) channels exist in every cell and are associated with numerous human diseases. Despite their obvious potential for therapeutics, BK channel drugs have lacked potency and selectivity, impeding clinical development. This project will explore novel drug mechanisms targeting BK channels, made possible by recent structural discoveries. The outcomes will assist in the design of more potent and selective therapeutics for health conditions such as hypertension.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029527</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Carter</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A one-two punch therapeutic strategy to overcome chemotherapy-induced cell plasticity in neuroblastoma</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$599,586.32</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cancer cell biology </Res_KW1>
        <Res_KW2>plasticity</Res_KW2>
        <Res_KW3>bioinformatics</Res_KW3>
        <Res_KW4>neuroblastoma</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>Neuroblastoma is an aggressive child cancer. Treatments fail because minor cancer cell populations are naturally drug resistant due to their unique genetic makeup. We will use novel genetic sequencing of individual tumour cells to comprehensively detail the full spectrum of cancer cell types in neuroblastoma and how single cancer cells are evading anticancer drugs. With this, we aim to design customised therapeutic approaches targeted specifically against drug-resistant cells in the tumour.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029547</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Alison Hogan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>TDP-43 nuclear depletion in MND - potential driver of neurodegeneration and therapeutic target</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$620,989.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>zebrafish</Res_KW2>
        <Res_KW3>protein localisation</Res_KW3>
        <Res_KW4>protein aggregation</Res_KW4>
        <Res_KW5>neurodegeneration</Res_KW5>
        <Plain_Description>A key neuropathology, insoluble aggregates of the protein TDP-43, are found in almost all ALS patients (~97%), ~50% of patients with FTLD (frontotemporal lobar degeneration), and in about 25% of individuals above the age of 80 years (LATE, limbic predominant age-related TDP-43 encephalopathy). This project will investigate the link between altered TDP-43 behaviour and cell death and test a novel means of preventing this toxicity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029583</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Michael Duffy</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Which Plasmodium falciparum virulence antigens elicit immunity associated with protection from severe malaria?</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$890,588.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | </Fields_of_Research>
        <Res_KW1>medical parasitology </Res_KW1>
        <Res_KW2>malaria</Res_KW2>
        <Res_KW3>humoral immunity</Res_KW3>
        <Res_KW4>virulence</Res_KW4>
        <Res_KW5>differential gene expression</Res_KW5>
        <Plain_Description>Malaria parasites kill by binding infected cells to blood vessel walls. The binding proteins appear more similar to each other in deadly parasites than in parasites that don’t cause severe malaria. We will identify the deadly parasite binding proteins, find out whether antibodies to them are protective, investigate how they bind and determine how common the deadly parasites are.  This knowledge will help to develop therapies to block binding and to assess the viability of vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029584</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Erin Shanahan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Microbe-immune interactions shape immune checkpoint inhibitor immunotherapy outcomes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,150,613.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | microbial ecology | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>microbial ecology</Res_KW2>
        <Res_KW3>gut immunity</Res_KW3>
        <Res_KW4>tumour immunity</Res_KW4>
        <Res_KW5>melanoma</Res_KW5>
        <Plain_Description>Treatment of melanoma remains a key challenge. A new generation of immunotherapy treatments that stimulate a patient's immune system to destroy melanoma cells are highly effective. However, not all patients respond to these treatments, and some will develop adverse reactions related to excessive immune activation. With our proposed research, we seek to understand the mechanisms behind non-response, and adverse reactions, in order to develop improved therapeutic strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029600</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Janessa Pickering</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Deciphering natural immunity to Strep A to prevent rheumatic heart disease</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$881,779.70</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical microbiology | biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>group a streptococcal disease </Res_KW1>
        <Res_KW2>pharyngitis</Res_KW2>
        <Res_KW3>protective immunity</Res_KW3>
        <Res_KW4>clinical microbiology</Res_KW4>
        <Res_KW5>microbial infections</Res_KW5>
        <Plain_Description>Strep A is a bacterium that commonly causes sore throats. This infection can lead to the development of Rheumatic Heart Disease (RHD), an autoimmune condition that kills >500,000 people globally each year. To discover new ways to prevent Strep A infection and prevent RHD, this project will investigate how some individuals are naturally able to resist Strep A infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029625</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Conor Kearney</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Discovery and targeting of novel immune checkpoints in cancer</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,212,963.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | systems biology | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>cancer chemotherapeutic agents</Res_KW2>
        <Res_KW3>cd8 t cells</Res_KW3>
        <Res_KW4>immune modulation</Res_KW4>
        <Res_KW5>immune evasion</Res_KW5>
        <Plain_Description>The human immune system is capable of recognising and eliminating cells that have become cancerous. Cancer Immunotherapies have revolutionized medical oncology and are now recognised as one of the core pillars of cancer treatment. Despite the success of immunotherapies, responses are limited to a subgroup of patients in particular cancer types and patients frequently relapse. This project aims to identify new druggable targets that improve current immunotherapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029630</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Laurent Frossard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Next generation of bionic limbs: from innovative assessment of neuromusculosketal functions of the residuum, personalized computational modelling to advanced additive manufacturing of prosthetic attachments</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$905,116.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | prosthetics and orthotics | engineering | biomedical engineering | rehabilitation engineering  | engineering | biomedical engineering | medical devices | </Fields_of_Research>
        <Res_KW1>prosthesis </Res_KW1>
        <Res_KW2>limb deformity</Res_KW2>
        <Res_KW3>neuromuscular diseases</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>biomechanics</Res_KW5>
        <Plain_Description>The project will contribute to improve painless, safe, and efficient fitting of prosthetic solutions required to restore independent mobility and quality of life for the growing population of individuals living with lower limb loss. Furthermore, we anticipate that this work will also contribute to improve the quality of prosthetic care while reducing the costs paid by taxpayers for the provision of costly sockets and prosthetic components.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029642</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Rogerson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Antibodies, white blood cells and protection from severe malaria</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,020,306.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>plasmodium falciparum </Res_KW1>
        <Res_KW2>antibody</Res_KW2>
        <Res_KW3>neutrophils</Res_KW3>
        <Res_KW4>cerebral malaria</Res_KW4>
        <Res_KW5>glycosylation</Res_KW5>
        <Plain_Description>We study antibodies that recognise PfEMP1s, proteins expressed on malaria infected red blood cells. We will identify the most dangerous PfEMP1 types, and the most protective antibodies, using samples from severe and mild malaria. Unusually, PfEMP1 antibodies often lack a key sugar. The deadly PfEMP1 types will then be studied with white blood cells, which can clear or kill the parasites. We will study how such antibodies develop, and how they function. Our work may lead to a PfEMP1 vaccine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029646</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgia Deliyannis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Halting transmission of respiratory viral infections using intranasally administered vaccines</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,279,664.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | immunology not elsewhere classified | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>sars-cov-2 </Res_KW1>
        <Res_KW2>covid-19</Res_KW2>
        <Res_KW3>vaccine</Res_KW3>
        <Res_KW4>mucosal immunity</Res_KW4>
        <Res_KW5>long covid</Res_KW5>
        <Plain_Description>Vaccines injected into muscle induce antibodies that circulate throughout the body, but these responses are usually insufficient to block infection in the airways where SARS-CoV-2 infection begins. Furthermore, airway infection provides a route for the virus to reach the brain, causing symptoms associated with ‘long COVID’. To improve protection against COVID-19 transmission, and minimise brain infection, we will investigate intranasal (IN) vaccination to induce strong immunity at the site.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029648</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Guei-Sheung Liu</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A vision to prevent vision loss: RNA base editing as a strategy to treat inherited retinal diseases</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,289,706.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>retinal dystrophy</Res_KW2>
        <Res_KW3>retinal degeneration</Res_KW3>
        <Res_KW4>retinal disease</Res_KW4>
        <Res_KW5>gene mutations</Res_KW5>
        <Plain_Description>Inherited eye diseases are significant contributors to global blindness and there is no cure to date. Traditional gene therapy only caters to limited forms of the disease, and blindness is unpreventable for most affected patients. Demand for alternative approaches remains. Modern RNA gene editing technology allows precise correction of the underlying genetic mutations for safer and more efficient gene therapies. This unprecedented approach would revolutionise current gene therapy approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029653</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Roger CHUNG</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Developing novel gene expression control mechanisms for Amyotrophic Lateral Sclerosis gene therapies</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$794,115.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>neurodegeneration</Res_KW2>
        <Res_KW3>neurodegenerative disorders</Res_KW3>
        <Res_KW4>gene therapy</Res_KW4>
        <Res_KW5>slow neurodegeneration</Res_KW5>
        <Plain_Description>Gene therapies represent an exciting therapeutic opportunity for the treatment of amyotrophic lateral sclerosis (the most common adult-onset MND), involving the delivery of a therapeutic gene to the target cell (such as the motor neuron). This project will develop a novel method for precise control of therapeutic gene expression by a gene therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029657</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Judy de Haan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A novel immunometabolic therapy for Type 2 diabetic cardiomyopathy.</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,374,762.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | biochemistry and cell biology | cell metabolism | </Fields_of_Research>
        <Res_KW1>diabetic cardiomyopathy </Res_KW1>
        <Res_KW2>cardioprotection</Res_KW2>
        <Res_KW3>anti-inflammatory</Res_KW3>
        <Res_KW4>anti-inflammatory agents</Res_KW4>
        <Res_KW5>metabolites</Res_KW5>
        <Plain_Description>Heart disease leading to heart failure remains a major burden for diabetic patients for whom treatments to prevent heart failure are currently unavailable. Preliminary data in our laboratory is pointing to a novel pathway that drives inflammation leading to these diabetic complications. The specific targeting of the main players of this pathway with a natural metabolite, itaconate, newly identified as a major anti-inflammatory mediator, offers a unique strategy to improve diabetic heart disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029659</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Carl Feng</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Untangling the complexity of granulomas in human mycobacterial diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,027,808.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>granuloma </Res_KW1>
        <Res_KW2>tuberculosis</Res_KW2>
        <Res_KW3>mycobacterial infection</Res_KW3>
        <Res_KW4>mouse models</Res_KW4>
        <Res_KW5>human</Res_KW5>
        <Plain_Description>Tuberculosis and leprosy are a significant health threat globally. Granuloma is well recognised as a pivotal tissue response regulating bacterial survival and host immunopathology. However, cellular structure governing the diverse granuloma function is unknown. This project will employ tissue imaging to determine lesion structures underlying the different disease outcomes. The findings will provide new knowledge in disease pathogenesis and assist in developing new therapies and animal models.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029660</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Leedman</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A new RNA-based therapeutic for human oral cancer</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,083,241.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>head and neck cancer </Res_KW1>
        <Res_KW2>novel therapeutic agents</Res_KW2>
        <Res_KW3>cisplatin resistance</Res_KW3>
        <Res_KW4>rna interference</Res_KW4>
        <Res_KW5>radiation therapy</Res_KW5>
        <Plain_Description>Oral cancer has a poor prognosis. RNA-based therapies offer a new avenue of treatment for these patients. Herein, we will explore the ability of a small RNA called a microRNA to stop oral cancer in its tracks. Specifically, we have developed a microRNA called miR-7 that inhibits the growth of oral cancer cells in the lab and also overcomes resistance to chemotherapy. As a prerequisite for progression to an early phase clinical trial, we will evaluate this novel therapy in preclinical models.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029668</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Fuller</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Molecular and Functional Dissection of Mineralocorticoid Receptor Signalling</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,232,404.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>aldosterone </Res_KW1>
        <Res_KW2>mineralocorticoid receptor</Res_KW2>
        <Res_KW3>glucocorticoids</Res_KW3>
        <Res_KW4>adrenal endocrinology</Res_KW4>
        <Res_KW5>hypertension</Res_KW5>
        <Plain_Description>The steroid hormone aldosterone controls salt balance and hence, blood pressure. It also has been shown to have a significant role in cardiac failure. Although drugs that block the aldosterone receptor are beneficial in the treatment of heart failure, they are limited by potassium retention in the kidney. In order to develop tissue-specific blockers of the aldosterone receptor, it is necessary to identify mechanisms by which the receptor can be activated and/or blocked in these tissues.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029698</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Pilar Blancafort</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>EPIGENOME ENGINEERING FOR THE THERAPEUTIC REPROGRAMMING OF THE MESENCHYMAL TO EPITHELIAL STATES IN BREAST CANCER</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,887,936.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | </Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>biotechnology</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>epithelial-mesenchymal transition (emt)</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>Epithelial to Mesenchymal Transition (EMT) is a mechanism used by cancer cells to switch from a localised and treatment-sensitive state to an aggressive and treatment-resistant state. EMT is common in triple negative breast cancers (TNBCs), which have limited targeted therapies. We propose new targeted treatments to switch off the major drivers causing EMT in TNBC. These will slow down or prevent cancer spread and make these aggressive BCs more sensitive to many other types of treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029719</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Mathias Francois</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting endothelial trans-differentiation in vascular lesions</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,218,773.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | analytical biochemistry | </Fields_of_Research>
        <Res_KW1>endothelial cells </Res_KW1>
        <Res_KW2>gene regulation</Res_KW2>
        <Res_KW3>transcription factor</Res_KW3>
        <Res_KW4>blood vessels</Res_KW4>
        <Res_KW5>congenital malformations</Res_KW5>
        <Plain_Description>Despite both the blood and lymphatic vasculature directly contributing to disease progression in a wide range of  pathologies such as cancers and cardio-vascular diseases, there is a lack of specific drugs that directly target the cells  that make up the inner lining of the vessels.  This research programme aims to discover the cellular and molecular mechanisms required for vessel growth and to  apply this knowledge to new ways of treating diseases such as vascular cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029730</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Alessandro Uboldi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>The role of ubiquitination in Toxoplasma differentiation into latent forms</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$611,061.48</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>toxoplasma gondii </Res_KW1>
        <Res_KW2>ubiquitination</Res_KW2>
        <Res_KW3>cell differentiation</Res_KW3>
        <Res_KW4>protein complexes</Res_KW4>
        <Res_KW5>protein degradation</Res_KW5>
        <Plain_Description>Infection with Toxoplasma parasites can lead to birth defects, blindness and life-threatening disease in people with weak immune systems. Disease occurs when parasites, which can remain in a dormant state in the body for years, “awaken” to cause tissue damage. We have identified proteins that are important for the long-term maintenance of Toxoplasma in the body and will seek to understand their function so that we may disable them to prevent long-term infection and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029740</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Lars Ittner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>New biological drugs to treat Alzheimer's disease</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,450,494.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | biochemistry and cell biology | synthetic biology | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>therapeutics</Res_KW2>
        <Res_KW3>excitotoxicity</Res_KW3>
        <Res_KW4>animal model</Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>Dementia is becoming a major health issue for Australians, but therapeutic options are limited and ineffective. We have previously identified a critical mechanism that drives memory loss and degeneration of the brain. Here, we will develop a novel class of drugs that are specifically designed to disrupt this disease mechanism in order to slow/halt progression of symptoms. This new therapeutic approach will be tested in diverse models of dementia in preparation for future clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029741</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Neeson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Exploring the role for CD4+ T cells in CAR-T cell efficacy against solid tumours</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$723,059.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>solid tumours </Res_KW1>
        <Res_KW2>gene therapy</Res_KW2>
        <Res_KW3>cd4</Res_KW3>
        <Res_KW4>t cells</Res_KW4>
        <Res_KW5>cytokine biology</Res_KW5>
        <Plain_Description>Patients with advanced treatment resistant cancer have few therapy options and have a poor clinical outcome. Chimeric antigen receptor (CAR)-T cells are a potential therapy for cancer patients, so far patients with advanced solid tumours have responded poorly. In this project we will fix this problem by addressing three distinct issues (1) poor CAR-T cell persistence in the patient (2) tumour inhibition of CAR-T cell function (3) the CD4+ T cells used to produce CAR-T cells for cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029752</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Owen Marshall</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Wake up call: deciphering the regulatory networks that reactivate neural stem cells</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$1,345,763.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | systems biology | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | genome structure and regulation | </Fields_of_Research>
        <Res_KW1>transcription factor </Res_KW1>
        <Res_KW2>transcriptional regulation</Res_KW2>
        <Res_KW3>systems biology</Res_KW3>
        <Res_KW4>neural stem cell</Res_KW4>
        <Res_KW5>chromatin structure</Res_KW5>
        <Plain_Description>Not Available</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029754</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel Hesselson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Enhancing heart repair to treat cardiomyopathies: Directed evolution of human KLF1 to increase cardioregenerative potency</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$956,358.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | molecular evolution | biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | biochemistry and cell biology | synthetic biology | </Fields_of_Research>
        <Res_KW1>molecular evolution </Res_KW1>
        <Res_KW2>tissue regeneration</Res_KW2>
        <Res_KW3>tissue repair</Res_KW3>
        <Res_KW4>cardiomyocytes</Res_KW4>
        <Res_KW5>transcription factor</Res_KW5>
        <Plain_Description>Diseases causing damage to heart muscle cells can lead to heart failure with a poor 5-year survival rate. This research will enhance the potency of a promising therapeutic that we recently discovered can stimulate the regrowth of heart muscle. The project will identify the best drug candidate and formulate it for testing in a preclinical heart attack model. The project aims to produce a therapeutic that is ready for the next stage of the drug development pathway.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029756</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Shivashankar Hiriyur Nagaraj</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Characterising the pharmacogenomic landscape of chronic disease in Australia's First Peoples</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,771,845.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander medicine and treatments | </Fields_of_Research>
        <Res_KW1>pharmacogenomics </Res_KW1>
        <Res_KW2>adverse drug reactions</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>capacity building</Res_KW5>
        <Plain_Description>The lack of genetic and drug safety data for Indigenous Australians creates alarming health inequities. However, this population is underrepresented in genomic studies. This project will provide new insight into the genetic basis of drug efficacy and safety in Indigenous Australians using a community-guided approach, leading to a customised genetic test that will serve as a personalised roadmap for optimal drug selection to streamline Indigenous patient care and improve health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029770</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Aron Chakera</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Flow-Assisted Same-Day Testing for Fungal Pathogens and Antimicrobial Susceptibility</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$478,988.03</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | mycology  | </Fields_of_Research>
        <Res_KW1>fungal diagnosis </Res_KW1>
        <Res_KW2>fungal infection</Res_KW2>
        <Res_KW3>diagnostic assay</Res_KW3>
        <Res_KW4>flow cytometry</Res_KW4>
        <Res_KW5>antimicrobial resistance</Res_KW5>
        <Plain_Description>Invasive fungal infections are increasing in prevalence and are associated with significant morbidity and mortality. Delays in detection, along with time needed for conventional antimicrobial susceptibility results leads to adverse patient outcomes. This project will demonstrate the potential for our novel culture-independent diagnostic method to detect fungal infections in clinical samples and provide rapid antimicrobial susceptibility profiles to guide clinical decision-making.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029785</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Christopher Stanley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Indoleamine 2,3-dioxygenase-1 (IDO1) is a master regulator of severe endothelial dysfunction in sepsis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,490,699.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - amino acids and metabolites | </Fields_of_Research>
        <Res_KW1>endothelial cells </Res_KW1>
        <Res_KW2>smooth muscle cell</Res_KW2>
        <Res_KW3>arterial function</Res_KW3>
        <Res_KW4>cardiovascular physiology</Res_KW4>
        <Res_KW5>sepsis</Res_KW5>
        <Plain_Description>We previously demonstrated that tryptophan metabolism was associated with decreased blood pressure in septic shock. New data suggests that increased tryptophan metabolism is not only linked to decreased blood pressure but is linked to complete cardiovascular decline. The proposed project will use animal models and humans with sepsis to i) enhance our understanding of sepsis pathology, and ii) develop our findings, moving them towards translation into a novel therapeutic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029800</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Elaine Sanij</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$761,355.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>ribosome biogenesis </Res_KW1>
        <Res_KW2>protein synthesis</Res_KW2>
        <Res_KW3>translation</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>ovarian cancer</Res_KW5>
        <Plain_Description>While women with the most common type of ovarian cancer, high-grade serous, initially respond to chemotherapy and PARP inhibitors, this is usually followed by cancer relapse and the development of drug resistance. Our work will identify new mechanisms of resistance and test novel and emerging therapeutic approaches to target resistant ovarian cancer. We aim to discover effective treatment options for the 1800 Australian women and 300,000 women worldwide diagnosed with ovarian cancer every year.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029808</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel Stjepanovic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Monitoring nicotine: Triangulating social media, global survey and wastewater data to inform future vaping and smoking policies</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,541,037.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | </Fields_of_Research>
        <Res_KW1>tobacco </Res_KW1>
        <Res_KW2>tobacco control</Res_KW2>
        <Res_KW3>health surveillance</Res_KW3>
        <Res_KW4>health surveys</Res_KW4>
        <Res_KW5>monitoring</Res_KW5>
        <Plain_Description>In Australia, nicotine addiction continues to be the main cause of preventable death through tobacco smoking. With the emergence of nicotine vaping products, we now face new challenges. This project will establish a surveillance system for smoking and vaping using cutting edge technologies and global partnerships. The development of this enhanced monitoring will provide health experts and government with the tools necessary to respond to the rapidly changing vaping and tobacco smoking landscape.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029809</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Thomas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Defining the Structure-Activity Relationship of a Targetable Neoepitope to Improve Outcomes in CALR+ Myelofibrosis</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$959,509.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>fibrosis </Res_KW1>
        <Res_KW2>haematopoietic stem cells</Res_KW2>
        <Res_KW3>monoclonal antibody</Res_KW3>
        <Res_KW4>acute inflammation</Res_KW4>
        <Res_KW5>protein tyrosine kinase (ptk)</Res_KW5>
        <Plain_Description>Primary myelofibrosis is a severe inflammatory blood cancer that affects both young and older adults, and is characterised by marrow fibrosis and chronic inflammatory symptoms with a 5-year survival of less than 50%. We have developed a number of novel non-toxic antibody therapies for myelofibrosis using an immunotherapy approach. Here we will carefully characterise our antibodies to match the correct drug to the correct mutation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029811</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Shoudong Huang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Development of a Low-Cost Minimally Invasive Robot System for Hip Replacement</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$654,363.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | control engineering, mechatronics and robotics | medical robotics | engineering | control engineering, mechatronics and robotics | assistive robots and technology | </Fields_of_Research>
        <Res_KW1>total hip replacement </Res_KW1>
        <Res_KW2>orthopaedic surgery</Res_KW2>
        <Res_KW3>osteoarthritis</Res_KW3>
        <Res_KW4>arthroplasty</Res_KW4>
        <Res_KW5>bone structure</Res_KW5>
        <Plain_Description>This project aims to develop a new robotic system for assisting hip replacement operations. The expected outcomes of this project will be a prototype robotic system that will (1) offer a more efficient and accurate minimally invasive acetabular preparation; (2) significantly speed up patient recovery, and significantly reduce early dislocation rates due to the novel minimally invasive autonomous robotic acetabular preparation; (3) significantly reduce the cost of robotic based hip replacements.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029854</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jakob Begun</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing microbial immunomodulatory function to improve treatment of inflammatory bowel diseases</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,655,520.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biological sciences | microbiology | microbial ecology | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>microbial ecology</Res_KW2>
        <Res_KW3>chronic inflammation</Res_KW3>
        <Res_KW4>metabolites</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>Inflammatory gut conditions, including inflammatory bowel diseases (IBD), are driven by interactions between the resident gut bacteria and the immune system. Current IBD therapies only block the immune system and there are no microbiota-derived therapies. This project aims to re-define IBD by the activity of an individual’s microbiota and use this information to tailor a bacterial-based complimentary product to treat their disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029871</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Sicong Tu</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Defining Metabolite Dysfunction in Amyotrophic Lateral Sclerosis: Developing Objective Scalable Neuro-Markers of Cortical Hyperexcitability</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$935,864.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>motor neuron disease (mnd)</Res_KW3>
        <Res_KW4>transcranial magnetic stimulation (tms)</Res_KW4>
        <Res_KW5>magnetic resonance imaging (mri)</Res_KW5>
        <Plain_Description>The grant will study neurochemical changes underlying excess brain activity (cortical hyperexcitability) in patients with amyotrophic lateral sclerosis, the most common form of motor neuron disease. Dynamic changes in glutamate, a major excitatory neurotransmitter, is predicted to drive the development of progressive cortical dysfunction. Novel non-invasive neuroimaging techniques will be developed to capture neurochemical abnormalities, informing novel therapies for neurodegeneration.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029873</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Vincent Harley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Improving the diagnosis of Differences of Sex Development (DSD)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,208,612.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>sex determination </Res_KW1>
        <Res_KW2>molecular diagnosis</Res_KW2>
        <Res_KW3>gene polymorphisms</Res_KW3>
        <Res_KW4>gonadal dysgenesis</Res_KW4>
        <Res_KW5>sertoli cell</Res_KW5>
        <Plain_Description>DSDs are surprisingly common, with an estimated frequency of 1%. However, half of DSD cases remain genetically undiagnosed. We will identify new causes of DSD. We will sequence DNA from patients and develop patient-specific cell culture systems to understand alterations in sex development. We expect to identify novel DSD genes which will be incorporated into DSD panels globally to raise diagnostic yield, which is currently at 40%.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029883</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Snezana Maljevic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Advancing humanised models for the preclinical development of targeted genetic therapies for brain disorders</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,663,586.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>antisense oligonucleotides </Res_KW1>
        <Res_KW2>in vivo</Res_KW2>
        <Res_KW3>neuronal differentiation</Res_KW3>
        <Res_KW4>adult stem cells</Res_KW4>
        <Res_KW5>neurogenetics</Res_KW5>
        <Plain_Description>Many neurological and neurodevelopment conditions are caused by genetic variants that affect the expression of the affected gene. Antisense oligonucleotides can be effective therapies for such conditions as they can specifically alter the expression of the target gene. We aim to improve the development of antisense therapies by generating new preclinical models which will facilitate the assessment of efficacy and shorten the period needed for the development and approval of such therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029889</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Thomas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Next-generation gene editing strategies to treat autosomal dominant retinitis pigmentosa</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$922,058.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | neurogenetics | biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>molecular biology </Res_KW1>
        <Res_KW2>genetic disorders</Res_KW2>
        <Res_KW3>dna targeted drugs</Res_KW3>
        <Res_KW4>retinitis pigmentosa</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>Inherited eye diseases have a devastating impact on affected individuals and often result in complete blindness. Unfortunately, these diseases are currently incurable. Recent research indicates that inherited blindness can be treated using new “genome editing” technology that corrects the mistake in the DNA that causes the disease. This project aims to develop innovative genome editing therapies for common inherited eye diseases using cultured cells and mice that model the human disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029912</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Fatima Valdes Mora</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Leveraging H3K27M vulnerabilities for targeted epigenetic therapy in Diffuse Intrinsic Pontine Glioma</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$708,692.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>brain neoplasms</Res_KW2>
        <Res_KW3>targeted therapy</Res_KW3>
        <Res_KW4>chromatin structure</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Diffuse intrinsic pontine glioma (DIPG) is a type of brain cancer with no cure and not treatment options. Most patients with DIPG have the same genetic mutation that makes the cancer cells very aggressive. This proposal aims to develop a new treatment that targets this disease-causing mutation and reverses the molecular changes that make DIPG so hard to treat, which could improve outcomes for children with DIPG.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029917</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr John Lin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Multi-wavelength optogenetic manipulation of basolateral neurons and synapses</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$906,335.58</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>synaptic transmission </Res_KW1>
        <Res_KW2>neurophysiology</Res_KW2>
        <Res_KW3>protein engineering</Res_KW3>
        <Res_KW4>neuroplasticity</Res_KW4>
        <Res_KW5>fear</Res_KW5>
        <Plain_Description>Neuroscience advances has been accelerated by the development of tools that can control neuronal activities with light illumination. This project will develop new tools to permit the experimenters to manipulate the activities of 2 populations of cells with 2 different colours of light. These tools will be valuable to study the interaction between different populations of cells in the brain, revealing the complexity of neurocircuitry and network activity responsible to complex behaviour.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029937</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Daniel Gray</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Reversing defects in thymic stroma to restore immune function</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,340,128.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>thymus </Res_KW1>
        <Res_KW2>t cell development</Res_KW2>
        <Res_KW3>stromal cells</Res_KW3>
        <Res_KW4>regeneration</Res_KW4>
        <Res_KW5>immune reconstitution</Res_KW5>
        <Plain_Description>The thymus produces T cells that are critical for fighting infection and cancer. However, the thymus shrivels early in life, making fewer T cells which contributes to poor immunity in the aged. By focusing on key structural cells that control thymus size and function, we will determine why the organ declines and identify ways to restore it. Our idea is to develop new treatments to protect this critical organ from damage and improve immune recovery in patients receiving radiation or chemotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029993</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Grant Logan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Leaving no child behind: enabling universal access to AAV gene therapies by vector bio-engineering to escape pre-existing natural immunity.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,699,728.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>adeno-associated virus</Res_KW2>
        <Res_KW3>molecular virology</Res_KW3>
        <Res_KW4>monoclonal antibody</Res_KW4>
        <Res_KW5>antiviral immunity</Res_KW5>
        <Plain_Description>The team is playing a critical role in Australia in an exciting translational phase of the gene therapy field to provide treatments for patients who otherwise have no treatment options. However, this has revealed the next challenge for the field, namely pre-existing immunity to the viral gene delivery system that prevents access to the life-changing technology.  This research project will circumvent the issue to enable universal patient access to this remarkable transformative technology.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030057</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Kaylene Young</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>WHAT CAUSES MULTIPLE SCLEROSIS ONSET AND PROGRESSION?</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$3,653,278.55</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>molecular neuroscience </Res_KW1>
        <Res_KW2>multiple sclerosis (ms)</Res_KW2>
        <Res_KW3>transgenic mouse</Res_KW3>
        <Res_KW4>central nervous system (cns)</Res_KW4>
        <Res_KW5>central nervous system (cns) diseases</Res_KW5>
        <Plain_Description>In multiple sclerosis (MS) immune cells attack the brain. A person's genes, environment and lifestyle choices can influence whether they develop MS and the severity of disease. But we don't know how these factors alter brain cell function to start or worsen MS. To figure this out, we studied families with multiple members who have MS. We identified gene mutations carried by people with MS, with the potential to change brain cells function. We will now determine how brain cells are affected.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030071</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Bondonno</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>The nitrate debate: does dietary source determine health impact?</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$679,504.56</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | food properties (incl. characteristics and health benefits) | </Fields_of_Research>
        <Res_KW1>nutrition </Res_KW1>
        <Res_KW2>cancer prevention</Res_KW2>
        <Res_KW3>dementia</Res_KW3>
        <Res_KW4>cardiovascular disease prevention</Res_KW4>
        <Res_KW5>diabetes prevention</Res_KW5>
        <Plain_Description>Nitrate could be a friend (improves health) or a foe (causes cancer) depending on what source it comes from. The major sources of nitrate are vegetables, meat, and drinking water. Our research will determine in what context nitrate is beneficial (protects against debilitating diseases) or causes harm (increases risk of cancer). This is critical because we cannot promote intake of vegetables rich in nitrate for health until we are clear on nitrate’s link with cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030086</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kate Gartlan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting cytotoxic T cell fates in bone marrow/stem cell transplantation</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,085,795.15</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | transplantation immunology  | </Fields_of_Research>
        <Res_KW1>graft versus host disease (gvhd) </Res_KW1>
        <Res_KW2>bone marrow transplantation</Res_KW2>
        <Res_KW3>cd8 t cells</Res_KW3>
        <Res_KW4>inflammatory cytokines</Res_KW4>
        <Res_KW5>allogeneic transplantation</Res_KW5>
        <Plain_Description>The only cure for many Leukaemia patients is a donor stem cell transplant, however most recipients develop graft- versus-host disease (GVHD). GVHD is induced by immune cells called T lymphocytes that are important for controlling cancer, but have detrimental off-target effects leading to reduced survival and quality of life. This study will expand our understanding of T cell responses after transplant, providing key data to inform new therapeutic strategies for GVHD prevention and treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030089</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark Larance</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Discovery of a New Modification in the Platelet Proteome</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$747,057.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | glycobiology | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>platelet function </Res_KW1>
        <Res_KW2>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW2>
        <Res_KW3>glycobiology</Res_KW3>
        <Res_KW4>proteomics</Res_KW4>
        <Res_KW5>platelet activation</Res_KW5>
        <Plain_Description>The modification of proteins with carbohydrates (glycosylation) plays a key role in most cells of the body, but many glycosylation events remain uncharacterised. This project builds upon a novel type of glycosylation we have discovered in platelets, the most important cell type for blood coagulation and clot formation. We will establish the function of this modification for platelet function and how this modification is disrupted in disease states such as type II diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030097</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Bradley Turner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Therapeutic targeting of ferroptotic motor neuron death in ALS</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$983,704.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>neuronal cell death</Res_KW2>
        <Res_KW3>lipid peroxidation</Res_KW3>
        <Res_KW4>motor neuron disease (mnd)</Res_KW4>
        <Res_KW5>antioxidant</Res_KW5>
        <Plain_Description>We recently discovered a new form of cell death involved in MND called "ferroptosis", literally meaning cell death triggered by iron. Ferroptosis is highly active in people with MND and laboratory models. This raises the exciting clinical implication that drugs which block ferroptosis may be effective for MND. We will evaluate novel genetic and drug approaches to block ferroptosis in laboratory models. Positive outcomes from this project may inform clinical studies in MND patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030112</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Dwan Vilcins</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Providing evidence to guide public health messages during bushfire smoke events</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,270,101.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | environmental epidemiology | </Fields_of_Research>
        <Res_KW1>bushfire </Res_KW1>
        <Res_KW2>air pollution</Res_KW2>
        <Res_KW3>indoor air pollution</Res_KW3>
        <Res_KW4>respiratory</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>Smoke from bushfires and hazard-reducing burns (HRB), collectively known as bushfire smoke (BFS), is toxic and poses a significant threat to human health. More information is needed on pollutants in smoke, how much penetrates homes, and what health effects result from exposure. Our novel study uses HRB to measure environmental, occupational, and household exposure before, during and after a BFS event. Results can inform more effective public health advice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030115</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Wayne Crismani</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Next generation diagnostics and quality of life in chronic conditions; using Fanconi anaemia as a model disease</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$797,705.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genetics not elsewhere classified | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>genetic screening </Res_KW1>
        <Res_KW2>clinical genetics</Res_KW2>
        <Res_KW3>recessive genetic disease</Res_KW3>
        <Res_KW4>cdna library screening</Res_KW4>
        <Res_KW5>dna repair</Res_KW5>
        <Plain_Description>This project focuses on improving the diagnosis and management of chronic diseases, particularly Fanconi anaemia (FA), a rare genetic disorder that affects several body systems. The first phase will involve developing cutting edge diagnostic tools for FA. The study then investigates the mechanism of androgen therapy in FA to find therapies that are more effective and affordable with fewer side effects for women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030126</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Gregory Anderson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>An unexpected role for the iron oxidase hephaestin suggests novel therapies for iron loading disorders.</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$846,993.32</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>haemochromatosis </Res_KW1>
        <Res_KW2>thalassaemia</Res_KW2>
        <Res_KW3>iron overload</Res_KW3>
        <Res_KW4>iron absorption</Res_KW4>
        <Res_KW5>iron storage disorder</Res_KW5>
        <Plain_Description>Hephaestin is an enzyme that has long been known to be important for dietary iron absorption. We now have evidence that hephaestin is necessary in other tissues as well, and particularly for red blood cell production. Because of its important role in maintaining body iron levels, using drugs to manipulate hephaestin activity has the potential to treat iron loading diseases such as haemochromatosis and beta-thalassaemia. This potential will be explored in this project.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030151</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Phillip Robinson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Endocytosis modulation as a novel approach for pain therapeutics</Grant_Title>
        <Admin_Institution>Children's Medical Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,444,544.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biological sciences | biochemistry and cell biology | protein trafficking | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>endocytosis </Res_KW1>
        <Res_KW2>drug development</Res_KW2>
        <Res_KW3>kinase inhibitors</Res_KW3>
        <Res_KW4>dynamin</Res_KW4>
        <Res_KW5>neuropathic pain</Res_KW5>
        <Plain_Description>The project will identify a new target for pain treatment, as current drugs are inadequate or have addiction risks. The work investigates the repurposing of existing drugs and develops long-duration drugs. The approaches will show these drugs work by the right mechanism and without undesirable liabilities. The improved drugs will be patented as new therapeutics, with the best tested in pain models to demonstrate efficacy. This is  a compelling case for a new direction in targeted pain therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030157</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Nestor</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Disambiguating Parkinson’s disease from disorders with mimicking symptoms using ultra-high-field (7 Tesla) multi-modal MRI</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$611,098.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | diagnostic radiography | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | clinical sciences | radiology and organ imaging | </Fields_of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>parkinsonism</Res_KW2>
        <Res_KW3>iron levels</Res_KW3>
        <Res_KW4>basal ganglia</Res_KW4>
        <Res_KW5>quantitative magnetic resonance imaging (mri)</Res_KW5>
        <Plain_Description>We are developing new Magnetic Resonance Imaging (MRI) techniques to diagnose different neurodegenerative diseases that cause parkinsonism (e.g., Parkinson’s disease, essential tremor, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy). Specifically, we will use ultra-high-field MRI to investigate brain iron abnormalities in these disorders. The project aims to improve understanding of disease mechanisms and find a cure or prevention for these severe conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030162</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Hui-Fern Koay</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing MAIT cells as the next frontier of solid tumour immunotherapy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$970,618.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>t cell immunity </Res_KW1>
        <Res_KW2>t cell immunotherapy</Res_KW2>
        <Res_KW3>t cell response</Res_KW3>
        <Res_KW4>therapeutic antibodies</Res_KW4>
        <Res_KW5>t cell activation</Res_KW5>
        <Plain_Description>There is great potential for Mucosal-Associated Invariant T (MAIT) cells to overcome current obstacles impeding conventional T cell immunotherapies, where MAIT cells can be exploited to target solid tumours in a safe, universal manner unrestricted by donor and recipient mismatch. This proposal combines our cutting-edge knowledge and data on MAIT cell biology, T cell engineering, and new nanobody production techniques to generate novel, efficacious MAIT cell therapies in cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030175</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Claudia Bruedigam</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting Lipid Droplet Homeostasis to Develop Therapies for Acute Myeloid Leukaemia</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$960,574.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </Fields_of_Research>
        <Res_KW1>acute myeloid leukaemia (aml) </Res_KW1>
        <Res_KW2>cell death</Res_KW2>
        <Res_KW3>lipid peroxidation</Res_KW3>
        <Res_KW4>cancer chemotherapy</Res_KW4>
        <Res_KW5>fatty acid metabolism</Res_KW5>
        <Plain_Description>Acute myeloid leukaemia (AML) is a very aggressive blood cancer that kills about 1000 Australians every year. AML patients are treated with chemotherapy, however, most patients are not cured by chemotherapy alone and the disease eventually comes back (relapses). We are developing a new type of treatment for patients with AML that targets the energy-storing organelles within the leukaemia cells. Our work has shown that this new type of treatment may prevent relapse after chemotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030186</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Pellicci</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Characterisation and Development of Human Gamma Delta T cells</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$984,055.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>t cell development </Res_KW1>
        <Res_KW2>t cell activation</Res_KW2>
        <Res_KW3>t cell receptor</Res_KW3>
        <Res_KW4>thymus</Res_KW4>
        <Res_KW5>cytokines</Res_KW5>
        <Plain_Description>Gamma delta T cells are specialised T lymphocytes that play protective roles against pathogens and cancer. For many years, it was thought that the major population of gamma delta T cells develops in fetal tissues, but we reveal a new pathway for gamma delta T cell development within the postnatal thymus of humans. We envisage that our proposal will lead to the identification of new factors that could be used to target these cells to treat human diseases such as cancer and infectious diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030216</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sarah Cohen-Woods</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting outcomes of adolescent disordered eating: identifying and integrating novel molecular and biopsychosocial risk models</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$624,126.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | biological psychology  | biological psychology not elsewhere classified | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>sub-clinical eating disorders </Res_KW1>
        <Res_KW2>eating disorders</Res_KW2>
        <Res_KW3>gene-environment interaction</Res_KW3>
        <Res_KW4>dna methylation</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>About 15% of Australian girls experience an eating disorder by age 19. It is critical to improve detection, progression, and health impacts of disordered eating. Identifying biological (including genomic), psychological, and social factors collectively, we can understand how they influence disordered eating, and how teenage disordered eating can lead to poor health outcomes, both physical and mental, in early adulthood. Our novel approach will inform treatment and intervention in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030225</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Rodrigo Suarez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>How do developmental imbalances of neural activity lead to autism spectrum disorder?</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,237,870.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | zoology | animal neurobiology  | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </Fields_of_Research>
        <Res_KW1>neurodevelopment </Res_KW1>
        <Res_KW2>cerebral cortex</Res_KW2>
        <Res_KW3>autism spectrum disorders</Res_KW3>
        <Res_KW4>calcium imaging</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>Autism spectrum disorder (ASD) can arise from genetic and/or environmental disruptions during pregnancy, yet the mechanisms how this occurs have been obscured by the lack of experimental models to study early brain formation. We have established new ways to study this in unprecedented detail exploiting marsupials' underdeveloped birth, and will now use a drug that leads to ASD-like traits to unravel how genes and neural activity interact to shape brain networks and social behaviours.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030242</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jiang Zhu</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Enhancing immunotherapy efficacy by dual targeting of TGF-β and 4-1BB</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$642,075.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>recombinant proteins</Res_KW2>
        <Res_KW3>solid tumours</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>transforming growth factor beta (tgf-beta)</Res_KW5>
        <Plain_Description>Immunotherapy does not work in most solid tumours, such as advanced prostate and breast cancers. These tumours can develop a harsh environment inside the tumour for the immune cells. As a result, the immune cells are compromised and the response to the therapy is poor. In this study, we will make a special protein that can improve the environment and re-activate the immune cells to attack tumour cells. By doing this, we will improve the clinical outcome of the current immunotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030247</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Fiona Brownfoot</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A novel device to detect fetal asphyxia in labour</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$744,019.70</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>fetal hypoxia </Res_KW1>
        <Res_KW2>stillbirth</Res_KW2>
        <Res_KW3>fetal mortality</Res_KW3>
        <Res_KW4>fetal distress</Res_KW4>
        <Res_KW5>fetal growth restriction</Res_KW5>
        <Plain_Description>Birth asphyxia is a leading cause of cerebral palsy, seizures, developmental delay and death in term babies. Current methods of detecting fetal distress are inaccurate and can be misinterpreted. In this project we are using new technology to develop a device to continuously assess fetal pH, a direct measure of fetal stress in labour. We will validate our sensor using neonatal cord blood at delivery and assess the accuracy of our device using a fetal sheep model of hypoxia and a clinical study.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030268</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Troy Cross</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Extreme Heat and Bushfire Smoke: Establishing Evidence-Based Acute PM2.5 Thresholds</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$942,060.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | sports science and exercise | exercise physiology | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>bushfire </Res_KW1>
        <Res_KW2>heat stress</Res_KW2>
        <Res_KW3>air pollution</Res_KW3>
        <Res_KW4>occupational health</Res_KW4>
        <Res_KW5>physical activity</Res_KW5>
        <Plain_Description>The 2019-20 bushfire crisis presented a uniquely Australian environmental challenge of extreme heat with fine particulate matter (PM2.5) pollution. To protect against the health impacts of similar future events, evidence-based guidance on PM2.5 levels that should be avoided is urgently needed. Our project will systematically identify the PM2.5 levels that different levels of physical activity should be stopped and how these thresholds are altered by temperature, age, and if a person has asthma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030291</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Shireen Lamande</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Rebalancing the proteostasis network with small molecule therapeutics to treat genetic skeletal diseases</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,191,171.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>cartilage </Res_KW1>
        <Res_KW2>bone</Res_KW2>
        <Res_KW3>genetic disorders</Res_KW3>
        <Res_KW4>molecular pathology</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Genetic skeletal disorders are a significant disease burden with very limited therapeutic options. We will use human induced pluripotent stem cell derived bone and cartilage “disease in a dish” models and mouse pre-clinical models of cartilage and bone disorders and to test new small molecule therapeutic strategies</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030303</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Li</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Precision medicine advancing renal transplantation</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$902,453.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | transplantation immunology  | biomedical and clinical sciences | clinical sciences | nephrology and urology  | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>kidney transplantation </Res_KW1>
        <Res_KW2>graft rejection</Res_KW2>
        <Res_KW3>histopathology</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>diagnostic</Res_KW5>
        <Plain_Description>Despite the years of advances, our ability to diagnose and prognosticate the outcomes following kidney transplant injury lacks precision. This limits our ability to balance immunosuppression intensity to treat rejection versus major infectious risks of treatment. This project harnesses the power of new technologies to study gene profiles across different histological structures of the kidney to more precisely diagnose rejection and determine the key prognostic features.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030320</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Morag Young</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>New Mineralocorticoid Receptor Pathways for Regulating Cardiac Fibrosis.</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$587,294.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>mineralocorticoid receptor </Res_KW1>
        <Res_KW2>glucocorticoids</Res_KW2>
        <Res_KW3>steroid hormone receptors</Res_KW3>
        <Res_KW4>intracellular signal transduction</Res_KW4>
        <Res_KW5>aldosterone</Res_KW5>
        <Plain_Description>Current therapies are not adequately reducing the burden of heart disease. Drugs that block a hormone receptor, the MR, are protective but cause side effects that stop patients taking medication. We have identified inflammatory cells as a key cell type where the MR is activated to cause heart disease. We will test new MR-dependent pathways controlling inflammation to establish new ways to block negative MR activation that will lead to safe and well-tolerated treatments for heart disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030321</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Charles Herring</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Investigating human brain development and neurodevelopmental disease origins through comprehensive (epi)genomic analysis</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$887,020.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | neurogenetics | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>neurodevelopmental disorders </Res_KW1>
        <Res_KW2>prefrontal cortex</Res_KW2>
        <Res_KW3>neurodevelopment</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>The epigenome controls gene activity during normal development and is disrupted in diseases. Genes in the human prefrontal cortex change until the third decade of life, indicating the need to consider these changes when studying mental disorders. Our research will investigate differences in the epigenome and gene activity between people with and without neuropsychiatric disorders to better understand how these disorders start and progress, with the goal of identifying targets for new treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030328</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Beng Chong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Immuno-thromboses that kill and maim: Pathogenesis and novel treatments</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,076,138.48</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>thrombosis </Res_KW1>
        <Res_KW2>thrombocytopenia</Res_KW2>
        <Res_KW3>platelets</Res_KW3>
        <Res_KW4>neutrophils</Res_KW4>
        <Res_KW5>disease pathogenesis</Res_KW5>
        <Plain_Description>Heparin-induced thrombocytopenia (HIT) is a serious immune reaction to the common blood thinner heparin. HIT causes platelet destruction and life-threatening thrombotic complications with high mortality. We will study the role of neutrophils and coagulation in thrombosis, spatially profile HIT clots, and examine the efficacy of novel molecules we created using a microfluidics system and a HIT mouse model. A radical shift in the concept of HIT is expected. This will improve patient treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030338</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Lachlan Thompson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A better cell therapy for Parkinson's disease.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,116,114.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>neural transplantation </Res_KW1>
        <Res_KW2>parkinson disease</Res_KW2>
        <Res_KW3>cell therapy</Res_KW3>
        <Res_KW4>stem cells</Res_KW4>
        <Res_KW5>neural regeneration</Res_KW5>
        <Plain_Description>A promising experimental therapy for Parkinson's disease is the use of stem cells that in order to replace the cells lost during the disease process. A challenge for this approach is that upon transplantation into the brain, in addition to the therapeutic cell types, there will also be unwanted cell types . This proposal seeks to establish a novel strategy for improving contribution of the therapeutic cells while also developing an improved way to deliver them.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030340</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Sophie Wiszniak</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Neural crest cells as modulators of Wnt signalling in heart development and congenital cardiac outflow tract defects</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$724,147.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>developmental biology </Res_KW1>
        <Res_KW2>congenital heart disease</Res_KW2>
        <Res_KW3>heart development</Res_KW3>
        <Res_KW4>wnt signalling</Res_KW4>
        <Res_KW5>neural crest</Res_KW5>
        <Plain_Description>Congenital heart defects are extremely common due to the complex nature of heart formation, and the multiple cell-types involved. Neural crest cells are one such cell-type that contribute to the heart, yet their involvement in congenital heart defects may be under-appreciated. We will assess new roles for neural crest cells in modulating cell-cell signalling events to underpin correct heart development, as well as how these signalling mechanisms are disrupted to cause congenital heart defects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030395</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jess Nithianantharajah</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Neural underpinnings of maladaptive decision making in mental disorders</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$988,131.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>behavioural science </Res_KW1>
        <Res_KW2>animal model</Res_KW2>
        <Res_KW3>neuron</Res_KW3>
        <Res_KW4>prefrontal cortex</Res_KW4>
        <Res_KW5>calcium imaging</Res_KW5>
        <Plain_Description>Individuals with schizophrenia experience severe functional impairment due to cognitive deficits in decision making abilities. This project uses advanced behavioural and cellular imaging tools to identify neurobehavioural markers in preclinical animal models and uncover new insights into changes in brain connectivity and activity that contribute to cognitive deficits. Our findings will aid the development of new treatments for cognitive symptoms in schizophrenia and related mental disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030422</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Anne Fletcher</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>COX2-driven T cell suppression in the colorectal cancer microenvironment</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,350,991.30</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>stromal cells</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>t cell activation</Res_KW5>
        <Plain_Description>Colorectal cancer (CRC) is still the second leading cause of cancer death in Australia. New drugs called checkpoint inhibitors, which increase survival in some cancers by targeting the patient's immune system, are ineffective for >95% of colorectal cancer patients. This project aims to make checkpoint inhibitor drugs work for more patients by targeting cancer-associated fibroblasts (CAFs), which nourish CRC and prevent immune cells from responding to checkpoint inhibitors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030445</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Brad Broughton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Novel bioengineering solution for improving post-stroke outcomes</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,102,304.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>biomaterials </Res_KW1>
        <Res_KW2>pharmacology</Res_KW2>
        <Res_KW3>ischaemic stroke</Res_KW3>
        <Res_KW4>neuroregeneration</Res_KW4>
        <Res_KW5>adult stem cells</Res_KW5>
        <Plain_Description>Stroke is a debilitating disease, yet current therapies are only suitable for 2-8% of patients, hence new approaches are desperately needed, particularly those that can reverse and/or repair stroke-induced brain injury. Excitingly, we have bioengineered an innovative, stable and brain-compatible hydrogel which encapsulates stem cells and we now propose to test whether this injectable hydrogel containing stem cells is able to repair the brain post-stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030452</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Jay Bertran-Gonzalez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Tuning neural circuits to suppress resurgence of unwanted behaviour</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$652,756.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>behaviour change </Res_KW1>
        <Res_KW2>extinction</Res_KW2>
        <Res_KW3>basal ganglia</Res_KW3>
        <Res_KW4>striatum</Res_KW4>
        <Res_KW5>conditioning</Res_KW5>
        <Plain_Description>Maladaptive action lies at the core of unhealthy behaviours such as overeating, substance abuse and addictions. Using modern neuroscience methods, this project will explore neural manipulations that eliminate maladaptive behaviour by uplifting extinction, an adaptive response by which humans and other animals naturally learn to inhibit actions. Our research will help develop effective therapeutic interventions that produce stronger and more enduring forms of behavioural suppression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030460</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Liviu-Gabriel Bodea</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Targetting the microglial integrated stress response to fight off Alzheimer’s disease</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$782,557.58</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>microglia </Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>cell signalling</Res_KW3>
        <Res_KW4>disease mechanisms</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>Alzheimer's disease (AD) is a common form of dementia that affects the aged population. Without any cure, better treatments are direly needed. As AD progresses, brain's immune cells called microglia switch from being protective to harmful. We found that in the presence of amyloid-ß, microglia activate their so-called integrated stress response. We propose to study this response and determine if it can be targeted to reduce AD. Understanding this better could help against other brain diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030464</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Ewa Goldys</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Low cost biosensors for liquid biopsies: towards practical implementation of precision oncology</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,144,607.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | analytical chemistry | sensor technology (incl. chemical aspects) | </Fields_of_Research>
        <Res_KW1>biosensor </Res_KW1>
        <Res_KW2>colorectal cancer treatment</Res_KW2>
        <Res_KW3>clinical decision making</Res_KW3>
        <Res_KW4>lung cancer</Res_KW4>
        <Res_KW5>pancreatic cancer</Res_KW5>
        <Plain_Description>The project will develop a novel technology for cancer monitoring using inexpensive easily accessible tests. This will enable non-invasive more frequent testing of patients during therapy increasing success of treatments. Such more frequent monitoring will facilitate timely intervention in case of any changes, resulting in improved treatment outcomes. Utilizing such cost-effective tests  will enhance accessibility and  result in reduced costs of treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030499</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Kassiou</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Developing Senolytics for treatment of Amyotrophic Lateral Sclerosis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,037,875.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>drug discovery </Res_KW1>
        <Res_KW2>medicinal chemistry</Res_KW2>
        <Res_KW3>drug design</Res_KW3>
        <Res_KW4>pharmacology</Res_KW4>
        <Res_KW5>neuropharmacology</Res_KW5>
        <Plain_Description>When the body senses damaged cells, it can usually eliminate them, but dangerous senescent cells upregulate proteins such as Bcl-2 and Bcl-xl which make them resistant to the body’s elimination processes. These senescent cells accumulate in amyotrophic lateral sclerosis (ALS). We are developing novel Bcl-2 and Bcl-xl inhibitors which selectively eliminate these senescent cells without eliminating healthy cells to examine the role of senescence in ALS and to develop new ALS treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030525</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Kate Vandyke</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Combining functional in vivo genomics and metabolomics to discover clinically relevant tumour vulnerabilities in multiple myeloma</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,494,105.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </Fields_of_Research>
        <Res_KW1>multiple myeloma </Res_KW1>
        <Res_KW2>cancer biology</Res_KW2>
        <Res_KW3>cell metabolism</Res_KW3>
        <Res_KW4>cancer therapy</Res_KW4>
        <Res_KW5>energy metabolism</Res_KW5>
        <Plain_Description>Multiple myeloma is a type of blood cancer that affects the bone marrow and currently has no cure. We have identified specific metabolic pathways that are essential for the growth of these cancer cells. The proposed project will investigate these pathways further using advanced techniques and samples from patients to develop new treatments that target these pathways. This research will improve our understanding of multiple myeloma and help develop better treatments for people with this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030541</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Guillermo Gomez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing an unexpected new role of the CD47:SIRPA axis to target glioblastoma invasion</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,118,719.30</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>microenvironment </Res_KW1>
        <Res_KW2>metabolic stress</Res_KW2>
        <Res_KW3>glioblastoma</Res_KW3>
        <Res_KW4>cancer immunology</Res_KW4>
        <Res_KW5>t cell immunotherapy</Res_KW5>
        <Plain_Description>This Proposal will investigate how brain tumour cells reprogram to invade the surrounding healthy brain tissue and suppress immune activity. Our results will lay the foundations for new anti-cancer treatments for brain cancer that reduce tumour cell invasion and that facilitate immunotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030552</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Grant Dewson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Restraining mitochondrial damage-induced inflammation in Parkinson's Disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$882,018.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>mitochondria </Res_KW1>
        <Res_KW2>neuronal cell death</Res_KW2>
        <Res_KW3>parkinson disease</Res_KW3>
        <Res_KW4>inflammation</Res_KW4>
        <Res_KW5>ubiquitin</Res_KW5>
        <Plain_Description>Inflammation is beneficial to fight an infection. However, prolonged inflammation can promote disease. Inflammation is seen in people with Parkinson’s Disease (PD) and may cause neuronal loss in PD. What causes this damaging inflammation in PD is unclear, but may be triggered when the powerhouse of cells, mitochondria, are damaged. This research aims to understand how a neuron “clears up” damaged, pro-inflammatory mitochondria and will explore its in the degeneration of neurons in PD.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030559</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Melinda Coughlan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the metabolic landscape in the human kidney in diabetes</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$916,004.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | metabolic medicine | biomedical and clinical sciences | clinical sciences | nephrology and urology  | biological sciences | biochemistry and cell biology | cell metabolism | </Fields_of_Research>
        <Res_KW1>kidney </Res_KW1>
        <Res_KW2>mitochondria</Res_KW2>
        <Res_KW3>energy metabolism</Res_KW3>
        <Res_KW4>diabetes</Res_KW4>
        <Res_KW5>diabetic nephropathy</Res_KW5>
        <Plain_Description>Mitochondria, the “power plants” of the cell, are damaged and accumulate in the kidney in diabetes leading to the onset of diabetic kidney disease. The objective of this study is to investigate exactly how these dysfunctional mitochondria accumulate in the human kidney and what fuel they use. It is anticipated that these studies will allow us to unearth new medicines to prevent kidney damage, particularly in individuals with or at risk of developing diabetic kidney disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030585</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Alicia Jenkins</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Markers and mediators of retinopathy and response to fenofibrate in people with Type 1 diabetes</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$866,385.45</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>diabetes mellitus </Res_KW1>
        <Res_KW2>diabetic retinopathy</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>vision loss</Res_KW4>
        <Res_KW5>intervention study</Res_KW5>
        <Plain_Description>In Type 2 diabetes fenofibrate tablets slow complications, but as yet there are no trial results in Type 1 diabetes (T1D) nor is the mechanism of protection clear. We suggest that a factor in cells, called PPAR-alpha, is key. Using existent samples from 200 T1D and 100 non-diabetic adults we will determine if T1D is associated with lower PPAR-alpha and related adverse factors in blood and in eye photos that can help predict eye, kidney and nerve damage and if and how fenofibrate is protective.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030603</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Graeme Lancaster</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Greasy Death – Determining the Physiological Importance and Therapeutic Potential of Altering the Susceptibility to Ferroptotic Cell Death</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$711,678.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - lipids  | </Fields_of_Research>
        <Res_KW1>lipids </Res_KW1>
        <Res_KW2>cell death</Res_KW2>
        <Res_KW3>neutrophils</Res_KW3>
        <Res_KW4>lymphoma</Res_KW4>
        <Res_KW5>dietary fatty acids</Res_KW5>
        <Plain_Description>Ferroptosis is a form of cell death dependent upon lipids. We have discovered that certain types of immune cells are very sensitive to this form of cell death, while other immune cell types are almost completely resistant. This application seeks to make discoveries that will: (1) reveal why certain immune cell types are resistant to ferroptosis, and (2) try to use this information for therapeutic benefit in cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028090</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Mariusz Skwarczynski</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>A nanonaccine against Invasive Group A Streptococcus and Rheumatic Heart Disease</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$608,061.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical delivery technologies | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>oral vaccine</Res_KW1>
        <Res_KW2>adjuvant</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>streptococcal invasive diseases</Res_KW4>
        <Res_KW5>rheumatic heart disease</Res_KW5>
        <Plain_Description>Group A Streptococcus (GAS) infection is responsible for deadly invasive infections and rheumatic heart disease, which is the most common cause of cardiac mortality in children and young adults. No GAS vaccine is available on the market. The project will produce vaccine candidates against GAS that will be able to induce robust immune responses against all strains without triggering adverse effects, and can be delivered orally allowing self-administration.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2028652</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Darryl Eyles</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Intranasal delivery of clozapine to reduce side-effects: The preclinical evidence</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$851,810.35</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical delivery technologies | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>clozapine</Res_KW1>
        <Res_KW2>side-effects</Res_KW2>
        <Res_KW3>nasal delivery</Res_KW3>
        <Res_KW4>animal model</Res_KW4>
        <Res_KW5>schizophrenia</Res_KW5>
        <Plain_Description>Clozapine is arguably the best current antipsychotic drug. It is the only recommended drug for treatment-resistant schizophrenia but comes with a range of debilitating and potentially lethal side effects. This grant is dedicated to producing data in animals showing that changing the route of administration to the nose will a) maintain clozapine’s antipsychotic effect, b) greatly reduce the dose required and c) substantially reduce side effect burden.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2029692</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Victor Anggono</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2023 Ideas Grants</Sub_Type>
        <Grant_Title>Unraveling the physiological and disease-enabling functions of Tau protein</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,010,892.64</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell neurochemistry | </Fields_of_Research>
        <Res_KW1>glutamate receptors</Res_KW1>
        <Res_KW2>receptor trafficking</Res_KW2>
        <Res_KW3>cellular nervous system</Res_KW3>
        <Res_KW4>molecular neuroscience</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>Our current understanding of the normal role of the protein Tau in the brain is lacking. This makes it hard to develop treatments for diseases like Alzheimer's and epilepsy, where Tau plays important roles. We have found that Tau affects glutamate receptors that can trigger seizures when they are hyperactive. This proposal aims to understand how Tau does this, and how it goes wrong in disease. This will help us create better treatments for these conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030826</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Walker</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Preclinical refinement of a UQ-Moderna vaccine developed to prevent StrepA infection</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,201,617.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>group a streptococcal disease</Res_KW1>
        <Res_KW2>vaccine development</Res_KW2>
        <Res_KW3>streptococcus pyogenes</Res_KW3>
        <Res_KW4>vaccine</Res_KW4>
        <Res_KW5>streptococcal infection</Res_KW5>
        <Plain_Description>The University of Queensland and Moderna have collaboratively developed an mRNA vaccine that prevents Streptococcus pyogenes (StrepA) infection. To support future clinical development of this StrepA mRNA vaccine, we will investigate whether fewer doses of vaccine (1 or 2 doses) provides equivalent protection compared to the standard 3 dose regime. We will confirm that our StrepA mRNA vaccine provides protection across multiple StrepA serotypes and investigate durability of vaccine protection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2030965</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Keall</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>A New Device for Targeted Radiation Therapy to Improve Cancer Patient Outcomes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$668,892.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </Fields_of_Research>
        <Res_KW1>radiation therapy</Res_KW1>
        <Res_KW2>radiation oncology</Res_KW2>
        <Res_KW3>medical imaging</Res_KW3>
        <Res_KW4>imaging</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>71% of radiation therapy centres want better targeted radiation therapy to improve patient outcomes but are limited by resources and capacity. Our academically, clinically and commercially successful team have invented a deep learning targeting device to meet this need. Our three research aims dovetail with the industry-identified need to retire risk, increase the value proposition and maximise product-market fit.  Success means reducing treatment toxicity for 440,000 patients per year.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031101</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Payne</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Development of an immune-modulating human peptide as a next generation topical therapy for inflammatory skin diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,017,999.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | dermatology | chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>anti-inflammatory agents</Res_KW1>
        <Res_KW2>peptides</Res_KW2>
        <Res_KW3>atopic dermatitis</Res_KW3>
        <Res_KW4>psoriasis</Res_KW4>
        <Res_KW5>topical drug delivery</Res_KW5>
        <Plain_Description>Psoriasis and eczema are common inflammatory skin conditions that cause significant physical, emotional and social burden to patients. Currently available topical steroids and antibody treatments can lead to significant side effects due to immune suppression of other tissues and organs. In this project we will perform critical experiments necessary for the development of a natural human peptide into an effective and safe topical drug candidate for the treatment of psoriasis and eczema.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031171</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tracy Putoczki</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Development of a new drug for Crohn's Disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$998,948.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Fields_of_Research>
        <Res_KW1>cytokine signalling</Res_KW1>
        <Res_KW2>cytokine receptor</Res_KW2>
        <Res_KW3>novel therapeutic agents</Res_KW3>
        <Res_KW4>fibrosis</Res_KW4>
        <Res_KW5>inflammatory bowel disease (ibd)</Res_KW5>
        <Plain_Description>Inflammatory bowel disease is a debilitating life-long condition. Current treatments are often ineffective, associated with risks, or stop working. Together with our industry partner, Nelcanen Therapeutics, we will develop a new therapeutic that could control and reverse disease and will progress this drug to clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031349</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Grayden</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Endovascular Focussed Ultrasound for Brain Stimulation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$906,148.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | medical devices | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>implant design</Res_KW1>
        <Res_KW2>ultrasound</Res_KW2>
        <Res_KW3>endovascular technology</Res_KW3>
        <Res_KW4>neurology</Res_KW4>
        <Res_KW5>brain disease</Res_KW5>
        <Plain_Description>Many people with neurological diseases do not benefit sufficiently from pharmaceutical treatment. Electrical stimulation of the brain can be used to treat these patients but requires brain surgery and electrical stimulation may not be sufficiently accurate. We aim to develop and test ultrasound stimulation to stimulate the brain from within blood vessels. This method will obviate the need for open brain surgery while improving the accuracy of stimulation, leading to better outcomes for patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031405</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Jane Pillow</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>DelivAssure: A novel fetal lactate sensor to improve detection of intrapartum fetal hypoxia</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,499,491.18</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </Fields_of_Research>
        <Res_KW1>fetal distress</Res_KW1>
        <Res_KW2>fetal hypoxia</Res_KW2>
        <Res_KW3>obstetrics</Res_KW3>
        <Res_KW4>fetal health</Res_KW4>
        <Res_KW5>hypoxic-ischaemic encephalopathy</Res_KW5>
        <Plain_Description>Labour and birth are a risky time for the fetus. Reduced blood flow to the placenta during uterine contractions can stress the fetus during birth and result in stillbirth or brain injury. We have developed an innovative technology that can continuously assess a baby's health and wellbeing during labour and delivery and identify if the baby is becoming stressed. This project will develop our technology to a stage when it can be used in human pregnancies, saving lives and improving health outcomes</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031477</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Pierre Qian</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Aurora Microwave Ablation System for Ventricular Arrhythmias</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,219,255.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>microwave</Res_KW1>
        <Res_KW2>cardiac arrhythmia</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>sudden cardiac death</Res_KW4>
        <Res_KW5>cardiovascular disease</Res_KW5>
        <Plain_Description>Deadly heart rhythm problems called ventricular arrhythmias (VA) are caused by scars in the heart, commonly in  patients with reduced heart function such as after a heart attack. Patients at risk are implanted defibrillators that  save lives but do not prevent VA, leading to traumatising recurrent device shocks. The project aims to develop a system   using microwaves to effectively destroy scars in the heart causing VA to improve the quality of life and longevity for  many patients with heart disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031506</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Brodie</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Helping Five Million People with Parkinson's Disease Walk</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$972,858.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | medical devices | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | health sciences | sports science and exercise | motor control | </Fields_of_Research>
        <Res_KW1>parkinson disease</Res_KW1>
        <Res_KW2>gait disorders</Res_KW2>
        <Res_KW3>mobility</Res_KW3>
        <Res_KW4>peripheral nerve</Res_KW4>
        <Res_KW5>preventive health</Res_KW5>
        <Plain_Description>Gait dysfunction leading to falls in people with Parkinson’s disease (PD) has enormous health impact. This Development Grant will accelerate the commercial proof-of-concept of our breakthrough noninvasive stimulation device to treat gait dysfunction. Outcomes include a new Class IIa medical device and supporting data ready for regulatory review and industry investment. Success would mean future patients with PD could rapidly experience improved gait, fewer falls and reduced health care costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031542</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Brad Sleebs</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Development of aspartyl protease inhibitors targeting the diarrheal parasite Cryptosporidium</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,453,577.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | microbiology | microbiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cryptosporidiosis</Res_KW1>
        <Res_KW2>cryptosporidium</Res_KW2>
        <Res_KW3>antimicrobial therapy</Res_KW3>
        <Res_KW4>medicinal chemistry</Res_KW4>
        <Res_KW5>drug development</Res_KW5>
        <Plain_Description>Cryptosporidium parasites cause cryptosporidiosis which is a severe diarrheal disease and is a leading cause of childhood mortality and morbidity. There are currently no effective drugs or vaccines to treat cryptosporidiosis.    We have identified that an antimalarial drug class with a known mechanism of action also kills Cryptosporidium parasites. We aim to enhance the anti-cryptosporidium efficacy and advance this drug class into human clinic trials with the support of our commercial partners.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031553</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Craik</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Developing novel peptide tracers for improving immunotherapy outcomes</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$612,781.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | </Fields_of_Research>
        <Res_KW1>peptides</Res_KW1>
        <Res_KW2>protein binding</Res_KW2>
        <Res_KW3>synthetic peptides</Res_KW3>
        <Res_KW4>protein-protein interaction</Res_KW4>
        <Res_KW5>peptide synthesis</Res_KW5>
        <Plain_Description>Immune checkpoint inhibitors are cancer drugs that help your immune system fight cancer, but predicting patient benefit using approved biopsy-based tests is erroneous and painful. This project aims to develop molecular imaging agents for accurate whole-body visualisation of tumours, allowing clinicians same-day feedback to select the proper treatment and monitor progress. This project will support future human clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031577</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Street</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Development of Methyltranferase like protein 5 (METTL5) Inhibitors for Treatment of Solid Tumours in Children and Adults</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,294,576.10</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>anticancer drug</Res_KW1>
        <Res_KW2>anticancer drug action</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>drug design</Res_KW4>
        <Res_KW5>structure-based drug design</Res_KW5>
        <Plain_Description>We aim to develop novel inhibitors of the RNA methyltransferase, METTL5, for the treatment of cancers with high unmet medical need in children (neurobastoma) and adults (breast, pancreatic, others). This work will allow us to develop the novel chemistry and "proof of concept" efficacy data in pre-clinical models that will support the future commercialization of this project.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031600</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Raymond Norton</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Development of a Kv1.3 Potassium Channel Inhibitor as a New Class of Treatment for Diabetic Kidney Disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$753,140.70</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>peptide inhibitors</Res_KW1>
        <Res_KW2>synthetic peptides</Res_KW2>
        <Res_KW3>kidney disease</Res_KW3>
        <Res_KW4>diabetic nephropathy</Res_KW4>
        <Res_KW5>therapeutic agents</Res_KW5>
        <Plain_Description>Diabetickidney disease (DKD) is a major public health problem, which is associated with kidney failure, cardiovascular disease and premature death. Current therapies often fail to stop disease progression. There is an urgent need for innovative strategies to prevent, arrest and reverse the development of DKD. This project will advance the development of a novel therapeutic for DKD that acts by a different mechanism from current drugs and has shown considerable promise in animal models of DKD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031655</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Scott</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>A Novel Targeted Therapy for Cancer</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,270,432.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>antibody cancer therapy</Res_KW1>
        <Res_KW2>molecular design</Res_KW2>
        <Res_KW3>targeted therapy</Res_KW3>
        <Res_KW4>molecular imaging</Res_KW4>
        <Res_KW5>drug delivery systems</Res_KW5>
        <Plain_Description>We have discovered a novel drug that only binds to a target found in tumours, but not in normal tissue. This provides an exciting opportunity to develop a new treatment for cancer patients that is tumour specific, less likely to have side effects, and more effective in treating cancer. In this grant we will undertake studies to develop this drug and perform experiments that validate the optimal therapeutic approach, ultimately leading to human clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031727</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Shaun Jackson</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2023 Development Grants</Sub_Type>
        <Grant_Title>Development of novel anticoagulants for stroke</Grant_Title>
        <Admin_Institution>Heart Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,243,312.51</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>ischaemic stroke</Res_KW1>
        <Res_KW2>thrombolysis</Res_KW2>
        <Res_KW3>thrombosis</Res_KW3>
        <Res_KW4>anticoagulants</Res_KW4>
        <Res_KW5>antithrombotic</Res_KW5>
        <Plain_Description>Stroke is a leading cause of death/disability worldwide. Identification of novel drugs that can break down blood clots and improve blood flow to the brain would represent a major advance in stroke treatment. We are developing new anticlotting drugs derived from natural anticoagulants produced by Australian bush ticks. Theses agents have potential to dramatically improve the quality-of-life of 1000's of stroke sufferers in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026175</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Diana Hansen</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 e-ASIA Joint Research Program</Sub_Type>
        <Grant_Title>Uncovering the burden of asymptomatic malaria: dissecting immune responses to infection to overcome immunosuppression and improve vaccination strategies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$749,917.65</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>adaptive immunity</Res_KW2>
        <Res_KW3>immunosuppression</Res_KW3>
        <Res_KW4>chronic infection</Res_KW4>
        <Res_KW5>vaccines</Res_KW5>
        <Plain_Description>This project will undertake a comprehensive immunological and molecular analysis of individuals experiencing asymptomatic malaria in an endemic area of Indonesia. The project will demonstrate that asymptomatic malaria it is not benign as previously thought, providing a framework for new policies supporting mass-screening and treatment of asymptomatic malaria. We will also identify critical immune responses to eradicate these persistent infections with innovative vaccination strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026359</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Sotiris Vardoulakis</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 e-ASIA Joint Research Program</Sub_Type>
        <Grant_Title>Climate change adaptation to smoke haze for improved child health in Southeast Asia</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$746,793.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>environmental sciences | climate change impacts and adaptation | human impacts of climate change and human adaptation | health sciences | epidemiology | environmental epidemiology | health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>environmental health</Res_KW1>
        <Res_KW2>climate change adaption</Res_KW2>
        <Res_KW3>air pollution</Res_KW3>
        <Res_KW4>bushfire</Res_KW4>
        <Res_KW5>community child health</Res_KW5>
        <Plain_Description>Wildfire smoke causes thousands of deaths in Southeast Asia every year, many of them in young children in Indonesia, Thailand, Cambodia, and Laos. Climate change will make wildfires in the region more frequent and intense, causing more severe and prolonged smoke haze. We will develop and evaluate public health tools aimed at protecting children from smoke haze, including an early warning system, clean air rooms in schools and nurseries, and targeted health advice for children and their carers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2026447</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Gordon</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 e-ASIA Joint Research Program</Sub_Type>
        <Grant_Title>Eliminating S. mekongi – the final push</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$749,978.20</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | health sciences | epidemiology | epidemiological methods | </Fields_of_Research>
        <Res_KW1>schistosoma</Res_KW1>
        <Res_KW2>environmental epidemiology</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>diagnosis</Res_KW4>
        <Res_KW5>mathematical modelling</Res_KW5>
        <Plain_Description>This cooperative research project aims to eliminate Schistosoma mekongi in Lao PDR and Cambodia by using an intensive multi-component “One Health” approach. Climate prediction models show that the Mekong region will be significantly impacted by climate change leading to extending transmission season of S. mekongi, as well as shifting or expanding habitats. Thus, now is the critical time to eliminate S. mekongi before the effects of climate change are felt.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2027707</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Rachel Thomson</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 e-ASIA Joint Research Program</Sub_Type>
        <Grant_Title>Nontuberculous mycobacterial (NTM) infections associated with climate change and major weather events: enhancing surveillance and mitigation strategies.</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$721,435.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>environmental sciences | pollution and contamination | surface water quality processes and contaminated sediment assessment | health sciences | epidemiology | disease surveillance | environmental sciences | climate change impacts and adaptation | ecological impacts of climate change and ecological adaptation | </Fields_of_Research>
        <Res_KW1>mycobacteria</Res_KW1>
        <Res_KW2>climate change</Res_KW2>
        <Res_KW3>drinking water</Res_KW3>
        <Res_KW4>environmental epidemiology</Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>This project will assess the impacts of major weather events and climate change on incidence and geospatial distribution of nontuberculous mycobacterial infection in 5 countries. Major events cause aerosol dissemination of NTM from the environment, resulting in acute increases in exposure; further increases in disease occur as a result of the impact on drinking water distribution systems. We will evaluate novel therapies to control NTM growth in the water systems to reduce further transmission.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032781</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Ki Wook Kim</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Characterising viruses that promote the development of type 1 diabetes</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$499,999.45</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | paediatrics | infant and child health | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW1>
        <Res_KW2>coxsackie virus infection</Res_KW2>
        <Res_KW3>virus detection</Res_KW3>
        <Res_KW4>virology</Res_KW4>
        <Res_KW5>sequencing</Res_KW5>
        <Plain_Description>T1D affects >135,000 Australians (>$2.9B health care costs in 2020), still without cure/prevention. Among the environmental factors investigated, strongest evidence supports the role of viruses (enteroviruses) as prime triggers of IA. Using comprehensive virome sequencing, we will characterise the complete genomes of all viruses that contribute significantly to the development of IA and T1D in two large study populations of Finland and Australia, where children have been followed from pregnancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032788</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Louise Ellis</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Strengthening resilience and mental wellbeing through the Support4Resilience toolbox for leaders in elderly care</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$499,225.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | health sciences | health services and systems | health services and systems not elsewhere classified | health sciences | health services and systems | aged health care | </Fields_of_Research>
        <Res_KW1>health services research</Res_KW1>
        <Res_KW2>health services</Res_KW2>
        <Res_KW3>wellbeing</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>occupational health</Res_KW5>
        <Plain_Description>This project aims to strengthen resilience and mental wellbeing among healthcare workers and informal caregivers by developing, testing and evaluating a Toolbox to support leaders in aged care. The Toolbox will be tested in six European countries and Australia, and will be adapted to different contexts, types of health care providers and health system levels. The Toolbox will be made available through an open access online platform and will promote resilient performance and worker wellbeing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032819</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Victoria Ross</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Evidence-based interventions for promotion of mental and physical health in changing working environments: PROSPERH Australia</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$499,914.20</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | psychology | clinical and health psychology | health psychology | </Fields_of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>occupational health</Res_KW3>
        <Res_KW4>program evaluation</Res_KW4>
        <Res_KW5>workplace</Res_KW5>
        <Plain_Description>PROSPERH will develop and evaluate an intervention that yields sustainable benefits on workplace mental/physical health indicators and economic outcomes. This will be achieved through investigating the impact of workplace changes and stressors; and testing an evidence-based, multi-level intervention targeting individual, peer and organisational aspects, tailored to telework/ ICT-based mobile work, health and construction sectors which have high rates of work-related MSDs, depression and anxiety.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031853</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tamsyn Van Rheenen</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NEURON Mechanisms of Resilience and Vulnerability to Environmental Challenges in Mental Health</Sub_Type>
        <Grant_Title>Resilience and vulnerability: from neural circuits to networks</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$854,701.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | psychology | biological psychology  | biological psychology not elsewhere classified | psychology | cognitive and computational psychology | cognition | </Fields_of_Research>
        <Res_KW1>resilience</Res_KW1>
        <Res_KW2>mental disorder</Res_KW2>
        <Res_KW3>mechanisms</Res_KW3>
        <Res_KW4>environmental influences</Res_KW4>
        <Res_KW5>neuroimaging</Res_KW5>
        <Plain_Description>We will study large groups of people who are either currently experiencing, or are at risk of experiencing, various mental health conditions. We will study their brains, biological traits, thinking skills, and other characteristics. We will study both risk and protective factors and use new and sophisticated analysis methods to uncover the relationships between them and how they differ between people. This will help us to understand why some people are more resilient than others.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2031881</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Natalie Matosin</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NEURON Mechanisms of Resilience and Vulnerability to Environmental Challenges in Mental Health</Sub_Type>
        <Grant_Title>Features of exposure to childhood adversity in the insular cortex in MDD and PTSD </Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,102,865.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>major depressive disorder</Res_KW1>
        <Res_KW2>posttraumatic stress disorder (ptsd)</Res_KW2>
        <Res_KW3>stress response</Res_KW3>
        <Res_KW4>molecular basis of disease</Res_KW4>
        <Res_KW5>neuroendocrinology</Res_KW5>
        <Plain_Description>This project aims to create the most comprehensive molecular atlases of the insular cortex which is an important region of the human brain and how it is impacted by early life adversity in depression and PTSD. This proposal presents an exciting possibility for patients as we develop the foundation to initiate a novel way to biologically identify patients exposed to early life adversity, and to identify new and more effective ways to medicinally treat them, overcoming trial-and-error prescribing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032021</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Hannan</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NEURON Mechanisms of Resilience and Vulnerability to Environmental Challenges in Mental Health</Sub_Type>
        <Grant_Title> Metabolic Underpinnings of Susceptibility to Adverse Childhood Experiences</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$499,484.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>brain disorders</Res_KW1>
        <Res_KW2>mental disorder</Res_KW2>
        <Res_KW3>early childhood</Res_KW3>
        <Res_KW4>psychiatric disorders</Res_KW4>
        <Res_KW5>neurological disorders</Res_KW5>
        <Plain_Description>Adverse childhood experiences (ACE) can impact on later susceptibility to a range of human disorders, including major forms of mental illness, such as schizophrenia, depression and anxiety disorders. The links between the brain and body, including metabolism, have been recognized as increasingly important in our understanding of the cause of various psychiatric disorders. This project will explore gene-environment and brain-body interactions to find new ways to prevent and treat mental illness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032046</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Dr Emmah Doig</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NIHR Collaborative Research Round 3</Sub_Type>
        <Grant_Title>The clinical and cost effectiveness of the Action Falls rehabilitation programme compared to usual care alone to reduce falls in stroke survivors (the FISS trial)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,653,727.05</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health and community services | health sciences | health services and systems | rural and remote health services | health sciences | allied health and rehabilitation science | rehabilitation | </Fields_of_Research>
        <Res_KW1>stroke rehabilitation</Res_KW1>
        <Res_KW2>falls prevention</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>accidental falls</Res_KW4>
        <Res_KW5>stroke</Res_KW5>
        <Plain_Description>Up to 75% of stroke survivors fall, resulting in injury, immobility, inability to work and increased healthcare. We don't know how to reduce falls after stroke. Action Falls has reduced falls by 43% in UK nursing homes and could be effective in stroke survivors. Our FISS-Australia trial will involve 464 stroke survivors to see if adding Action Falls to usual care reduces falls over 12 months. Patients, family members and clinicians will be interviewed about their views of the intervention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2032084</APP_ID>
        <Date_Announced>2023-12-15T00:00:00</Date_Announced>
        <CIA_Name>Prof David Beard</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NIHR Collaborative Research Round 3</Sub_Type>
        <Grant_Title>ACL STARR: Anterior Cruciate Ligament Stratified Accelerated Repair or Reconstruction Single blind randomised control trial for patients with proximal ACL injuries treatment with ACL repair v ACL reconstruction.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,545,537.48</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | surgery | biomedical and clinical sciences | clinical sciences | orthopaedics  | biomedical and clinical sciences | clinical sciences | sports medicine | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>knee</Res_KW2>
        <Res_KW3>orthopaedic surgery</Res_KW3>
        <Res_KW4>cost-effectiveness</Res_KW4>
        <Res_KW5>disability</Res_KW5>
        <Plain_Description>The Anterior Cruciate Ligament (ACL) is an important knee ligament. It is often injured leading to joint instability and pain. Different surgical options are available to restore stability. Most commonly, reconstruction is used, which inserts replacement tissue from other parts of the body. An alternative is to stitch the original ligament back in place. This treatment is new and poorly evaluated. Our study will find out which is the best technique for Australians who experience ACL injury.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
</root>